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1. Introduction 
1.1. Alzheimer’s Disease 
Alzheimer’s disease is a devastating and the most common neurodegenerative disorder with 
currently 47 million people world wide suffering from the disease or a related form of dementia. 
Importantly, due to increased life expectancies this number is projected to increase to more than 
131 million by 2050 (World Alzheimer Report, 2016) and does not take into account that 
currently only an estimated quarter of people suffering from AD is being diagnosed. Besides the 
obvious burden this puts on family members of patients, the disease imposes a socioeconomic 
challenge to the entire population, as the total worldwide cost of dementia is estimated to 
become a trillion dollar by 2018. The most recent estimations by Hebert and colleagues 
sustained their report from 2003 in which they predict a two-fold increase of patients affected 
with AD in the next 20 years to 10.5 million in the USA alone (Hebert, Weuve et al. 2013).
The disease is initially characterised by two principal phases. A first mild cognitive impairment 
(MCI) phase which is symptomatically similar to age associated memory impairment (AAMI), 
and thus difficult to diagnose. And a second phase characterised by increasing decline of 
cognitive abilities such as perception, speech, and learning and memory. In the final stages, the 
patient is likely to loose speech, shows severe apathy and exhaustion, and is unable to execute 
simple tasks, and thus fully dependent on caregivers (Forstl and Kurz 1999). These symptoms 
are accompanied by different morphological characterisations, which are described post mortem 
e.g. according to Braak stage I-VI by the spreading of symptoms from initially the 
transentorhinal region (stage I-II), to the limbic regions (e.g., hippocampus, stage III-IV), finally 
to the neocortex (stage V-VI). Molecularly AD has been linked to protein aggregation, thus the 
two pathological hallmarks of AD have been major targets in AD research to treat causative 
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Figure 1.1: Alzheimer disease in the 
United States (2010-2050) estimated 
using the 2010 consensus.
Patients suffering from AD will double in 
the next 20 years in the USA.Y-axis 
shows millions of persons affected with 
AD, x axis shows years from 2010 to 
2050. Especially age groups 85 (blue) 
and above and from 75 to 84 (red) will 
contribute to increased AD cases while 
65-75 will not majorly contribute to the 
trend, due to the late onset of the 
disease. Dotted lines indicate current 
timepjoint and a doubling of patients 
affected by 2037. Illustration adapted 
from Hebert and colleagues. (Hebert, 
Weuve et al. 2013).
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factors. Firstly, amyloid precursor protein (APP) derived Aβ plugs, and secondly neurofibrillary 
tangles (NFTs) composed of the microtubule associated protein tau. In rare familiar cases of the 
disease genetic mutations of these genes have been identified, which contributed to a basic 
understanding of the pathology. In contrast, while mostly displaying similar molecular 
pathologies, sporadic AD it is likely multifactorial. 
Several risk factor have been reported including, amongst others, genetic predispositions such 
as the apolipoprotein E (ɛ4) allele (APOE4) which was identified in genome wide association 
studies (GWAS) (Coon, Myers et al. 2007), head injury (Guo, Cupples et al. 2000), exposure to 
pollution (Calderon-Garciduenas, Reed et al. 2004), or nutrition (Luchsinger, Tang et al. 2002, 
Gustafson, Rothenberg et al. 2003). Further, twin studies report an influence of non-genetic risk 
factors in AD and dementia. This influence contributes 21 % to 42 % to the appearance and 
progression of the disease, underlining the importance of the interplay between genetic risk 
factors and environmental circumstances (reviewed by Fischer 2014). However, an exact cause 
of the disease remains unknown. Despite intergovernmental agreement that AD is a global 
public health priority (WDC, 2014/15) and establishing organisations such as G7-led “Global 
Action on Dementia”, which encourages major efforts in research, there is to date no cure and 
no efficient treatment available to alter the course of the disease. Importantly, if a treatment for 
dementia would be identified, it will be crucial to make it easily available and provide high 
coverage. This puts four principal research strategies into focus namely modulating causative 
factors via antibody based therapies (Selkoe and Hardy 2016), target processing of causative 
factors by small molecules (Vassar, Kuhn et al. 2014), target causative factors directly by small 
molecules (Doig and Derreumaux 2015), and symptomatic treatments which are not targeting 
causative factors but instead circumvent pathological events (Fischer 2014, Benito, Urbanke et 
al. 2015). 
1.2. Molecular hallmarks of Alzheimer’s Disease 
1.2.1. Amyloid precursor protein and amyloid β 
In 1906 Alois Alzheimer dissected brain of patient Auguste Deter, the first case study of the 
disease, and described plaques of an unknown substance throughout the brain. It was until 
1985 when Masters and colleagues biochemically purified and described amyloid β (Aβ) for the 
first time (Masters, Simms et al. 1985). The genetic location of the precursor of Aβ (amyloid 
precursor protein; APP) was localised on human chromosome 21 in 1987 (Goldgaber, Lerman 
et al. 1987, Kang, Lemaire et al. 1987), linking AD and trisomy-21 (Down-Syndrome), a genetic 
defect accompanied by cognitive impairment and Aβ plaque depositions in the patients brains 
(Lott and Head 2005). Despite frequent studies and new links to neuronal processes, the 
physiological role of APP remains uncertain. The integral membrane protein is ubiquitously 
present including in the synapses of neurons, where it was reported to regulate synaptic 
formation, structure, and function (Priller, Bauer et al. 2006, Tyan, Shih et al. 2012). Further 
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reports associated APP to changes in neural plasticity (Klevanski, Herrmann et al. 2015), 
acquisition of aversive memory (Priller, Bauer et al. 2006, Senechal, Kelly et al. 2008), cell 
adhesion, (Breen, Bruce et al. 1991), neuronal migration (Copenhaver and Ramaker 2016), 
neurite outgrowth (Milward, Papadopoulos et al. 1992, Qiu, Ferreira et al. 1995), and 
modulation of mitochondrial metabolism (Lopez Sanchez, Waugh et al. 2017). However, the 
underlying mechanisms not well defined and often disputed.
APP is processed by sequential cleavage of α- and β- and secretase into two carboxyterminal 
fragments, which are in turn a substrate to the γ-secretase processing them to either p3 or Aβ, 
and the APP intracellular domain (Chow, Mattson et al. 2010). Of note, the A673T mutation in 
APP has been identified do have a preventive effects towards AD likely due to its proximity to 
the β secretase cleavage site (Jonsson, Atwal et al. 2012, Kokawa, Ishihara et al. 2015). To 
initiate activity, γ–secretase requires at least four components, namely presenilin (PS1 or PS2), 
nicastrin (Nct), presenilin enhancer 2 (Pen2), and anterior pharynx defective 1 (Aph-1) (Wolfe 
2008). Cleavage to Aβ occurs in the endosomal compartment and Golgi network, thus it 
believed that it is produced in those sub-cellular localisations and afterwards secreted through 
exocytosis. Of note, while reason remains unclear, also intracellular Aβ was observed in human 
AD and animal models (Wirths, Multhaup et al. 2001, Gomez-Ramos and Asuncion Moran 
2007). Due to frequent cleaving events at alternative sites the length of Aβ can range from 36 to 
43 AA, while the predominant form is 40 AA long (Portelius, Brinkmalm et al. 2009, 
Mawuenyega, Kasten et al. 2013). 
The conversion from non-toxic and soluble Aβ into clumped toxic from, rich in β-sheets is 
considered a key event towards AD (Hardy and Selkoe 2002, Mattson 2004, Goate and Hardy 
2012) and targeting amyloid pathology still represents a promising therapeutic approach 
(Haass and Selkoe 2007, Selkoe and Hardy 2016). Importantly, different Aβ species show 
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Figure 1.2: Processing of the amyloid precursor protein.
Through proteolytic cleavage, transmembrane APP is cut by α- 
β- and γ-secretase into a N-terminal APP fragment, Aβ 
monomer and APP Intracellular Domain (AICD). Aβ 
monomers, which can range between 38 AA and 42 AA in 
length then start to form oligomers that ultimately aggregate to 
plaques (adapted from Principles of Neural Science, Kandel et 
al., 2013).
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distinct amyloidogenic tendencies, while e.g. Aβ1–40 or 1–38 are less and e.g. Aβ 1–42, Aβ 3–
40 more prone to aggregate. As for APP itself the physiological function of Aβ and pathological 
aggregation of its’ distinct isomers is not well understood. Of the all possible species Aβ1-40 and 
Aβ1-42 are by far the most studied. While both species can form oligomers considered to be 
toxic, Aβ1–42 is the main species found in early stage diffuse plaques, Aβ1-40 strongly 
correlates to mature plaques (Iwatsubo, Odaka et al. 1994). Additionally, Aβ1-40 oligomers were 
observed to damage the neuronal membrane (Canale, Seghezza et al. 2013) and was found to 
contribute to the formation of AD (Shin, Ogino et al. 1997). Further, oligomeric non-plaque Aβ 
aggregates are investigated as the primary pathogenic form of Aβ. These toxic oligomers, are 
thought to bind to surface receptors on neurons and alter the structure of the synapse or to form 
channels, thus disrupting neuronal communication. (Lacor, Buniel et al. 2007). One of the first 
explanations of neuronal dysfunction and toxicity mediated by Aβ species is the channel 
hypothesis first proposed by Arispe and colleagues (Arispe, Rojas et al. 1993). It postulates that 
unregulated Aβ ion channels result in a loss of ionic homeostasis, ultimately leading to neuronal 
dysfunction and cell death. Importantly, despite the fact that Aβ deposition is pathologically 
increased in AD, neurotoxic and oligomeric species are not exclusive to AD, but can be detected 
in other diseases and cognitively healthy elderly (Price and Morris 1999), an observation 
underlining the importance to take additional molecular hallmarks of AD into account. To be able 
to investigate the pathology efficiently good models are needed. One of the most applied 
models is the C57Bl6j-Tg(Thy1-APPsew;Thy1-PS1 L166P) mouse model for AD-like 
amyloidosis, herein APP/PS1. The model co-expresses KM670/671NL mutated APP and L166P 
mutated PS1 under the control of a neuron-specific Thy1 promoter element. The model shows 
several AD hallmarks including cerebral amyloidosis starting at 6–8 weeks, a ratio of human 
amyloid which corresponds to AD (Aβ42 to Aβ40 of 1.5 in pre-pre-plaque and 5 in post-plaque, 
respectively). Further, the model shows extensive congophilic parenchymal amyloid and 
minimal amyloid angiopathy, as well as dystrophic synaptic boutons and hyperphosphorylated 
tau-positive neuritic structures. This makes APP/PS1 a well suited model to study therapeutic 
strategies and the pathological mechanism of amyloidosis.
1.2.2. The microtubule associated protein Tau 
After the first characterisation of histopathological hallmarks in the brain of the first AD patient it 
took another 68 years until the successful isolation of neurofibrillary tangles (NFTs) from 
autopsied brains in 1974. Subsequently, their protein composition and identification of the major 
contributor, a protein of approximately 50  kDa, today known as the microtubule-associated 
protein tau was achieved (Iqbal, Wiśniewski et al. 1974, Weingarten, Lockwood et al. 1975). 
Even before that, NFT density was shown correlate with dementia and disease severity 
(Tomlinson, Blessed et al. 1970) and is today still the basis for classification of AD based on its’ 
topography by Braak staging (Braak and Braak 1991). Findings from these and following 
studies strongly led to the tau pathology becoming a major area of research. Today 
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entanglement of tau is generally considered to play a key role in the pathogenesis of 
Alzheimer’s disease. 
Tau is encoded by a single gene (MAPT) on human chromosome 17. In the human brain, the 
transcript is subject to alternative splicing which results in 6 isoforms. The translated proteins 
differ from one another in the number of amino-terminal inserts of 29 amino acids each, and the 
presence of three or four microtubule-binding domain repeats (Goedert, Spillantini et al. 1989), 
which have been linked to changes in microtubule affinity and altered disease progression 
(Goedert and Jakes 1990, Dickson, Kouri et al. 2011). Loss of the protein does not develop a 
detrimental phenotype in mouse models, possibly due to compensation by proteins of the same 
family (Harada, Oguchi et al. 1994). Tau was implicated in neurotransmission where it could act 
through the Fyn pathway (Roberson, Halabisky et al. 2011) and may serve in the nucleus in 
neuronal DNA and RNA protection (Violet, Delattre et al. 2014). In the healthy brain taus’ main 
function is to promote assembly of tubulin subunits into microtubules and to stabilise the 
structure (Drubin and Kirschner 1986, Kadavath, Hofele et al. 2015). Importantly, this process is 
orchestrated by differential post-translational modifications of tau and particularly by its degree 
of phosphorylation, however, hyperphosphorylation suppresses this activity (Alonso, Zaidi et al. 
1994) and can lead to tau aggregation under pathological conditions.
Post translational modifications (PTMs) of tau were first reported in 1992. Yasuo and colleagues 
identified several abnormally hyperphosphorylated sites on tau from the brains of individuals 
with AD, using mass spectrometry (Hasegawa, Morishima-Kawashima et al. 1992). Today 63 
sites are known to be modifiable and 6 distinct PTMs were identified in models for human tau 
pathology (Morris, Knudsen et al. 2015). When tau becomes hyperphosphorylated, microtubule 
association is reduced and tau becomes prone to self-aggregation into paired helical filaments 
(PHFs) (Friedhoff, von Bergen et al. 1998), which manifest as neurofibrillary tangles (NFTs) in 
the neuronal soma, neuropil threads in neurites, and dystrophic neurites surrounding Aβ 
plaques (Grundke-Iqbal, Iqbal et al. 1986). These hyperphosphorylated tau species show 
several-fold increased levels in AD patient brains, while the amount of non-hyperphosphorylated 
tau, however, is comparable between AD brains and normal aged brains (Khatoon, Grundke-
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Figure 1.3: Aggregation of the microtubule associated protein tau.
Tau promotes assembly of microtubules and stabilises the structure. Hyperphosphorylation reduces 
affinity with microtubules and leads to aggregation, ultimately resulting in NFTs and cytotoxicity.
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Iqbal et al. 1992, Kopke, Tung et al. 1993). In line with this, the protein phosphatase 2A (PP2A), 
which dephosphorylates hyperphosphorylated tau in healthy individuals was found to be 
compromised in brain tissue from individuals suffering from AD (Gong, Grundke-Iqbal et al. 
1994). However, it remains unclear which one of the several phosphorylation sites are essential 
for disease pathogenesis and which sites become phosphorylated after the formation of tau 
pathology. Additionally, It is not well understood which of the tau phosphorylation sites identified 
are essential for disease pathogenesis and which sites may become phosphorylated only after 
the formation of tau pathology in the tauopathies.
Further, there is significant evidence that mis-folded tau can propagate, exhibit prion like 
properties and to spread trans-synaptically (de Calignon, Polydoro et al. 2012, Liu, Drouet et al. 
2012, Goedert, Masuda-Suzukake et al. 2017). This was demonstrated amongst others by 
studies showing that injection of brain extracts from tau transgenic mice or human tauopathy 
into the brains of mice expressing wild-type human tau, results in tau aggregation around the 
injection site and connected brain regions (Clavaguera, Bolmont et al. 2009, Ahmed, Van der 
Jeugd et al. 2014). Of note, several other PTMs of tau were identified, including ubiquitination 
(Cripps, Thomas et al. 2006), truncation (Zhang, Song et al. 2014), sumoylation (Dorval and 
Fraser 2006), and acetylation (Min, Cho et al. 2010, Min, Chen et al. 2015). Acetylation of tau 
has received little attention in the past but is emerging as an important PTM in its’ physiological 
and pathological functions. Tau lysine (K) acetylation at residues 259, 290, 321 and 353 is 
decreased in AD but occurs in healthy human brain, and appears to protect tau from increased 
phosphorylation and suppresses tau aggregation (Cook, Carlomagno et al. 2014). Conversely, 
acetylation of tau at K 174, 274 and 280 was detected in AD brains, and may be pathological 
(Min, Chen et al. 2015). These findings suggest, that specificity is the key in the functionality of 
Tau acetylation. Sirtuin 1 (SIRT1) and the histone deacetylase 6 (HDAC6) were identified as the 
enzyme responsible for the deacetylation of tau and inhibition of HDAC6 enhanced tau 
acetylation and decreased tau phenotype in vivo (Cook, Carlomagno et al. 2014). This 
demonstrated that tau acetylation influences tau phosphorylation and aggregation directly, and 
suggests that tau acetylation could be a feasible target to ameliorate the pathology.
It is well established that tau hyperphosphorylation and other PTMs lead to aggregation and 
formation of NFT. This was repeatedly linked to neurotoxicity in AD (Lasagna-Reeves, Castillo-
Carranza et al. 2011, reviewed in Spires-Jones, Kopeikina et al. 2011), however to date there is 
no efficient treatment or cure available. Current approaches include immunotherapies using 
specific antibodies, pharmacological modulation of phosphorylation e.g. by PP2A enhancement 
(reviewed inVoronkov, Braithwaite et al. 2011), and symptomatic treatments without targeting 
causative factors (Fischer 2014, Benito, Urbanke et al. 2015). 
In any of these approaches tau transgenic mouse models are valuable to investigate the role of 
tau protein in AD and other tauopathies. However, common models often display motor 
dysfunction which is fatal for appropriate scoring in cognitive testing. An appropriate model for 
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testing the influence of a treatment on cognition using behavioural tests is the mouse model 
C57Bl6j-TG(THY1.2-Tau22) (herein Tau22) that expresses human 4-repeat tau mutated at sites 
G272V and P301S under control of the Thy1.2-promotor (Schindowski, Bretteville et al. 2006). 
This model does not show any motor dysfunction, while recapitulating key features of tau 
pathology such as hyperphosphorylation of tau on AD-relevant epitopes (AT8, AT100, AT180, 
AT270, 12E8, pSer396, and AP422), NFT like somatic inclusions and mild astrogliosis. The 
model is characterised by deficits in hippocampal synaptic transmission and impaired behaviour 
with increased anxiety, delayed learning from 3 months, and reduced spatial memory at 10 
months of age. Taken together, this makes Tau22 a well suited model to study therapeutic 
strategies and the pathological mechanism of amyloidosis.
1.3. Learning and Memory 
In higher animals the complex environment imposes the ability to learn and memorise events 
and features such as resources or threats as it is crucial for survival. Without this ability, future 
avoidance of harmful situations would be impossible and there would be no option to profit from 
previously discovered environmental factors, such as food resources. While, learning and 
memory are highly dependent on one another, both processes have to be treated as distinct 
(Bailey, Bartsch et al. 1996). The ability to acquire, consolidate, maintain and retrieve memory is 
far spread amongst metazoan and studied in different model organisms including C. elegans, D. 
melanogaster, and M. musculus. Historically the understanding of the fundamentals of learning 
and memory took a milestone in 1890 when William James stated in his ‘Law of Neural Habit’ 
that “when two elementary brain processes have been active together or in immediate 
succession, one of them, on reoccurring, tends to propagate its excitement into the other”. The 
principle of contiguity derived from this initial revelation and states that the co-activity of 
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Figure 1.4: A possible memory taxonomy.
Different forms of memory and the most relevant cognitive tests associated for mouse models including 
contextual Fear conditioning, open field, elevated plus maze, Morris water maze and Barnes maze. 
Adapted from Quillfeldt 2006 
TA
SK
S
Procedural Declarative
 
Non-Associative Associative Associative
Ha
bit
ua
tio
n
Se
ns
itiz
at
ion
Ha
bit
 fo
rm
at
ion
Classical 
conditioning
(no escape)
Operant 
conditioning
(escape)
Exploration, 
habituation 
(new context)
Operant-like, 
spatial memory
Fear 
conditioning
Open field 
habituation
Morris 
water maze
Barnes 
maze 
Memory
Elevated 
Plus Maze
Non-Associative
Introduction
fundamental brain processes drives association. After Ramón y Cajál identified single neurons 
in the nervous system in 1911, the term “synapse” was designated as an interface for neuronal 
communication. Donald O. Hebb refined this statement in 1949 proposing that “when an axon of 
cell A is near enough to excite a cell B and repeatedly or persistently takes part in firing it, some 
growth process or metabolic change takes place in one or both cells such that A's efficiency, as 
one of the cells firing B, is increased”.
In turn, the capability of neuronal circuits to adapt based on activity patterns is a crucial feature 
in learning and sustaining new information. In fact, the model of neuronal plasticity is essential 
in research investigating the cellular and molecular basis of understanding how memory is 
stored and retrieved. Although we do not fully understand the underpinnings of learning and 
memory, systematic approaches have been undertaken to gain insight into certain forms of 
learning and memory. Commonly memory is separated into “declarative” and “non-declarative” 
memory (Polster, Nadel et al. 1991, Dudai 2002). Non-declarative memory holds information 
e.g. about motor procedures and changes performance rather than conscious retrieval (Lum, 
Conti-Ramsden et al. 2012). In contrast, declarative memory is described as the memory used 
for facts and information we can retrieve and declare to others and further divided into 
associative and non-associative learning and their persistence. Importantly, both declarative and 
non-declarative memory include heavily hippocampus dependent forms of memory. 
1.3.1. The hippocampus in learning and memory 
Memory storage involves several brain areas which differ depending on the quality of the 
memory. The best studied example is the memory acquisition through integration of information 
in the hippocampus on short-term, which is then transferred to higher cortical regions such as 
the prefrontal cortex for permanent storage. Importantly, a recent paper by Kitamura and 
colleagues demonstrated that memory engram cells are formed in the prefrontal cortex and the 
hippocampus simultaneously and are later consolidated by an unknown mechanism (Kitamura, 
Ogawa et al. 2017). Thus, the hippocampus is a highly important brain area commonly 
recognised to be crucial for memory acquisition and consolidation, particularly in spatial 
memory. It is located in the medial temporal lobe in primates and below the cerebral cortex in 
other mammalians. In other vertebrates the important function of the hippocampus is fulfilled by 
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Figure 1.5: The Hippocampus. 
Dentate gyrus (DG, bottom) and cornus ammonis 
sub regions (CA1, CA2, CA3) receive innervation 
via the perforant pathway (PP) from the entorhinal 
cortex (EC, top). Signalling within the hippocampus 
occurs mostly directed from DG through mossy 
fibres (MF) through CA areas to EC. Adapted from 
Kandel 2013
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evolutionary homologous but differently organised structures (Rodriguez, Lopez et al. 2002). 
The most important findings contributing to our understanding of hippocampal function stem 
from the case study of the patient known as “H.M.”. Due to seizures he had his medial temporal 
lobe, including the hippocampus, surgically removed in 1957 and suffered from then on from 
severe anterograde amnesia of his declarative but not his procedural memory (Scoville and 
Milner 1957). The findings from this case study were complemented with several ablation 
experiments in non-human primates and rodents which underlined the hippocampal 
involvement in spatial learning (Moser, Moser et al. 1993), associative learning and recognition 
(Mahut, Zola-Morgan et al. 1982), and in the consolidation of fear memory (Sutherland, O'Brien 
et al. 2008). Structurally and functionally the hippocampus is further divided into dentate gyrus 
(DG) and cornus ammonis (CA), while the latter is subdivided into CA1, CA2, and CA3. The 
hippocampus signals to different brain regions from the CA, which in turn receives input from 
the DG via mossy fibers (Scharfman 2007) and receives input via the perforant path from the 
entorhinal cortex. Further, the hippocampus has been shown to connect to the amygdala 
(Saunders and Rosene 1988), the septum (Farr, Uezu et al. 1999), basal ganglia (Thierry, 
Gioanni et al. 2000), hyptothalamus (Cui, Gerfen et al. 2013), ventral tegmental area (Kahn and 
Shohamy 2013) prefrontal cortex (Thierry, Gioanni et al. 2000) and the cerebellum (Yu and 
Krook-Magnuson 2015). The dorsal and ventral regions of the hippocampus have been shown 
to serve different functions. While the dorsal hippocampus has been reported to be involved in 
spatial memory (Lee and Kesner 2003), the ventral hippocampus was linked to fear and stress 
response due to its closer association to the amygdala (Bast, Zhang et al. 2001). Notably, the 
hippocampus and more precisely the DG is one of the scarce sites of adult neurogenesis (Ming 
and Song 2005). Importantly, it has been shown that Inhibition of adult neurogenesis interferes 
with hippocampus-dependent memory function (Winocur, Wojtowicz et al. 2006).
Further, the hippocampus is highly relevant in AD, as the gradual loss of hippocampus 
dependent memory abilities is one of the first severe cognitive hallmarks of the disease. This is 
accompanied by the most striking molecular pathologies, namely Aβ plaque deposition, NFT 
formation and neuronal loss, which occur first in the hippocampus and spread to higher brain 
areas (cf. Braak staging) (Dickson 1997, Serrano-Pozo, Frosch et al. 2011).
1.3.2. Persistence of memory 
Memory storage can be divided into two principal categories depending on their persistence. 
Firstly, short-term memory (STM) which can hold very limited information and decays in order of 
seconds. Secondly, long-term memory (LTM), a much longer lived storage which can hold a 
large number of memories for hours do days and converges into the life time lasting persistent 
memory, which is resistant to disruption. The precise timely definition of memory stages is under 
debate (Cowan 2008), as the precise biological mechanisms are not trivial to identify. The 
temporary definition of STM is dependent on the field of research, as neurologists define it to 
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last from seconds to a few minutes (Peterson and Peterson 1959), while cellular neurobiologists 
consider STM last for up to a few hours (Goelet, Castellucci et al. 1986). 
STM is characterised by its particularly quick access with limited capacity. A precise 
measurement of the latter is difficult, due to individual variation between subjects in how many 
information items or “chunks” can be stored as this process is dependent on the chunk quality 
and can be distorted by rehearsal (Cowan 2008). However, an average value of around seven 
items temporarily sorted in STM is estimated with some variance (Miller 1956). Hypothetically, a 
memory inflicting event would occur in a specific brain region, such as the hippocampus, and 
result in a specific excitation pattern (“engram”), which represents the memory trace and decays 
over time (Mongillo, Barak et al. 2008). Of note, this proposed passive mode of decay is still 
very controversial and within engram research an actively studied topic (Lewandowsky, Duncan 
et al. 2004, Kitamura, Ogawa et al. 2017).
Conversely, LTM is characterised by virtually unlimited storage capacity, however, with longer 
access latency (Bailey and Kandel 2008). As for STM the precise timing defining memory as 
LTM is debated, as the initial phase of memory storage, “consolidation” is highly variable 
(Bailey, Bartsch et al. 1996). For example, cellular consolidation takes place within a few 
minutes after an event (Schafe, Nader et al. 2001), while system consolidation can take up to 
weeks and longer (Dudai 1996). Further, different brain areas, memory qualities, and species 
show considerably large variations in the consolidation process (Shadmehr and Brashers-Krug 
1997). The remarkable theoretical capacity of LTM was impressively demonstrated by the case 
study of AJ, the first case study of hyperthymestic syndrome in which episodic memory is 
pronounced. AJ was capable of recalling precisely what she did on a given date and what week 
day it fell on for her entire life (Parker, Cahill et al. 2006).
The underlying mechanism of both STM and LTM are still of current interest in 
neurodegenerative disorders since an impairment can be observed in a variety of diseases 
including post-traumatic stress disorder (PTSD) (Landré, Destrieux et al. 2012), age associated 
memory impairment (AAMI) (Bender, Naveh-Benjamin et al. 2010, Chen and Naveh-Benjamin 
2012), Multiple sclerosis (Thornton and Raz 1997), Schizophrenia (Landgraf, Steingen et al. 
2011), and AD (MacDuffie, Atkins et al. 2012)
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Figure 1.6: Time dependent 
stages of memory.
Short-term memory (STM) has 
limited storage (±7 chunks) and 
decays within seconds to hours. 
Long-term memory (LTM) with 
large storage for memories and 
lasts for hours do days and 
converges into pers istent 
memory, which is resistant to 
disruption and lasts for a 
lifetime. (adapted from Dudai 
2002)Time
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1.3.3. Association of memory 
In this form of memory an association between two stimuli or between stimulus and response is 
learned. Associative learning is the most common form of memory acquisition in everyday life, 
including amongst others learning of a foreign language, playing an instrument, or fear of painful 
situations. Further, it is divided into operant conditioning and classical or pavlovian conditioning. 
The latter was first described by Nobel Prize laureate Ivan P. Pavlov in 1927 (re-published 
Pavlov 2010). In his studies on digestion, Pavlov described salivation in dogs upon the sight of 
the empty food dish. This observation led him to design an experimental paradigm, in which a 
neutral stimulus, the ringing of a bell, was followed by the offering of meat powder to the test 
subjects. The test subjects associated the ringing of the bell or “conditioned stimulus” (CS) with 
the access to meat powder or “unconditioned stimulus” (US). After several repetitions of the 
conditioning, salivation was evoked in the animals by the presentation of the CS (“ringing bell”), 
without application of the US (“food”), thus a conditioned response (CR) was learned (re-
published Pavlov 2010). Today, several animal behavioural tests are variations of pavlovian 
learning including the common contextual fear conditioning (McIlwain, Merriweather et al. 2001, 
Rudy, Huff et al. 2004), an important tests in hippocampus dependent memory research.
Conversely, in operant conditioning, the outcome of the experiment depends only on the 
subject’s behaviour, which itself triggers the associative stimulus. Burrhus F. Skinner, coined the 
term with his invention of the operant conditioning chamber, while Edward L. Thorndike 
conducted the first experiments in 1898. In Skinners experiments rats were subjected into a 
chamber in which it was allowed to explore freely. Further the chamber contained a lever, which 
the rat would most likely hit by accident, rewarding the animals with food. After several 
accidental repetitions the number of events in which the lever was pressed increased until the 
rat had no more desire to eat. Notably, the Skinner box still has diverse applications. Operant 
conditioning was adapted to different spatial navigation tasks to test memory in operant-like 
spatial learning paradigms. Most relevant today are the Morris water maze, a pool with several 
visual cues to find a submerged invisible escape platform (Morris 1981) and the Barnes maze a 
circular plate with 4 visual cues and 20 holes, one of which harbours an escape cage, 
specifically designed to detect memory deficits associated with senescence (Barnes 1979).
In contrast, non-associative learning is solely dependent on a single quality stimulus, instead of 
establishing a connection between at least two stimuli of different quality and quantity. Non-
associative learning can be separated into sensitization, habituation, and conversely 
dishabituation. In sensitization the response to a given stimulus is enhanced above the baseline 
trough the presentation of a strong stimulus. Frequent repetition of the presentation of a 
stimulus identical in quality and quantity leads to a reduced reaction, considered as habituation. 
In contrast, dishabituation, restores the response to a formally habituated stimulus, usually by 
applying another, often strong, stimulus. In 1987 Eric Kandel and colleagues established these 
mechanisms in the neural system responsible for the gill withdrawal reflex in the sea slug 
Aplysia californica, and further demonstrated that these mechanisms were due to alterations in 
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the synapses between sensory and motor neuron. Interestingly, they also showed that the 
decrease of the gill withdrawal due to repeated stimulation during short-term was based on 
decreased transmitter release. Conversely, in long-term habituation, which is an effect present 
after repeated stimulation for days, the altered stimulus response was due to a reduction of 
synaptic connections between the two neurons involved. Besides demonstrating non-
associative learning Kandel and colleagues revealed the concept of a basic cellular mechanism 
of both short- and long-term memory effects in invertebrates.
1.3.1. Molecular mechanisms of learning 
Memory storage on a cellular level has been of great interest in neuroscience and it is believed 
that the formation and strengthening of neuronal connections trough synapses, so called 
synaptic plasticity, is a cellular correlate of learning and memory. Thereby, synaptic strength is in 
principle dependent on frequency and repetition of a stimulus as stated in the Hebbian 
postulate. 
During STM the cellular and molecular changes occurring in memory forming neurons are 
thought to be based on the covalent modifications of pre-existing proteins by a broad spectrum 
of different kinases (Goelet, Castellucci et al. 1986, Bailey and Kandel 2008), conversely 
modifications required for LTM formation are more extensive and requite de-novo protein 
synthesis. Neurons change their structure, form new synapses, and grow dendritic spines after 
training. To enable such changes, synthesis of structural molecules, including proteins, is 
necessary. This was demonstrated in 1962 by Flexner et al. (Flexner, Flexner et al. 1962), when 
they applied the protein synthesis inhibitor (PSI) puromycin to mice upon which they showed 
deficits to learn and retain memory, remarkably intracerebral injections of PSI resulted in LTM 
deficits even 1 day past training, stressing the importance of de novo protein synthesis. These 
results were subsequently supported with different PSIs and various model organisms (Agranoff 
and Klinger 1964, Barondes and Cohen 1966, Gold 2008). Importantly, the disruption of LTM by 
protein synthesis inhibition did not affect STM (Flood, Rosenzweig et al. 1973), which was only 
abolished after application of Ca2+ influx interference agents, targeting the synaptic NMDA 
receptor (Gibbs and Ng 1977). 
In search for a model to study cellular learning in vertebrates Bliss and Lømo discovered in 
1973 that isolated brain sections of the rabbit hippocampus respond differently dependent on 
electrical stimulation (Bliss and Lomo 1973). They discovered that neuronal responses 
remained stable when stimulated with a mild, low frequent electric pulse, while tetanic 
stimulation caused excessive firing of neurons and resulted in an increased excitatory 
postsynaptic potential (EPSP), which remained elevated over time. The increase of synaptic 
response after tetanic stimulation was termed long-term potentiation (LTP). Conversely, synaptic 
efficiency was reduced upon a long patterned stimulus, a phenomenon described as long-term 
depression (LTD). Of note, while LTP and LTD resemble physiological learning events in 
associativity, durability, and the need for de novo protein synthesis (for late phase LTP) (Frey 
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and Morris 1998), it remains uncertain to which extend they are a cellular counterpart to 
learning and memory (Bliss and Collingridge 1993).
Formation of LTM in response to a stimulus requires de-novo protein synthesis an in turn 
differential gene expression. This mechanism is best investigated in the induction of LTP and 
the two necessary receptors glutamate receptors, namely NMDA-type and AMPA-type (Dale 
and Kandel 1993, Trudeau and Castellucci 1993). The simultaneous activation of the two 
receptor types results in calcium influx. In turn, this starts an enzymatic cascade ultimately 
resulting in short-term effects at the post-synapse by an increase of AMPA-R and increase of 
available transmitter, mediated by Adenylate cyclase (AC). If the stimulation is prolonged, long-
term synaptic alterations are initiated. The increased activity of AC results in high levels of cyclic 
adenosine monophosphate (cAMP) and in turn acts as a second messenger and activates the 
protein kinase A (PKA), which together with the mitogen-activated protein kinase (MAPK) 
relocates to the nucleus and promotes transcription through phosphorylation of transcription 
factors (TFs). (Bacskai, Hochner et al. 1993, Martin, Casadio et al. 1997, Kandel 2001). The 
initiation of transcription is a tightly controlled process involving the interaction of chromatin and 
various proteins, including TFs. They are highly conserved in evolution, while some are 
essential for the basic process of transcription, others orchestrate the selective repression and 
activation of certain genes. TFs are regulated temporally e.g. in development and circadian 
clock or upon an external stimulus. They then control transcription indirectly or bind specific 
DNA motifs directly. A well studied example is the TATA binding protein (TBP), which binds to a 
DNA consensus sequence characterised by repeating T and A in the promoter region of a gene, 
thereby regulating RNA synthesis (White and Jackson 1992, Watson 2014). Together with TBP 
associated factors, TBP constitutes the polymerase II pre-initiation complex, thus enhances the 
transcription of the respective gene sequence (Lee and Young 2000). However, regulation of 
gene expression is a complex process orchestrated by several basal and regulated TFs, 
particularly in memory formation activation protein 1 (AP1), early growth response factor (Egr), 
CCAAT enhancer binding protein (C/EBP) and the cAMP response element binding protein 
(CREB) were demonstrated to play important roles.
The latter (CREB) is a particularly well studied factor in learning and memory. CREB binds the 
cAMP response element (CRE), which is contained within the control region of a gene and is 
activated by cAMP. The binding of TFs to CRE was shown to determine the expression level of 
certain genes by regulating RNA polymerase activity. Binding of CRE through different TFs was 
shown to regulate RNA polymerase activity and thereby determines the expression level of a 
given gene (Montminy, Low et al. 1986, Montminy and Bilezikjian 1987). Most of the findings 
stem from implicit memory in invertebrates, however a similar yet more complex signalling 
cascade that leads to the activation of CREB has also been observed in the mammalian brain 
(Barco, Alarcon et al. 2002, Lonze and Ginty 2002, Pittenger, Huang et al. 2002). However, the 
precise mechanism is to date still unresolved, though the importance of CREB in learning and 
memory was underlined by experiments, which showed CREB binding interference abolished 
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LTP and LTM formation (Dash, Hochner et al. 1990, Pittenger, Huang et al. 2002, reviewed by 
Kandel, Dudai et al. 2014). In summary this pathway is an excellent demonstration how an 
external stimulus is first conveyed to the transcriptional machinery and subsequently translated 
into gene expression changes. It demonstrates that synaptic plasticity in LTM formation is 
dependent on transcriptional plasticity ultimately leading to protein synthesis. Importantly, in 
research on memory, cognitive abilities, and impairments in particular this puts systems into 
focus which are able to orchestrate the crosstalk between environmental input and regulation of 
gene expression. This is further supported by the observation of de-regulated gene expression 
in brain diseases linked to memory impairment including AD (Blalock, Buechel et al. 2011, Kim, 
Moon et al. 2012, Mills, Nalpathamkalam et al. 2013). In line with this, epigenetics and 
chromatin remodelling in particular gained large interest in the past decades to understand 
transcriptional regulation. The importance of histone acetylation in learning was first 
demonstrated in a mouse model, where mice showed impaired memory consolidation after the 
activity of the CBP/KAT3A was reduced (Alarcon, Malleret et al. 2004, Korzus, Rosenfeld et al. 
2004). Afterwards, it was repeatedly demonstrated that alteration in the chromatin state 
modulated LTP, LTM related synaptic plasticity, and spatial memory (Guan, Giustetto et al. 2002, 
Fischer, Sananbenesi et al. 2007, Guan, Haggarty et al. 2009, Lubin, Gupta et al. 2011, Benito, 
Urbanke et al. 2015, Kosarussavadi, Pennington et al. 2017).
1.4. Epigenetics  
The sequencing the entire human genome in the late 20th century (Lander, Linton et al. 2001, 
Venter, Adams et al. 2001) held promising potential to identify inheritable diseases and formerly 
unknown genetic features. However, the genetic information is not complete without an index 
orchestrating the transcriptional machinery. As early as 1957 Conrad Waddington published in 
his “strategy of genes” a hypothesis explaining how cells with identical genetic background 
could develop into distinct cell types and form different tissues and is thus the founder of the 
epigenome (epi = Greek: επί-over, above, outer). This is today thought to not only orchestrate, 
but extend genetic information beyond DNA base pairing and be able to interact with the 
environment and translate external input into genomic instructions. Under certain circumstances 
the epigenetic code be transmitted the progeny and is involved in the differentiation from cell to 
organism (Jenuwein and Allis 2001). In humans the DNA was estimated to contain between 
19,000 and 25,000 protein coding genes (International Human Genome Sequencing 2004, 
Ezkurdia, Juan et al. 2014), and a total of 3x109 base pairs (bp) including non-coding 
sequences (Vogel 1964). Stretched out this would be around 2 meters of DNA which needs to fit 
into a single nucleus (Molfese 2011). To achieve this compression the genetic information is 
packed into nucleosomes, which consist of 147 bp of DNA wrapped around a histone octamer 
containing each of the four core histones twice (Woodcock and Dimitrov 2001), an accessibility 
trade-off to achieve a 10,000-fold condensation. Chromatin is not uniform, but varies in its’ 
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packaging from the mostly inactive, highly condensed heterochromatin to the transcriptionally 
active and less condensed euchromatin. Most eukaryotic genes are transcribed by RNA 
polymerase II and in vitro experiments have shown that Pol II cannot traverse through 
nucleosomes (Chang and Luse 1997). These spatial restrictions are overcome by ATP-
dependent nucleosome remodellers with orchestration of transcriptional processes by the 
epigenetic machinery (Das and Tyler 2013). 
The three main areas of epigenetic modifications are Non-coding RNA species, DNA 
methylation, and integration of non-canonical histones/post-translational modifications of 
histone termini (“histone tails”). Non-coding RNAs constitute the majority of the transcriptome, 
the best studied subgroup are micro RNAs (miRNAs), which are 19-22 nucleotides in length and 
catalyse gene silencing by binding to mRNA (Im and Kenny 2012). DNA methylation is 
conveyed via DNA methyl-transferases (DNMTs) by addition of methyl groups to CpG islands, 
which is generally thought to mediate transcriptional repression (Miller, Campbell et al. 2008), 
while demethylation is poorly understood. Thereby, the transcriptional state of certain areas can 
be altered through altered chromatin-structure (Allis, Jenuwein et al. 2007). Further, the charged 
and flexible histone tails are modifiable at several residues by several PTMs.
1.4.1. Chromatin plasticity 
Early studies on bulk histone acetylation demonstrated that high acetylation levels correlate with 
higher accessibility to interacting proteins (Hebbes, Clayton et al. 1994, Krajewski and Becker 
1998). Further, it was observed that the ground state of chromatin, independent of 
transcriptional activity, shows intermediate levels of H3 and H4 acetylation, due to a mix of un-
targeted HAT and HDAC activities (Vogelauer, Wu et al. 2000) thus wide acetylation of histone 
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Figure 1.7: The epigenetic landscape.
The identical genetic information is illustrated as a marble, cell fate as valleys. Depending on epigenetic 
orchestration (e.g. DNA methylation) the same genetic information gives rise to e.g. Astrocytes, 
Oligodendrocytes or Neurons. Adapted from Waddington, 1957 
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H3 and H4 leads to less condensed chromatin, which does not tightly correlate with active 
transcription per se, but rather indicates area of transcriptional capability. Interestingly, in the 
rodent hippocampus H3 and H4 acetylation is differently regulated after fear conditioning. Here, 
H3 acetylation was elevated after exposure to a novel environment paired with a foot shock, 
while H4 acetylation was increased when the pre-exposure was extended (Levenson, O'Riordan 
et al. 2004). Of note, this demonstrated that learning induces measurable changes in 
hippocampal histone acetylation levels, which was confirmed in subsequent studies by 
pharmacologically elevating acetylation levels (Fischer, Sananbenesi et al. 2007, Fontan-
Lozano, Romero-Granados et al. 2008, Koshibu, Graff et al. 2009). However the precise 
mechanisms and functional consequences of most acetylation events and recruited complexes 
remain largely unknown (Filippakopoulos and Knapp 2012). The histone octamer is constituted 
of H2A, H2B, H3, H4 and the histone linker H1 or their non-canonical substitutes (Kamakaka 
and Biggins 2005). The structure of the small 11 to 22 kDa proteins is among the most 
evolutionary conserved (Kornberg and Lorch 1999) and contains a high amount of lysine and 
arginine. The basic structure of the four core histones is similar consisting of a central fold-
domain, amino- and carboxy-terminal (tails). While the fold-domain contributes to the histone 
octamer, the tails are involved in regulatory cellular processes and chromatin structure (Morales 
and Richard-Foy 2000). A broad array of PTMs, which often occur simultaneously, has been 
identified including methylation (Taverna, Li et al. 2007), ubiquitinylation (Davie and Murphy 
1990), glycosylation (Sakabe, Wang et al. 2010), sumoylation (Shiio and Eisenman 2003), 
phosphorylation (Stucki, Clapperton et al. 2005), and acetylation (reviewed in Rousseaux and 
Khochbin 2015), each signalling to the chromatin polymer in their specific way (Cheung, Allis et 
al. 2000). The by far best studied modifications of histone tails are the N-terminal methylation 
and acetylation (reviewed in Bannister and Kouzarides 2011, Molfese 2011). The addition and 
removal of these moieties is mediated by the counteracting activities of enzymes, so-called 
writers and erasers. Such modifications directly affect the interaction of histones with the DNA 
and thus alter the chromatin state (Bannister and Kouzarides 2011). Biochemical studies on 
histones of the central nervous system showed incorporation of [14C]-acetate into the histones 
of different rat brain regions during a learning experiment. A well studied example of the 
mediation of the necessary changes is histone acetylation, by histone-acetyltransferases (HAT, 
writer) and histone-deacetylases (HDAC, eraser) (Johnson and Turner 1999, reviewed in 
Fischer, Sananbenesi et al. 2010). The key mediators of these changes, HATs and HDACs, are 
both highly specialised enzyme families that (de)acetylate specific amino residues of the target 
histone tail. Thus both HATs and HDACs are a diverse family. While the former are not well 
studied, the latter are dependent on the cofactors NAD+ or Zn2+ and comprise 18 members in 
human and are divided into 4 classes based on their homology to yeast HDACs (de Ruijter, van 
Gennip et al. 2003, Seto and Yoshida 2014). The Class I consists of Rpd3-like proteins 
(HDAC1, HDAC2, HDAC3, HDAC8), Class II of Hda1-like proteins (HDAC4, HDAC5, HDAC6, 
HDAC7, HDAC9, HDAC10), Class III Sir2-like proteins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, 
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SIRT6, SIRT7), and Class IV protein (HDAC11). In neuroepigenetics particularly Class I and 
Class II HDACS have gained large interest du to their cognition modulation capabilities 
(reviewed in Fischer 2014). 
1.4.2. HDACs in learning and memory 
Class I HDACs are located in the nucleus and range from 22 kDa to 55 kDa in size with great 
homology of the catalytic sites. Every member of the group has been investigated and linked to 
cognitive function with similar results, suggesting a general role as molecular inhibitors of 
memory formation. For example, HDAC2, the best studied member of the class, was found to 
be expressed throughout the brain by several neuronal cell types and oligodendrocytes but not 
astro-and microglia (Yao, Zhang et al. 2013). Further, HDAC2 was shown to impair contextual 
fear learning and spatial memory formation when overexpressed and to improve memory 
function when deleted in neurons of mice (Guan, Haggarty et al. 2009). This was sustained by 
structural findings showing that loss of HDAC2 increased the number of synapses (Guan, 
Haggarty et al. 2009). Importantly, another study showed that enhanced learning behaviour in 
HDAC2 deficient mice correlated with increased hippocampal acetylation of Histone  4 at 
lysine 12 (H4K12) acetylation. This mark was repeatedly demonstrated to play a key role in 
memory reinstatement in the ageing hippocampus through alternative splicing (Peleg, 
Sananbenesi et al. 2010, Benito, Urbanke et al. 2015). 
Class II HDACs are larger compared to Class  I, ranging between 120  kDa to 135 kDa and 
feature a nuclear export signal (NES) as well as a nuclear localization signal (NLS), which is in 
line with their shuttling function. Class II HDACs are further divided into Class IIa (HDAC4, 
HDAC5, HDAC7, HDAC9) and Class IIb (HDAC6, HDAC10) based on their homology, as 
Class IIb contains a second catalytic domain not present in other HDACs. 
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HATs
HDACs
Figure 1.8: The counteracting function of writers and easers.
Writers (e.g. HATs) add PTMs to histone tails thereby increasing accessibility for the transcriptional 
machinery, thus transcription is promoted. Conversely, erasers (e.g. HDACs) remove modifications, 
which leads to more compact state, here the transcriptional machinery is hindered, thus gene expression 
is reduced. Note that at baseline some modifications are present in more condensed state. 
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HDAC6 is outstanding in its class since the main targets are cytoplasmatic proteins such as 
tubulin or heat-shock protein 90 (Zhang, Li et al. 2003, Ding, Dolan et al. 2008). Further, loss of 
HDAC6 in mice does not show a phenotype and does not influence cognitive function, including 
memory (Govindarajan, Rao et al. 2013). Importantly, HDAC6 was shown to also deacetylate 
the microtubule associated protein tau (Zhang, Li et al. 2003, Ding, Dolan et al. 2008, Noack, 
Leyk et al. 2014). Since HDAC6 levels positively correlate with tau burden (Cook, Gendron et al. 
2012) this process was linked to tau clearance. Additionally, the authors demonstrated that 
HDAC6-mediated loss of Tau acetylation makes the protein susceptible to pathological 
phosphorylation (Cook, Gendron et al. 2012). In a drosophila model HDAC6 reduction was 
shown to rescue hyper-phosphorylated Tau induced microtubule instability and 
neurodegeneration (Xiong, Zhao et al. 2013). In line with this, it could be shown that HDAC6 
deficiency rescued memory function in the APP/PS1 model for AD (Govindarajan, Rao et al. 
2013).
In summary, these are well studied examples of how the addition and removal of chemical 
moieties to the highly flexible histone tails is orchestrated. However, there is a gap in the current 
understanding of how chromatin structure which is seemingly littered with PTMs is translated 
into precise biological outcomes or extends the informational content. This cannot only be 
explained by steric interaction between histone tails and DNA. The combinatorial nature of 
these modifications are believed to give rise to the histone code, which is recognised by 
proteins so-called chromatin readers that serve as scaffold to recruit complexes that activate or 
repress transcription (Strahl and Allis 2000).
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Figure 1.9: Chromatin readers read the histone code.
Readers of the histone code recognise specific moieties at histone N-terminals. Upon recognition readers 
serve as scaffold and recruit further factors such as HATs, HDACs, or TFs to the site and initiate 
differential outcomes, e.g. structural changes in chromatin and/or transcriptional changes. 
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1.4.3. The Readers of the Histone Code  
The histone code hypothesis stems from the function of three protein classes. Writers and 
erasers, which add and remove histone tail modifications and the so-called readers, which 
recognise the wide variety of modification patterns at the histone tails and scaffold for various 
transcriptional regulators (Strahl and Allis 2000). In addition to steric interaction between DNA 
and histones, which is most relevant in core histone modifications (Cosgrove, Boeke et al. 
2004), the combinatorial pattern recognition of chromatin readers provides a fine-tuned 
mechanism to regulate chromatin dynamics and in turn selective transcriptional changes. 
Complexes associating with specific marks are often composed of multiple readers that each 
can feature several recognition sequences. This allows for coordinated binding so several PTMs 
and may provide a lock and key mechanism to target specific genomic regions and generate 
precise biological responses. It is this precise mode of histone PTM recognition that is the 
foundation of the histone code hypothesis (Jenuwein and Allis 2001). 
The first chromatin reader was discovered in 1999 as the bromodomain containing PCAF, which 
was found to bind acetylated lysine (Dhalluin, Carlson et al. 1999). Since then a wide variety of 
readers interacting with different motifs including those previously mentioned were identified 
(Tan, Luo et al. 2011). However, the best studied members are readers of methylation and 
acetylation (Yun, Wu et al. 2011). Of the readers identified the heterogenous family of 
bromodomain containing proteins are currently in the focus of research as they have been 
shown to modulate transcription (Bartholomeeusen, Xiang et al. 2012) and demonstrate 
promising drug targets in cancer (Qiu, Jackson et al. 2015, da Motta, Ledaki et al. 2017) and 
cognition (Korb, Herre et al. 2015, Sartor, Powell et al. 2015, Benito, Ramachandran et al. 
2017). The bromodomain is comprises around 110 amino acids and selectively recognises 
acetylated lysine residues. This conserved domain was found in transcriptional regulators and 
chromatin-remodelling proteins, among others HATs such as PCAF and TAF1, but also 
members of the BET family of nuclear proteins (BRD2, BRD3, BRD4, and BRDT) (Zeng and 
Zhou 2002). Particularly the latter contribute significantly to the understanding of how chromatin 
changes are translated into specific genomic commands. For example, it was shown that BRDT 
binds H4 that is diacetylated at K5 and K8 (Moriniere, Rousseaux et al. 2009), while BRD2 
specifically recognises the acetylation of H4K12ac (Kanno, Kanno et al. 2004, Umehara, 
Nakamura et al. 2010). Particularly, the recognition of H4K12ac is of great interest to elucidate 
the role of readers in learning and memory, since deregulation in learning-induced hippocampal 
H4K12 acetylation prevented hippocampal gene expression associated with memory formation 
correlated with significantly impaired memory in mice (Peleg, Sananbenesi et al. 2010). H4K12 
acetylation was also demonstrated to be associated with spatial and fear learning (Bousiges, 
Neidl et al. 2013). Further, acetylation of H4K12 is associated with differential transcription of 
immediate early genes and memory consolidation (Bousiges, Vasconcelos et al. 2010, 
Bousiges, Neidl et al. 2013) a mechanism which is repressed by APP (Hendrickx, Pierrot et al. 
2014). Elevated acetylation of H4K12 was also observed in human patients with MCI (Plagg, 
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Ehrlich et al. 2015). The notion that H4K12ac and readers thereof are key factors in learning 
and memory was underlined by our finding that H4K12ac is reduced around the transcription 
start site (TSS) in models for AAMI and AD. Further, decreased acetylation of the site correlates 
with memory impairment, while reinstating acetylation correlates with improved spatial learning 
and reinstated transcriptional activity (Benito, Urbanke et al. 2015). The acetylation of H4 was 
linked to alternative exon usage mediated by alteration of the elongation rate. An increase of 
acetylation facilitated RNA polymerase II (RNAPol-II) and exon exclusion in 3 different instances 
(Schor and Kornblihtt 2009, Hnilicova, Hozeifi et al. 2011, Zhou, Hinman et al. 2011), a 
mechanism that was linked to the precise reinstatement of acetylation at H4K12 in 2 models for 
cognitive decline (Benito, Urbanke et al. 2015). This underlines not only the importance of 
readers of this mark but indicates that chromatin modifications and readers thereof modulate 
learning in memory, possibly in a splicing dependent manner. Importantly, it was shown for Brd4 
that it is recruited to H4 upon a extracellular signal where it distinguishes unactetylated H4 from 
acetylated at K5 and K12 (Dey, Chitsaz et al. 2003), where it regulated splicing during a heat 
shock (Hussong, Kaehler et al. 2017)
1.4.4. On chromatin assisted alternative splicing 
Two models were proposed by Zhou a colleagues explain the influence of chromatin marks on 
alternative splicing events (Zhou, Luo et al. 2014). Firstly, “kinetic coupling” essentially assumes 
a competition between transcriptional elongation and the splicing machinery, since alternative 
exons require more time to be recognised and thus are skipped when elongation speed 
increases. Secondly, the “chromatin splicing adaptor system” explains the same phenomenon 
by chromatin associating proteins that recognise and bind specific histone marks and direct 
splicing factors to the site of transcription, in turn resulting in two outcomes A) core components 
of the spliceosome are recruited to remove introns B) splicing regulators are recruited through 
chromatin remodelling proteins to directly affect the inclusion or exclusion of alternative exons. 
These models could be envisioned to synergistically contribute to alternative exon usage in a 
scenario in which a chromatin reader scaffolds at its respective mark and recruits elongation 
factors and spliceosome components to TSS. Through cluster density of multiple initiation and 
elongation complexes elongation speed would be regulated. Strong representation would result 
in slowed down elongation leading to exon inclusion along the gene body, while a cleaner 
chromatin structure with few scaffolds would increase elongation speed resulting in exon 
skipping.
1.5. Annexins 
This family of Ca2+ dependent proteins was recently linked to chromatin remodelling, trough its 
member annexin A2 (Oh, Gao et al. 2013). The annexins are a large family of proteins 
consisting of more than 160 members and are present in all higher eukaryotic cell types, 
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indicating fundamental cellular roles (Gerke and Moss 2002). Out of the family, 12 different 
members were identified in mammals, namely A1-A11 and A13 (Gerke and Moss 2002, Moss 
and Morgan 2004). All mammalian annexins show similar key functions. The first function 
identified was the affinity towards membrane bound phospholipids in presence of Ca2+. Further, 
interactions with various proteins, in particular with members of the S100 family were identified 
(Rintala-Dempsey, Rezvanpour et al. 2008). Following the initial findings, several binding 
partners and cellular roles of the annexins were identified including extracellular receptor 
activity, membrane trafficking, membrane-cytoskeleton interactions, signal transduction, and 
RNA binding. Generally annexins are today considered to be a family of multifactorial proteins 
(Gerke and Moss 2002, Gerke, Creutz et al. 2005, Hitchcock, Katz et al. 2014, Lauritzen, Boye 
et al. 2015). While all annexins show cytosolic localisation, some members were shown to 
translocate or reside with a fraction inside the nucleus, including annexin A11 and A2, 
(Eberhard, Karns et al. 2001, Tomas and Moss 2003). 
Annexin A2 (AnxA2) is a well studied member of the Annexin family. Like all annexins, it has a 
highly conserved core domain with four homologous repeats of 70–80 amino acids (AAs), so 
called annexin repeats, and a mild curvature with a concave and a convex side. The core 
domain stretches from AA 31 to AA 338 with known binding sites for Ca2+, heparin, actin and 
phospholipids, which are homologue to other annexins (Drucker, Pejic et al. 2013). The 30 AA 
long N-terminus (tail) contributes significantly to separate functions of AnxA2 from other 
annexins. The tail is subject to complex regulation by PTMs that are in turn modifying its cellular 
functions. AnxA2 is a direct substrate of SRC kinase and Ser11, Ser25 and Tyr23 comprise 
important phosphorylation sites to control sub-cellular localisation (Grindheim, Saraste et al. 
2017). Additionally, the tail region is crucial for protein-protein interaction, especially for S100/
AnxA2 complex formation (Eberhard, Karns et al. 2001, Nazmi, Ozorowski et al. 2012, Liu, 
Myrvang et al. 2015). Indeed, AnxA2 shows two main configurations either as 36-kD monomer 
or as a heterotetramer in which two monomers bind to a pair S100A10 (p11) (Waisman 1995). 
Moreover, AnxA2 binds multiple other intra- and extracellular ligands to convey different cellular 
responses (Vedeler, Hollas et al. 2012). AnxA2 is broadly studied in cancer where it was linked 
to tumour progression (Wang and Lin 2014). However, it remains to be elucidated whether 
AnxA2 is protective or contributes metastasis. 
Besides showing distinct pools in the cytosol and nucleus (Vishwanatha, Jindal et al. 1992) 
AnxA2 was demonstrated to shuttle between the compartments. While the precise mechanism 
is not fully understood, the distribution of Annexin A2 seems to be controlled by the release from 
the AnxA2/p11 heterotetramer initiated by tail phosphorylation and conveyed via the nuclear 
export signal (NES) located from AA 3 to AA 12 (Eberhard, Karns et al. 2001). Shuttling of 
AnxA2 was observed from the membrane to the nucleus (Liu and Vishwanatha 2007). And 
involvement of AnxA2 in cellular processes was reported from ECM to nucleus, suggesting 
further translocations (Raynal and Pollard 1994, Deora, Kreitzer et al. 2004, Zheng, Foley et al. 
2011, Xiu, Liu et al. 2016, Aukrust, Rosenberg et al. 2017). For example, a change in 
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localisation was observed in response to increased genotoxic stress in ageing (Wei and Lee 
2002, Strosznajder, Jesko et al. 2005, Lin and Beal 2006).
In the cytosol AnxA2 was reported to mediate the aggregation and fusion of liposomes in a Ca2+ 
dependent manner by binding to negatively charged phospholipids (Blackwood and Ernst 1990, 
Liu, Fisher et al. 1995). This mechanism contributed to the findings of a study in cancer, where 
the authors showed that high extracellular levels of AnxA2 correlate with metastasis, a poor 
prognosis, and neoangiogenesis (Mussunoor and Murray 2008). Another study suggest this 
effect could be complemented by exosomal AnxA2 which promotes angiogenesis in breast 
cancer (Maji, Chaudhary et al. 2017). A finding that is in line with a report in an in vivo mouse 
model for AnxA2 deficiency, where the authors showed defects in neovascularization and fibrin 
homeostasis (Ling, Jacovina et al. 2004). The membrane bound function is complemented with 
the function of AnxA2 at the extracellular matrix (ECM). Here, AnxA2 was shown to be involved 
in ECM degradation and ECM remodelling through the activation of serine proteases (Sharma 
and Sharma 2007). Importantly, modulation of the ECM has been proven to bidirectionally 
modulate memory formation, and to promote synaptic plasticity and memory extinction (Dityatev 
and Schachner 2003, Senkov, Andjus et al. 2014, Tsilibary, Tzinia et al. 2014).
In contrast, nuclear AnxA2 was linked to RNA binding and transcription in multiple occasions. 
Several studies found AnxA2 to be present in the nucleus and to associate to the nuclear matrix 
(Arrigo, Darlix et al. 1983, Vishwanatha, Jindal et al. 1992, Eberhard, Karns et al. 2001, 
Grindheim, Hollas et al. 2016). Already in early studies AnxA2 was implicated with DNA 
replication, based on the interaction with the DNA-polymerase α (Jindal, Chaney et al. 1991). A 
finding which was complemented with another report demonstrating a direct binding of AnxA2 to 
DNA in vitro (Boyko, Mudrak et al. 1994) and to recognise and potentially recruit primers 
(Kumble, Iversen et al. 1992, Vishwanatha, Jindal et al. 1992). More recent studies linked 
AnxA2 either directly to transcriptional regulation or placed it upstream of cascades ultimately 
leading to altered gene expression. For example, it was linked to a kinase cascade regulating 
the angiotensin 2 induced transcription of cyclooxygenase 2 (Derbyshire, Halfter et al. 2005). 
Another instance where AnxA2 was found upstream of a signalling cascade was reported in the 
increase of NF-B and catenin after progastrin stimulation (Sarkar, Swiercz et al. 2011). Further, 
it was reported that AnxA2 is involved with the transcriptional regulation of its direct interaction 
partner S100A10, plasmin, and fascin in L5178Y cells (Hou, Yang et al. 2008). Additionally, 
AnxA2 was reported toact upstream of the signal transducer and activator of transcription 6 
(STAT6), promoted its nuclear entry and in turn activates transcription (Das, Shetty et al. 2010). 
Interestingly, AnxA2 was found to be accumulated at the proximal Col1A2 region, putting it into 
close association with the transcriptional machinery, where it could facilitate the binding to the 
produced mRNA, thus controlling collagen protein synthesis (Schafer, Hitchcock et al. 2015). 
This is in line with previous findings implicating AnxA2 as a RNA binding protein, which is 
possibly also involved in RNA processing (Vedeler and Hollas 2000, Filipenko, MacLeod et al. 
2004, Mickleburgh, Burtle et al. 2005, Hollas, Aukrust et al. 2006, Aukrust, Hollas et al. 2007). 
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This was further supported by Filipenko and colleagues who suggested that AnxA2 either 
increases c-myc RNA stability and its transport to polysomes or is an activator of its translation 
(Filipenko, MacLeod et al. 2004). Additionally, AnxA2 was reported to be a cellular RNA binding 
protein, modulating the frameshifting efficiency of viral RNA, which suggests an anti-viral 
function, and implies AnxA2 in RNA metabolism for other cellular mRNA (Kwak, Park et al. 
2011).
While reports on AnxA2 focus largely on cancer research, little is known about its roles in the 
brain. Wang and colleagues demonstrated that AnxA2 and SNAP-23 interact in a Ca2+ 
dependent manner (Wang, Chintagari et al. 2007). Interestingly, SNAP-23 is enriched in 
dendritic spines where it co-localizes with components of the postsynaptic density and 
modulates NMDA receptor currents (Suh, Terashima et al. 2010). In depression treatment with 
selective serotonin re-uptake inhibitors, AnxA2 was shown to associate to the SMARCA3 
chromatin remodelling complex in neurons, and to orchestrate action of the complex possibly 
through its actin binding capabilities (Oh, Gao et al. 2013). Additionally, AnxA2 was shown to 
change its location during spatial learning in neurons (Zhao, Waisman et al. 2004) and is 
associated with frontotemporal dementia (FTD) (Gauthier-Kemper, Weissmann et al. 2011). In 
induced astrocytes of FTD patients AnxA2 was found to be upregulated and to interact with Tau 
(Hallmann, Arauzo-Bravo et al. 2017).
In summary, AnxA2 is a multifactorial protein with specific actions from the extracellular space 
all the way into the nucleus and possibly transmits signals not only by initiation of cascades but 
by shuttling. In the nucleus AnxA2 has repeatedly been implicated with the transcriptional 
machinery, RNA binding, and moreover with the SMARCA3 chromatin remodelling complex, 
placing it into close context with the epigenetic machinery. 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2. Objectives 
Alzheimer’s Disease (AD) is detrimental neurological disorder that arises on the background of 
amyloid plaques, neurofibrillary tangles and neuronal cell death as the major hallmarks. Due to 
increased life expectancies the number of patients affected with AD is predicted to increase 
dramatically in the next decades. However, to date there is no cure and no efficient treatment 
available to alleviate the burden AD imposes on our society. The onset and progression of 
sporadic AD are believed to critically depend on combinations of genetic and environmental risk 
factors. Such genome-environment interactions are mediated via the epigenetic machinery. 
There is increasing evidence that epigenetics plays a key role in neurodegenerative diseases 
and offers novel therapeutic strategies for neuroprotection and regeneration.
The motivation of my thesis work was therefore (1) to investigate the epigenetic processes in 
cognitive function in health and diseases; (2) to study the therapeutic potential of novel 
compounds with a specific focus on efficacy in an advanced stage of the diseases: and (3) to 
develop a neuronal cell culture system that would allow the analysis of transcriptome plasticity 
after manipulation in a single-cell specific manner. More specifically the three pillars of my thesis 
work were:
1. Identify proteins that interact with the learning-associated epigenetic mark H4K12ac and 
their involvement in cognitive function and potential as new therapeutic targets agains AD
Age-associated memory impairment is tightly linked to acetylation of H4K12. Thus, my 
aim was to identify chromatin readers of this mark and to test whether they are 
potential drug targets for a symptomatic treatment of AD.
2. Find novel drug- and genetic-based targets for symptomatic treatment of AD
a) Test the efficacy of anle138b to reinstate physiological cellular function and in vivo 
cognitive performance  
Amyloid pathology is believed to be causative for the onset of AD. However, strategies 
targeted towards the clearance of amyloid plaques have so far failed in translational 
research. As part of my thesis work I tested the novel compound anle138b in AD-like 
amyloidosis, which was reported to be beneficial in other aggregopathies.
b) Test the efficacy of deleting HDAC6 to ameliorate AD-associated symptoms  
Previous data of the lab suggested that inhibition of histone-deacetylase 6 (HDAC6) 
ameliorates memory impairment in a mouse model for amyloid deposition. In addition, 
to amyloid burden, Tau-pathology is a key hallmark of AD. I therefore generated Tau 
mutant mice that lack HDAC6 and characterised their cognitive phenotypes
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3. Develop a technology to study neuronal network dynamics at the subpopulation and 
individual cellular level
A high-risk high-gain aim of my thesis was to develop a neuronal cell culture system 
that would allow us to manipulate selected cells in a neuronal network and 
subsequently analyse transcriptome plasticity separately in cells directly and in-directly 
affected by disease-associated cells. The rational behind this approach were data 
from other cellular systems (e.g. immune cells) in which only few cells need to 
undergo transcriptional changes in order to affect (either in a beneficial or detrimental 
manner) the entire cell population. I envisioned that such as system for neuronal 
networks would allow us to address the dynamics of various disease processes 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3. Material and Methods 
3.1. Animals 
3.1.1. Animal welfare  
All animals in context of this thesis were bred and housed under standard Laboratory conditions 
with both food and water supplied ad libitum and a 12 h light cycle. Animals were bred in-house 
and kept for ageing in groups of up to 5 animals. Before behavioural experiments animals were 
relocated to a separate behaviour room and single caged to avoid hostile behaviour after 
individual tests. Animals were allowed to habituate to the new environment for 1-2 weeks prior 
to behavioural testing. If not stated otherwise only male mice were used in behavioural 
experiments. Depending on experiments animals for cell culture were bred in house (AnxA2-/-) 
or delivered from Janvier (CD1-SWISS, E15). Pregnant animals were housed solitarily or in 
groups of 2 in case of Janvier delivered animals. 
3.1.2. Thy1.2-Tau22 x HDAC6-/- transgenic mice  
Tg(Thy1-MAPT)22Schd (THY-Tau22) mice were a gift from Luc Buee and originally described 
by Schindowski and colleagues (Schindowski, Bretteville et al. 2006). HDAC6+/- (Govindarajan, 
Rao et al. 2013) mice on 129 background were first backcrossed to C57BL/6JRj for 
10 generations to generate a largely identical genetic background compared to THY-Tau22. The 
resulting strain was bred by crossing male THY-Tau22+/T to female HDAC6-/+. Male mice of the 
genotype TAU+/+, Hdac6+/y (control); TAUT/+, Hdac-/y (HDAC6 KO); TAU+/T, Hdac-/y (TAU / 
HDAC6 KO) or TAU+/T, Hdac+/y (Tau) were aged for 6 month or 13 month of age to asses early 
stage and late stage pathology respectively (Fig. 3.1).
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Figure 3.1: Generation of genetic background with double transgene.
Maternal generation on 129 Background was backcrossed for 10 generations to C57BL6/j (A). Paternal 
THY-Tau22+/T were mated to maternal HDAC6-/+ resulting in either Tau+/+, HDAC6+/y (control); Tau /+, 
HDAC6-/y (HDAC6 KO); Tau+/T, HDAC6-/y (TAU / HDAC6 KO) or Tau+/T, HDAC6+/y (Tau). Cohorts were 
then aged to either 6 or 12 month (B).
10x
HDAC6 -/+Tau +/T
6 months
13 months
Behavior
B
HDAC6 KO Control Tau Tau / HDAC6 KO
A 
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3.1.3. AnxA2 null mutant mice 
Animals for behavioural tests at 6 month of age were a kind gift of Manuela Schmidt and were 
originally generated by exchanging econ 3 and 4 by a NEO cassette (Ling, Jacovina et al. 
2004). Animals were tested at 6 month of age and until then housed as described beforehand. 
For KO cultures and behaviour at 13 month Female AnxA2 null mutants who did not undergo 
behaviour were crossed to genetic background (C57BL/6JRj) in house to generate 
heterozygous progeny. AnxA2+/- where then mated to generate homozygous knockouts and 
wild-type littermates for behavioural experiments at 13 month of age. 
3.1.4. Genotyping 
To identify animal genotypes mouse tail biopsies were digested in 200 µl DirectPCR tail-lysis 
buffer (Viagen Biotech) with 40 µg Proteinase K (Roth) in a TermoMixer comfort (Eppendorf) at 
1400  rpm, 55  ºC for 2 h and inactivated at 85  ºC for 45min. Samples were then incubated at 
4 ºC for 1 h to allow residual debris to precipitate. Subsequently, PCR master mix composed of 
2.5 µl Dream Tag buffer, 2 µl dNTP, 0.125 µl DreamTaq, 18.375 µl H2O, 0.5 µl primer (each 
forward and reverse, 10 µM) was prepared and supplemented with 1 µl Template. Primers were 
supplemented according to mouse line for either HDAC6, NEO-casette, Tau22, or AnxA2 (Table 
3.1) and Cycler settings according to table 3.2-3.5. Electrophoresis on 1.5  % agarose gel 
containing 0.06 µl/ml Midori Green (Takara CloneTech) was then used to visualise amplicons 
and results documented using the FAS V Gel Documentation System (Nippon genetics).
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Table 3.1: Primers used for cloning, genotyping and pPCR
Name Sequence
AnxA2_perfectmatch_F CAAGGGAGGCTCTCAGCGATAC
AnxA2_perfectmatch_R CTGTGCTGAGCCCTTCAGTCA
AnxA2_Nhe1_F TAGCTAGCCAAGGGAGGCTCTCAGCGATAC
AnxA2_BamH1_R ATGGATCCCTGTGCTGAGCCCTTCCGTCA
F_AnxA2_exon3_genotype TGCCTACGGGTCAGTCAAAC
R_AnxA2_exon3_genotype GCAGGGATACAAAGCACCCT
Thy-Tau22_F_genotype ATGGCTGAGCCCCGCCAGGAG
Thy-Tau22_R_genotype TGGAGGTTCACCAGAGCTGGG
HDAC6_F_genotype GCCAGGGATTGGGTTAACACAAGCTAG
HDAC6_R_genotype CACACGCACGCACACCAGATAAACAC
NEO_F_genotype AGGATCTCCTGTCATCTCACCTTGCTCCTG
NEO_R_genotype AAGAACTCGTCAAGAAGGCGATAGAAGGCG
AnxA2_Mali7_sybr_F AGAGAAGGACCAAAAAGGAGC
AnxA2_Mali7_sybr_R CATACTGGGCAGGTGTCTTC
Material and Methods
3.1.5. Intracranial Injections 
To inject adeno-associated viral particles (AAV) into the dentate gyrus (DG) of 3 month old male 
mice, animals were anesthetized (Ketamin 20 µl, Xylarem 16 µl, NaCl 0.9 % 164 µl; 100µl/10g) 
and subsequently treated with analgesic (Buprenorphine 30 µl, NaCl 0.9 % 470 µl; 50µl/animal). 
Animals were then fixated in a 3-point stereotaxic setup and cranial skin was removed in a 
longitudinal incision to expose the skull. Holes for injection were drilled bilateral symmetrically 
relative to bregma (mediolateral: +/- 1mm; anteroposterior: -1.75mm). For injection glass 
capillaries were prepared by filling with mineral oil to reduce gas compression during injection 
and washed with 2100 nl PBS before virus uptake. 2000 nl of virus sample were loaded and 
capillaries at 0.01mm/s introduced 2mm on the dorsoventral axis into brain tissue until DG was 
reached. The tissue was given 3 min to fully invaginate the capillary before injection of 900 nl 
virus solution at 250 nl/min. Afterwards, the solution was given 3 min to diffuse into the tissue 
before retracting the capillary at 0.01  mm/s. This procedure was repeated for the other 
hemisphere before sealing the cranial skin with polyacryl glue. Anti-Sedative (Antipemazol 
10  µl, NaCl 0.9% 190  µl; 50µl/10g) was injected at least 45 min post sedation to terminate 
anaesthesia.
Table 3.2: Genotyping PCR Protocol Tau22              Table 3.3: Genotyping PCR HDAC6
Step Temp. (ºC) Time (min) Step Temp. (ºC) Time (min)
Denaturing 95 3 Denaturing 95 3
Amplification 
(x30)
95 1
Amplification 
(x35)
95 1
58.7 1 58.6 1
72 1 72 1
Elongation 72 10 Elongation 72 10
Table 3.4: Genotyping PCR NEO casette Table 3.5: Genotyping PCR AnxA2
Step Temp. (ºC) Time (min) Step Temp. (ºC) Time
Denaturing 95 3 Denaturing 95 2 min
Amplification 
(x35)
95 1
Amplification 
(x30)
95 30 s
60.4 1 58.6 30 s
72 1 72 30 s
Elongation 72 10 Elongation 72 10
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3.2. Behaviour 
3.2.1. Behavioural testing 
Behavioural phenotypes were assessed using a battery of tests comprising a subset of 
assessments listed below and conducted within tight temporal boundaries. If not stated 
otherwise, movement was recorded using a camera setup and Videomot 2 software (TSE). 
Plastic surfaces were thoroughly cleansed with 70 % EtOH to remove olfactory traces after each 
subject. All tests were performed serially for individual mice. 
3.2.1.1. Open field test 
To asses motility and anxiety like behaviour, animals were tested in the Open Field (Hall 1934). 
In brief, Animals were individually placed in a uniform, grey arena (40 x 50 x 40 cm) and allowed 
to explore the environment for 3 min. For analysis the Arena was virtually divided into 16 
identical squares of which presence in the central 4 were scored as exposed and compared 
relative to quadrants proximate to the wall. Prolonged time spent in exposed areas was 
considered as a readout for reduced anxiety given comparable motility.
3.2.1.2. Novel object recognition 
To test for both long term memory (LTM) and short term memory (STM) (Ennaceur and 
Delacour 1988), animals were subjected to the Novel Object Recognition test on the day after 
the open field test. Subjects were placed in the same grey open filed arena (40 x 50 x 40 cm) as 
used for the open field test. This time containing 2 identical objects 12 cm away from proximate 
walls for habituation and allowed to explore freely for 3 min. Subsequently, animals were 
returned to the home cage and allowed to rest for 5 min. To test STM one of two identical 
objects was exchanged with a novel object of different shape, texture and colour. Now the 
mouse was returned to the arena and again allowed to freely explore both objects. Increased 
percent of time spent at the novel object was taken as a indicator for STM. Analogous LTM was 
tested 24h after STM by subjecting the individual to another novel object. Here, too the 
increased percent of time spent at the novel object was taken as an indicator for LTM. Number 
and duration of investigations at either of the objects was scored manually during the trails 
using Videomot 2.
3.2.1.3. Elevated plus maze 
Anxiety like behaviour was assessed in the Elevated plus maze (Pellow, Chopin et al. 1985), a 
uniformly grey cross maze with two open and two walled (closed) arms 10 x 40 cm each with 
walls 20 cm high. Individual animals were placed in the centre of the elevated plus maze, nose 
facing the closed arm opposite of the operator. Time spent in open arms and centre was scored 
as time exposed and taken as a measure of anxiety relative to time spent in walled arms.
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3.2.1.4. Morris water maze 
To assess hippocampus dependent spatial learning and memory, the Morris water maze was 
conducted (Sutherland and Rudy 1988). Animals were placed into a pool (1.2m diameter) with 
opaque water (22 ºC) and four distinct optical cues (one in each quadrant). The target quadrant 
contained a clear plastic platform at a fixed location submersed by 0.5 cm, hence invisible to 
tested animals. Each trial started when the subject was placed at one of the randomly 
alternating visual cues. It ended either if the animal rested 2 s on the target platform or after 1 
min if the animal failed to complete the task. In the latter case the animal was guided to the 
platform and allowed to rest for 30s. This procedure was repeated four times per day, starting at 
a different visual cue at each trial. Animals were trained until the first cohort robustly displayed 
an average latency to find the hidden platform (escape latency) of less than 20s. Then, on the 
subsequent day, a probe test was performed, during which the submersed platform was 
removed. The probe test started when the animal was placed in the quadrant distal to the 
former platform area. The animal was then allowed to explore the maze freely for 1 min after 
which it was removed from the maze and returned to the home cage.
Time spent in the target quadrant, crossings of the platform area and search strategies were 
taken as a read out for spatial memory. Alternatively, training was prematurely terminated, if 
none of the cohorts showed clear indications of learning after 8 days. 
3.2.1.5. Barnes maze 
To further test for hippocampus dependent spatial memory, Barnes maze was employed 
(Barnes 1979). Besides the advantage of an additional spatial memory test, the barnes maze is 
less stressful to the animal allowing the detection of more subtle phenotypes, given a certain 
curiosity and motility (Whishaw and Tomie 1996). The barnes maze is composed of a white 
circular PVC plate (diameter 92 cm) with 20 holes located around the rim and 4 distinct visual 
cues, one located at each quadrant. The central hole in the quadrant distal to the operator entry 
site contained an escape cage, while maintaining identical appearance compared to other 
holes. To increase aversion of the maze and hence increase motivation to find the escape cage, 
the maze was brightly lit using 4x60W Light bulbs and 2xLED flood lights (30W) positioned 
above the maze.
The Training protocol was adapted from Attar and colleges (Attar, Liu et al. 2013) with several 
adjustments. In brief, the protocol is separated into three stages habituation, training, and 
testing. On day one animals were placed in the centre of the maze into a clear PVC tube (15cm 
diameter) for 15s to habituate the mouse to the environment. Then the subject was slowly 
guided to the target hole by gently moving the tube. The animal was allowed to explore the 
target for 3 min. If it did not enter the escape cage, it was gently nudged with the PVC tube to 
enter. Once in the escape cage the subject was allowed to rest for 1 min before returning to 
home cage. On consecutive days 2-4 individuals were placed in the centre and covered with a 
grey cylinder for 15s to randomise start orientation. Subsequently, mice were allowed to explore 
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the maze for 2 min. If the target was not entered, mice were again nudged to do so. After 
entering target they were allowed to rest for 1 min. On day 5 a probe test was performed during 
which the escape cage was removed. Mice were again placed into a grey cylinder in the centre 
of the maze for 15s. After release subjects were given 2 min to explore the maze. Time spent in 
target area or target quadrant was evaluated and taken as a read out for spatial memory as 
indicated for each experiment. If one of the tested cohorts did not show significantly increased 
time spent in target, the training was prolonged for additional 4 training days and one 
subsequent probe test. 
3.2.1.6. RotaRod 
To assess motor coordination and balance, mice were subjected to the TSE RotaRod test. 
Subjects were placed on a rotatable rubber coated bar above a metal grid. During training the 
bar rotated at 5 rpm for 180 s. If the mouse fell off it was placed back for the time remaining. 
During motor test animals were placed on the rod, which gradually accelerated during 180 s 
from 5 to 40  rpm. Latency to fall was measured using TSE RotaRod Advanced software and 
indicative of motor function.
3.2.1.7. Forced swim test 
To asses despair the forced swim test was used (Porsolt, Le Pichon et al. 1977). Animals were 
placed for 3 min into a 5 L beaker filled with 20 cm water to avoid that subjects could touch the 
ground. Animals were recorded in 1080p (iPhone 6s, Apple) and floating subsequently manually 
scored as the absence of movement other than stabilisation strokes using Quicktime (Apple) 
and Stopwatch (Apple). 
3.2.1.8. Contextual fear conditioning 
Classical pavlovian conditioning was performed in a NIR Video Fear Conditioning system (Med 
Associates Inc.). The system features a solid, sound proofed chamber (58 cm x 30 cm × 27 cm, 
length x width x height) with lighting (12V) and white noise generator. A clear plexiglas cage (35 
cm × 20 cm × 20 cm, length x width x height) featuring an electrifiable, removable grid floor is 
located inside the chamber. Lighting, noise and electrical stimulus were automatically controlled 
by the NIR Video Fear Conditioning software according to operator settings. Analogous to the 
classical pavlovian paradigm the conditioned stimulus is presented as cage environment (CS) 
and the unconditioned stimulus (US) as foot shock. On the first day (training) animals were 
allowed to freely explore the camber for 3 min, while white noise was played. An electrical foot 
shock (0.5 mA) was applied for the last 2 s of each trial. On the second day (recall) animals 
were again allowed to freely explore the chamber for 3 min without the application of a foot 
shock. Light was switched on and animals were recorded during the entire trial. Behaviour was 
assessed in linear analysis mode and considered freezing if the Motion Index was below a 
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threshold of 18 for at least 30 frames. Scoring was done automatically with the NIR Video Fear 
Conditioning software provided with the system.
3.2.2. Intracardial perfusion 
Animals were anaesthetised with a lethal dose of Ketamin/Xylazine (Ketamin 20 µl, Xylarem 
150 µl, NaCl 0.9 % 30 µl, 100 µl per 10 g body weight). After being reflex irresponsive subjects 
were fixated with needles on a dissection mat. The ribcage was opened and heart was exposed. 
Now the right ventricle was punctured, while the left ventricle was perfused with ice cold PBS 
using a peristaltic pump at 5 rpm for 6 min (Heidolph, Pupmdrive 5201). Subsequently, PBS was 
exchanged for ice cold 4 % PFA in PBS which was injected for additional 5 min. After perfusion 
the brain was extracted and post-fixed in 4 % PFA for 24h. For cryo- protection the brain was 
subjected to 10 %, 20 %, and 30 % Sucrose/PBS for 24 h each and subsequently embedded in 
Jung tissue freezing medium (Leica Microsystems) for cryosectioning at 30 µm in a Leica CM 
1850 UV cryostat at -20 °C.
3.3. Molecular cloning 
3.3.1. Molecular cloning of AnxA2 
To generate an AAV based overexpression construct AnxA2 was amplified from mouse cDNA 
using custom made AnxA2_perfectmatch primer (sequence see Table 3.1) and Fusion High-
Fidelity DNA Polymerase (NEB) according to manufacturer's protocol. The PCR product was 
purified by 0.6% agar (Roth) gel-electrophoresis in TAE-buffer (40  mM Tris-acetate, 1  mM 
EDTA) followed by extraction with QIAquick Gel Extraction Kit (Qiagen) and ligated into pGEM-T 
easy (Promega) according to manufacturer’s protocol. The plasmid was then transformed into 
Sure2 cells for Plasmid preparation. The resulting Plasmid DNA was subjected to PCR using 
AnxA2_Nhe1_F and AnxA2_BamH1_R (sequence see Table 3.1) to add feasible restriction 
sites and mutate the stop codon to be able to generate fusion proteins. The PCR product was 
purified as previously described and digested with BamHI-HF and Nhe1-HF (NEB) at 37 ºC for 
15min and inactivated at 80  ºC for 20min. The digested construct was ligated into an 
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Primer R
AnxA2 496..1581
START 548..550
Primer F
aav-6P-AnxA2_NheIBamHI
6372 bp
skipped STOP 1565..1567
EGFP 1601..2320
qPCR EGFP Primer F
qPCR EGFP Primer R
Figure 3.2: Illustration of AAV-6P-
AnxA2GFP-NoTB-SEWB. 
Notably, the AnxA2 overexpression 
construct features a skipped STOP codon 
to generate the GFP fusion protein. 
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accordingly digested AAV-6P-GFP-NoTB-SEWB, a custom made AAV plasmid featuring the 
synapsin promotor and GFP sequence. Constructs were ligated using T4 DNA Ligase (NEB) 
according to manufacturer's protocol. The ligation product (AAV-6P-AnxA2/GFP-NoTB-SEWB) 
was transformed in Sure2 cells, amplified, and validated by restriction digest and Sanger 
sequencing (economy barcode run, SeqLab. The resulting in the plasmid is illustrated in Figure 
3.2.
3.3.2. Bacterial transformation 
For transformation of plasmids a 20 µl aliquot of SURE 2 Supercompetent Cells (Agilent) was 
thawed on ice, and transformed according to manufacturer's guidelines. In brief, bacteria were 
supplied with 0.1-50  ng of desired plasmid and incubated for 30 min on ice. Subsequently, 
bacteria were heat pulsed at 42 ºC in a ThermoMixer (Eppendorf) for exactly 30 s. Immediately 
afterwards, the sample was transferred to ice and chilled for 2 min. Then 500 µl of 37 ºC LB-
broth were added and incubated at 37 °C for 1 hour while shaking at 250 rpm. Then 200 µl and 
20 µl (high and low density plating) of the transformation mixture were applied to separate LB 
agar (AppliChem) plates containing Ampicillin as antibiotic and dispersed using glass beads. 
Colony growth was checked after plates were incubated at 37 ºC O/N.
3.3.3. Plasmid isolation 
After O/N incubation of bacteria on LB-Agar+Ampicillin colonies were picked using 10 µl pipette 
tips. Each colony was incubated o/n at 37 ºC and 160 rpm in 8 ml LB-broth containing Ampicillin 
as antibiotic in a New Brunswick Innova 44 incubator. Bacteria were harvested at 4000 g at 4 ºC 
for 10 min, then plasmids were isolated using QIAprep Spin Miniprep Kit (Qiagen) following the 
manufacturer's instructions. Plasmid sequences were first validated by restriction digest and 
secondly by Sanger sequencing (economy barcode run, SeqLab). After successful plasmid 
validation, large over-night cultures were set up. To generate sufficient amounts for viral 
production 2-8 L of LB-broth (AppliChem) plus Ampicillin were incubated o/n at 37  ºC and 
160 rpm in a New Brunswick Innova 44 incubator. Subsequently, cultures were precipitated at 
6000g for 15 min at 4 ºC in a RC6 (Sorvall). Plasmids were isolated using NucleoBond® Xtra 
Midi Kit (Macherey-Nagel) following the manufacturer's instructions. Isolated plasmids were 
again validated by restriction digest and Sanger sequencing.
3.3.4. Adeno-associated-viral particle (AAV) production 
Adeno-associated virus preparation was adapted from McClure and colleagues (McClure, Cole 
et al. 2011) with several adjustments. Required Plasmids (pRV1, pH21, pFΔ6) were amplified 
and extracted by MidiPrep as described before and digested for sequence validation 
(pRV1(XbaI) 7.5 kb, 3.8 kb; pH21(EcoRI) 4.5 kb, 2.8 kb, 0.2 kb; pFΔ6 (HindIII) 5.5 kb, 3 kb, 
3 kb, 2.3 kb,1.5 kb). For viral particle assembly five HEK293T 14.5 cm dishes were grown to 
70-80 % confluence in standard DMEM with low glucose containing 10 % foetal bovine serum 
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(Gibco) and 100 U/ml penicillin/ 100  μg/ml streptomycin. 3 hours before transfection medium 
was removed and replaced with fresh medium. For one batch (5, 14.5 cm dishes) 62.5 μg AAV 
plasmid, 125 μg pFΔ6, 31.25 μg pRV1, 31.25 μg pH21 and 1650 μl 2.5 M CaCl2 were mixed in 
12 ml dH2O and sterile filtered. Whilst vortexing 13 ml 2x HEPES (250  mM NaCl, 1.5mM 
Na2HPO4, 50 mM HEPES, pH 7.05) were quickly added to the solution and heavily vortexed. 
The solution was allowed to stand for 2 min until a white precipitate started to form. Now 5 ml of 
the transfection solution was added to each 14.5 cm culture dish. Depending on expression 
cells were incubated for 48 h - 72 h. For harvest, the supernatant was removed from plates. 
Cells were then washed and scraped from the dish. Following, the samples were centrifuged for 
5 min at 1000 g, 4 ºC and resuspended in lysis buffer (20 mM Tris, 150 mM NaCl, pH 8.0, 0.5 % 
NaDOC, Benzonase). The slurry was then incubated for 30  min at 37  ºC and occasional 
vigorous shaking. Reaction was quenched by adding 21.63 mg/ml NaCl and incubating at 56 ºC 
for 30 min. After one freeze thaw cycle (-80  ºC freezing O/N, 37ºC thawing) the sample was 
centrifuged for 30  min at 4000  g and subsequently layered onto a discontinuous Iodixanol 
(Sigma) gradient (top to bottom 6.5 ml, 15  %; 4 ml, 25  %; 3 ml, 40  %; 3 ml, 54  %) in a 
ultracentrifuge tube. To avoid collapse of the ultracentrifuge tubes, any air volume was filled with 
with PBS-MK. Then viral preparation was centrifuged for 1.5h at 60.000  rpm (rotor: Ti 70, 
Beckmann). Subsequently the 40/54 % interphase was removed, diluted to 10 ml using PBS-
MK and concentrated in an Amicon 100K (Millipore) at 2000g and RT. The samples were 
centrifuged repeatedly for 5 min until 500 µl resided in the concentration unit . The concentration 
was repeated 3 times by refilling the concentrator to 10 ml with PBS-MK. Subsequently, the viral 
solution was sterile filtered and stored at 4ºC and -80 ºC for longterm storage respectively.
3.4. Cell culture 
3.4.1. Dissociated primary neuronal culture 
Prior to dissection culture dishes were coated with Poly-D-lysine (Sigma) 0.5 mg/ml O/N at RT 
or alternatively at 37  ºC for 1 h. Plates were then washed 3 times with ddH2O. Pregnant 
females were sacrificed at E17.5, embryos were extracted, anaesthetised in ice cold PBS, and 
immediately decapitated. Depending on experimental approach hippocampi or cortices were 
dissected and transferred into 15 ml falcon on ice cold PBS. After dissection ice cold PBS was 
removed and 4.5 ml warm PBS and 500 µl with 2.5 % trypsin were added to the tissue under a 
sterile bench and incubated in a water bath on 37 ºC for 13 min for digestion. Subsequently, 5 
ml processing medium (PM) (DMEM, 10 % FBS, 1 % P/S) were added to quench the digestion. 
The sample was then supplemented with 10 µl DNAse to degrade released DNA, the tube was 
inverted once and the tissue allowed to sediment to the bottom before removal of medium. The 
digested tissue was washed three times with PM without disturbing the tissue. After washing, 
medium was removed and tissue homogenised in 1 ml PM by carefully pipetting the chunks up 
and down in a 1 ml pipette (5-10 strokes). Cells were then precipitated at 200 g, 37 ºC for 5 min 
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and resuspended in maintenance medium (MM) (Neurobasal, Gibco; 2 % B27, Gibco; 1 % 
Penicillin/Streptomycin, AppliChem; 1 % GlutaMAX,Gibco). Subsequently, neurons were plated 
at 6,84x104 cells/cm2 (hippocampal) or 15.3x104 cells/cm2 (cortical). Cells were maintained in a 
CO2 cell culture incubator (New Brunswick/Binder) and 30  % medium were changed twice 
weekly.
3.4.2.Chemical neuronal stimulation 
Neuronal cultures were stimulated on day in vitro (DIV) 10 with a final concentration of 20 mM 
KCl, 50  µM NMDA or 200  µM H2O2 in equal volumes to mimic specific physiological 
challenges. Stimulation was applied for 10 min, then medium was removed and cells gently 
washed with DPBS. Immediately after washing conditioned medium was applied and cells 
incubated for an additional 10 min for recovery. Afterwards, medium was removed and plates 
washed once with DPBS, then 100  µl TRIzol (Thermo Fisher) were added and the cells 
harvested and processed as described in “3.5.6.RNA isolation”.
3.4.3. Dissociated primary neuronal SILAC culture 
To establish stable isotope labelling with amino acids in cell culture (SILAC) in post mitotic 
primary neurons neuronal cultures were produced as described in “3.4.1 Dissociated primary 
neuronal culture”. Dissociated primary neuronal culture. Only cortical neurons were seeded at a 
density of 15.3x104 cells/cm2 in 14.5cm culture dishes. Additionally, MM was replaced by SILAC 
medium containing either light or heavy Arginine and Lysine (L-Lysine-13C6,15N2, L-
Arginine-13C6,15N4; Euroisotop) as follows SILAC F12:DMEM (Pierce), 0.388 mM L-Arginine, 
0.798 mM L-Lysine , 2 % B27, 1 % Penicillin/Streptomycin, 1 % GlutaMAX. To achieve sufficient 
labelling 22x106 cortical neurons were plated per 14.5 cm dish in 20 ml of SILAC medium. After 
3 days, 6 ml of medium were replaced with 6 ml of fresh SILAC medium. This was repeated 
every 2 days until DIV10 after which labelled nuclear protein lysates were isolated (cf. “3.5.1 
SILAC nuclear protein isolation”).
3.4.4. Heterogenous primary neuronal cultures 
After preparing a dissociated hippocampal cell suspension from E17.5 embryos as described 
above, cells were diluted to 10 ml PM and then precipitated at 200 g at 37 ºC for 5 min. Cells 
were then resuspended in 500 µl Hibernate E (Gibco) with 2 % B27 and 1 % P/S and split 
depending on number of infection constructs into 1.5 ml centrifuge cups. 20 µl of concentrated 
AAVs carrying the desired construct were added to each cell aliquot. Infection samples were 
then incubated for 2h at 70 rpm, 37 ºC in shaking incubator. Afterwards, cells were resuspended 
in 1  ml MM and further diluted in 10  ml MM, then centrifuged 5  min at 300  g and 37  ºC. 
Subsequently, cells were washed twice in 10 ml MM. The supernatant was removed and cells 
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diluted in MM containing 100 µM heparin (sigma) to avoid AAV propagation (Mietzsch, Broecker 
et al. 2014) and plated at 6,8x104 cells/cm2 in 6 well dishes, as illustrated in figure 3.3.
3.4.5. Optogenetic stimulation 
Neurons were either infected with AAV1/2-ChiEF-tdTomato for optogenetic stimulation (primary 
stimulated neurons) or with AAV1/2-FOS-eYFP as activity reporter (secondary stimulated 
neurons). Optogenetic stimulation was performed on DIV10, pulse duration and inter stimulation 
intervals (ISI) were adapted from to Schoenenberger and colleagues (Schoenenberger, Gerosa 
et al. 2009) using a custom built stimulator. In brief, the stimulation was conducted inside a 
Galaxy 170 R cell culture incubator (New Brunswick). Culture dishes containing neurons were 
placed on the stimulation unit 30  min prior to stimulation and then left to rest to avoid 
mechanical stimulation. The protocol was then initiated using a remote control. During the 
stimulation 300  ms pulses alternated with 1 s ISI for 10 repetitions if not stated otherwise. 
Neurons were allowed to rest for 30  min before further preparation. AAV-oChIEF-tdTomato 
plasmid was a gift from Roger Tsien (Addgene plasmid # 50977), pOTTC476 - pAAV c-fos eYFP 
was a gift from Brandon Harvey (Addgene plasmid # 47907).
3.4.6. Single cell sorting 
After optogenetic stimulation (see Optogenetic stimulation) medium was removed carefully and 
cells wash once with 37 ºC DPBS. Subsequently, 200 µl Neuron Isolation Enzyme (with papain) 
from Pierce™ Primary Cell Isolation Kit (Thermo) was added and incubated for 5 min at 37 ºC. 
The dish was then put on ice, 1 ml ice cold sorting buffer (DPBS, 2 % FBS) was added and cells 
transferred into 14  ml centrifuge tube. Suspension was pipetted 5 times up and down to 
separate the cells and filled up to 10 ml with sorting buffer. Neurons were precipitated for 5 min 
at 4  ºC, 200g. Afterwards, the supernatant was removed and cells carefully resuspended in 
10 ml sorting buffer. This washing step was repeated once before re-suspending cells in 500 µl 
sorting buffer. Before sorting viability was assessed for 10µl of the suspension using Trypan 
blue in a 1:1 dilution (Sigma). Now neurons were sorted directly into lysis buffer to avoid 
transcriptional changes. Sorting was based on the ectopically expressed fluorescence tag 
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resuspend cells
split sample
add AAV
incubate cells 
with AAV
merge cells from both 
infections in desired ratio
Figure 3.3: Production of heterogenous PNC. 
Cells are resuspended from pellet split into different tubes and infected with the desired construct, 
delivered by an AAV. Finally, the infected cells are seeded in desired ratios.
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introduced by AAV infection (see Heterogenous primary neuronal cultures) using a FACS ARIA 
III (BD Bioscience). If not stated otherwise, samples were kept at 4 ºC.
3.4.7. Anle138b treatment 
Primary hippocampal cultures were produced as mentioned beforehand. On DIV9 cells were 
treated either with 1 µM anle138b or 10 µM Aß1-40 and incubated for 24 h in a CO2 cell culture 
incubator (New Brunswick/Binder). Subsequently, anle138b pre-treated cultures were 
supplemented with 10 µM Aß1-40, while Aß1-40 pre-treated cultures were supplemented with 1 
µM anle138b. After 48 hours the cultures were subjected to either CyQuant or MTT assay.
3.4.8. JS28 treatment 
JS28 was a kind gift from Johanna Senger and Prof. Dr. Manfred Jung, from the 
Pharmazeutische und Medizinische Chemie of the Albert-Ludwigs-Universität Freiburg. For 
treatment the compound was dissolved in ddH2O and applied at the indicated concentrations on 
DIV10. After 24 h cultures were harvested and protein extracted according to protocol (cf. 
“3.5.2. Total protein extraction") and tubular acetylation quantified using Western blot (cf. “3.5.5. 
Western blotting”) and anti-acetylated Tubulin antibody (T7451, Sigma Aldrich).
3.4.9. Metabolic rate assay 
Metabolic rate of neurons in cell culture was assayed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich) as adapted from Mosmann (Mosmann 1983). 
The assay is based on the metabolic conversion of MTT (bright yellow) to its formazan (purple), 
i.e. for a high metabolic rate the absorption at 570 nm is increased and vice versa. MTT was 
added to cell culture at a final concentration of 0.5 mg/ml and subsequently incubated for 1 h at 
37  ºC. Then MTT containing medium was removed and the resulted formazan dissolved in 
DMSO by shaking for 15  min while protected from light. Absorption at 570  nm was then 
assessed using a Infinite 200 PRO (Tecan) or FLUOstar Omega (BMG Labtech). Results were 
extracted using Excel (Microsoft) and illustrated using Prism 7 (GraphPad) statistical 
significance was tested using t-test for condition comparison or one-way ANOVA for group 
comparisons.
3.4.10. Membrane integrity assay 
To asses membrane integrity of neurons in cell culture CyQUANT Direct assay (Thermo Fisher) 
was conducted according to manufacturer's instructions. The kit is composed of two stains, the 
first being a fluorescent stain for DNA which penetrates membranes. The second dye absorbs 
fluorescent activity of dye one, however is not able to penetrate intact but only leaky membrane. 
After 30min incubation fluorescence was measured with a Tecan infinite 200 for Aß 1-40 or 
FLUOstar Omega (BMG Labtech) for Aß1-42 (-D,-L) and aSynuclein. Results were extracted 
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and analysed using Excel (Microsoft) and displayed using Prism 7 (GraphPad) statistical 
significance was tested using t-test for condition comparison or one-way ANOVA for group 
comparisons.
3.5. Molecular Analysis 
3.5.1. In-silico oligo nucleotide design 
Oligonucleotides for cloning, PCR, and Sybr Green qPCR were designed using ApE v2.0.47 
(Wayne Davis W. http://biologylabs.utah.edu/jorgensen/wayned/ape/) for target assembly. 
OligoCalc was used to calculate melting Temperature (http://biotools.nubic.northwestern.edu/
OligoCalc.html) and in-silicoPCR (Kent, J. http://genome.ucsc.edu/cgi-bin/hgPcr) was used to 
control for off-targets in case of primers. Alternatively, for qPCR the UPL Assay Design Centre 
(Roche) (https://lifescience.roche.com/en_de/brands/universal-probe-library.html) was used to 
design UPL qPCR Primers. All oligo nucleotides were synthesised by Sigma Aldrich.
3.5.2. Total protein extraction 
Total protein was extracted from tissue by homogenisation with a BeadRuptor 24 (Onmi 
International) in 2 tissue volumes Tx Buffer+SDS ( (0.2 M Tris base, 1.5 M NaCl, 0.05 % Tween 
20, 1 % SDS). Samples were then incubated for 10 min on rotating wheel at 4 ºC, 20 rpm and 
subsequently sent to Bioruptor Plus (Diagenode) 15min (30sec on/off cycle, 4  ºC). Samples 
were now centrifuged for 10  min at 10,000  g and 4  ºC to precipitate residual debris. The 
supernatant containing total protein was then transferred into a new tube.
3.5.3. Nuclear protein enrichment 
For nuclear Protein enrichment tissue was homogenised in a BeadRuptor 24 (Onmi 
International) with 2 tissue volumes Tx Buffer (0.2 M Tris base, 1.5 M NaCl, 0.05 % Tween 20) 
then put on a rotating wheel for 10 min at 4 ºC to allow swelling of the cells and subsequently 
centrifuged for 10 min at 2,000 rpm, 4 ºC. The supernatant was then transferred to a new tube 
(cytosolic fraction) and the pellet washed once in Tx buffer. After washing, supernatant was 
discarded, 1 tissue volume Tx Buffer+1  % SDS added, and samples incubated on rotating 
wheel for 5  min at 20  rpm, 4 ºC. Subsequently, samples were sent to Bioruptor Plus 
(Diagenode) for 15min (30 sec on/off cycle, 4 ºC) and then centrifuged for 10 min at 10,000 g, 4 
ºC to remove residual debris. Afterwards, the supernatant was transferred into a fresh tube 
(nuclear enriched protein). 
3.5.4. Sub-cellular fractionation 
To understand the sub cellular localisation of proteins, cells and tissue were separated into 
membrane, cytoplasmatic, cytoskeleton, nuclear, and chromatin bound fraction. To do so, 
protein extraction was carried out using the Subcellular Protein Fractionation Kit for Cultured 
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Cells (Thermo scientific) according to manufacturer's instructions. Procedure deviated from 
protocol if the kit was used to extract protein from tissue. Here, samples were first homogenised 
in 300  µl PBS+Proteinase inhibitors (Roche) following centrifugation at 2000  g, 4  ºC. The 
supernatant was discarded and started from step 1 according to manufacturer's protocol.
3.5.1. SILAC nuclear protein isolation 
To isolate nuclear protein in a low detergent environment cells were first rinsed twice in ice cold 
DPBS (Pan Biotech) then scraped off the dish in 2 ml fresh DPBS into a protein LoBind micro 
centrifuge tube (Eppendorf). Cell samples were the centrifuged for 5 min at 700 g on 4 ºC and 
the supernatant discarded. Then Packed cell volume was estimated (PCV) and 5x PCV lysis 
buffer (10 mM HEPES, pH 7.9 1.5 mM MgCl2, 10 mM KCl2, 0 .3 M Sucrose,1 mM DTT, 1x 
Protease Inhibitor Cocktail, 0.15 μL TSA, 10 μL NAD) were added. The cell pellet was then 
gently resuspended to avoid foam formation and then incubated for 15 min on 4 ºC to allow the 
cells to swell. Afterwards samples were centrifuged for 5 min at 420g on 4 ºC after which the 
supernatant was removed and the pellet resuspended in 2x PCV fresh lysis buffer. Cells were 
now homogenised using a narrow-gauge No. 27 (B.Braun) hypodermic needle in 15 strokes. 
Subsequently, lysis was checked under the microscope using trypan blue (Sigma) as stain. If 
homogenisation was not satisfactory the samples were given an additional 5 strokes until lysed. 
Samples were then centrifuged for 20 min at 10000 g on 4 ºC and the supernatant containing 
the cytosolic fraction transferred to a new protein LoBind tube. The residual nucleic pellet was 
resuspended in 2/3 x PCV extraction buffer ( 20 mM HEPES, pH 7.9 1.5 mM MgCl2, 0.42 M 
NaCl, 0.2 mM EDTA, 25% (v/v) Glycerol, 0.7 mM DTT, 1x Protease Inhibitor Cocktail, 0.23 μL 
TSA, 15 μL NAD) using a narrow-gauge No. 27 (B.Braun) hypodermic needle in 10 strokes. 
Samples were then gently shook for 30 min at 4  ºC and afterwards centrifuged for 5 min at 
21000  g on 4  ºC. The resulting supernatant containing soluble chromatin fraction was 
transferred to a fresh tube and stored at -80 ºC until used for H4K12ac peptide pulldown and 
subsequent liquid-chromatography mass-spectrometry/mass-spectrometry (LC MS/MS). 
3.5.2. Immunohistochemistry 
To stain for specific protein epitopes in brain tissue, cryo-sections (cf. “3.2.2. Intracardial 
perfusion”) were washed 3x 5 min in PBS to remove cryo-medium. The sections were then 
permeabilised by incubating twice for 10 min RT in 0.1 % Triton-X in PBS and subsequently 
blocked for 60  min in blocking buffer (PBS, 0.3  % TritonX and 5  % goat serum). Now the 
primary antibody anti-AnxA2 (1:200, Abcam) was added to fresh blocking buffer and incubated 
with samples at 4 ºC O/N. The next day samples were washed three times for 10 min in PBS 
with 0.2 % TritonX and 1 % goat serum. The secondary antibody (Alexa488 anti-Rb) was then 
applied in 1:1000 dilution to the samples in blocking buffer for 2  h at RT in the dark. Then 
sections were washed three times in PBS, subsequently stained with DAPI (1:10000 in PBS) for 
30 min, washed again twice in PBS and mounted in Mowiol (Roth).
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3.5.3. Immunocytochemistry 
To perform epitope based antibody staining in cell culture, neuronal cells were seeded on glass 
coverslips (15 mm, Thermo Fisher) which were previously treated with nitric acid (Roth) O/N, 
washed 3 times with H2O and stored in 70% EtOH until use. Before seeding, coverslips were 
coated O/N with 0.5 mg/ml Poly-D-lysine (Sigma), while rocking. On DIV10 cells were treated as 
described, then medium was removed and cells gently washed with 37 ºC DPBS (Pan-Biotech). 
Immediately after washing, 4% paraformaldehyde (PFA, Roth) was added and samples 
incubated 10 min at RT for fixation. Subsequently, fixative was discarded and cells gently 
washed with DPBS to remove residual PFA. Slides were then permeabilised by incubating for 
10 min at RT in 0.1 % Triton-X in PBS and subsequently blocked for 60 min in blocking buffer 
(PBS, 0.3 % TritonX and 5 % goat serum). Then the primary antibody was added in fresh 
blocking buffer (1:200 AnxA2, 1:1000 cFOS, 1:500 ɣH2Ax) and incubated at 4 ºC O/N. The next 
day slides were washed three times for 10 min in PBS with 0.2 % TritonX and 1 % goat serum. 
The secondary antibody (Alexa488 anti-Rb, Alexa633 anti-mM) was then applied 1:1000 to the 
samples in blocking buffer 2h at RT in the dark. Slides were then mounted using Vectrashield 
with DAPI (Vector Laboratories).
3.5.4. Confocal imaging 
Confocal microscopy was performed on a ZEISS LSM 710 (Zeiss) 5x or 63x oil objective. Image 
acquisition was done using ZEN lite (ZEISS). 
3.5.5. Western blotting 
For detection of protein levels SDS-PAGE with nitrocellulose membrane transfer and 
immunostaining “Western blot” was performed. Protein samples (10-50 µg) containing Protein 
inhibitor cocktail (Roche) were diluted 1:5 in loading buffer (250 mM Tris·HCl, pH 6.8, 10 % 
SDS, 30 % Glycerol, 10 mM DTT, 0.05 % Bromophenol Blue) heated to 95  ºC for 5 min and 
then briefly chilled on ice. Subsequently, samples were either loaded on self casted 12  % 
polyacrylamide SDS-PAGE gels, or Mini-PROTEAN® TGX™ Precast Gels 4-20% (BioRad) for 
chromatin fractionation. Electrophoresis was done at 60 V for 45 min to allow stacking followed 
by 120 V for 1:30 h for separation. Proteins were then blotted on nitrocellulose using the Trans-
Blot® Turbo™ (BioRad) for semi dry blotting and 0.2 µm Nitrocellulose Transfer Packs (BioRad) 
for 30 min at 25 V and 1 A. Afterwards, the membrane was removed and stained in Ponceau 
red (0.2 % PonceauS, 3 % AcCH3) for 5 min to visualise transferred protein. The membrane 
was then cut as required for multiple immune staining. Membranes were then washed 5 min in 
TBS-T (136.89 mM NaCl, 2.68mM, 23.11 mM Tris base, 0.1%Tween, pH 7.4) and blocked in 
5  % BSA (Roth) TBS-T (0.2  µm filtered, Millex syringe filter, Millipore). After blocking, 
membranes were incubated with primary antibody (AnxA2, abcam 1:500; Gapdh 1:1000; Actin, 
Novus 1:1000; H3, abcam 1:1000) in 5 % BSA in TBS-T O/N. Following, membranes were 
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washed three times in TBS-T, stained with secondary antibodies IRDye 800CW Goat anti-
Rabbit or IRDye 680RD Goat anti-Mouse (1:10000) for 1h at RT. Afterwards membranes were 
washed twice in TBST before scanning on a Li-Cor Odyssey infrared fluorescence scanner. 
Quantification was done with Li-Cor Image studio Lite using median background subtraction, 
normalised to loading control in Microsoft Excel 2011, plotted and analysed in GraphPad using 
two-tailed t-test. 
3.5.6. RNA isolation 
For qPCR and next generation sequencing of cultured cells RNA was isolated using TRIzol 
(Invitrogen) according to vendors instructions with several alterations. In brief, cells were 
washed once after medium was removed and lysed in one volume (1xV) TRI Reagent (100 µl 
per 24 well dish, 200μl per 12 well dish, 400  μl per 6 well dish) while thorough vortexing. 
Alternatively brain samples were homogenised in 1xV TRI Reagent (100 µl ACC, 200 µl DG, or 
500 µl CA1, CA3, Ctx, Cb) in a BeadRuptor 24 (Onmi International), subsequently another 1xV 
was added. After lysis, samples were incubated for 5 min on RT before 0.2xV chloroform were 
added. Samples were vortexed thoroughly for 15 s and incubated at RT for 15 min before 
centrifugation at 12000 g for 15 min at 4 ºC. After centrifugation the aqueous phase containing 
the RNA was transferred into a fresh tube without any carryover of other phases. Now 0.5xV 
Isopropanol was added per sample, vortexed and incubated o/n at 4  ºC. On the next day 
samples were centrifuged at 12000 g for 30 min at 4 ºC, the supernatant was discarded and the 
resulting RNA pellet washed twice in 1xV 75 % EtOH and subsequently dried for 5 min at RT. 
Finally, RNA was resuspended in 30-50 µl PCR grade H2O (Sigma).
For next generation sequencing from tissue RNA was isolated with NucleoSpin® TriPrep Kit 
(Macherey-Nagel) according to manufacturer's instructions. Afterwards, RNA concentration was 
measured in NanoDrop 2000 (Thermo Scientific) and integrity checked using Bioanalyzer 
(Agilent) “Nano” lab-on-a-chip according to manufacturer's instructions.
3.5.7. cDNA generation 
cDNA was generated using Transcriptor First Strand cDNA Synthesis Kit (Roche) according to 
manufacturer's instructions. In brief reagents were composed as indicated in table 3.6 and 
incubated according to table 3.7.
3.5.8.
3.5.9. Quantitative real time PCR 
To quantify specific mRNA levels quantitative real time PCR (qPCR) was used. Primers were 
either designed using UPL Assay Design Centre (Roche) (https://lifescience.roche.com/en_de/
brands/universal-probe-library.html) or for Sybr Green assays custom designed as described in 
“3.5.1. in-silico oligo nucleotide design”. Samples were supplemented with primers and reagents 
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according to table 3.8 and 3.10 and measured in a LightCycler480 (Roche) with settings 
according to table 3.9 and 3.11.
Table 3.8: Sybr Green qPCR protocol                      Table 3.9: Sybr Green reagent composition
Step Temperature 
(ºC)
Time Reagents Volume 
(µl)
Denaturing 95 5 min PCR-H2O 1.9
Amplificatio
n (x45)
95 10 s Primer F (1:10) 0.3
65 15 s Primer R (1:10) 0.3
72 10 s SYBR Green MM 7.50
Melting 95 15 s cDNA (20ng) 5
67 30 s
95 Acquisitio
n
Cooling 40 10 s
Table 3.10: UPL Master Probe qPCR protocol                   Table 3.11: UPL reagent composition
Step Temperature 
(ºC)
Time Reagents Volume 
(µl)
Denaturing 95 ºC 5 min PCR-H2O 6.05
Amplificatio
n (x45)
95 ºC 10 s Primer F (1:10) 0.15
60 ºC 30 s Primer R (1:10) 0.15
72 ºC 1 s LC 480 MM 7.50
Cooling 40 ºC 30 s UPL Probe (10 
µM)
0.15
cDNA 1
Table 3.6: cDNA synthesis reagents                             Table 3.7: cDNA synthesis incubation
Reagent Volume (µl) Time 
(min)
Temperature (ºC)
Buffer 4 10 25
RNase inhibitor 0.5 30 55
dNTP 2 5 85
Reverse transcriptase 0.5
Random hexamer 
primers
2
RNA (1 µg) 11
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3.5.10. RNA sequencing 
To perform whole transcriptome analysis single-end RNA sequencing was performed from 
previously extracted RNA. Single- end libraries were prepared from 500 ng total RNA using the 
TruSeq RNA Library Preparation Kit v2 according to manufacturer's instructions. Library quality 
was validated using the Agilent 2100 Bioanalyzer (Agilent Technologies) using a RNA 6000 
Nano Kit, Nanodrop 8000 (Thermo Fisher), Qubit 2.0 fluorometer (Life technologies). 
Afterwards, the flow cell was clustered using TruSeq SR Cluster Kit v3-cBot-HS following 
Illuminas standard protocol.
3.5.11. Single cell sequencing
Single cell sequencing was performed by Massively Parallel Single-Cell RNA-Seq for Marker-
Free Decomposition of Tissues into Cell Types "MARSeq" according to Jaintin and colleagues 
with the exception of using 6 bases RMTs (Jaitin, Kenigsberg et al. 2014). Sequencing was 
conducted at DZNE core “Platform for Single Cell Genomics and Epigenomics”. In brief, after 
FACSorting and cell lysis RNA was reverse transcribed during which RMT and UMI-barcodes 
were added to the RNA polyA-tail. Subsequently transcripts were treated with Exonuclease I to 
remove nucleotides from single-stranded DNA, then samples were pooled and the second 
strand synthesised, after which samples were in vitro transcribed and treated with DNAse. RNA 
was then fragmented and library constructed.
3.5.12. RNAs sequencing data analysis 
For processing of sequencing data, a customised in-house software pipeline was used. 
Illuminas bcl2fastq 1.8.4 was used to convert base calls from BCL to FASTQ.   Along with base 
calling, adapter trimming, removal of Unique Molecular Identifiers (UMI) and demultiplexing 
were performed. Quality control of raw sequencing data was performed using FastQC 0.11.5 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were then mapped using 
STAR aligner 2.5.2b (Dobin, Davis et al. 2013) to the mouse transcriptome 
(Mus_musculus.GRCm38.86). Unmapped reads were re-mapped to the mouse genome 
(mm10). Default settings were used except mismatches were not allowed for the reads <19b, 
reads between 20b to 39b were allowed one mismatch, incrementing one mismatch for every 
additional 20b. Read counting on genes or exons was done using HTSeq 0.9.1 (htseq-count, 
intersection-non-empty) (HTSeq, http://www-huber.embl.de/users/anders/HTSeq) . 
3.5.13. Differential gene expression analysis 
To identify differentially expressed genes, identification and removal of unwanted variation 
(RUVs) was performed using RUVSeq 1.8.0 (Risso, Ngai et al. 2014). Then DESeq2 1.14.1 
(Anders, Reyes et al. 2012) was used for differential expression analysis. Transcripts were 
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considered differentially expressed with an adjusted (Benjamini-Hochberg) p-value<0.05 and 
basemean≧25. 
For functional analysis an additional fold-change cutoff was applied for in vivo data at 
log2FC±0.2 and for in vitro data log2FC±0.5. Venny (http://bioinfogp.cnb.csic.es/tools/venny/) 
was used to calculate gene set overlaps. WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/, 
(Zhang, Kirov et al. 2005)) was used for Gene Ontology (GO) functional analysis with categories 
being significantly enriched with p<0.05 and false discovery rate (FDR)<0.05 if not otherwise 
indicated. For relative expression (normalised reads per million, NPM) total normalised reads 
per sample were summed and divided by 1,000,000 which resulted in the scaling factor. 
Normalised read counts from gene of interest were then multiplied by scaling factor and divided 
by gene length. For illustration purposes values were additionally multiplied by 100.
3.5.14. Gene Set enrichment analysis 
Gene set enrichment was analysed using GSEA (Mootha, Lindgren et al. 2003, Subramanian, 
Tamayo et al. 2005). Normalised counts from DESeq2 were converted to GCT files then ranked 
and analysed with following settings, Chip platform: gseaftp.broadinstitute.org://pub/gsea/
annotations/GENE_SYMBOL.chip; number of permutations: 1000; permutation type: phenotype 
(in vivo) or GeneSet (in vitro).
3.5.15. Differential exon usage 
Identification of differentially expressed exons was done using DEXSeq 1.22 (Anders, Reyes et 
al. 2012) according to authors instructions using mm10 reference genome and exon counts 
from in-house pipeline. Functional analysis was performed for uniquely identified exons with an 
adjusted p-value<0.05 and log2FC±0.2. Venny (http://bioinfogp.cnb.csic.es/tools/venny/) was 
used to calculate gene set overlaps. Cytoscape 3.0 plugin ClueGO 2.3.3 (Bindea, Mlecnik et al. 
2009) (Bonferroni adjusted p-value<0.05, κ -score=0.4) GO term fusion was used for gene 
network visualisation using GO ontology for molecular function, biological process and cellular 
compartment if not otherwise indicated.  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4. Results 
4.1. Annexin A2 is a reader of acetylated H4K12 and impacts 
spatial memory 
4.1.1. Annexin A2 is a reader of H4K12ac and is ubiquitously expressed in 
brain regions associated with learning and memory 
Peleg and colleagues previously reported that reduced acetylation of histone 4 at lysine 12 
(H4K12ac) correlates with age-associated cognitive impairment (Peleg, Sananbenesi et al. 
2010). The acetylation level is orchestrated by HATs (writers) and HDACs (erasers) that add 
and remove acetyl residues respectively. To interpret the code emerging from these 
modifications, specific proteins, so called chromatin readers, are required. These proteins 
recognise specific patterns at the histone tail and subsequently initiate corresponding changes 
in cellular function. Thus, I investigated by which mechanisms acetylation of H4K12 can affect 
the chromatin state and in turn the transcriptional outcome. I assumed that the most relevant 
targets to convey the histone modification into cellular function would be proteins selectively 
associating with the acetylated version of H4K12 but not with the unmodified. In an unbiased 
shotgun approach I used stable isotope labelling with amino acids in cell culture (SILAC) to 
label dissociated primary neuronal cultures, as first published by Spellmann and colleagues 
(Spellman, Deinhardt et al. 2008). In brief, this technique uses media with amino acids (AA) of 
higher molecular weight to label proteins in culture. One of the cultures is exposed to 
conventional (light) AA, while the other is exposed to stable isotopes (heavy), thus making it 
possible to quantify differential binding of proteins to a given bait. We pulled down soluble 
nuclear proteins from the cell lysate using a H4K12 or H4K12ac mimic as baits. This allowed us 
to selectively capture proteins with a high affinity to the acetylation mark associated with the 
H4K12ac bait but not H4K12. To be able to quantify the affinity of the peptides to the chromatin 
mark, we performed an experiment in which the acetylated bait was incubated with heavy 
isotope-labelled amino acids and the unmodified bait was incubated with the light-labelled 
amino acids (forward experiment). In the complementary experiment, we incubated peptides 
and baits vice versa (reverse experiment), to assure there is no bias for heavy labelled proteins. 
To identify chromatin reader specifically binding H4K12ac, we performed LC-MS/MS (Fig. 4.1A). 
High isotope incorporation is crucial for the success of the experiment, however mature neurons 
are post-mitotic and thus protein turnover is low. To achieve high incorporation rate we changed 
30% of medium every other day which resulted in 93,1% labelling efficiency (Fig. 4.1B). LC-MS/
MS revealed 4 peptides significantly associated with the acetylated version of the H4K12 bait 
but not with the unmodified version (log2 ratio forward<2, log2 ratio reverse<2) (courtesy of 
Nadin Zimmermann, MPI-bpc, working group chromatin-biochemistry). One of these peptides 
significantly binding acetylated H4K12 belonged to BRD4, a member of the bromodomain-and 
extra terminal (BET) protein family. It is a validated H4K12ac reader in immortal cell lines 
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Figure 4.1: ANXA2 is expressed the brain and binds selectively acetylated H4K12ac. Illustration of 
the preparation of heavy and light amino acid labelled primary neuronal culture with subsequent 
chromatin purification and forward and reverse peptide pulldown using H4K12ac or H4K12 bait. Peptides 
were quantified based on mass differences introduced by heavy isotope labelling using LC-MS/MS. 
Green area indicates range of expected chromatin readers (A). Peptides were efficiently labeled with 
heavy Arginine and Lysine isotopes at 93.1% of total peptides in heavy samples (B). LC-MS/MS identified 
4 readers specific for H4K12ac but not H4K12 (log2 ratio forward<2, log2 ratio reverse<2, padj<0.05) 
enrichment ratio with ANXA2 being the most significant of the at the time annotated (C). Western blot 
showed ANXA2 was present across cell fractions and highly abundant in chromatin fraction (D). AnxA2 
mRNA was present in dentate gyrus (DG), cornus ammonis (CA1, CA3), anterior cingulate cortex (ACC), 
cortex (Ctx) and cerebellum (Cb) (qPCR, n=4) (E). ANXA2 (green) protein can be detected by 
immunohistochemistry across brain regions, including hippocampus and cortical layers (bar=500µM). 
ANXA2 co-localises with DAPI as shown for DG (blue) (bottom, bar=25µM) (F). Western blot showed 
ANXA2 was present in DG, CA1, and CA3 (G) and significantly increased in CA1 when quantified and 
normalised to β-Actin (p= 0.0320, unpaired two tailed t-test, n=4) (H). Error bars indicate SEM, *= p<0.05, 
**= p<0.001, ***= p<0.0001. (A) was conducted with Dr. Eva Benito, (B-C) are courtesy of Nadin 
Zimmermann. 
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(Filippakopoulos and Knapp 2012, Jung, Philpott et al. 2014), confirming our approach. Other 
identified readers in ascending affinity for the H4K12ac bait were: ADPRT1 (PARP1), a 
poly(ADP-ribosyl)transferase; ANXA2, a calcium-dependent phospholipid-binding protein; and 
GM1103 (at the time not annotated, now ZBTB2), presumably involved in transcriptional 
regulation (Jeon, Choi et al. 2009, Kim, Koh et al. 2015) (Fig. 4.1C). Notably, in neuronal lysates 
these readers showed higher affinity to the H4K12ac bait than the previously reported BRD4 
which could indicate a higher selectivity for the mark.
To study the role of neuronal H4K12ac readers in greater detail and to understand how this 
modification changes the epigenetic landscape, I decided to focus on ANXA2. It showed the 
highest affinity to H4K12ac amongst the annotated readers and had been reported to interact 
with chromatin (Das, Shetty et al. 2010, Oh, Gao et al. 2013). I hypothesised that a reader of a 
chromatin mark that is relevant to learning and memory would in turn itself be important for 
cognitive performance. Thus I focused on neuronal tissue and started to characterise the sub-
cellular localisation of ANXA2 in the cortex of 3 month old mice, using Western blot. ANXA2 was 
detected as a robust band at approximately 36 kDa and located in all cellular compartments 
tested, namely cytosol, membrane, and nucleus. As it corresponds to chromatin readers, AnxA2 
was particularly strong in the chromatin-bound fraction (Fig.  4.1D). Further, I tested AnxA2 
mRNA expression by qPCR in brain regions associated with learning and memory, as well as in 
the cerebellum for comparison. This revealed the strongest expression in cerebellum (Cb) and a 
robust and comparable expression of AnxA2 mRNA across other subregions, namely dentate 
gyrus (DG), cornus ammonis (CA1, CA3), anterior cingulate cortex (ACC) and cortex (Ctx) (Fig. 
4.1E). Subsequently, I tested where ANXA2 was present at the protein level across different 
brain regions. Immunohistochemistry showed robust expression of ANXA2 throughout the 
hippocampus including the DG, CA1, CA3 and across cortical layers. DAPI co-localisation 
indicated nuclear localisation in 3 month old mice (Fig. 4.1F). Since the quantitative resolution in 
immunohistochemistry is restricted, I additionally performed Western blot analysis for 
hippocampal subregions. Here too, ANXA2 was present throughout the DG, CA1, and CA3 of 3 
month old mice (Fig. 4.1G). ANXA2 protein levels were significantly increased in CA1 compared 
to other subregions (p= 0.032, unpaired two tailed t-test) (Fig. 4.1H). Thus, we identified AnxA2 
as a neuronal reader of H4K12ac in an unbiased screen and hypothesised that it might be 
involved in cognitive function. I characterised its expression at the mRNA and protein level and 
found it to be expressed in the cortical and particularly in hippocampal subregions. These 
results were encouraging to continue the characterisation of ANXA2 in the aged mouse to asses 
whether the reported age-dependent changes in acetylation of H4K12 translate into alterations 
of its reader.
4.1.2. Translation and localisation of ANXA2 change in ageing 
As mentioned above, Peleg and colleagues showed that acetylation of H4K12 was less 
abundant in aged mice and correlated with their cognitive decline (Peleg, Sananbenesi et al. 
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2010). Thus, I investigated whether ANXA2, as a reader of H4K12ac, would change in 
expression or localisation during ageing. To investigate this, I compared mRNA levels in 3 and 
16 month old animals using qPCR. I learning and memory associated brain regions (DG, CA1, 
CA3, ACC, Ctx) and Cb. However, I found no significant differences between the groups 
(Fig.  4.2A). I also analysed protein levels in hippocampal subregions DG, CA1, CA3 using 
Western blot and found that ANXA2 was present throughout the regions in 16 month old 
animals (Fig.  4.2B). In contrast to 3 month old mice, no difference between hippocampal 
subregions was detected. However, comparing protein levels between the young and old cohort 
revealed significantly lower ANXA2 levels in CA1 of aged mice (p=0.032, unpaired two tailed t-
test) (Fig.  4.2C). Since I previously observed a nuclear localisation of ANXA2 in the 
hippocampus of 3 month old mice, I performed immunohistochemistry on sagittal sections of 
both, 3 month and 16 month old animals to compare both cohorts. This revealed an increase of 
nuclear ANXA2 signal in aged mice compared to young controls (Fig.  4.2D). Fluorescence 
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Figure 4.2: Protein levels of ANXA2 are reduced in CA1 and increased in nuclei of DG in aged 
mice. AnxA2 mRNA was not changed in dentate gyrus (DG), cornus ammonis (CA1, CA3), anterior 
cingulate cortex (ACC), cortex (Ctx) and cerebellum (Cb) between 3 and 16 months of age (qPCR, n=4) 
(A). Protein levels of ANXA2 were similar in DG, CA1, and CA3 of 16 month old mice (n=4) (B). 
Quantification of (B) showed significantly decreased protein levels in CA1 of 16 month old WT mice 
compared to the 3 month old control (p=0.032, t-test, n=4) (C). ANXA2 was expressed in the 
hippocampus of 3 and 16 month old mice scale bar=250µM (D, top). In the DG nuclear ANXA2 was 
increased in the aged group compared to young as revealed by immunohistochemistry on sagittal 
sections scale bar=10µM (D, bottom). CTCF intensity quantifications from (D) (p=0.0003, t-test, n=16) 
(E). Western blot analysis of sub cellular fractionations for nuclear protein (NP) and cytosolic protein (CP) 
of DG, CA1, CA3 of 3 month versus 16 month old mice arrow indicates difference between 16 and 3 
month old mice (F). Error bars indicate SEM, *= p<0.05, **= p<0.001, ***= p<0.0001. 
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intensity quantifications (CTCF) of the immuno-staining indicated the difference to be significant 
(p=0.0003, t-test, n=16) (Fig. 4.2E). This finding was further supported by Western blot analysis 
of sub-cellular fractionations of hippocampal regions DG, CA1, CA3 of 3 month versus 16 
month old mice. ANXA2 was increased in the nuclear fraction of the DG of aged animals 
compared to young, while other areas did not show nuclear ANXA2 and comparable cytosolic 
levels (Fig.  4.2F). ANXA2 did not show an alteration in localisation in CA1 and CA3 when 
comparing 3 month and 16 month old animals. 
So far, the data indicate that AnxA2 is a neuronal chromatin reader with high affinity for 
H4K12ac. It is robustly expressed in learning and memory related areas and particularly in the 
hippocampal subregions. Most interestingly, there seems to be a relation between ANXA2 sub-
cellular localisation and raging, with AnxA2 accumulating in the nucleus in 16 month old animals 
compared to 3 month old animals. Bases on this evidence, there are two probable explanations: 
the increase of AnxA2 levels in the nucleus in DG of aged animals and the decrease in CA1 
could either counteract cognitive decline or be a detrimental phenotype in ageing. In order to 
distinguish these possibilities and to establish whether there is a functional relationship between 
AnxA2 levels and sub-cellular distribution and cognition, I went on to study the influence of 
increased AnxA2 levels in the hippocampus in a gain of function model.
4.1.3. AnxA2 overexpression impairs hippocampus-dependent spatial memory 
The characterisation of the localisation and expression levels of ANXA2 in the young and aged 
mouse brain, revealed that ANXA2 was increased in the DG nuclear fraction while also 
decreased in the CA1 of aged mice. Thus, I designed two sets of complementary experiments 
to address the role of ANXA2 in learning and memory: firstly, a gain of function approach with 
AnxA2 overexpression and secondly, AnxA2 knockout. 
In order to overexpress AnxA2, I chose adeno-associated viral constructs (AAVs) due to their 
high specificity and low tendency to spread compared to other viral delivery methods. I 
produced two AnxA2 and one control construct expressing eGFP. In brief, I cloned murine 
AnxA2 under the control of the hSyn promoter for neuron-specific expression into the AAV 
backbone and fused it to eGFP for tracking (hSyn-AnxA2/GFP, “ANX”) (Fig. 4.3A). To study the 
impact of ANXA2 sub-cellular localisation on learning and memory, I produced an alternative 
version of the vector with a nuclear localisation signal (NLS) fused in frame with eGFP. The 
backbone with eGFP under the control of the hSyn promoter (hSyn-GFP, “GFP”) was used as 
control (Fig.  4.3A). As expected, NLS addition to the C-terminus of eGFP led to nuclear 
accumulation of the ANXA2 fusion protein (hSyn-AnxA2/GFP/NLS, “NLS”) when compared to 
ANXA2-GFP in primary neuronal culture (DIV10) (Fig. 4.3B). For behavioural experiments, the 
AAV particles were injected into the DG of 3 month old mice, which resulted in hippocampus 
specific and DG-enriched overexpression of the constructs (Fig. 4.3 C-E). After three weeks of 
viral incubation, I performed a behavioural test battery consisting of anxiety (elevated plus maze 
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“EPM”, open field test “OF”), fear memory (contextual fear conditioning “FC”) and spatial 
memory tests (Morris water maze “MWM”, and Barnes maze “BM”). 
ANXA2 overexpression in ANX or NLS did not significantly change the percent of time spent in 
the open arms of the EPM, indicating comparable anxiety levels across groups (Fig. 4.4A). This 
finding was further supported by comparable levels of exposure and travel speed between all 
tested groups in the OF, also indicating motor skill was unaffected (Fig.  4.4B+C). After 
demonstrating similar levels of anxiety, I performed hippocampus-dependent cognitive tests. In 
FC, an associative memory task, all groups showed comparable initial freezing during training 
and significantly increased freezing after the learning stimulus on the successive day 
(F(1,78)=130.3, p<0.0001, two-way ANOVA) with no significant difference between cohorts 
(Fig.  4.4D).Thus, AnxA2 overexpression had no significant influence on associative fear 
memory. I performed a second spatial memory test, the MWM, which is more heavily dependent 
on the hippocampus. Animals were trained for 12 consecutive days during which the latency to 
find the submerged platform (escape latency) was taken as a measure of learning performance. 
Probe tests (PT) were performed on days 6, 11, and 13, when the first cohort reached a plateau 
at a cumulative escape latency of less than 20 s. ANX and GFP performed similarly during the 
acquisition (p>0.05, F(1,26)=0.11, two-way-ANOVA), while the NLS cohort showed reduced 
performance in the MWM compared to ANX (F(1,28)=6.34, p=0.018, two-way-ANOVA) and GFP 
controls (F(1,26)=5.67, p=0.025, two-way-ANOVA) (Fig. 4.4E). However, this observation was 
not supported by the evaluation of spatial memory on any of the PT (Fig. 4.4F+G), indicating a 
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Figure 4.3: Expression of ANXA2 in cytosol and nucleus using AAVs. Three vectors were produced 
using identical backbones and hSynP for neuronal specificity. The control construct hSynP-GFP only 
harboured GFP (“GFP, black”). A second construct hSynP-AnxA2-GFP additionally featured information 
for 339 AA AnxA2 fused to GFP (“ANX, red”). A third construct hSynP-AnxA2-GFP-NLS featured the 
339  AA AnxA2 fused GFP with the addition of a NLS at the GFP C-terminal (“NLS, blue”). AAV1/2 
hybrids were used for delivery of the constructs (A). ANXA2 was expressed mainly in the cytosol (ANX) 
or the nucleus (NLS) in primary neuronal cultures (DIV10, 6 days post infection) scale bar=25 µM (B). 
Schematic coronal illustration of stereotactic intracranial injection of AAVs into DG using micro-capillaries 
(C). Mouse brain 11 weeks after injection of hSynP-AnxA2-GFP-NLS into the DG of 3 month old male 
mice. Hippocampus was morphologically unaffected and showed robust transgene expression 
exclusively in hippocampal regions (D). Schematic of treatment protocol, 3 month old male mice were 
injected with the respective virus, incubated for 3 weeks with subsequent behavioural test battery and 
sacrificed prior to molecular biology analysis (E).
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Figure 4.4: Behavioural testing of ANXA2 overexpressing mice shows influence of ANXA2 on 
cognitive function. Elevated plus maze (EPM) test for anxiety showed similar amount of time spent in 
open arms as percent of total time for all groups (GFP, black, n=13; ANX, red, n=15; NLS, blue, n=15) 
(F(2,40)=0.4348, p=0.650) (A). Time spent in central area relative to total experimental duration of the 
open field test (OF) sustained the EPM finding by demonstrating comparable anxiety levels 
(F(2,39)=1.175, p=0.320) (B) and further showed similar travel speed (cm/min) in all cohorts 
(F(2,40)=0.5874, p=0.561) (C). All cohorts displayed similar initial freezing (displayed as percent of total 
time) in contextual fear conditioning during training and recall. Importantly, cohorts showed a significant 
increase in freezing after training (recall) (F(1,78)=130.3, p<0.0001, two-way ANOVA) (D). Morris water 
maze revealed ANX and GFP performed similar while NLS exhibited increased escape latency 
compared to both ANX (F(1,28)=6.343, p=0.018, two-way-ANOVA) and GFP controls (F(1,26)=5.673, 
p=0.025, two-way-ANOVA) (E). Performance in probe test on day 6 was similar between groups 
(F(2,40)=0.034, p=0.967) (F). Probe test on day 13 showed increased time spent in target for all groups 
without significant difference between groups (F(2,40)=0.320, p=0.728) (G). GFP controls and ANX used 
cognitively challenging search strategies (direct-focused) (H+I). NLS tended to use less demanding 
strategies (circling-thigmotaxis) and passivity (J). Display of cumulative strategy scores from (H-J) 
indicated NLS use lower cognitive scores compared to ANX and GFP (K). One-way ANOVA was used, if 
not stated otherwise. Error bars indicate SEM, *= p<0.05, **= p<0.001, ***= p<0.0001.
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subtle phenotype. Since the introduced manipulations could affect learning capabilities without 
affecting memory consolidation, I investigated search strategies in the maze. GFP controls 
showed a longitudinal increase in strategies with higher cognitive scores (direct-focused search) 
and in turn a decrease in low cognitive scores (circling-thigmotaxis) (Fig. 4.4H). ANX showed a 
similar performance with pronounced focused search from training day 3 onwards (Fig. 4.4I). In 
contrast, NLS used less cognitively challenging strategies (accidental circling-thigmotaxis) and a 
slow longitudinal increase of higher cognitive strategies (direct-focused), as well as increased 
passivity (Fig. 4.4J). These findings were also represented in the cumulative scores, were NLS 
performed poorly compared to other cohorts (Fig. 4.4K). 
Behavioural results suggested that overexpression of ANXA2 AnxA2 may play a subtle role in 
modulating spatial memory performance in the mouse hippocampus. To gain a greater insight 
into this modulatory function, I tested animals with the Barnes maze, a more subtle subtle 
spatial and hippocampus-dependent, which is less stressful to the animal and thus reduces 
noise in the data (Harrison, Hosseini et al. 2009). The paradigm was modified from Attar and 
colleagues to further reduce stress to the test subjects (Attar, Liu et al. 2013) (Fig.  4.5A). 
Memory function was scored based on the time spent in the quadrant containing an escape 
cage hidden below one of 20 holes (target, T) relative to the other quadrants (left, L; opposite, 
O; right, R) Fig.  4.5B). Importantly, all cohorts travelled comparable distances, ruling out a 
motivational or motor impairment (Fig. 4.5C). After three days of training a PT was performed, in 
which the GFP cohort showed significantly increased time spent in the target quadrant as 
compared to off-target quadrants (F(3,48)=9.49, p<0.0001, one-way ANOVA). NLS animals 
performed similarly to controls and spent significantly longer time in the target quadrant 
compared to other quadrants (F(3,55)=5.46, p=0.002, one-way ANOVA). In contrast, ANX failed 
to learn the task after 3 days of training, indicated by equal percentages of time in all quadrants 
(F(3,49)=0.35, p=0.792, one-way ANOVA) (Fig.  4.5D). Importantly, this difference was 
significant also when compared to GFP controls (F(2,38)=3.43, p=0.043, one way ANOVA) 
(Fig. 4.5E). To evaluate if the ANX cohort was able to learn this task, I continued the training for 
an additional 4 days after 2 days recovery to reduce memory extinction. Also in the second PT 
all cohorts displayed comparable distance travelled (F (2,40)=1.07, p=0.353, one way ANOVA) 
(Fig. 4.5F). Additional training resulted in longer time spent in the target quadrant in both GFP 
and NLS cohorts (GFP: F(3,46)=14.75, p<0.0001; NLS: F(3,55)=65.04, p<0.0001, one-way-
ANOVA), which also had shown significant preference for the target quadrant. Importantly, ANX 
too spent significantly more time in the target quadrant compared to other quadrants during the 
second PT (F(3,51)=27.41, p<0.0001, one-way ANOVA) (Fig.  4.5G), indicating that ANX are 
generally capable of learning the task. Of note, cohorts did not differ in the second probe test 
(F(2,39)=0.54, p=0.586, one-way ANOVA). However, ANX still showed a trend towards less time 
spent in the target quadrant, when compared directly to other cohorts (Fig. 4.5 H). 
While NLS showed a mild impairment in learning in the MWM, none of the groups deviated 
significantly from chance level in their time spent in target quadrant. This finding put the 
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reliability of the MWM in this line of experiment into question. However, in the BM control 
animals and NLS show robust learning and memory, while ANX learned the task after additional 
training. Taken together this data indicates an involvement of AnxA2 in learning and memory.
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Figure 4.5: Spatial memory is impaired in mice overexpressing ANXA2 in hippocampal DG 
neurons. Barnes maze (BM) test paradigm for GFP, black, n=13; ANX, red, n=15; NLS, blue, n=15. 
Animals were habituated for one day followed by 3 consecutive training days with one session each and 
a subsequent probe test (PT). Animals were allowed to rest for 2 days after PT then trained for additional 
4 days and followed by a second PT (A). BM experimental setup consisted of a round white plate (92 cm 
diameter) and 20 holes separated into 4 quadrants. Target quadrant (T, blue) featured an escape cage 
hidden below the target hole (green), off target quadrants were separated into left (L), opposite (O), and 
right (R) (B). All cohorts traveled comparable distances (cm) during first BM probe test (PT) 
(F(2,40)=0.004, p=0.996) (C). During first PT GFP (F(3,48)=9.485, p<0.0001) and NLS (F(3,55)=5.46, 
p=0.002) spent significantly longer time in T. ANX did not show a preference for T (F(3,49)=0.35, 
p=0.792) (D). Direct comparison of percent time spent in T from (D): ANX spent significantly less time in 
T compared to GFP controls (F(2,38)=3.43, p=0.043) (E). All groups travelled comparable distance (cm) 
during the second PT (F(2,40)=1.07, p=0.353) (F). Second PT showed significant preference in all 
cohorts for T (GFP: F(3,46)=14.75, p<0.0001; NLS: F(3,55)=65.04, p<0.0001; ANX: F(3,51)=27.41, 
p<0.0001) (G). Direct comparison of percent time spent in T from (G) showed no significant difference 
between groups (F(2,39)=0.54, p=0.586) (H). One-way ANOVA was used for multiple group comparison, 
error bars indicate SEM, *= p<0.05, **= p<0.001, ***= p<0.0001.
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4.1.4. ANXA2 null mutants display facilitated spatial memory 
To further sustain the finding that ANXA2 is involved in correct hippocampus-dependent spatial 
memory, I studied the influence of ANXA2 in a loss of function model. Considering the 
accumulation of AnxA2 in the DG of old animals and the impaired spatial memory in mice 
overexpressing ANXA2, I hypothesised that ANXA2 deficiency would result in the 
complementary phenotype. To test this, I used ANXA2 knockout (KO) and wild-type (WT) 
littermates and confirmed the absence of ANXA2 protein in whole brain lysate (Fig. 4.6A). Next, 
I subjected the mice to a behavioural test battery composed of an anxiety test (OF) and 
hippocampus-dependent memory tasks for fear memory (FC) and spatial memory (MWM, BM). 
In the OF test both KO and WT performed similarly with no significant difference between 
cohorts in both measures; time spent exposed (Fig.  4.6B) and travel speed (Fig.  4.6C). To 
assess hippocampus-dependent associative memory FC was performed. During training WT 
and KO displayed comparable initial freezing behaviour and a minor trend towards increased 
freezing in KO. Also during recall both groups showed similar freezing behaviour, while both 
cohorts displayed significantly increased freezing compared to the pre-shock condition 
(F(1,20)=48, p<0.0001, two-way ANOVA) (Fig. 4.6D). Further, I tested the animals in the MWM 
for spatial memory assessment. PTs were conducted for both groups when one cohort reached 
an average escape latency of less than 20 s, after 4 and 8 days respectively. KO had overall 
lower latencies to reach the escape platform compared to WT, indicating facilitated memory 
acquisition and consolidation (F(1,70)=7.24, p=0.009, 2-way ANOVA) (Fig. 4.6E). The first PT 
indicated a trend in KO to spend more time in target quadrant as compared to WT (Fig. 4.6F). 
This persisted, yet less strikingly, throughout the second PT, while WT spent slightly more time 
in the target quadrant compared to the first PT (Fig. 4.6G). Notably, neither of the groups spent 
time in the target quadrant above chance level (25 %) during PTs. Since these findings point 
towards an enhancement in the KO cohort, which can be explained by search strategies rather 
than target occupancy, I investigated search strategies during the training period for both WT 
and KO. WT showed fluctuating usage of high cognitive strategies (direct-focused search) 
during all 8 days of training (Fig. 4.6H). In contrast, KO showed an increase of high cognitive 
strategies from day 3 on and they sustained these strategies throughout the experiment 
(Fig. 4.6I). These findings were further confirmed by the cumulative cognitive scores per day, 
here, KO outperformed WT from training day 3 onward (Fig. 4.6J). 
Subsequently, animals were tested in the more sensitive BM to detect more subtle changes, as 
previously exemplified. The test was conducted for WT and KO as previously described for the 
overexpression experiments (Fig.  4.7A), where time spent in the quadrant (T) formerly 
containing the hole to the escape cage was compared to other quadrants (left, L; opposite, O; 
right, R) as a proxy for spatial memory (Fig, 4.7B). During the first probe test both WT and KO 
travelled equal distances, indicating equal motivation and motility (Fig. 4.7C). During the first PT 
WT did not spent more time in target compared to off-target quadrants (F(3,16)=1.76, p=0.196, 
one-way ANOVA), while KO animals showed enhanced performance and spent significantly 
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Figure 4.6: ANXA2 null mutants show enhanced performance in spatial memory. ANXA2 protein 
was not detectable in total brain lysates as demonstrated by Western blot (A). Open field (OF) showed 
equal length of time spent in the centre for both wild-type (WT, black, n=7) and ANXA2-/- mice (KO, green, 
n=7) (p=0.495, unpaired t-test) (B). OF did not show differences in travel speed (p=0.759, unpaired t-test) 
(C). WT and KO showed comparable initial freezing in training (p=0.297, unpaired t-test) and recall 
(p=0.812, unpaired t-test) but significant increase in percent of total time freezing when comparing 
training and recall (F(1,20)=48, p<0.0001, two-way ANOVA) (D). During MWM training KO showed 
significantly shorter escape latencies compared to WT (F(1,70)=7.242, p=0.009, two way ANOVA) (E). 
probe tests (PT1, PT2) were performed when cohorts reached average escape latency < 20 s. Percent of 
time spent in target during PT1 showed a non-significant tendency of KO to spend more time in T 
compared to WT (p=0.118, unpaired t-test) (F). Percent of time spent in the target quadrant during PT2 
too showed non-significant tendency of KO to spent more time in T compared to WT (p=0.485) (G). In 
MWM WT showed fluctuating usage of high cognitive strategies (direct-focused search) during MWM 
training (H). KO showed increased use of higher cognitive strategies (I). Cumulative cognitive scores per 
day indicated KO outperformed WT from training day 3 onward (J). Error bars indicate SEM, *= p<0.05, 
**= p<0.001, ***= p<0.0001.
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more time in the target (F(3,20)=42.68, p<0.0001, one-way ANOVA) (Fig. 4.7D). This difference 
was also significant between groups, indicating facilitated memory formation in KO (p=0.047, 
unpaired t-test) (Fig. 4.7E). After additional 4 days of training both cohorts were again subjected 
to a PT, as before displaying similar distances travelled (Fig. 4.7F). Now, also WT animals spent 
significantly more time in the target quadrant (F(3,16)=105.5, p<0.0001, one-way ANOVA), while 
time spent in target of KO did not change. (F(3,16)=12.93, p=0.0002, one-way ANOVA) 
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Figure 4.7: ANXA2 null mutants significantly outperformed WT in the Barnes Maze. Barnes maze 
(BM) testing paradigm; animals were first habituated, then trained on 3 consecutive days with one 
session each and a subsequent probe test (PT). Animals were allowed to rest for 2 days after PT, then 
trained for additional 4 days followed by a final PT (A). BM experimental setup consisted of a round white 
plate (92 cm diameter) and 20 holes separated into 4 quadrants. Target quadrant (T, blue) featured an 
escape cage hidden below target hole (green), off-target quadrants were separated into left (L), opposite 
(O), and right (R) (B). During the first PT both WT (black, n=7) and KO (green, n=7) travelled comparable 
distances (cm) (p=0.796, unpaired t-test) (C). First PT showed no significant preference of WT for T 
(F(3,16)=1.76, p=0.196, one-way ANOVA), while KO spent significantly more time in T compared to 
L,O,R (F(3,20)=42.68, p<0.0001, one-way ANOVA) (D). Direct comparison of percent of time spent in 
target of WT and KO showed significant increase of KO over WT (p=0.047, unpaired t-test) (E). During 
second PT both groups showed similar distance (cm) travelled (p=0.851, unpaired t-test) (F). Second 
probe test showed significant preference for T in both WT (F(3,16)=105.5, p<0.0001, one-way ANOVA) 
and KO (F(3,16)=12.93, p=0.0002, one-way ANOVA) as percent of time spent compared to L,O,R (G). 
Direct comparison of percent of time spent between WT and KO did not show significant difference 
during PT2 (p=0.990, unpaired t-test) (H). Error bars indicate SEM, *= p<0.05, **= p<0.001, ***= 
p<0.0001.
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(Fig.  4.7G). Also when comparing the percentage of time spent in target quadrant between 
groups, no difference was detected, indicating that both groups learned the task equally after 7 
days of training (Fig. 4.7H). 
In summary, these observations are in line with previous findings and support the hypothesis 
that ANXA2 is involved in memory formation, acting as a repressor in hippocampus-dependent 
memory tasks. To understand the mechanism by which ANXA2 conveys the cognitive 
modulation, I investigated transcriptomic changes in hippocampal subregions of cohorts 
showing significantly different memory performance in the BM.
4.1.5. ANXA2 affects the cellular membrane and RNA processing in vivo  
So far, I established a role for AnxA2 in spatial memory, potentially through hippocampus 
subregion-specific mechanisms. I then went on to perform a molecular characterisation of the 
transcriptional status of relevant brain regions in animals that I used for behavioural analysis. 
Before the analysis of molecular mechanisms, the animals were allowed to rest for 4 days after 
finishing the behavioural test battery to reinstate basal transcriptional levels. Then the animals 
were sacrificed and hippocampal subregions DG and CA1, both crucial for spatial memory, were 
isolated and used for next-generation RNA sequencing. I used both, the viral-mediated 
overexpression animals and the KO animals with their respective controls. It was surprising to 
see that there was no differential gene expression regardless of the AnxA2 manipulation in any 
of the tissues with one exception: AnxA2 in CA1 of the KO cohort at a log2FC cutoff of 0.5 
(adjusted p-value (padj)  <  0.05) (Fig.  4.8A). Also lower cutoffs did not lead to meaningful 
enrichment in pathway or overrepresentation analysis (data not shown). I was still interested in 
potentially smaller changes that would affect multiple genes in any given pathway, even if 
individual genes may not reach significance after multiple testing correction. Thus, a robust tool 
to study transcriptome-wide subtle changes, taking into account the full ranked gene list 
regardless of arbitrary cutoffs, namely gene set enrichment analysis (GSEA), was performed. 
This revealed several gene sets enriched in DG and CA1 of KO animals (Fig. 4.8B, Appendix 
Fig. 1A) but no significant difference in ANX DG or CA1 (data not shown). Importantly, GSEA in 
KO DG showed 5 main groups of gene ontology (GO) categories, which I manually parsed to 
reduce redundancy and collapsed under the terms “membrane-bound processes”, “genomic”, 
“epigenetic”, “splicing”, and “RNA processing”. Terms associated with each of the categories 
were mainly negatively enriched for KO with the exception of “Retrograde Vesicle Mediated 
Transport Golgi to ER”, which showed positive enrichment. The individual GO categories 
highlighted two distinct mechanisms, the first targeting the cellular membrane and the latter 
modulating the genomic landscape and therefore possibly RNA processing. These findings 
indicated first hints towards potential mechanisms. The absence of differentially expressed 
genes could possibly be explained by non-neuronal cells or an activity-dependent mode of 
function. Thus, I went on to pinpoint the mechanism underlying the cognitive changes in a 
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neuron specific approach and hypothesised that modification of ANXA2 would impose changes 
to the transcriptome when neurons were stimulated, rather than in a basal state. 
4.1.6. Neurons respond to ANXA2 overexpression by differential regulation of 
genes involved in developmental processes and stimulus response 
One possible reason why I only detected rather mild changes in gene expression in ANX and 
NLS animals compared to GFP could be due to the fact that non-neuronal cell types could have 
masked changes that occur in neurons upon AnxA2 manipulation. To study the influence of 
ANXA2 overexpression specifically on neurons, primary neuronal cultures were infected on 
DIV5 with ANX-AAV or GFP-AAV as control, incubated until DIV10 and vehicle treated (Fig. 
4.9A). Differential gene expression analysis in basal conditions in ANX compared to GFP 
overexpressing neurons showed a total of 853 differentially expressed genes at padj<0.05 (550 
up, light red; 303 down, light blue) (Fig  4.9B). Over-representation analysis (ORA) of 
differentially regulated genes (padj<0.05) showed a strong link to neurogenesis and 
developmental processes (Top10 GO biological processes, padj<0.05, FDR<0.05, sorting by 
ratio of enrichment) (Fig. 4.9C). To investigate biologically more meaningful subsets I applied an 
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Figure 4.8: Gene set enrichment analysis reveals dual involvement of ANXA2 in membrane and 
RNA processing. RNAseq of ANX DG (blue) and ANX CA1 (yellow) versus GFP DG and GFP CA1 
respectively and KO DG (red) and KO CA1 (green) versus DG WT and CA1 WT respectively. Analysis 
showed differential expression only for one gene (AnxA2) at an (Benjamini-Hochberg) adjusted p-
value<0.05 and log2 fold-change (log2FC)±0.5 (A). Gene set enrichment analysis (GSEA, Broad 
Institute) in KO DG versus WT DG revealed 30 differentially regulated gene sets (padj<0.05, FDR<0.25), 
manually collapsed into ‘Membrane bound processes’, ‘Genomic’, ‘Epigenetic’, ‘Splicing’, ‘RNA 
processing’. Gene sets were sorted according to normalised enrichment score within their collapsed 
category. Positive enrichment (WT) is indicated in red, negative enrichment in blue (KO) (B). 
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additional log2 fold-change (log2FC±0.5) cutoff, which resulted in 2 differentially expressed 
genes aside from AnxA2. One was Gda, which is possibly involved in microtubule assembly, the 
other was 6330403L08Rik a gene of unknown function. For a less conservative cutoff of 
padj<0.05, log2FC0.3 only 53 genes were differentially expressed and one GO category, 
fibronectin binding, significantly enriched (Top10 GO molecular function, padj<0.05, FDR<0.05), 
pointing towards changes in the extracellular matrix (ECM) (Appendix Fig. 1B). These relatively 
mild differences in gene expression that affect a large number of genes could explain why 
transcriptome analysis found only few genes to be differentially expressed in vivo, because mild 
changes would have been covered by non-neuronal cells. The findings suggested that ANXA2 
acts broadly but mildly on neuronal stimulus response, possibly targeting the ECM. An 
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Figure 4.9: ANXA2 overexpressing neurons show wide but mild changes in gene expression and 
react to NMDA stimulation in an ECM-dependent manner. On DIV5 primary neurons were infected 
with either ANX-AAV or GFP-AAV and further incubated until simulation with vehicle (basal) or 50µM 
NMDA on DIV 10 for 10 min. Then medium was replaced and cultures incubated with conditioned 
medium to recover before harvest and RNAseq (A). Differential expression analysis after RNAseq of 
basal ANX versus GFP neurons showed 853 differentially expressed genes in ANX (padj<0.05; 550 up, 
light red; 303 down, light blue) of which 3 were significant at padj<0.05 and log2FC±0.5 (2 up, red; 1 
down, blue), x-axis indicates number and percent of total differentially expressed genes (B). ORA of GO 
biological processes (BP) for genes with at padj<0.05 in (B) showed neurogenesis and developmental 
processes and single organism behaviour (padj<0.05, FDR<0.05, sorted according to ratio of enrichment) 
(C). Overlap for genes differentially expressed (padj<0.05) in basal (854 genes) and NMDA stimulated 
(706 genes), basal signature (326 gens) was removed from stimulated condition resulting in 380 genes 
for ORA of GO BP. This showed nucleoside and most prominent ECM associated integrin binding GO 
terms enriched (padj<0.05, FDR<0.05, sorted according to ratio of enrichment) (D). Overlap from (D) with 
additional log2FC±0.5 cutoff showed only 7 differentially repressed genes (Grin3b, Tas1r3, Dnah10, 
Sdcbp2, Naaladl1, Mamdc4, and Myh7b) (E).
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additional mode of action could be through mechanisms associated with RNA processing as 
indicated by in vivo GSEA. 
Since I also hypothesised that AnxA2 might be a neuronal activity sensor and get engaged only 
when neurons are activated, I tested the influence of ANXA2 overexpression in challenged 
neurons. The ANXA2-dependent modulation of stimulus response was investigated by applying 
NMDA, since ANXA2 was previously reported to relocalise after NMDA treatment (Valapala, 
Maji et al. 2014). Cells were treated with vehicle (basal) or 50µM NMDA for 10 min followed by 
10 min recovery before harvesting (Fig. 4.9A). In an effort to distinguish genes that are directly 
ANXA2- and activity-dependent, genes differentially expressed in basal condition were removed 
from GO analysis (Fig 4.9D, purple/green) and only genes exclusively deregulated in stimulated 
condition (padj<0.05) were analysed. ORA showed pronounced GO term enrichment for 
nucleoside binding processes, as well as integrin binding, pointing towards involvement of the 
extracellular matrix (ECM) in ANXA2-dependent stimulus response (padj<0.05, FDR<0.05, 
sorting by ratio of enrichment) (Fig  4.9D, green). To investigate the GO term contribution of 
highly differentially expressed genes, I applied an increased log2FC±0.5 cutoff, which found 9 
genes to be downregulated in NMDA treated neurons, of which 7 were exclusive to NMDA 
treatment. Among the genes detected were Grin3b (subunit of an NMDA receptor), Tas1r3 (taste 
receptor related to G-protein coupled receptor activity), Dnah10 (dynein, associated with 
ATPase activity), Sdcbp2 (involved in protein-protein interactions), Naaladl1 (related to 
peptidase activity), Mamdc4 (possibly involved in transport of receptors), and Myh7b 
(contributing nucleotide and actin filament binding) (Fig. 4.9E). Taken together these findings on 
ANXA2 overexpression are in line with studies on ANXA2 reporting its binding to the 
cytoskeleton and taking a role in trafficking (Bharadwaj, Bydoun et al. 2013). Further, analysis of 
all significantly deregulated genes in vitro suggested the involvement of ECM deregulation as 
also observed in vivo (Fig. 4.8B, Appendix Fig.1A). Based on the qualitative rather than the 
quantitative mode of action of chromatin readers such as ANXA2, I hypothesised that the read 
histone mark is already occupied to a large extend in the WT condition. Overexpression leads to 
an occupation of the few additional available chromatin sites. Thus, changes observed in a gain 
of function model must be even more pronounced in a loss of function model, given that here 
chromatin marks lay idle. Therefore, I investigated the effect of ANXA2 absence specifically in 
neurons.
4.1.7. ANXA2 is involved in ECM and stimulus response processes 
ANXA2 deficiency lead to enhanced spatial memory in mice. To understand the effect of ANXA2 
absence specifically on neurons, I investigated primary hippocampal neuronal cultures from 
ANXA2 null mice. Analogously to the experiments in ANXA2 overexpression, AnxA2-/- (KO) and 
wild-type (WT) primary neuronal cultures were incubated until DIV 10 and then treated for 10 
min with either vehicle for basal analysis or 50 µM NMDA for stimulation condition. The 
stimulation medium was then washed out and conditioned medium applied to allow the cells to 
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respond before harvest and RNA sequencing (Fig. 4.10A). Differential expression analysis of 
KO hippocampal neurons compared to WT showed 862 genes (470 up, light red; 392 down, 
light blue) to be differentially regulated at padj<0.05. Of these genes 230 were differentially 
expressed at a cutoff of padj<0.05 and log2FC±0.5 (149 up, red; 81 down, blue) (Fig. 4.10B). As 
expected ANXA2 deficiency led to higher fold changes for differentially expressed genes than 
overexpression approach in the basal state, possibly due to the lacking occupation of H4K12ac 
sites by ANXA2. Top 10 GO molecular function over representation analysis with a cutoff of 
padj<0.05 and FDR<0.05 (sorting by ratio of enrichment) was performed, using differentially 
expressed genes (padj<0.05, log2FC±0.5). This indicated the influence of ANXA2 deficiency on 
terms mainly associated with the ECM (blue) and cell response and activity (green). Other 
enriched categories, not directly associated with one of the main terms, were protein and 
sulphur compound binding (Fig. 4.10C). To further corroborate these findings, I investigated the 
transcriptome of basal KO and WT neurons using gene set enrichment analysis (GSEA). Here 
too, GO terms associated with the ECM were enriched in KO neurons (Top20 GO categories 
shown, Fig  4.10D). Moreover, terms not only associated with ECM sustainment but also 
disassembly were enriched. This led me to investigate more closely genes involved in both 
processes, and I found ECM disassembly genes to be generally increased, particularly 
metalloproteases (Mmp2, Mmp3, Mmp11) a family repeatedly reported to degrade collagens 
and to play a role in learning and memory (Terni and Ferrer 2015, Bach, Tzovara et al. 2017, 
Wiera, Nowak et al. 2017). Also Fn1, Nid1, and Ctsk have been linked to cognitive performance 
and synaptic plasticity (Dityatev and Schachner 2003, Vasudevan, Ho et al. 2010, Dauth, 
Sirbulescu et al. 2011) (Fig.  4.10E). Furthermore, Bgn and Lum have been reported to be 
important for synaptic plasticity and change due to activity and HDAC inhibition (Amenta, Creely 
et al. 2012, Sewal, Patzke et al. 2015). Additionally, the ECM components, and relevant 
modulators of synaptic plasticity Ncan and Tnc were downregulated. In contrast, 
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Figure 4.10: ANXA2 deficiency alters the ECM and susceptibility to stimulation. 
Primary neurons from ANXA2-/- or WT mice were treated for 10 min with 50 µM NMDA or vehicle (basal) 
and allowed to recover for 10 min prior to harvest and RNA isolation for sequencing (A). RNA 
sequencing revealed 862 (470 up, light red; 392 down, light blue) genes differentially expressed between 
KO and WT at padj<0.05 cutoff. Stringent cutoff for further analysis at log2FC±0.5, padj<0.05 showed 
230 genes differentially expressed (149 up, red; 81 down, blue), x-axis indicates number and percent of 
total differentially expressed genes (B). Top10 overrepresentation analysis (ORA) for genes from (A) at 
log2FC±0.5, padj<0.05 yielded GO categories associated with extracellular matrix or cell response 
(padj<0.05, FDR<0.05, sorted according to log10 ratio of enrichment) (C). Gene set enrichment analysis 
of basal neurons showed enrichment of ECM-associated GO terms within the top20 GO categories in 
KO when compared to WT (padj<0.05, FDR<0.25) ranking according to normalised enrichment score 
(NES) (D). Relative expression (normalised reads per million, NPM) showed differentially expressed 
genes (padj<0.05) relevant to ECM disassembly and learning and memory (e.g. Dcn, Fn1, Gsn, Ctsk, 
Nid1) (E). Relative expression (NPM) of ECM structure genes relevant to learning and memory and 
substrates of matrix-metalloproteases (MMPs) (F).Top10 ORA for molecular function GO categories in 
NMDA stimulated KO neurons compared to WT. Basal signature was removed (intersection) to reduce 
noise in gene response to stimulus. Enriched GO categories (padj<0.05, FDR<0.05, sorted according to 
log10 ratio of enrichment) in stimulated KO neurons include chromatin and DNA binding and were 
generally associated with cell response (green) except from macromolecular complex binding(other, 
black) and glycosaminoglycan binding (extracellular matrix, blue) (G). 
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metalloproteases and their direct substrates such as collagen (Col6A3, Col3A1, Col4A1) were 
increased (Dityatev and Schachner 2003). To understand how the observed changes in ANXA2-
deficient neurons modulate stimulus response, I compared transcriptional changes of neurons 
deficient of ANXA2 to WT after NMDA stimulation. For the analysis only differentially expressed 
genes were used (padj<0.05, log2FC±0.5) and the 166 genes differentially expressed in the 
basal state excluded (intersection) leaving 187 of total 353 significantly deregulated genes in 
KO compared to WT in the NMDA treated condition (Fig. 4.10G). These 187 genes matching 
this cutoff were then subjected to GO overrepresentation analysis to investigate molecular 
function (padj<0.05 and FDR<0.05, TOP 10 displayed sorted by ratio of enrichment). In contrast 
to the basal condition, only one term associated with the ECM (glycosaminoglycan binding, 
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blue) and one miscellaneous (macromolecular complex binding, black) were enriched, while all 
other significantly enriched GO categories were closely associated with cell response including 
chromatin binding and DNA binding (green) (Fig. 4.10G). 
In summary, the results supported the in vivo experiments, which suggested that ANXA2 had a 
broad but mild impact on the transcriptional response. ANXA2 was involved with gene sets 
associated with the ECM and could modulate the cell response upon stimulus through an 
alteration of chromatin and DNA binding, amongst others. AnxA2 is a multifactorial protein and 
reader of H4K12ac, a chromatin mark previously linked to alternative exon usage (Benito, 
Urbanke et al. 2015). Additionally, in vivo GSEA indicated a role in RNA processing. Thus, I 
investigated alternative splicing to gain a deeper mechanistic insight.
4.1.8. NMDA but not KCl treatment changes exon usage in WT hippocampal 
neurons 
In order to get a baseline picture of splicing processes and dynamics in neuronal cells in 
response to a stimulus, I tested WT neurons in a stimulated condition to establish a baseline for 
physiological ANXA2 levels. For stimulation I chose NMDA, since ANXA2 was previously shown 
to be responsive to NMDA treatment (unpublished data, Kreutz M., PG Neuroplasticity, Leibniz 
Institute For Neurobiology, Magdeburg) (Valapala, Maji et al. 2014). Additionally, I applied KCl 
as an alternative stimulus to cover different mechanisms of excitation. WT neurons were treated 
with 20 mM KCl on DIV10 for 20 min and subsequently harvested and subjected to RNA 
sequencing to analyse differentially used exons bits (herein exons), using DEXseq (Fig. 4.11A). 
Neurons treated with 20 mM KCl showed three significantly included exons (Pcdh8, GO 
category “calcium ion binding”, Dusp1 GO category “phosphatase activity”; Rpl41, GO category 
“RNA binding”; padj<0.05, log2FC±0.2). Exon exclusion was not detected compared to basal 
condition (Fig. 4.11B). In contrast, stimulation with 50 µM NMDA for 10 min with 10 min recovery 
in conditioned medium prior to harvest (Fig. 4.11C) invoked a total of 719 differentially used 
exons (310 included, light red; 409 excluded, light blue) with padj<0.05. At an additional cutoff of 
log2FC±0.2 148 exons (68 included, red; 80 excluded, blue) were differentially expressed. This 
subset was used for further analysis (Fig. 4.11D). Pathway analysis of differentially used exons 
(padj<0.05, log2FC±0.2) showed significant clusters (padj<0.05) associated with neuronal 
activity such as neurotransmitter secretion, action potential and elongation. Intriguingly, histone 
methylation (specifically including H3K4me, associated with active transcription) was the main 
cluster enriched for differential exon usage. Taken together, this data showed a specific 
response in alternative exon usage upon NMDA but not KCl treatment in neurons, targeting 
pathways associated with epigenetics and learning and memory. Since, this demonstrates the 
difference of alternative exon usage in response to stimulus, I went on to study the effect of 
ANXA2 on exon usage during NMDA stimulation.
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4.1.9. ANXA2 overexpression and deficiency show opposing effects on exon 
usage and target pathways crucial for neuronal signal transduction 
ANXA2 is a reader of H4K12ac, a chromatin mark previously linked to differential splicing and 
cognitive decline in ageing (Benito, Urbanke et al. 2015). Naturally, I asked how this change in 
splicing is conveyed from a histone PTM to translation. Since, in vivo GSEA implicated 
involvement of ANXA2 in splicing and RNA processing, ANXA2 could read the histone 
modification and initiate the respective transcriptional machinery leading to alterations in exon 
usage, ultimately contributing to the behavioural phenotype observed. 
To explore this, I used the same ANXA2 overexpression samples previously investigated for 
differential expression (Fig.  4.9A). Differential exon usage analysis showed 207 exons to be 
differentially expressed at padj<0.05. When an additional log2FC±0.2 cutoff was applied, 150 
exons were regulated significantly different. Interestingly, the majority of these exons (123, blue) 
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Figure 4.11: NMDA but not KCl treatment induces alternative exon usage in primary neuronal 
culture. 20 mM KCl treatment was applied to DIV10 neurons for 20 min. Subsequently, neurons were 
harvested and subjected to RNA sequencing (A). Neurons treated with KCl included exons for only 3 
genes (Pcdh8, Dusp1, and Rpl41) in a significantly different manner (padj<0.05, log2FC±0.2, genes in 
descending order of log2FC). (B). 50 µM NMDA treatment was applied to neurons at DIV10 for 10 min. 
Neurons were allowed to recover for 10 min in conditioned medium prior to harvesting and RNA 
sequencing (C). DEXseq showed 719 exons differentially used between basal and stimulated neurons 
(310 included, light red; 409 excluded, light blue; padj<0.05). At an additional log2FC±0.2 cutoff 148 
exons were differentially expressed (68 included, red; 80 excluded, blue; padj<0.05, log2FC±0.2), x-axis 
indicates number of differentially used exons and percentage of total exons differentially expressed (D). 
ClueGO pathway analysis of 148 differentially expressed exons of (D) (padj<0.05, log2FC±0.2) showed 
stimulus response and epigenetic pathways were enriched (padj<0.05), proximity within cluster 
represents interaction strength, circle size represents padj (E).
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were skipped, while only few (27, red) were included compared to GFP control (Fig. 4.12A). In 
comparison to differential gene expression (3 differentially expressed genes), differential exon 
usage was more pronounced (122 genes with 150 differentially expressed exons). In addition, 
differential expression was mutually exclusive with the exception of one gene (AnxA2, E021 due 
to fusion to GFP), when comparing genomic identifiers (Fig.  4.12B). ClueGO analysis of 
differentially expressed exons in basal ANXA2 overexpressing neurons showed terms 
associated with microtubule fibre structure (regulation of supramolecular fibre organisation, 
negative regulation of supramolecular fibre organisation, regulation of microtubule 
(de-)polymerisation) and neuron projection extension (padj<0.05). This pointed towards an 
alteration in neuronal cytoskeletal structure, crucial for appropriate signal transmission 
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Figure 4.12: Differential exon usage between ANXA2 overexpression and deficiency is inverted 
and targets structural genes associated with neuronal projection.
Differential exon usage analysis in AnxA2 overexpressing neurons compared to GFP showed a total of 
207 exons differentially expressed. The majority of exons, >75 %, were skipped (50 included, light red; 
157 skipped, light blue; padj<0.05). Of these, 150 (27 included, red; 123 skipped, blue; padj<0.05, 
log2FC±0.2) exons were differentially expressed at an additional log2FC±0.2 cutoff (A). Comparison of 
genomic identifiers (GIs) from differential exon usage (padj<0.05, log2FC±0.2; DEXseq, 122 GIs) and 
differential gene expression (padj<0.05, log2FC±0.5; DEseq, 3 GIs) showed overlap for one gene 
(AnxA2) (B). ClueGO biological process (BP) analysis of 150 differentially expressed exons of (A) 
showed GO terms associated with microtubule fibre structure and neuron projection extension 
(padj<0.05) (C). Differential exon usage analysis in Anxa2 KO neurons compared to WT showed >70% 
exon inclusion with a total of 397 exons differentially expressed (260 included, light red; 137 skipped, 
light blue; padj<0.05). Of these, 88 exons were differentially expressed at an additional log2FC±0.2 cutoff 
(81 included, red; 8 skipped, blue; padj<0.05, log2FC±0.2) (D). Comparison of GIs from differential exon 
usage (padj<0.05, log2FC±0.2; DEXseq, 83 GIs) and differential gene expression (padj<0.05, 
log2FC±0.5; DEseq, 230 GIs) showed overlap for two genes (Tmod3, Gfap) (E). ClueGO analysis of 88 
differentially expressed exons in (D) showed GO BP terms enriched associated with neuron 
development, neuron projection and synaptic transmission (padj<0.05) (F).
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(Fig 4.12C). In a complementary approach, I investigated the influence of ANXA2 deficiency on 
splicing. To this end, I analysed the RNAseq results from previous differential gene expression 
analysis of KO neurons with and without NMDA stimulus for differential exon usage. This 
revealed differential regulation of 397 exons at padj<0.05 of which 89 were considered 
significant at an additional log2FC±0.2 cutoff. Importantly, in direct contrast to overexpression 
experiments ANXA2 deficiency lead to major exon inclusion (81, red) and few skipped exons (8, 
blue) essentially mirroring the previous experiment (Fig.  4.12D). Here too differential exon 
usage and differential gene expression showed few commonly deregulated genes (Tmod3, 
E001; Gfap, E006) when comparing genomic identifiers (Fig.  4.12E). Pathway analysis of 
differentially used exons (padj<0.05, log2FC±0.2) using ClueGO showed mainly enriched GO 
terms associated with metabolism, autophagy, synaptic transmission, and neuronal projection 
(Fig.  4.12F). Notably, differential exon usage in overexpression and knockout experiments 
showed inverted ratios between exon skipping and inclusion. However, altered genes contribute 
to closely related GO categories associated with neuronal structures necessary for signal 
transduction.
4.1.1. ANXA2 manipulation changes NMDA-dependent splicing response 
Finding significantly altered exon usage in both ANXA2 overexpression and deficiency in the 
basal state, was highly interesting. Particularly the finding that associated GO terms strongly 
suggest changes in structural composition was intriguing, since this is a necessary basis for 
neuronal signal transduction. Thus, I investigated whether this structural change would influence 
the cellular response to challenged conditions. To this end, I stimulated primary neuronal 
hippocampal cultures overexpressing or deficient of ANXA2 with NMDA or vehicle and 
subjected them to RNA sequencing, as previously described (Fig 4.9A). 
As shown beforehand, overexpression and ANXA2 deficiency led to significantly changed exon 
usage, thus, I removed the basal state for both stimulated conditions. Doing so I also showed 
that differentially regulated exons in the basal states were mostly distinct when comparing 
overexpression and KO. The only overlapping genes were NfIx (GO annotation: transcription 
factor activity, sequence-specific DNA binding), Supt5h (GO annotation: poly(A) RNA binding 
and chromatin binding) and Map6 (GO annotation: microtubule binding) (Fig. 4.13A). Notably, 
Rusc2 was the only gene showing differential exon usage in all conditions and was closely 
linked to intellectual disability and microcephaly (Abramowicz 2016, Alwadei, Benini et al. 2016). 
When comparing stimulated conditions of AnxA2 KO and overexpression common genes 
showing differential exon usage were Ankrd13b (may regulate EGFR internalisation), 
HNRNPA2B1(GO annotations: nucleic acid binding and RNA binding; acts as a nuclear reader 
of the N6-methyladenosine), Map4 (GO annotations: poly(A) RNA binding and microtubule 
binding), and Mapt (GO annotations: protein kinase binding and microtubule binding) 
(Fig. 4.13A). 
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As expected, the majority of differentially regulated exons was found after NMDA stimulation in 
both ANXA2 overexpression and KO. After removal of exons differentially expressed in the 
basal state AnxA2 KO neurons showed differential exon usage in genes associated with 
development, cellular regulation, RNA localisation, and cellular respiration. Further, the main 
cluster formed around synaptic vesicle transport including intracellular transport, chemical 
synaptic transmission, regulation of synaptic plasticity and learning or memory (ClueGO, 
padj<0.05, used gene set indicated) (Fig. 4.13B). Notably, of differentially expressed exons 138 
were excluded while 15 were included in the NMDA stimulated condition (Fig.  4.13C). 
Accordingly, I analysed differential exon usage in neurons overexpressing ANXA2 and 
stimulated with NMDA as described beforehand. After removal of the basal signature, GO term 
analysis showed significant enrichment (padj<0.05) in categories associated with protein 
localisation, growth cone, synaptic vesicle, and regulation of neurotransmitter levels 
(Fig. 4.13D). In this analysis, the majority of 153 differentially used exons was excluded and 35 
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Figure 4.13: NMDA stimulation of AnxA2 overexpressing or deficient neurons changes exon 
usage in genes relevant to synaptic plasticity. 
Venn diagram of differentially used exons of all 4 tested conditions showed little overlap for ANXA2 
overexpression and KO. Stimulation with NMDA introduced alternative exon usage in both KO and 
overexpression compared to basal state (A). Stimulation with NMDA in AnxA2 KO neurons induced 
alternative exon usage mainly in genes associated with synaptic vesicle transport and learning and 
memory after removal of basal differentially expressed genes (B). Of differentially expressed exons in 
NMDA stimulated KO neurons 138 exons were excluded while 15 were included (C). NMDA stimulation 
of neurons overexpressing ANXA2 showed differential exon usage in genes mainly associated with 
regulation of neurotransmitter release and growth cone (axon guidance) (D). Of differentially expressed 
exons in NMDA stimulated ANXA2 overexpressing neurons 153 exons were excluded while 35 were 
included (E). All exons used in the analysis were significant at padj<0.05, log2FC±0.2.
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included (Fig.  4.13E). These findings strongly suggested that ANXA2 is closely involved in 
alternative exon usage specifically in genes relevant for synaptic plasticity and in turn learning 
and memory. Intriguingly, the terms enriched in both KO and overexpression are 
complementary, yet more pronounced in KO, also represented by numbers of genes expressed. 
Notably, this finding was also reflected in the initially observed phenotype in AnxA2 KO and 
overexpression. The obvious question was how the alternative exon usage similar in 
overexpression and KO would induce opposing behavioural phenotypes. To elucidate this 
question I analysed the properties of alternatively used exons. 
4.1.2. ANXA2 regulates energy metabolism by alternative 5’ usage in a H4K12ac-
associated manner
ANXA2 overexpression and deficiency showed inverted ratios in alternative exon usage. 
However, NMDA stimulation lead to significant exon skipping, affecting related biological 
processes in both mutations. To understand how a seemingly similar mechanism contributes to 
opposing behavioural phenotypes I plotted each changed exon as percentage of the total 
maximum transcript length at the relative location in the gene body which was divided into 100 
bins starting from 0. Additionally, I plotted H4K12ac ChIP peaks, which showed enrichment 
around the TSS. I hypothesised that the peaks must correlate to exons alternatively used in 
ANXA2 mutant, if the exon usage changes are causally linked to ANXA2 in a H4K12ac-
dependent complex. 
Plotting NMDA treated WT compared to control showed alternative exon usage along the entire 
gene body with little enrichment towards the 3’ end of gene bodies (100) and did not coincide 
with H4K12ac signature (Fig  4.14A). NMDA stimulated ANXA2 overexpressing neurons 
compared to basal state showed increased alternative exon usage along the gene body and 3’, 
also a subtle increase of alternatively used exons was observed towards the TSS (Fig 4.14B). 
Importantly, when comparing NMDA-treated AnxA2 KO to unstimulated control, I observed few 
differentially used exons along the gene body, while I found substantial deregulation coinciding 
with H4K12ac peaks (Fig  4.14C). Merging the alternative exon usage signatures of each 
condition underlined the enrichment along the gene body towards the 3’ UTR in WT and 
overexpression but not KO, which showed enrichment around H4K12ac peaks (Fig.  4.14D). 
Importantly, 51% of alternative exon usage in ANXA2 deficient neurons was restricted to the first 
10% of the gene body, while the rest of the gene bodies harboured 49% of total differentially 
used exons and showed no enrichment for any KEGG pathways. Analysis of genes associated 
with the H4K12ac peak in NMDA stimulated KO revealed KEGG pathways related to energy 
metabolism such as citrate cycle, pyruvate metabolism, glycolysis but also diseases such as 
Parkinson’s disease and AD (Fig. 4.14E).
Taken together these findings suggest that ANXA2 acts as a reader of H4K12ac, not only 
contributing to differential exon usage in genes associated with learning and memory but also 
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by specifically targeting alternative 5’ exon usage in genes closely associated with energy 
metabolism. How precisely this contributes to improved spatial memory function remains to be 
elucidated. However, one can speculate that the alternative 5’ usage in AnxA2 KO neurons 
could impact the regulation of protein synthesis through altered ribosomal recruitment (Filbin 
and Kieft 2009, Rojas-Duran and Gilbert 2012), thus generating an energetically favourable 
environment.
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Figure 4.14: ANXA2 regulates energy metabolism by alternative 5’ usage in an H4K12ac 
associated manner.
Histogram of percent of differentially used exons (left y-axis) in treated neurons compared to basal state, 
and number of H4K12ac ChIP peaks (right y-axis) both illustrated relative to gene body length (-10% - 
0% - 100%) for NMDA treated WT neurons (A), NMDA treated ANXA2 overexpressing neurons (B), 
NMDA treated KO neurons (C), and merge of A-C (D). KEGG pathway analysis (p<0.05, FDR<0.05) for 
exons alternatively used 10% downstream of TSS showed energy metabolism pathways. Same analysis 
for exons differentially expressed in 10%-90% gene body length showed no enrichment for KEGG 
pathways (p<0.05, FDR<0.05) (E). All exons used in the analysis were significant at padj<0.05, 
log2FC±0.2.
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4.2. Novel treatment strategies for Alzheimer’s Disease (AD) 
I targeted the two essential molecular pathologies of Alzheimer’s disease in two lines of 
experiments by testing novel agents to ameliorate the pathogenesis. Patients suffering from AD 
display Aβ plaques and neurofibrillary tangles (NTFs) but also significantly increased HDAC6 
levels are observed. Reducing HDAC6 was previously reported to reinstate memory 
impairments in a mouse model for AD-like amyloidosis (Govindarajan, Rao et al. 2013). Further, 
HDAC6 reduces microtubule acetylation levels, decreasing their stability and deacetylates Tau, 
promoting its phosphorylation and aggregation. Thus, the first set of experiments targeted 
HDAC6 inhibition and deficiency to increase TAU and microtubule acetylation, thereby 
ameliorating the pathology induced by NTFs. In the second set of experiments we tested the 
novel compound anle138b. The compound was previously reported to be beneficial in different 
aggregopathies, including a model for AD-like tauopathy (Wagner, Krauss et al. 2015). In our 
experiments we used anle138b to targeted amyloid beta (Aβ) induced pathology by 
pharmacologically inhibiting membrane pores caused by Aβ oligomers.
4.2.1. Targeting the interaction between TAU and HDAC 6 to ameliorate AD-like 
tauopathy 
In several instances the decrease of TAU acetylation has been demonstrated to promote TAU 
aggregation (Cook, Gendron et al. 2012, Noack, Leyk et al. 2014, Selenica, Benner et al. 2014). 
Microtubuli and TAU were shown to be a direct substrate of HDAC6 (Hubbert, Guardiola et al. 
2002, Ding, Dolan et al. 2008). This suggests that inhibiting HADAC6 would increase TAU and 
microtubuli acetylation and in turn reduce TAU deposition while enhancing microtubuli stability. 
Additionally, increasing acetylation levels through HDAC6 removal has proven beneficial in 
mitigating the pathology in models for Aβ amyloidosis, one of the two pathological molecular 
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Figure 4.15: JS28 does not change tubular acetylation in PNC. 
Western blot analysis of primary hippocampal neurons treated for 24 h with JS28 at concentrations from 
0.03 µM to 1 µM did show changes in tubular acetylation normalised to β-actin (A). Additional Western 
blot from primary hippocampal cultures after 24 h JS28 application at concentrations from 0.125 µM - 
2 µM normalised to β-actin (B). No change could be observed. Error bars indicate SEM.
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hallmarks of AD (Govindarajan, Rao et al. 2013). To investigate whether HDAC6 could be a 
feasible drug target in the other molecular hallmark of AD, namely TAU deposition and 
neurofibrillary tangles (NFT), I tested the effect of HDAC6-dependent acetylation in a model for 
AD-like tauopathy. To this end, I tested the novel compound JS28, which was suggested to 
specifically inhibit HDAC6 and in turn increase tubular acetylation levels at nano molar 
concentration (unpublished data, Senger and Jung). In contrast to this report from cell lines, I 
found JS28 not to alter tubular acetylation in primary hippocampal culture as demonstrated in 
Western blot. Therefore JS28 was not a suitable compound for further in vivo testings 
(Fig. 4.14A+B). 
Since these results ruled JS28 testing in vivo, I took an alternative approach and generated a 
genetic in vivo model. Therefore, I crossed heterozygous male mice of the THY-Tau22 mouse 
model for AD-related Tau pathology expressing the humanised quadruple repeat tau, with 
heterozygous Hdac6 knockout females. The resulting male wild-type (control); Tau+/T, Hdac6-/y 
(HDAC6 KO); Tau+/T, Hdac6-/y (TAU/HDAC6 KO) or Tau+/T, Hdac6+/y (Tau) offspring was tested. 
Since Tau pathology progresses age-dependently, control, HDAC6 KO, Tau/HDAC6 KO, and 
Tau mice were aged for 6 or 13 months to generate two cohorts, an early-stage and a late-stage 
of the phenotype (Fig 4.15A). Basic anxiety, motor and cognitive performance were assessed in 
a behavioural test battery starting with anxiety tests (open field, elevated plus maze), followed 
by a spatial navigation and memory task (Morris water maze) and classical pavlovian fear 
memory test (contextual fear conditioning) (Fig 4.15B). 
4.2.1.1. Anxiety is modulated by Hdac6 deficiency in THY-Tau22 transgenic mice. 
At 6 months of age mice expressing the TAU transgene spent significantly more time in exposed 
areas (F(1,52)=10.92, p=0.002, 2-way ANOVA), indicating less anxious behaviour in the open 
field. Post-hoc testing found the increase of anxious behaviour to be significant when compared 
to HDAC6 KO (p=0.037, Tukey). No interaction between the transgenes was observed 
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Figure 4.16: HDAC6 and TAU mating scheme and behavioural paradigm. 
Mating scheme of parental transgenic mouse lines and resulting offspring genotypes, Tau+/+, Hdac6+/y 
(control, n=15); TAUT/+, HDAC6-/y (HDAC6 KO, n=15); TAU+/T, Hdac6-/y (TAU/HDAC6 KO, n=20) or TAU+/
T, HDAC6+/y (Tau, n=15). Cohorts were tested after 6 and 13 months respectively (A). The behavioural 
test battery was performed for open field test, elevated plus maze, Morris water maze and contextual fear 
conditioning on consecutive days. Afterwards, animals were returned to home-cage (HC) for 4 days 
before sacrifice (B).
Op
en 
Fie
ld
Mo
rris
 W
ate
r M
aze
Ele
vat
ed 
Plu
s M
aze
sacrifice
4 days HC
Co
nte
xtu
al F
ear
 Co
ndi
tion
ing
A
HDAC6 -/+
Tau +/T
6 months
13 months
Behavior
HDAC6 KO 
Control 
Tau 
Tau / HDAC6 KO 
B
Results
(Fig.  4.16A). To investigate potential motility differences and to further rule out motor 
impairments common in most Tau pathology models, travelling speed in the open field was 
measured. This did not show a significant difference between Tau and control and confirmed 
that the TAU transgene in this model does not contribute to motor deficits in the open field test, 
which is in line with previous reports (Schindowski, Bretteville et al. 2006, Van der Jeugd, Blum 
et al. 2013) (Fig. 4.16A). I found travel speed was increased dependent on the expression of the 
Tau transgene (F(1,61)=7.14, p=0.01, 2-way ANOVA). Again, this observation was found to be 
significantly different in post-hoc testing when HDAC6 KO were compared to Tau/HDAC6 KO 
littermates (p=0.025, Tukey) (Fig. 4.16B). To assess the observed anxiety phenotype in more 
detail, I performed an elevated plus maze test. In contrast to a previous report (Schindowski, 
Bretteville et al. 2006), no anxiety phenotype could be observed at an early-stage time-point in 
Tau. All groups spent significantly more time in the closed arms and no difference between 
groups could be detected (Fig.  4.16C).
4.2.1.2. Absence of HDAC6 modulates hippocampus-dependent memory in the early-
stage AD-like tauopathy model. 
Aside from increased anxious behaviour, the expression on quadruple repeat Tau was reported 
to cause impairment in spatial memory (Van der Jeugd, Blum et al. 2013). To test if HDAC6 
deficiency has a beneficial effect on cognitive function in the Tau pathology model, I conducted 
the Morris water maze test for spatial navigation and memory, a highly hippocampus-dependent 
task. Animals were trained on consecutive days during which the latency to find the submersed 
platform (escape latency) was taken as a measure for learning performance. Probe tests (PT) 
were performed when one of the cohorts reached a plateau in their performance. As expected, 
control animals showed the lowest escape latency, indicative of fast memory acquisition. 
However, I did not observe significant differences between the groups for the early-stage 
cohorts (F(3,40)=1.034, p=0.388, 2-way ANOVA), which is in line with my previous findings in 
the elevated plus maze test where I did not detect the previously reported anxiety phenotype 
(Schindowski, Bretteville et al. 2006) (Fig. 4.16D). 
To elucidate the role of HDAC6 deficiency in cognition, I performed an additional memory test, 
namely contextual fear conditioning, a hippocampus-dependent classical pavlovian conditioning 
paradigm with additional involvement of the amygdala. As expected, during training all groups 
displayed comparable initial freezing. When the animals were tested after the conditioning 
stimulus during recall, a significant difference between the groups based on HDAC6 deficiency 
was detected using 2-way ANOVA F(1,63)=7.84, p=0.007). Importantly, no interaction between 
the transgenes was observed. In turn, controls and Tau did not show differences in freezing 
behaviour (Fig.  4.16E). Taken together these findings indicate that the Tau22 mouse model 
shows increased activity but no anxiety phenotype compared to wild-type controls at 6 months 
of age. The model does not show spatial or contextual fear memory impairments at 6 months of 
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age. Notably, HDAC6 deficiency impacts contextual fear memory in Wt and TAU transgenics, 
suggesting a beneficial effect in the presence of a pathological cognitive deficit. 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Figure 4.17: Hdac6 KO mildly modulates Tau pathology at 6 months of age (early-stage). 
TAU+/+, Hdac6+/y (control, n=15); TAUT/+, Hdac6-/y (HDAC6 KO, n=15); TAU+/T, Hdac6-/y (TAU/HDAC6 KO, 
n=20) or TAU+/T, Hdac6+/y (Tau, n=15) were tested in the open field for anxiety. While no interaction 
between the transgenes was observed, 2-way ANOVA revealed a significantly increased time spent 
exposed in animals expressing the TAU transgene (F(1,52)=10.92, p=0.0017). Post-hoc testing found 
this difference to be significant when HDAC6 KO were compared to Tau/HDAC6 KO (p=0.037, Tukey) 
(A). Similarly travel speed was decreased in groups expressing Tau (F(1,61)=7.14, p=0.01). Again post-
hoc testing revealed a significant difference when HDAC6 KO were compared to Tau/HDAC6 KO 
(p=0.025, Tukey) (B). Elevated plus maze did not reveal a significant difference between cohorts with no 
interaction of the transgenes (C). Morris water maze did not show significant differences between groups 
during early-stage (D). During fear conditioning all cohorts showed equal freezing. After training, during 
recall cohorts deficient of HDAC6 showed significantly increased freezing F(1,63)=7.84, p=0.007) with no 
interaction with the Tau transgene. If not otherwise indicated, 2-way ANOVA was used for statistical 
testing, error bars indicate SEM, *= p<0.05, **= p<0.001, ***= p<0.0001.
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4.2.1.3. Removal of HDAC6 reinstates anxiety behaviour in aged mice 
To explore the interaction between Tau pathology and HDAC6 KO along ageing, I subjected the 
aged cohort (13 months of age) to the same behavioural test battery as the early-stage cohort. 
Late-stage groups expressing the TAU transgene displayed overall higher exposure in the open 
field test when compared to TAU wild-type littermates (F (1,44)=16.48, p=0.0002, 2-way 
ANOVA). Post-hoc testing revealed that this increase was only significant for Tau/HDAC6 KO 
when compared to control (p=0.002, Tukey) and HDAC6 KO (p=0.003, Tukey) but not Tau 
(Fig. 4.17A). Importantly, 2-way ANOVA did not report an interaction between the transgenes. To 
rule out involvement of motor dysfunction, I measured the travel speed during the open field and 
observed significantly decreased movement in cohorts expressing the TAU transgene 
(F(1,43)=6.11, p=0.018, 2-way ANOVA) (Fig. 4.17B). To asses anxious behaviour in more detail, 
I additionally tested all groups in the elevated plus maze and found a significant interaction 
between both transgenes (F(1,39)=20.16, p<0.0001, 2-way ANOVA). Post-hoc testing revealed 
that the Tau cohort showed a decreased preference for the closed arms when compared to 
control, indicating reduced anxiety (p<0.0001, Tukey post-hoc), which is in line with a previous 
report (Van der Jeugd, Blum et al. 2013) (Fig. 4.17C). Importantly, this phenotype was reversed 
by HDAC6 deficiency, thus the difference between TAU wild-type and transgenic animals was 
absent in the Hdac6 knockout condition (p=0.47, Tukey). Tau/HDAC6 KO performed similar 
compared to control and HDAC6 KO. Thus they spent more time in closed quadrants compared 
to Tau, demonstrating re-instatement of anxious behaviour. 
4.2.1.4. HDAC6 deficiency does not affect memory in late-stage Tau. 
I could not observe a cognitive deficit at an early-stage time point in Tau expressing groups. I 
went on to test spatial memory in late-stage groups. In line with the findings of the early-stage 
cohort, I could not identify an effect of HDAC6 deficiency in the late-stage cohort. However, I 
found clearly increased escape latencies based on the expression of the TAU transgene 
(F(1.579,15.79)=19.09, p=0.0001, one-way ANOVA), indicative of impaired memory acquisition 
in TAU transgenic cohorts (Fig 4.17D). In contextual fear conditioning, I could observe a higher 
tendency towards initial freezing in the late-stage cohorts as compared to early-stage groups. 
Importantly, Tau did not show impaired behaviour during training or after conditioning when 
compared to control. However, similarly to the early-stage cohort, there was a trend towards 
increased freezing during recall trials in groups deficient of HDAC6 (F(1,41)=6.62, p=0.014, two-
way ANOVA), indicating increased memory performance (Fig. 4.17E). 
In summary, some of the findings contrast current literature on the Tau22 mouse model for AD-
like tauopathy. Nonetheless, the findings emphasise the beneficial effect of HDAC6 deficiency in 
both age groups in contextual fear memory, where memory response is elevated above control 
levels. Additionally the reinstatement of anxious behaviour in this model underlines the 
relevance of HDAC6 modulation in the disease, particularly since an exceeding effect has been 
demonstrated for AD-like amyloid deposition (Govindarajan, Rao et al. 2013).
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Figure 4.18: Hdac6 KO rescues Tau anxiety phenotype at 13 months of age. 
Aged cohort of TAU+/+, Hdac6+/y (control, n=12); TAU+/+, Hdac6-/y (HDAC6 KO, n=12); TAU+/T, Hdac6-/y 
(TAU/HDAC6 KO, n=10) or TAU+/T, Hdac6+/y (Tau, n=14). Open field test did not show an interaction 
between the transgenes (F(1,44)=1.93, p=0.172), but showed increased freezing for cohorts expressing 
the TAU transgene (F (1,44)=16.48, p=0.0002) (A). Similarly, travel speed showed no significant 
interaction between the transgenes (F(1,43)=0.44, p=0.51), but travel speed was reduced for TAU 
expressing groups (F(1,43)=6.11, p=0.018) (B). Percent of time spent in the closed arms of the elevated 
plus maze revealed a significant interaction between the transgenes (F(1,39)=20.16, p<0.0001). Post-hoc 
testing found Tau to spent significantly less time in closed arms compared to controls (p<0.0001, Tukey 
post-hoc). This effect reversed in the absence of HDA6 (p<0.474, Tukey post-hoc) (C). Morris water 
maze showed separation in escape latency based on presence of Tau transgene (F(1.579,15.79)=19.09, 
p=0.0001, one-way ANOVA) (D). Contextual fear conditioning showed no significant difference between 
groups before training (F(1,36)=0, p>0.999), however cohorts deficient of HDAC6 showed significantly 
increased freezing during recall (F(1,41)=6.62, p=0.014) (E). If not otherwise indicated, 2-way ANOVA 
was used for statistical testing, error bars indicate SEM, *= p<0.05, **= p<0.001, ***= p<0.0001.
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4.2.1.“The diphenylpyrazol compound anle138b blocks Aβ channels and 
rescues disease phenotypes in a mouse model for amyloid pathology” 
This Project  resulted in a manuscript already published in EMBO Molecular Medicine on 1
05/12/17 (see Appendix for full article). 
In this research article, we showed that oral administration of the diphenylpyrazol compound 
anle138b reinstated hippocampal, synaptic and transcriptional plasticity in the APP/PS1 mouse 
model for amyloidosis and AD. We tested 2 groups a pre-plaque group at 6 months of age and a 
post-plaque group at 10 months of age. Both groups were treated with anle138b or placebo for 
4 months before begin of the experiments. We investigated long-term potentiation (LTP) in 
animals treated with anle138b before deposition of plaques or after amyloid deposition and 
report a full reversion of the APP/PS1 phenotype. Furthermore, we demonstrated that LTP 
rescue translated into a full and partial reinstatement of spatial memory in pre- and post-plaque 
groups respectively, in the hippocampus-dependent Morris water maze. Since AD pathogenesis 
correlates with deregulated gene expression we investigated transcriptome changes in both 
groups and found that in pre-plaque group 202 genes were differentially expressed between 
control and APP/PS1. Downregulated genes represented gene ontology (GO) terms associated 
with energy metabolism, mitochondria function, cytoskeleton integrity and synaptic plasticity, 
while categories linked to cell growth were enriched by unregulated genes. Importantly, when 
control and anle138b-treated APP/PS1 of the pre-plaque group were compared, only 27 genes 
remained differentially regulated and no significantly enriched pathways could be identified. 
Thus the APP/PS1 transcriptional phenotype was almost fully reversed by anle138b in the pre-
plaque group. 
In the post-plaque group, the APP/PS1 placebo-treated cohort showed 130 genes differentially 
regulated when compared to controls. These genes were also deregulated in APP/PS1 
anle138b-treated when compared to controls and an additional 117 genes were differentially 
expressed which were linked to induction of inflammatory responses. This indicated that the 
reinstatement of the observed phenotypes with anle138b treatment was not based on reduction 
of amyloid induced inflammation. To obtain mechanistic insight, we characterised membrane 
conductivity in the presence of anle138b using black lipid membranes (BLM). This work was 
conducted in collaboration with Gillmann and Lee. We showed that Aβ1-40 treatment of DOPS/
POPE (1:1) membranes induced stepwise growth of membrane conductance (Fig  4.18A). 
Importantly, anle138b doped membranes showed fluctuation but no stepwise increase and 
reduced bulk conductance (Fig 4.18B). These results indicated that anle138b treatment alters 
pore dynamics, resulting in short lived and less stable available pores. 
To sustain the notion that anle138b alters Aβ1-40 pore properties in vivo, I established a protocol 
which allowed me to treat primary hippocampal neurons with Aβ1-40 monomers or oligomers and 
 This project was executed in cooperation with Ana Martinez Hernandez (coordinated the experiments, performed 1
behaviour testing of mice, RNAseq and amyloid plaque analysis), Alan L. Gillman (performed electrophysiology on 
black membranes), and Joon Lee (AFM measurements of Aβ on membranes)
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asses membrane permeability and cell viability (Fig 4.18C). Using this protocol, I showed that 
the addition of Aβ1-40 oligomers but not Aβ1-40 monomers significantly decreased fluorescence, 
indicating reduced membrane selectivity as measured by using the CyQuant cell permeability 
assay (Fig 4.18D). Importantly, this effect was reversed when neurons were pre-treated with 
anle138b 24 h before the addition of Aβ (Fig 4.18D). In order to show that this restoration was 
not due to an anle138b mediated reduction of cell death, I tested the viability of hippocampal 
neurons in the presence and absence of anle138b, using the metabolism based MTT assay. 
The hippocampal neuronal viability was equally affected by Aβ1-40 monomer and oligomer 
treatment in my experimental setup (Fig  4.18E). To test if the effect on membrane integrity 
depended on the pre-incubation with anle138b, I reversed the application of Aβ species and 
anle138b (Fig. 4.18F), analogous to the post-plaque treatment in vivo. Also in this case did the 
Aβ oligomer but not monomer exhibit a negative effect on membrane integrity. Application of 
anle138b was also able to suppress the effect of toxic Aβ oligomers on membrane integrity, 
when the experimental procedure was reversed and anle138b was supplemented after 
hippocampal neurons had been incubated with Aβ oligomers for 24 h (Fig 4.18G). At this time 
point neurons had already shown reduced viability (Fig 4.18H). To a certain extent, this scenario 
resembled that of the post-plaque group in that neuronal damage preceded anle138b treatment. 
These results were in line with our data demonstrating that anle138b reversed LTP and partially 
restored memory deficits in the post-plaque group. In summary, we demonstrate that anle138b 
treatment reverses key pathological hallmarks in a model for Aß pathology before and after 
onset of the pathology. These findings are in line with previous beneficial reports in Tau 
pathology models and underline the clinical relevance of anle138b to treat both molecular 
pathologies of AD. 
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Figure 4.19: Anle138b ameliorates Aβ1-40 induced membrane permeability.
Application of Aβ1-40 to black lipid membrane induced stepwise increase in conductance. This increase 
followed the direction of current, thus inverted when the applied voltage was reversed (top), while 
application of anle138b abolished increase beyond 10 pA (bottom) (courtesy of Gillman and Lee, cf. text) 
(A). Detail of anle138b doped trace from (A) discreet conductance levels (dashed, blue) suggested 
events for three individual pores (B). On DIV 10 hippocampal neurons were treated with anle138b (1 
µM) or vehicle 24 h prior to Aβ1-40 mono or oligomers (10 µM, n=4/group) application. Fluorescence was 
measured as indicator for membrane integrity 48 h after Aβ application using a CyQUANT assay 
(Thermo Fisher) (C). Vehicle treated neurons showed significantly impaired membrane integrity after Aβ 
oligomer application compared to control (p=0.007, t-test) or monomer treatment. Importantly, membrane 
integrity was rescued when anle138b was applied beforehand (D). Same experimental conditions as (D) 
but MTT assay was used to measure cell viability. Aβ treatment (mono- and oligomer) lead to reduced 
viability compared to control in (p=0.002, t-test) regardless of anle138b (E). The experiment was 
conducted as described in (C) but with reversed application of anle138b and Aβ1-40 species (F). A 
significant group difference was revealed by one-way ANOVA. Tukey post-hoc testing found significantly 
reduced membrane integrity application of Aβ1-40 oligomers without anle138b (p=0.003 vehicle: control 
vs. Aβ oligomers). Importantly, treatment with anle138b after oligomer application reversed this effect 
(G). Cell viability was assessed using MTT assay and same experimental approach as (G). Aβ1-40 
oligomers reduced cell viability in the presence and absence of anle138b (Group difference p<0.5, One-
way ANOVA with post-hoc testing) (H). Error bars indicate SEM.
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Results
4.3. Analysing neuronal network dynamics in primary 
hippocampal cultures 
Little is known about the interplay of cells within a neuronal network which is active during a 
stimulus. It is unknown whether neurons that are active differ in their transcriptional state 
compared to those secondarily activated by the initially stimulated cells. To be able to 
distinguish the populations fluorescent tags and genetic tools need to be introduced into 
subsets of the network. Thus, I established a new method to transmit genetic modification into 
defined subsets of neuronal cells independent of promoter usage or genotype using AAV 
deliverable constructs. Optogenetic tools offer high spatial and temporal specificity, to introduce 
stimulation into the network. However, available devices for optogenetic stimulation did not meet 
the requirements. Thus, I designed and built the Luminous Channelrhodopsin Inductor For 
Research - LuCIFR.
4.3.1. Efficient composition of neuronal networks with multiple mutations 
In order to build neuronal networks in which defined percentages, down to single cells, harbour 
a desired modification, I turned to adeno-associated viruses (AAVs). They are highly efficient 
viral particles with near absolute infection efficiency in culture and can deliver genetic constructs 
of up to 4.5 kb. This is sufficient for most cargos including protein overexpression, fluorescence 
tagging, CRISPR/Cas9, or Optogenetic tools. In brief, the construct delivery protocol I 
developed requires freshly dissociated primary hippocampal neurons, which are resuspended in 
medium containing a CO2 resource. AAVs are then added to the suspension at high titer and 
incubated for 1 h at 37ºC after which cells are seeded at the desired concentration (Fig. 4.19A, 
cf. “3.4.4. Heterogenous primary neuronal cultures”). The construct delivery efficiency is 
dependent on viral titer and scalable by increasing the infectious units per reaction (Fig. 4.19B). 
Notably, high titer infections require presence of heparin at 5 µg/µl in the maintenance medium 
to absorb AAVs released from cellular debris. Under my supervision, Lukas Faiß  used this 2
protocol during his B.Sc. thesis to deliver Channelrhodopsin2 (ChR2 H134R) to a distinct sub-
populations of neurons in a culture. He found Photo-stimulation of neuronal cultures with 10% 
ChR positive (ChR+) neurons showed increase in cFOS protein levels 30 min after activation in 
 Driving transcriptome changes in a neuronal network - a new model, Georg-August-Universität, Göttingen2
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Figure 4.20: Production of heterogeneous neuronal cultures.
Neuronal cells were resuspended in infection medium, supplemented with AAV and seeded at desired 
ratios (A). Illustration of heterogeneous cultures with two subpopulations, one expressing GFP and 
another expressing mCherry after infection at low titer (top) and high titer (bottom) AAV (B). 
Heterogeneous culture with 10% ChR2+ (H134R) neurons. After light stimulation cFos was induced in 
surrounding but not ChR2+ (H134R) cells as indicated by arrows (top). No induction was visible in the 
absence of ChR (bottom) (C). FACSorting of heterogenous cultures seeded at 1:9 (ChIEF-tdTomato:Fos-
eYFP-reporter) shows 13.8% and 88.3% sorted from parent population (D). 3:7 (ChIEF-tdTomato:Fos-
eYFP-reporter) seeding ratio results in 27.2% and 76.1% sorted cells from parent population (E). Cell 
purity after FACS in sample of 20 sorted cells (F) and single sorted cells (G) for ChIEF-tdTomato and 
Fos-eYFP-reporter. Experiments for (C) were performed by Lukas Faiß under my supervision.
Results
 93
low infection 
high infection
AAV-GFP AAV- mCherry
resuspend cells
split sample
add AAV incubate cells 
with AAV
merge cells from both 
infections in desired ratio
Merge
10% ChIEF, 90% FOS 
A
B
C
D
E
F
G
30% ChiEF, 70% FOS 
Channelrhodopsin cFos DAPI Merge
+ ChR
+ Light
- ChR
+ Light
ChIEF-td-Tomato Fos-eYFP reporter
Results
secondarily stimulated cells but not primarily stimulated ChR2+ cells (Fig. 4.19C). To follow up 
on this intriguing finding I established another protocol to be able to separate cells that 
expressed Channelrhodopsin and cells that were activated secondarily by ChR+ photo-activated 
cells. To this end, I first switched from ChR2H134R to the faster and more sensitive ChIEF 
variant fused to tdTomato and introduced an activity reporter using Fos promoter-driven eYFP 
expression. The two constructs were delivered to separate subpopulations of the same PNC at 
a ChIEF+ to FOS-reporter+ cell ratio of 1:100, 1:9, 3:7 and 1:1. On DIV10 neurons were photo-
stimulated and sorted according to their fluorescence tag using FACS. With the newly 
established protocol I was able to achieve high sorting purity of intact cells from heterogeneous 
cultures. At a seeding ratio of 1:9 FACS showed a ratio 13.8% and 88.3% (Fig. 4.19D); for a 
seeding ratio of 3:7 FACS resulted in 27.2% and 76.1% of parental population (Fig.  4.19E). 
Sorting efficiency was assed using fluorescence microscopy for a pool of 20 ChIEF+ and FOS-
reporter+ cells each (Fig. 4.19F) and showed no single false positive. Single cell sorting into 96 
well plates gave identical results in purity and accuracy (Fig. 4.19G). To investigate molecular 
properties of primary and secondarily stimulated cells I sorted 384 cells according to the 
established protocols and together with the LIMES-institute in Bonn subjected them to 
Massively Parallel Single-Cell RNA-Seq (MARSeq) (Jaitin, Kenigsberg et al. 2014) . The results 
of this data however are pending at the time of writing this thesis. 
4.3.2. Introducing the Luminous Channelrhodopsin Inducer For Research 
(LuCIFR) 
Current commercial solutions for light-induced activation of cells in culture using optogenetics 
lack several key aspects relevant to molecular experiments which are conducted in CO2 
incubators. Self-made solutions often trade accuracy for affordability or are too complex to be 
built in standard research facilities. Thus, I designed a new solution targeting specifically the 
needs of molecular biologists working with live cells in incubators. A fundamental difference in 
the approach is that LuCIFR is engineered to give high precision while maintaining easy access 
to the user at an affordable price. At the time of writing LuCIFR is licensed to industrial partners, 
thus I will focus on prototypes, as the exact blueprints of LuCIFR are classified (EUIPO#: 
004093268). 
Prototype A featured 6 high power LEDs in a plastic enclosure controlled by an H-bridge 
receiving input from an Arduino UNO micro-controller and powered via USB (Arduino) and a 
constant current source (LED/H-bridge) (Fig.  4.20A). The second iteration (prototype B) was 
upgraded with a bluetooth module for wireless communication (Fig 4.20A+B). Custom-written 
software was used to receive and transmit stimulation protocols from the operator via bluetooth. 
For stimulation blue LEDs at 475 nm were used to cover the peak absorption spectrum of 
Channelrhodopsin (ChR2H134R) (Fig. 4.20D). The LED was setup in a way that only the top 
80º angle was used per well to avoid edge intensity drop off, and the LED was placed in 2.08 
cm distance to the dish. This setup resulted in a stimulation intensity 0.057 lm/mm2 which in turn 
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allowed the incorporation of a dispersion filter due to high photo current (Fig.  4.20C). 
Stimulation efficiency was electrophysiologically tested by patch clamping (courtesy of Markus 
Stahlberg). Test stimulation of ChR2H134R expressing primary neurons using prototype A 
shows high responsiveness of the cells to light stimulus during a single pulse 2 Hz stimulation 
and 20 Hz stimulation. At 25 Hz long term stimulation ChR2H134R reaction showed a plateau 
due to channel recovery latency (Fig. 4.20E), while prototype A stimulation frequency exceeds 
16 MHz with 25 ns pulse delay. Stimulation efficiency was also tested by qPCR with cFos 
mRNA expression levels as read-out (courtesy of Lukas Faiß). Notably, cFos was increased 
slightly 15 min post stimulation and significantly 30 min after stimulation. For prototype B I 
received the “Innovation to application award” which allowed the further development of the 
hardware and to build a waterproof enclosure together with A3M (engineer, Braunschweig) and 
Neumanns Büro (industrial designer, Braunschweig) (Fig 4.20G-L).  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Figure 4.21: LuCIFR a new optogenetic stimulator for molecular biology.
Prototype-A showing breadboard micro controller, constant current source, high Power LED cluster in 
waterproof enclosure (A). Basic circuit of prototype-B shows bluetooth module upgrade and change from 
H-bridge to Tip120 transistor control (B). Illustration of LED % luminous flux spectrum coverage and 
ChR2(H134R) absorption spectrum shows peak at activation peak (D). Only 80% of total emission angle 
are used for direct illumination (dark blue), rest is scattered (light blue) (D, top). LED is positioned central 
below well with 2.08 cm distance to dispersion filter (D, bottom). Patch clamping (performed by Markus 
Stahlberg) shows reactivity of ChR2+ primary neurons to prototype-B stimulation for single pulse, 2 Hz, 
20 Hz, and plateaus at 25 Hz (E). cFos is increased in qPCR 15 min and significant 30 min after 
Illumination with prototype-B (qPCR performed by Lukas Faiß) (F). Illustration of LuCIFR after further 
development supported by the “innovation to application” award in waterproof enclosure, illumination 
area (white) and docking station (G-L). 
Results
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5. Discussion 
Alzheimer’s disease (AD) is a multifactorial disease with detrimental social and economic 
impact. The number of patients affected is expected to almost triple by the year 2050, 
increasing socio-economic pressure on relatives and society (World Alzheimer Report 2016). 
Despite tremendous efforts, to date there is no cure and no efficient treatment available. It is 
commonly accepted that the appearance and progression of AD depend on the interplay 
between genetic risk factors and environmental influence. The epigenetic machinery is exactly 
at this interface. To this end, I dedicated significant efforts to study novel players of the 
epigenetic machinery that might serve as new therapeutic targets in cognitive deficits and in AD. 
I identified ANXA2 as a novel H4K12ac chromatin reader in neurons and went on to 
characterise its involvement in learning and memory. My observations suggest that ANXA2 is a 
baseline inhibitor of spatial memory function and that deleting it could be a suitable strategy to 
enhance cognitive performance. Mechanistically the data suggests that ANXA2 influences two 
key aspects relevant to learning and memory. Firstly, ANXA2 contributes to extracellular matrix 
stability, which is known to be a regulator of synaptic plasticity. Secondly, ANXA2 regulates 
genes relevant for energy metabolism through alternative 5’ usage. Although I did not 
specifically test the effect of ANXA2 deletion/inhibition in AD models, my data suggest that this 
could be a suitable strategy. On the other hand, I dedicated part of my work to explore novel 
therapeutic targets with the potential to become therapies against AD. I used both a 
pharmacological approach (anle138b and JS28) and a genetic model of HDAC6 deletion (Tau/
HDAC6). Both strategies reveal promising beneficial effects in different models for AD. 
In addition to studying concrete aspects of AD pathophysiology and epigenetic regulators of 
cognition, I also developed a novel technical strategy to study network dynamics in neurons. 
First I designed and optimised a novel AAV-based vector system to target individual neuronal 
populations. I demonstrated the in vitro effectiveness of this system with a proof-of-principle 
experiment involving channelrhodopsin-mediated activation of neuronal subpopulations. 
Importantly, this system is highly customisable and could be easily adapted for other types of 
applications. As a complementary approach, I designed and engineered a novel device for 
optogenetic stimulation in cell culture (LuCIFR). By combining the vector-based subpopulation 
targeting with FACS sorting, single-cell sequencing and the novel optogenetic device, I came up 
with a revolutionary technical approach to study network dynamics and individual population 
contributions to different kinds of processes, including activity- and network-dependent 
transcriptomic profiles. 
Thus, I used 3 complementary approaches to study molecular pathways in cognitive processes 
with an emphasis on therapeutic applications. I established a role for ANXA2 as a chromatin 
reader involved in spatial memory, contributed to the characterisation of 2 highly novel AD 
treatment strategies (HDAC6 deletion and anle138b), and developed a technical strategy to 
study neuronal network dynamics. Although each of these approaches bears different 
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implications for further research and will have to be pursued separately, collectively they 
constitute a significant advance in the field of molecular neurocognitive research and have great 
potential for further development. In the following sections, I will discuss each of the approaches 
separately with an emphasis on their significance in the context of the current state of research 
and their potential implications.
5.1. ANXA2- a novel reader of H4K12ac 
Alzheimer’s Disease (AD) and many other neurological disorders develop from the interplay 
between genetic and environmental factors. It is therefore highly relevant to study proteins that 
mediate this cross-talk between the genome and the environment. There are newly emerged 
key players of the epigenetic machinery, namely chromatin readers, that are becoming more 
and more relevant for our understanding of disease mechanisms and therapeutic strategy 
development. I identified and characterised ANXA2, a novel chromatin reader of acetylated 
H4K12. Importantly, I demonstrated for the first time that ANXA2 is a baseline inhibitor of spatial 
memory and that genetically inhibiting it could have a beneficial effect on memory that 
recapitulates the effects of HDAC inhibitors (Guan, Haggarty et al. 2009, Stefanko, Barrett et al. 
2009, reviewed in Fischer, Sananbenesi et al. 2010, Benito, Urbanke et al. 2015). This puts 
readers into focus as new drug targets. Importantly, chromatin reader inhibitors to date have 
been reported to be much more specific as compared to HDAC inhibitors (Korb, Herre et al. 
2015, Magistri, Velmeshev et al. 2016, Benito, Ramachandran et al. 2017). Thus a targeted 
drug to ANXA2 could be applied to treat dementia symptomatically, as it would not target a 
causal factor but circumvent it through transcriptional adaptation. Such a drug would be 
beneficial not only in AD but also in age-associated memory impairment and further dementia 
associated diseases.
5.1.1. ANXA2 reads the histone code in the mouse brain 
Peleg and colleges demonstrated that defective learning-associated acetylation of lysine 12 on 
Histone 4 (H4K12ac) correlates to age-associated cognitive impairment (Peleg, Sananbenesi et 
al. 2010). Intrigued by this finding, I wanted to understand how this specific post-translational 
modification (PTM) of a histone tail could be translated into transcriptomic changes and more 
specifically how this PTM can play a major role in cognitive decline in the framework of new 
epigenetic players. The prevalent model for how PTMs, and acetylation in particular, influence 
transcription is that histone tails are dynamically modified by writers (e.g., HATs) and erasers 
(e.g., HDACs), induce conformational changes and would make the DNA more or less 
accessible to the transcriptional machinery (Strahl and Allis 2000). Further, Strahl and Allis 
proposed that proteins without own enzymatic capabilities could recognise specific PTMs and 
serve as a scaffold for larger complexes involved in transcriptional regulation. These so-called 
“chromatin readers” are capable of binding individual or combinatorial patterns of PTMs at 
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histone tails and thus “translate” the histone code by turning epigenetic information into highly 
orchestrated transcriptional patterns. Obviously, this model can rise to high complexity, making it 
very relevant to identify entities that have an influence on neuroepigenetic mechanisms. Based 
on the evidence that H4K12ac is a very important mark for cognitive function, in particular in 
age-associated memory decline, I hypothesised that a chromatin reader of this PTM would itself 
be relevant to learning and memory and contribute to the understanding how a PTM is 
translated into a cognitive phenotype. To identify new targets, Eva Benito and I used stable 
isotope labelling with amino acids (SILAC) to produce protein lysates of soluble chromatin 
(Spellman, Deinhardt et al. 2008). These lysates were exposed to a H4K12ac or H4K12 mimic 
as a bait to capture peptides associating with the mark. This was followed by a pulldown and 
LC-MS/MS to identify bound peptides (collaboration with Nadin Zimmermann) (Fig.  4.1A-C). 
Using this approach, any peptide showing a significant preference for the acetylated compared 
to unmodified H4K12 was a highly interesting target. Notably, the screening revealed four 
proteins significantly binding the mark, one of which was BRD4. BRD4 is a member of the BET 
(Bromodomain and extra-terminal domain) family of proteins and one of the best studied 
chromatin readers in the brain (Korb, Herre et al. 2015, Sartor, Powell et al. 2015, Li, Ma et al. 
2016, Benito, Ramachandran et al. 2017). This finding was highly encouraging for our 
approach, especially because BRD4 displayed the lowest affinity to the mark compared to the 
other identified chromatin readers. This entails that the other targets we identified are potentially 
even more interesting from a functional perspective. While this is speculative, the increased 
selectivity to H4K12ac could indicate a more stable scaffold or higher impact on the adjacent 
genomic region.
In this unbiased screen, we identified ANXA2, which not only showed the second highest affinity 
to acetylated H4K12, but also happens to be a protein with extensively studied functions in the 
cytosolic compartment. ANXA2 implicated with tumour progression (Wang and Lin 2014) and 
activation of STAT6 (Das, Shetty et al. 2010). It was also associated with frontotemporal 
dementia (Gauthier-Kemper, Weissmann et al. 2011, Hallmann, Arauzo-Bravo et al. 2017) and 
was shown to change sub-cellular location during spatial learning (Zhao, Waisman et al. 2004). 
Furthermore, it was reported to be able to shuttle from the membrane to the nucleus (Liu and 
Vishwanatha 2007), bind and repair DNA (Boyko, Mudrak et al. 1994, Madureira, Hill et al. 
2012), RNA (Filipenko, MacLeod et al. 2004), recognise primers as a cofactor for DNA 
polymerase α (Kumble, Iversen et al. 1992, Vishwanatha, Jindal et al. 1992) and was implicated 
with the SMARCA3 chromatin remodelling complex in neurons (Oh, Gao et al. 2013). Taken 
together, theses findings suggest a widespread role of ANXA2 in cellular functions, but the role 
as a chromatin reader specifically is to the best of my knowledge novel and has not been 
reported before. Considering the previously reported functions of ANXA2 associating with 
genomic functions such as transcription, primer recognition, splicing and chromatin structures 
could potentially be linked to the common function as a chromatin reader.
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Mapping ANXA2 in the mouse brain showed that ANXA2 is ubiquitously expressed in brain 
areas associated with higher cognitive function. Moreover, the protein was found in every sub-
cellular compartment tested from membrane to cytosol and nucleus, which is in line with earlier 
reports (Raynal and Pollard 1994, Deora, Kreitzer et al. 2004, Zheng, Foley et al. 2011, Xiu, Liu 
et al. 2016, Aukrust, Rosenberg et al. 2017). The nuclear localisation in particular has not been 
studied in great detail, although ANXA2 was reported to be present in the nucleus and to 
associate to the nuclear matrix (Arrigo, Darlix et al. 1983, Vishwanatha, Jindal et al. 1992, 
Eberhard, Karns et al. 2001, Grindheim, Hollas et al. 2016). Direct chromatin association was 
first shown in this work, where I demonstrated that this pool is not only nuclear but specifically 
chromatin-bound, emphasising the proposed role as a reader (Fig. 4.1D). When characterising 
the spatial expression across brain regions, I found no differences in RNA expression in 
hippocampal sub-regions. However, protein levels were significantly higher in the CA1 as 
compared to other brain regions in 3 month old mice (Fig. 4.1G-H). Immunohistochemistry did 
not indicate a difference in protein level between CA1 and other brain regions (Fig. 4.1F). This 
can be attributed to the non-denaturing conditions of the staining (in contrast to denatured in 
Western blot), since this has been repeatedly reported to influence ANXA2 detection in different 
compartments (Grindheim, Hollas et al. 2014, Grindheim, Hollas et al. 2016, Aukrust, 
Rosenberg et al. 2017). Since ANXA2 was low in nuclear fractions at 3 months of age, the high 
ANXA2 protein levels in Western blot from total CA1 lysate probably stem from high abundance 
in non-nuclear compartments, such as cytoplasm or extracellular space. (Fig.  4.2F). To 
investigate how ANXA2 changes in a model for age-associated cognitive impairment, I 
investigated the expression and localisation of ANXA2 in 16 month old mice. Here, ANXA2 
mRNA levels and protein levels were similar between hippocampal subregions. However, CA1 
showed significantly decreased protein levels when compared to 3 month old animals (Fig. 42A-
C), a phenomenon likely due to increased protein turnover (unpublished data, dept. Neuro- und 
Sinnesphysiologie, UMG, Göttingen). 
To understand to what extent ANXA2 is involved in cognitive function, I produced neuron-
specific AAV-mediated overexpression constructs. I injected the constructs into the 
hippocampus and tested the mice in cognitive tasks. In these tests I found, that mice 
overexpressing ANXA2 showed a spatial memory deficit. Conversely, ANXA2-deficient mice 
showed enhanced spatial memory in the same test. These findings suggest, that reducing levels 
of ANXA2 in the hippocampus is beneficial for memory performance. Thus, the observed 
decrease of ANXA2 in the CA1 of aged mice suggests a compensatory effect potentially aimed 
at mitigating age-associated memory impairments (AAMI).
Additionally, ANXA2 was enriched in the nuclei of the aged DG. Genotoxic stress is increased in 
ageing (Wei and Lee 2002, Strosznajder, Jesko et al. 2005, Lin and Beal 2006). However, 
ANXA2 was reported to translocate upon genotoxic stress and to mitigate DNA damage 
(Madureira, Hill et al. 2012). Thus, it is conceivable that ANXA2 translocated to the nucleus to 
mitigate DNA damage in ageing. This shift in turn could lead to an over-clustering of ANXA2 at 
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the chromatin and reduce transcriptional plasticity, which is necessary for memory formation. 
This is further supported by a recent finding from Madabushi and colleagues. They 
demonstrated that DNA double-stranded breaks (DSBs) govern the expression of neuronal 
early response genes and thereby possibly memory formation (Madabhushi, Gao et al. 2015). 
However, DSBs are increased in the absence of ANXA2 (Appendix Fig. 1F) and inhibited in its 
presence (Madureira, Hill et al. 2012). This suggests that absence of ANXA2 in the CA1 of aged 
mice facilitates stimulus-induced gene expression to compensate for reduced transcriptomic 
plasticity. Conversely, genotoxic stress could promote nuclear entry in the DG of aged mice in 
order to reduce genotoxic stress at the chromatin, thereby reducing transcriptional plasticity.
5.1.2. AnxA2 overexpression impairs of spatial memory 
I investigated the sub-cellular properties of ANXA2 by generating cytosolic ANXA2-GFP (ANX) 
and nuclear ANXA2-GFP-NLS (NLS) overexpression constructs to mimic the situation in the 
aged hippocampus. NLS showed a mild deficiency in the Morris water maze learning curve; 
however, during the probe test none of the groups displayed significant spatial representation of 
the platform location including controls, making it very difficult to interpret these results 
functionally. Thus, I applied the Barnes maze test, a more subtle and less stressful spatial 
memory task suitable for milder phenotypes (Harrison, Hosseini et al. 2009). In contrast to the 
Morris water maze, this revealed a robust spatial memory deficit in ANX, while NLS and controls 
memorised the task (Fig. 4.5D+E). Initially this appeared counterintuitive but could be attributed 
to an unforeseeable crosstalk of the recombinant NLS construct and the wild-type nuclear 
export signal (NES). This is particularly important since the mechanism by which ANXA2 
translocates into the nucleus is not fully understood. The wild-type ANXA2 NES is located at the 
N-terminus, a region reported to be crucial for protein-protein interaction, especially for S100 
proteins which are key in ANXA2 complex formation (Eberhard, Karns et al. 2001, Nazmi, 
Ozorowski et al. 2012, Liu, Myrvang et al. 2015). Thus, to remove the NES the site could not be 
mutated to generate a nuclear ANXA2 mutant, without risking to inhibit potentially crucial 
interactions. Further, wild-type ANXA2 is a direct substrate of SRC kinase which phosphorylates 
ANXA2 at multiple sites. Of those, cytosolic phosphorylation of serine 25 appears to play a key 
role in initiating relocation of the protein (Liu, Rothermund et al. 2003, Liu and Vishwanatha 
2007, Yan, Luo et al. 2007, Luo, Yan et al. 2008). Thus, it is assumed that ANXA2 needs to be 
post-translationally modified or bound to specific partners to translocate into the nucleus. To 
what extent these modifications are necessary for nuclear- or chromatin-dependent actions 
remains unknown. However, the addition of a NLS at the GFP C-terminus forced ANXA2 into 
the nucleus likely without undergoing necessary PTMs. After entering the nucleus ANXA2-NLS 
might have been exported from the nucleus immediately without taking action due to the active 
NES and lack of PTMs. Due to these and its initial cytosolic presence and in turn availability for 
post-translational modifications, only ANX could act in its physiological role. This suggests that 
NLS data have to be interpreted with great caution while ANX data are robust and reveal a 
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significant influence of neuronal AnxA2 overexpression on highly hippocampus-dependent 
spatial memory in vivo, without impacting other behavioural tests. 
Chromatin readers are thought to act in a qualitative rather than a quantitative way. Relevant 
chromatin marks tend to be limited and it is the combinatorial pattern that generates differential 
transcriptomic outcome, opposed to the number of chromatin readers covering the available 
marks (Yun, Wu et al. 2011). Thus, I turned to a loss of function in vivo model to be able to 
further define the role of ANXA2 as a chromatin reader. Notably, AnxA2 null mice did not show 
alterations in locomotion or anxiety, while spatial learning was facilitated in the Morris water 
maze. An enhancement that was further supported by the increased use of higher cognitive 
strategies for learning the platform position. In short, AnxA2 KO mice used more direct search 
strategies that require spatial encoding and thus learned the task more efficiently. Control 
animals had a comparatively lower percentage of direct searching strategies and relied on 
slightly more random search patterns to during the task. However, this improved cognitive ability 
was not present during the probe test. This apparent disconnection between the learning and 
the memory phenotype could be due to several reasons: firstly, it might indicate differential 
search and learning strategies, as supported by the in-depth analysis of cognitive scores. 
Secondly, it could be that the Morris water maze is not a suitable task for subtle phenotypes, 
such as those expected in this context. As expected, the Barnes maze revealed a significantly 
enhanced spatial memory in AnxA2 KOs, despite a comparably smaller sample size due to 
limited availability of animals from this line. A main concern in any non-conditional knockout 
experiment is specificity of the phenotype. While developmental effects cannot be ruled out in 
the KO, this issue was addressed by demonstrating an opposing behavioural effect in 
hippocampal overexpression of ANXA2 exclusively in neurons (Fig. 4.3D). Additionally, GSEA 
showed a differential impact of KO in CA1 and DG, suggesting a specific role of ANXA2 in these 
hippocampal areas (Fig. Appendix 1A, Fig. 4.8B). To address concerns regarding a systemic 
effect, a conditional or possibly CRISPR-mediated knockout could be used to recapitulate the 
phenotype reported.
The observed enhancement of spatial memory in ANXA2 deficiency is possibly mediated by the 
availability of H4K12ac to other chromatin readers that promote memory function. Further, 
ANXA2 could indeed be a baseline repressor of hippocampus-dependent memory formation. 
Since ANXA2 acts in multifactorial complexes, ruling out involvement of functions other than the 
action as chromatin reader is challenging. In fact, elucidating the concrete molecular 
mechanism by which ANXA2 is involved in cognitive function would require systematic 
investigation of is partners and binding patterns in vivo. In an attempt to gain some insight into 
the kind of downstream processes that ANXA2 is involved in regulating, I investigated the 
transcriptome of AnxA2 overexpression and KO animals using RNAseq.
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5.1.3. ANXA2 acts from the extracellular matrix to the nucleus 
Before sequencing AnxA2 overexpression and KO mutant tissue, animals were allowed to rest 
for 4 days after the behavioural experiments to remove any testing bias. Differential gene 
expression (DE) analysis of RNAseq data showed few genes differentially expressed at a 
physiologically meaningful cutoff. There are mainly two possible reasons for this: masking of the 
neuronal ANXA2-dependent gene expression profile by non-neuronal cells or a stimulus-
dependent mode of action of ANXA2.
In order to test these hypotheses, I turned to an in vitro primary culture system where I could 
have highly pure neuronal populations, thus eliminating masking effects from other cell types. 
This system also allowed me to carry out different stimulation protocols under highly controlled 
conditions, thus enabling to study the activity-dependent mode of action of ANXA2. These 
experiments revealed broad but mild changes upon ANXA2 overexpression in a basal condition. 
A large number of genes was differentially expressed with mostly lower than 1.4 fold-changes 
(log2FC±0.5). To test the stimulus response in ANXA2 overexpression I used NMDA to 
challenge the neurons, since NMDA receptor activity was previously reported to induce ANXA2 
translocation (Valapala, Maji et al. 2014). After NMDA treatment, ANXA2 overexpressing 
neurons showed differential gene expression compared to GFP expressing controls. While this 
is interesting, the results need to be treated with caution since no fold-change cutoff was 
applied. Differentially regulated genes with log2FC±0.5 are generally considered to be more 
meaningful, since the potential to have a measurable influence on cellular processes is 
increased. Interestingly, at this cutoff several genes showed significant differential expression. In 
line with reports associating ANXA2 to cytoskeleton binding, this function, as well as protein and 
vesicle trafficking were represented, underlining the involvement of ECM deregulation 
(Appendix Fig.  1B)(Dityatev and Schachner 2003, Bharadwaj, Bydoun et al. 2013, Gabel, 
Delavoie et al. 2015). 
As previously observed in behavioural experiments, I expected the loss of function model to 
reveal more drastic changes, due to the mode of action of chromatin readers. Accordingly, 
transcriptomic changes were pronounced at a log2FC±0.5 cutoff in AnxA2 null neuronal 
cultures. Importantly, functional enrichment supports the previous indications that ANXA2 acts 
on at least two key aspects summarised as “extracellular matrix” and “cell response”. These 
observations support my hypotheses as to why I could observe minimal changes in vivo. I 
wondered whether small, individually non-significant changes in ANXA2 overexpression and 
AnxA2 KOs animals would nonetheless collectively represent similar functions as the ones 
observed in vitro. Thus, I analysed gene sets instead of differential gene expression using gene 
set enrichment analysis (GSEA). This confirmed an involvement of membrane-bound 
processes, and additionally revealed epigenetic changes and RNA processing/splicing in KO 
compared to WT. Interestingly, these changes were restricted to the DG, while CA1 showed only 
enrichment for membrane-bound processes (Appendix Fig. 1A). The involvement of membrane- 
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and nuclear-bound terms again emphasised that ANXA2 has different roles dependent on its 
location and its interaction partners.
As a whole, transcriptomic profiling revealed several interesting functional categories, 
suggestive of the kinds of mechanisms by which ANXA2 might influence learning and memory. 
There were two main aspects: on the one hand, ANXA2’s the role in sustaining the ECM and on 
the other to the ability of ANXA2 to translocate from the membrane to the nucleus to convey 
information (Reeves, Gordish-Dressman et al. 2009). While gene expression changes are 
significant between KO and WT neurons, it is possible that the absence of ANXA2 was in part 
compensated by other proteins with redundant functions. This is particularly important for 
proteins belonging to the same family as previously stated by Vedeler and colleagues (Vedeler, 
Hollas et al. 2012).  In fact, AnxA1 and AnxA5, both sharing core features with ANXA2, were 
increased in KO (Appendix Fig. 1C). This conceivably could have contributed to a reduced 
impact of ANXA2 deficiency. For example, since AnxA1 was found to be present in the cytosol 
(Vishwanatha, Jindal et al. 1992), it could contribute to a reduced effect of ANXA2 deficiency on 
cytoplasmatic function. ANXA2 was previously reported to be involved in ECM degradation and 
ECM remodelling (Sharma and Sharma 2007). In my experiments the impact of ANXA2 
deficiency on ECM was further emphasised by GSEA, showing enrichment for the GO terms 
“extracellular matrix” and “extracellular matrix disassembly”. Importantly, genes that contributed 
to these GO terms were also found to be differential expressed. Moreover, these genes have 
previously been linked to ECM-dependent synaptic plasticity (Star, Kwiatkowski et al. 2002, 
Dityatev and Schachner 2003, Bu 2009, Vasudevan, Ho et al. 2010, Dauth, Sirbulescu et al. 
2011, Amenta, Creely et al. 2012, Sewal, Patzke et al. 2015, Terni and Ferrer 2015, Bach, 
Tzovara et al. 2017, Wiera, Nowak et al. 2017). Thus ANXA2’s involvement in the extracellular 
matrix and its disassembly could suggest an increased ECM turnover. This is further supported 
by the differential expression of ECM genes relevant to synaptic plasticity. Although at this stage 
this is speculative, the transcriptomic analysis shed some light onto possible modes of action of 
ANXA2 and contributed to the explanation of the facilitated learning phenotype through an 
increase of synaptic plasticity based on altered ECM dynamics. 
5.1.4. ANXA2 orchestrates RNA modifications that correlate to the H4K12ac 
signature  
When testing ANXA2 deficient neurons in stimulus response I found substantial gene 
expression changes. These were associated with cellular response but particularly DNA and 
chromatin binding. This is in line with the previously proposed functions of ANXA2 in DNA 
binding, primer recognition and chromatin remodelling (Kumble, Iversen et al. 1992, 
Vishwanatha, Jindal et al. 1992, Boyko, Mudrak et al. 1994, Madureira, Hill et al. 2012). Further, 
it is conceivable that these previously reported functions are associated with the here identified 
role as a chromatin reader (Fig. 4.1C). These findings suggest that by removing ANXA2 from 
the nucleus, neurons become more susceptible to stimulation and in turn transcriptionally 
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active. The role of ANXA2 in the ECM and signal transduction from membrane into nucleus 
could arguably contribute to the increased stimulus response. I investigated the possibility that 
ANXA2 is involved in RNA processing directly at the chromatin, since I previously found 
indications of altered RNA splicing in vivo. Additionally, ANXA2 has been identified as an RNA-
binding protein and is possibly also involved in RNA processing (Vedeler and Hollas 2000, 
Filipenko, MacLeod et al. 2004, Mickleburgh, Burtle et al. 2005, Hollas, Aukrust et al. 2006, 
Aukrust, Hollas et al. 2007). After showing that neurons respond to NMDA stimulation with 
alternative exon usage in learning-associated genes, I demonstrated that AnxA2 
overexpression led to substantial exon exclusion. While little is known about bulk changes in 
differential exon usage, histone 3 and 4 acetylation was previously linked to exon selection 
through regulation of the transcriptional elongation rate (Zhou, Luo et al. 2014). A similar 
phenomenon has previously been described by our group, in which we found a link between 
deficits in H4K12ac and exon usage, with H4K12ac deficits correlating with exon exclusion, as 
well as changes in spatial memory (Benito, Urbanke et al. 2015). Further, acetylation of H4 was 
linked to alternative exon usage by modulation of the elongation rate (Izquierdo 2008, Hnilicova, 
Hozeifi et al. 2011). Thus, an increase of histone acetylation facilitated RNA polymerase II 
(RNAPol-II) and exon exclusion in 3 different instances (Schor and Kornblihtt 2009, Hnilicova, 
Hozeifi et al. 2011, Zhou, Hinman et al. 2011). In fact, the exon exclusion observed in AnxA2 
over-representation closely resembles our previous finding when acetylation of H4K12 was 
increased. This could suggest that the effect of hyper-acetylation at histone 4 acts by a similar 
mechanism on splicing as over-representation of the chromatin reader at the same mark. 
Importantly, this observation was sustained by the opposing effect, significant exon inclusion, in 
the ANXA2 deficient condition. This is in line with the effect observed in hypo-acetylated H4K12 
and correlates with the behavioural observations. Investigation of the processes affected by 
alternative exon usage revealed similar GO terms associated with cytoskeletal structure and 
neuronal extension in both overexpression and KO neurons, while the latter showed more 
complex associations to cellular projection and synaptic transmission. Importantly, differential 
exon usage targeted particularly the microtubuli network including the microtubule-associated 
protein TAU, which could be a possibility to ameliorate pathophysiological changes associated 
with AD or other Tauopathies’ progression (Hempen and Brion 1996). Further, the enriched GO 
categories in differential exon usage of both AnxA2 KO and overexpression, suggest differential 
priming of neurons. Thus, one could speculate that the altered cytoskeleton structure and 
specifically changes in molecular motors would contribute to ready-to-react state in which signal 
transmission would be facilitated. This notion is further supported by the specific signature after 
NMDA stimulation. Here, enriched GO terms were closely linked to vesicle release and learning 
and memory. Clusters were generally more extensive in KO neurons, which is in line with overall 
altered gene response in KO (Fig. 4.10G). Exon skipping was increased in the overexpression 
experiment, suggesting increased elongation rate and interference caused by over-clustering 
(cf. “kinetic coupling”, chapter “1.4.4. On chromatin assisted alternative splicing”). Importantly, 
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also ANXA2 deficient neurons showed significant exon exclusion. In contrast to overexpression 
and wild-type, exon exclusion in KO occurred vastly more frequently in proximity to TSS 
(Fig.  4.14C). Exon exclusion occurs in both KO and overexpression, which could indicate a 
similar fundamental mechanism. However, KO show a more specific outcome with alternative 
exon usage accumulating at the TSS. It is therefore conceivable that AnxA2 KO leads to a very 
specific change within the gene topology, while overexpression acts less precisely on the entire 
gene body. While this is speculative, the lack of ANXA2 could lead to the initiation of 
transcription at an alternative site downstream of the original mark. During PolII initiation short 
~50 bp sequences of the 5’ are transcribed before elongation (Kwak, Fuda et al. 2013). Thus 
the observed decrease of exons in the 5’ could point towards facilitated or alternative PolII 
initiation, leading to base skipping and in turn exon exclusion in the first 10% downstream of 
TSS. In KO neurons, the exon skipping at the TSS upon stimulation could indicate facilitated 
initiation of the transcriptional machinery, correlating with H4K12ac, as indicated by ChIPseq. 
Thus ANXA2 deficiency could cause faulty transcription of initial sequences due to improper 
assembly of the transcriptional machinery (cf., “chromatin splicing adaptor system”, chapter 
“1.4.4. On chromatin assisted alternative splicing”).
Genes affected by this event were mostly associated with energy pathways and particularly 
NAD metabolism, an effect not observed for any other condition. Based on the target genes of 
5’ exon skipping and our initial screen one could hypothesise that in the KO condition H4K12ac 
is read by an alternative chromatin reader. Although this idea clearly requires further 
investigation, it is tempting to speculate that the alterations in NAD metabolism could could be 
due to a replacement of ANXA2 by PARP1 (ADPRT1). This reader was also identified in our 
initial screen and is strongly tied to NAD metabolism (Luo and Kraus 2012).
In summary, we identified several novel readers of acetylated H4K12, including ANXA2. I 
showed that ANXA2 protein is present in the nuclei of DG cells, while it decreases in the CA1 in 
the ageing brain. I further demonstrated that ANXA2 and has a significant impact on spatial 
memory. The data suggest that ANXA2 accumulation in the nucleus of the DG in aged animals 
could constitute a detrimental phenotype in ageing and that the reduction in CA1 compared to 
young mice would be a compensatory mechanism to counteract age-associated memory 
impairment. This effect is most likely conveyed by an interplay of the complex roles ANXA2 
takes in different cellular compartments. A multifactorial protein like ANXA2 cannot be reduced 
to a single outcome as this would be disadvantageous to the interpretation of the data. 
However, the data suggest that the mechanism can be separated into non-nuclear (ECM, signal 
transmission) and nuclear (chromatin reader, differential exon usage) effects. Firstly, ANXA2 
could contribute to ECM stability and reduce turnover, which is why a reduction of ANXA2 levels 
could lead to improved spatial memory, possibly through enhanced synaptic plasticity. 
Conversely in its nuclear role ANXA2 influences alternative exon usage. Importantly, the 
outcome of the ANXA2 orchestrated alternative exon usage events is analogous compared to 
the manipulation of H4K12ac itself (Benito, Urbanke et al. 2015). In fact, to the best of my 
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knowledge, this is the first report of ANXA2 as a possible key player being instrumental in 
translating histone PTMs into alternative splicing. Given the data presented here and the 
previously reported beneficial effect of reinstating H4K12 acetylation on cognition, I propose to 
further investigate on the beneficial influence of ANXA2 deficiency in age-associated memory 
impairment and cognitive decline. 
5.1.5. A side note on ANXA2 life-long deficiency in learning and memory 
In an alternative line of experiments I found ANXA2 to inhibit DNA double strand breaks in 
neurons (Appendix Fig. 1F). At the same time it was demonstrated that DSBs are relevant to the 
induction of immediate early genes and possibly in turn memory formation (Madabhushi, Gao et 
al. 2015). Connecting these two observations, I hypothesised that the increase of DSBs in 
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Figure 4.22: A model of the multifactorial chromatin reader ANXA2 in neurons including relevant 
literature.
ANXA2 is responsive towards ageing (possibly through genotoxicity) and NMDA stimulation. ANXA2 is 
involved in cellular protein binding and trafficking of e.g. RNAs or vesicular bodies. Further, ANXA2 in 
associated with the extracellular matrix and possibly its turnover. ANXA2 was reported to be part of the 
chromatin remodelling complex SMARCA3 and to translocate into the nucleus. In this work we 
demonstrated that ANXA2 binds to acetylated H4K12 where it likely serves as a scaffold to initiate 
transcription or in parallel RNA processing. When ANXA2 is overexpressed, severe exon skipping along 
the entire gene body is observed, which indicates malfunction of the elongation process. This could 
possibly be mediated by steric inhibition due to increased number of transcription initiation sites and thus 
excessive kinetic coupling during elongation. When ANXA2 is absent exon skipping is most significant in 
the 5’ of energy metabolism associated genes. This can be explained by either another chromatin reader 
taking over ANXA2s role, however, initiating at a downstream site, or a malfunctioning RNA PolII 
initiation.
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AnxA2 KOs would contribute to an increased in immediate transcriptional response. I was able 
to verify the increased susceptibility to stimulus driven gene expression in differential expression 
analysis of RNAseq data (Fig. 4.10G). However, it is not clear whether this change is indeed 
causally linked to increased DSBs.
In the ageing brain the repeated induction of DSBs in the hippocampus could in the long-term, 
be detrimental due to increased probability of mutations and thus impaired transcription. Thus, I 
hypothesised that aged animals would show decreased memory. I tested ANXA2 deficient 
animals in the Barnes maze test for spatial memory and found that mice at 13 months of age 
showed a memory impairment compared to wild-type control (Appendix Fig. 1G-K). At the time 
of writing this phenomenon needs further investigation, especially in respect to the influence on 
the reported function of ANXA2 in splicing, but underscores the relevance of ANXA2 in learning, 
memory and ageing.
5.2. HDAC6 modulation and Anle138b: two convergent 
strategies as novel therapeutic avenues to treat AD 
Alzheimer’s Disease is a detrimental neurodegenerative disorder affecting 47 million people 
world wide. This puts a great burden on patients affected and their family, but also a socio-
economical challenge our society as whole. While the disease mechanisms are not fully 
understood, two molecular aggregopathies have been identified, namely neurofibrillary tangles 
of TAU (NFTs) and Aß plaques. Both pathologies have been of major interest in research of AD. 
However, to date there is no efficient treatment available to ameliorate or even cure the disease. 
Clinical trails targeting either NFTs or Aß plaques have failed Phase II clinical trials of anti-
amyloid β antibodies (Panza, Frisardi et al. 2012, Gold 2017). An alternative approach to reduce 
the socio-economic burden and to improve late-life quality in the short-term is to develop 
symptomatic treatments. A promising approach is to circumvent the molecular pathologies and 
instead reinstate cellular functionality indirectly, e.g. by reinstating transcription or cellular 
integrity. The development and progression of sporadic AD is closely associated with 
environmental risk factors. This puts the epigenetic machinery into focus, since it translates 
environmental input into cellular outcomes. A promising target of the epigenetic machinery is 
HDAC6, which deacetylates TAU and microtubuli. Both of these processes are detrimental 
factor in AD progression (Cook, Stankowski et al. 2014). Importantly, removal and inhibition of 
HDAC6 has already been shown to be beneficial in AD-like amyloidosis. Thus I tested the effect 
of HDAC6 deficiency in a mouse model for AD-like tauopathy and found a reinstatement of 
anxious behaviour. 
In a second set of experiments we tested the novel compound anle138b in AD-like amyloidosis. 
We report that anle138b reinstates to some extent synaptic plasticity and spatial memory. This 
effect is possibly mediated through reinstatement of membrane integrity by inhibiting the 
functionality of Aß-pores. This finding is of particular encouraging since anle138b was reported 
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to act beneficial in other aggregopathies including AD-like tauopathy (Wagner, Krauss et al. 
2015). 
5.2.1. HDAC6 deficiency rescues anxiety in the THY-Tau22 mouse model for 
AD 
In patients suffering from AD or other Tauopathies significantly increased HDAC6 levels are 
observed. HDAC6 reduces tubulin and TAU acetylation levels, which in turn is associated with 
disturbance of the microtubule network and correlates negatively with disease progression 
(Hempen and Brion 1996, Ding, Dolan et al. 2008, Kim, Choi et al. 2012). 
Thus, I wondered whether decreasing HDAC6 in a Tauopathy model could be beneficial for 
disease pathophysiology. This strategy has proven useful in the past, where reducing HDAC6 in 
an APP mouse model led to improved cognitive performance (Govindarajan, Rao et al. 2013). 
By crossing TAU HDAC6-/- to THY-Tau22 mice, I investigated the effect of removing HDAC6 on 
TAU pathology. To test previously described phenotypes of the THY-Tau22 model in anxiety, 
locomotion, and hippocampus-dependent memory, I conducted a broad battery of behavioural 
tasks. In line with a previous report (Schindowski, Bretteville et al. 2006) I demonstrated a 
reduction of anxious behaviour in TAU transgenic animals in late-stage pathology. Importantly, 
this deficit was completely rescued by HDAC6 deficiency. In contrast to a previous report 
(Schindowski, Bretteville et al. 2006), I did not observe reduced anxiety in TAU transgenic 
animals at early-stage. A possible explanation might be increased genetic variance after 
crossing THY-Tau22 and Hdac6-/- despite the identical C57B6j background, although other 
factors cannot be excluded. I found decreased anxiety in TAU transgenic animals in the Open 
field, a test that has previously not been reported for this mouse line. In contrast to the Elevated 
plus maze (EPM), anxiety was decreased in the TAU animals at early-stage (6 month old) as 
well as late-stage (13 month old), and HDAC6 deficiency did not ameliorate the phenotype. 
Notably, I did not observe any significant motility impairment in TAU transgenics, which is in line 
with previous reports (Schindowski, Bretteville et al. 2006, Van der Jeugd, Blum et al. 2013). 
None of the early-stage cohorts showed a significant improvement in spatial memory. While 
controls displayed the shortest escape latency, it was still unusually high and might explain the 
lack of difference between mutants and controls. In contrast, at late-stage pathology TAU 
transgenic animals showed significantly increased escape latencies, as previously reported 
(Schindowski, Bretteville et al. 2006). HDAC6 removal did not significantly ameliorate this 
defect. Interestingly, I detected a previously not reported increase of contextual fear memory in 
Hdac6 KO compared to controls regardless of TAU transgene expression in both the early-stage 
and late-stage cohorts. This observation could be due to the change in genetic background of 
the Hdac6-/- line, from a 129 to a C57B6j background. This change was necessary because the 
former has previously been reported to be less suitable for cognitive testing. 
Taken together, these findings show in vivo evidence for reinstatement of behavioural 
abnormalities due to genetic HDAC6 deficiency in any model of TAU pathology, more 
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specifically anxiety behaviour. In line with this finding, a previous study reported that 
pharmacological HDAC6 inhibition by tubastatin in the rTg4510 mouse model for TAU 
deposition restored memory function and reversed a hyperactivity phenotype (Selenica, Benner 
et al. 2014). In contrast to other models, including rTg4510, the THY-Tau22 mouse model does 
not develop motor deficits (Schindowski, Bretteville et al. 2006), a crucial prerequisite for 
reliable behavioural testing.
Post-translational modifications (PTMs ), especially phosphorylation, of TAU were in the past 
well investigated. However, little is known about the effect of acetylation. HDAC6 inhibition was 
shown to directly increase Tau, tubulin, and microtubule acetylation (Zhang, Li et al. 2003, 
Noack, Leyk et al. 2014). Elevated HDAC6 activity was reported to increase phosphorylation of 
TAU within Tau’s microtubule-binding domain by an unknown mechanism (Cook, Stankowski et 
al. 2014). It is assumed that both phosphorylation and acetylation of TAU within the microtubule 
binding repeat region decreases affinity towards microtubuli, which would in turn facilitate 
axonal transport by molecular motors such as dynein and kinesin-1 (Drechsel, Hyman et al. 
1992, Biernat, Gustke et al. 1993, Bramblett, Goedert et al. 1993). Additionally, acetylation of 
TAU inhibits its polymerisation and could potentially lead to reduced intracellular deposits (Cook, 
Carlomagno et al. 2014) and inhibition of HDAC6 suppressed neuritic TAU bead formation in 
neurons and mice, a process correlating with plasticity impairment (Tseng, Xie et al. 2017). Thus 
the reinstated anxious behaviour through removal of HDAC6 is possibly due to an increase of 
microtubule stability and enhanced clearance of pathogenic TAU species. The latter is likely 
mediated trough high acetylation levels which inhibits TAU phosphorylation and aggregation.
Further, our group previously reported that loss of HDAC6 ameliorates hippocampus-dependent 
memory deficits and renders neurons resistant to amyloid-β-mediated impairment of 
mitochondrial trafficking, likely trough enhanced tubulin acetylation (Govindarajan, Rao et al. 
2013). This is in line with findings showing that tubulin acetylation enhanced the recruitment of 
kinesin-1 and dynein (Dompierre, Godin et al. 2007) and is a possible mechanism by which 
HDAC6 deficiency could contribute to the restoration of anxiety behaviour. While the precise 
mechanism remains unknown, the data presented reveal a beneficial effect of HDAC6 
deficiency in a TAU pathology model for AD, which is also relevant to other Tauopathies and 
encourages further investigation on the underlying mechanism. Importantly, our group 
demonstrated that HDAC6 deficiency contributes to an amelioration of behavioural phenotypes 
in APP and TAU models, the two main molecular hallmarks of AD. This would be the first report 
of an entity that interacts with both molecules and provides a cognitive benefit. A specific 
inhibitor to HDAC6 would therefore be a highly promising candidate for clinical trials in AD. Such 
an inhibitor would be the first drug to ameliorate both molecular pathologies of AD, a finding that 
is only pre-empted by the herein presented results on the compound anle138b.
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5.2.1. Anle138b rescues LTP and ameliorates spatial memory deficits in APP/
PS1 mouse model for AD 
We used the APP/PS1 mouse model for AD to investigate the potential of the diphenylpyrazole 
anle138b as a therapeutic agent in AD. The APP/PS1 mouse model for AD is well-established 
and recapitulates neuronal dysfunction. In these mice memory decline can be detected after 
four months and plaques form after 6 months of age (Kummer, Hammerschmidt et al. 2014). 
Anle138b was previously demonstrated to have beneficial effects in models for aggregopathies 
such as Parkinson’s and Alzheimer’s disease (Levin, Schmidt et al. 2014, Deeg, Reiner et al. 
2015, Wagner, Krauss et al. 2015, Fellner, Kuzdas-Wood et al. 2016). The compound is a 
hydrophilic and intended to modulate causative factors of AD, such as amyloid aggregation. 
Anle138b was shown to be administrable via food pellets and able to enrich in the brain, while 
remaining non-toxic up to a dose of 2 g/kg (Wagner, Krauss et al. 2015). We found that oral 
administration of anle138b restored LTP in the pre- and post-plaque cohort and that it reinstated 
spatial memory fully in the pre-plaque and partially in the post-plaque cohort. Notably, we did 
not observe any effect of anle138b treatment on wild-type animals, which is reassuring in terms 
of translating the use of this compound into the clinic. Transcriptome analysis of the pre-plaque 
group showed full reinstatement of genes linked to metabolic function and neuronal plasticity, 
which were down-regulated in the placebo group. Interestingly, few neuroinflammatory terms 
were enriched even in the placebo group. In contrast, changes in the post-plaque placebo group 
were dominated by increased inflammation and anle138b treatment did not impact 
transcriptomic deregulation. Yet, a significant therapeutic effect was observed in the post-plaque 
group, reinstating synaptic function despite detrimental inflammatory processes. In light of 
clinical trials that target amyloid deposition, a main argument for the failure of such trails is that 
clearance of plaques is ineffective at later stages of the disease. Anle138b treatment, seems to 
circumvent this mechanism, nonetheless targets pathological processes, in turn allowing 
synaptic functionality to recover despite persisting inflammatory processes. 
One previously proposed mechanism that is compatible with our results is the pore formation 
hypothesis. It states that neurotoxic compounds, such as Aβ oligomers, form permeable pores 
that impair neuronal function and lead to cell death (Arispe, Rojas et al. 1993). However, 
experimental evidence existed only to a limited degree, since a combination of different in vivo 
and in vitro techniques was required to test this notion. 
A main indication for the proposed mechanism stems from our observation using artificial bilayer 
membranes, so called black lipid membranes (BLM), which show little conductance when intact. 
In our experiment we observed a stepwise growth of membrane conductance after Aβ 
application, which suggests a combined action of several individual pores in the BLM. Earlier 
experiments have shown that Aβ mutated at F19P shows barrel structure but no ionic 
conductance (Capone, Jang et al. 2012, Connelly, Jang et al. 2012). The F19P mutation also 
changes in β-sheet confirmation, which collapsed the pore (Connelly, Jang et al. 2012). Our 
data are in line with these findings and suggest that anle138b induces a conformational change 
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in the Aβ pores, which reduces or eliminates ionic conductance. Our in vivo evidence, 
demonstrating reduced membrane integrity in neurons after Aβ1-40 application, further supports 
this idea. Importantly, this effect was abolished when neurons were supplemented with 
anle138b before or after Aβ1-40 treatment, mimicking the pre-and post-plaque cohort 
respectively. This potential “patching” of Aβ pores and in turn protective effect on membrane 
integrity is in line with our findings in the post-plaque group, where the compound reinstated 
LTP without affecting gene expression.
It is very likely that anle138b acts through additional mechanisms, as it has also been shown to 
be beneficial in models of other aggregopathies such as Parkinson’s disease (Levin, Schmidt et 
al. 2014), Creutzfeldt-Jakob (Wagner, Ryazanov et al. 2013), and TAU pathology (Wagner, 
Krauss et al. 2015). The interaction with TAU is particularly interesting, because this would be 
the first report of a compound being beneficial for amyloidosis and aggregation of tau, thus 
targeting two molecular hallmarks of AD.
5.3. Illuminating neuronal network dynamics 
Our brain is composed of around 85 billion neurons and approximately as many glia cells 
(Azevedo, Carvalho et al. 2009). For future treatment and cure of neurodegenerative diseases it 
is essential to understand the precise interplay between neurons in the complex network of the 
brain. It is not understood how neuronal activity propagation influences the surrounding network 
and how feedback from adjacent cells changes the transcriptome of a formerly active cell. To 
decipher these network dynamics on a single cell level few model systems are available and 
lack either accessibility, spatial precision, temporal resolution or clinical relevance. Thus I built a 
now model system addressing these current obstacles to study neuronal network behaviour on 
a single cell level.
The system is comprised of a biological component and second a hardware component. The 
former allows to introduce a genetic modification into a tightly controlled sub-population of cells 
in culture without depending on different promotors. The latter is a optogenetic stimulation unit 
tailored for the needs of cell cultures application for molecular biology.
In the described experiments, I composed accurately titrated networks from neurons with two 
mutually exclusive ectopically expressed genes. First “pacemakers”, a subpopulation of light 
activatable neurons expressing channelrhodopsin which is primarily stimulated cells. Second 
“reporters”, which were secondarily stimulated by pacemakers and expressed eYFP upon 
activation. After the experiment each cell was extracted from the network and subjected to high 
throughput single cell sequencing depending on their ectopically expressed gene. 
On the biological side, I developed a protocol that results in highly targeted gene delivery. To 
transmit genetic information I relied on adeno-associated viruses (AAVs) as vectors because of 
several reasons. AAVs are safe to handle and easy and economical to produce (McClure, Cole 
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et al. 2011). They are not associated with any known human disease but generate long-term 
transgene expression in non-dividing cells such as neurons and display relatively low 
immunogenicity (Rapti, Louis-Jeune et al. 2012). Further, AAV serotypes (AAV1 to AAV13) differ 
in structures of their capsids and offer in turn differential infectious properties (Agbandje-
McKenna and Kleinschmidt 2011). For many AAV serotypes it was reported that binding to cell 
surface glycans is crucial for infection (Summerford and Samulski 1998, Handa, Muramatsu et 
al. 2000, Kaludov, Brown et al. 2001). In contrast, AAV2 was shown to bind heparan sulfate 
proteoglycans and can be competitively inhibited by heparin (Summerford and Samulski 1998, 
Schmidt, Voutetakis et al. 2008). All of these features were important in the choice of AAV for 
construct delivery. However, the outstanding property to be inhibited by heparin made me select 
of AAV serotype 2, as this allowed inhibition of viral spread during long-term incubation. Thus, to 
generate a system for specific construct introduction I relied on AAV serotype 2, and 1/2 hybrids 
and inhibited propagation during long term incubation (> 10 days) by supplementing heparin to 
the medium to sponge viral particles released from dissociating cells. Additionally, the relatively 
low infection rate of AAV2’s can efficiently be counteracted with high titers and thus enables 
short infection incubation times as it was necessary for pre-seeding construct delivery (Kern, 
Schmidt et al. 2003). 
The protocol was then used by Lukas Faiß, under my supervision, to deliver ChR2 into 10% of a 
primary neuronal culture (PNC) and found FOS increase in cells stimulated by ChR2+ but not in 
pacemakers themselves, a finding that is contrary to current literature where fully transfected 
cultures showed increase in FOS levels after simulation (Schoenenberger, Gerosa et al. 2009). 
This led us to hypothesise that not only the stimulus quality but also the amount and intensity of 
feedback to the pacemaker is relevant to the stimulus response. To investigate this 
phenomenon in more detail I devised an experiment in which 0% ,1%, 10%, 30%, or 50% 
pacemakers were introduced into a reporter culture. The cells were then stimulated with 
LuCIFR-prototypeB according to published protocols (Schoenenberger, Gerosa et al. 2009), 
dissociated, FACS sorted and subjected to single cell sequencing using MARS. Unfortunately, 
at the time of writing this thesis the outcome is pending. However, I am positive it will give more 
insight into how active neurons influence the transcriptional level of neighbouring cells and what 
role the amount of active cells plays in neuronal network activation.
The system established now allows to introduce almost any genetic mutation into dissociated 
primary neuronal cultures, neuronal/glia hybrid cultures, 3D cultures or any other system where 
an infection before seeding can be applied. Thanks to the continuous improvement of genetic 
tools to introduce and remove target genes, this approach can be adapted for any number of 
cell culture experiments future investigators will have in mind.
Complementing the construct delivery system I engineered the optogenetic stimulation device 
“LuCIFR” which is currently in licensing negotiations with partners in industry, unfortunately this 
prohibits a description of the current technology. However, LuCIFR is designed as the ideal 
complement to the previously described genetic construct delivery protocol to introduce 
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optogenetic tools into cell culture and circumvents disadvantages of currently available devices. 
To our knowledge LuCIFR is the first stimulation unit designed for high throughput and entry 
level molecular-biology cell culture experiments. For exploratory optogenetic work in traditionally 
molecular biology laboratories the acquisition of commercially available stimulation solutions is 
too expensive, which in turn forces them to build self-made devices, often with the outcome of a 
light stimulus of unknown parameters and limited control of the same. Although, publications 
describing instructions for good optogenetic devices exist (Grossman, Poher et al. 2010, 
Gerhardt, Olson et al. 2016), availability of workshops to build such devices is restricted to most 
labs. However, since precision and standardisation are key prerequisites to reproduce an 
experimental outcome, LuCIFR was designed to protocol any event, to be rugged, waterproof, 
highly precise, and reproducible, while remaining affordable to anyone and thus outperforming 
self-made and commercial devices alike. 
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6. Summary 
Alzheimer’s disease (AD) is the most common dementia-associated neurodegenerative 
disorder. It has detrimental social and economic impact not only on patients, but also their family 
and society as a whole. Current estimations predict a total of 131 million affected with the 
disease in 2050 (World Alzheimer Report, 2016), increasing socio-economic pressure. To date 
there is no cure and no efficient treatment against AD available. Appearance and progression of 
AD depend on the interplay between genetic and environmental risk factors, which is intimately 
linked with the epigenetic machinery, since it is exactly at the interface between the environment 
and the genome. With the aim of exploring novel strategies to ameliorate or prevent age-
associated dementia, I used 3 complementary approaches that led to the identification of 
suitable drug- and genetic-based targets.
First, to identify novel drug targets I performed a screening for proteins specifically binding the 
memory-associated histone mark H4K12ac. I identified ANXA2 as a significant chromatin 
reader. I could show that ANXA2 not only changes sub-cellular localisation during ageing, but is 
causally involved in cognitive function. My findings suggest that ANXA2 is a baseline inhibitor of 
spatial memory function. Since ANXA2 is naturally multifactorial, it is challenging to pinpoint a 
precise mechanism. However, my data indicates that ANXA2 influences two key aspects 
relevant to learning and memory: on the one hand it contributes to extracellular matrix 
dynamics, which has previously been reported to be a regulator of synaptic plasticity. On the 
other hand, I found evidence that supports a role of ANXA2 in modulating energy metabolism 
through alternative 5’ usage. Although I did not manipulate ANXA2 in an AD model, my 
observations suggest that inhibiting it could be a suitable strategy to ameliorate memory 
impairment in AD.  
Second, to test whether previously identified targets could constitute novel treatment strategies 
against AD, I explored the benefits of two pharmacological compounds (JS28 and anle138b) 
and a genetic model of HDAC6 deletion (Tau/HDAC6). My findings on HDAC6 depletion show a 
reversal of the common anxiety phenotype in a mouse model for AD-like tauopathy. This 
suggests that specific inhibition of HDAC6 could be a suitable treatment strategy specifically 
aimed at normalising anxiety in AD. This is complemented with other findings reporting a benefit 
of HDAC6 depletion in AD-like amyloidosis (Govindarajan, Rao et al. 2013). One of the 
pathological AD mechanisms is the pore formation hypothesis. It states that Aß oligomers pierce 
through neuronal membranes forming ion-channels and thereby shorting signal transduction 
and causing cell death. We assessed the efficacy of anle138b as a pore formation inhibitor upon 
Aß exposure and report highly beneficial effects of the molecule in a recent issue of ”EMBO 
molecular medicine”. Anle138b reinstated LTP and spatial memory even at late stages of 
amyloid deposition in the APP/PS1 mouse model for AD-like amyloidosis. We present evidence 
that anle138b could act through induction of conformational changes to the Aß pore structure 
and that membrane integrity is reinstated after anle138b treatment both in vitro and in vivo. This 
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supports previous findings that suggested a beneficial function of anle138b in other 
aggregopathies, including AD-like tauopathy.
Third, I developed a new technical strategy aimed at studying network dynamics. In order to 
understand complex diseases, such as AD, it is essential to study neurons in the network and 
go beyond cellular events to systems-level events. I designed and optimised a novel AAV-based 
vector system to introduce genetic constructs into neuronal subpopulations. I demonstrated the 
effectiveness of this approach in a proof-of-principle experiment, introducing channelrhodopsin 
to investigate the influence of low-density activity on neuronal networks. Importantly, this system 
is highly customisable and could be adapted for a broad range of applications. To complement 
the channelrhodopsin-driven neuronal network activity, I designed and engineered a new 
optogenetic stimulator for cell culture (LuCIFR). By combining vector-based subpopulation 
targeting with FACS sorting, LuCIFR-based stimulation and single-cell sequencing, I established 
a new technical approach to study network dynamics in subpopulations and individual cells.  
In this thesis I explored several molecular pathways involved in cognitive function with an 
emphasis on therapeutic applications. I identified ANXA2 as a chromatin reader and inhibitor of 
spatial memory function, contributed to the characterisation of 2 highly novel AD treatment 
strategies, and developed a new system to decipher neuronal network dynamics. While each of 
these topics comprises its own field for future investigations, I am positive they will impact 
neurodegenerative and neurocognitive research and hopefully contribute to future treatments of 
cognitive impairments and AD. 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Appendix Figure 1
CA1 in vivo GSEA showed lower overall enrichment and mostly Membrane-bound processes (padj<0.05, 
FDR<0.25) (A). Differential gene expression of basal ANXA2 overexpressing neurons with increased 
cutoff (padj<0.05, log2FC±0.3) showed enrichment in GO ORA analysis of molecular function exclusively 
fibronectin binding (B). AnxA1 and AnxA5 were increased in RNAseq differential expression analysis in 
AnxA2 KO neurons (C). KEGG pathway analysis of differentially used exons in WT NMDA treated 
neurons compared to basal showed oxidative phosphorylation enriched (D). KEGG pathway analysis of 
differentially used exons in ANX NMDA treated compared to GFP NMDA treated neurons showed no 
enrichment (E). Wester blot analysis of neurons treated with 200  µM H2O2 showed increased DNA 
double strand breaks as indicated by ɣH2A.x signal in the absence of ANXA2 (F). 13 month old AnxA2 
null and WT mice travelled similar distance during the first probe (PT1) test in the Barnes maze test for 
spatial memory. Importantly, KO mice spent significantly less time in the target area during PT1 (G, left). 
PT2 after 4 additional training sessions in the Barnes maze showed both cohorts travel similar distances. 
Importantly also KO were able to learn the task and spent significantly more time in the target area (G, 
right).
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Appendix Table 1: Top 10% TSS proximity exons diﬀerentially expressed in NMDA treated KO vs. WT
genesymbol genename
Epdr1 ependymin related protein 1 (zebrafish)
Prkab2 protein kinase, AMP-activated, beta 2 non-catalytic subunit
Napg N-ethylmaleimide sensitive fusion protein attachment protein gamma
Napa N-ethylmaleimide sensitive fusion protein attachment protein alpha
R3hdm4 R3H domain containing 4
Rhoa ras homolog family member A
Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1
Cd81 CD81 antigen
Crym crystallin, mu
Cyp51 cytochrome P450, family 51
Eno2 enolase 2, gamma neuronal
Gpi1 glucose phosphate isomerase 1
Hint1 histidine triad nucleotide binding protein 1
Igfbp3 insulin-like growth factor binding protein 3
Mdh2 malate dehydrogenase 2, NAD (mitochondrial)
Mapt microtubule-associated protein tau
Nnat neuronatin
Mrpl49 mitochondrial ribosomal protein L49
Pea15a phosphoprotein enriched in astrocytes 15A
Psen1 presenilin 1
Eif4a3 eukaryotic translation initiation factor 4A3
Rab1a RAB1A, member RAS oncogene family
Rad23b RAD23 homolog B, nucleotide excision repair protein
Mcfd2 multiple coagulation factor deficiency 2
Ran RAN, member RAS oncogene family
Sstr2 somatostatin receptor 2
Spr sepiapterin reductase
Srp14 signal recognition particle 14
Timp3 tissue inhibitor of metalloproteinase 3
Ube2b ubiquitin-conjugating enzyme E2B
Vdac1 voltage-dependent anion channel 1
Ywhag tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide
Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)
Dlat dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex)
Map2k1 mitogen-activated protein kinase kinase 1
Ankrd13b ankyrin repeat domain 13b
Rpl8 ribosomal protein L8
Srr serine racemase
Tnpo3 transportin 3
Atraid all-trans retinoic acid induced differentiation factor
Tmem222 transmembrane protein 222
Nhp2 NHP2 ribonucleoprotein
Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1
Syt5 synaptotagmin V
Atp6ap1 ATPase, H+ transporting, lysosomal accessory protein 1
Paf1 Paf1, RNA polymerase II complex component
Mpc1 mitochondrial pyruvate carrier 1
Ift20 intraflagellar transport 20
Apip APAF1 interacting protein
Serinc1 serine incorporator 1
Dynll1 dynein light chain LC8-type 1
Arpp19 cAMP-regulated phosphoprotein 19
Ube2d3 ubiquitin-conjugating enzyme E2D 3
Mplkip M-phase specific PLK1 intereacting protein
Ndufa7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a)
Anp32e acidic (leucine-rich) nuclear phosphoprotein 32 family, member E
Farsa phenylalanyl-tRNA synthetase, alpha subunit
Sdhb succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
Mrpl18 mitochondrial ribosomal protein L18
Snap47 synaptosomal-associated protein, 47
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Bcas2 breast carcinoma amplified sequence 2
Pdhb pyruvate dehydrogenase (lipoamide) beta
Ndufs3 NADH dehydrogenase (ubiquinone) Fe-S protein 3
Faim2 Fas apoptotic inhibitory molecule 2
Arpc2 actin related protein 2/3 complex, subunit 2
Micu3 mitochondrial calcium uptake family, member 3
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The diphenylpyrazole compound anle138b blocks
Ab channels and rescues disease phenotypes in a
mouse model for amyloid pathology
Ana Martinez Hernandez1,2,†, Hendrik Urbanke1,†, Alan L Gillman3,† , Joon Lee3,†, Sergey Ryazanov4,5,
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Nasrollah Rezaei-Ghaleh4,8, Petra Wilken5,6,9, Fernando Teran Arce3,‡, Jens Wagner10,
Martin Fuhrman10, Mario Caruana11, Angelique Camilleri11, Neville Vassallo11, Markus
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Abstract
Alzheimer’s disease is a devastating neurodegenerative disease
eventually leading to dementia. An effective treatment does not
yet exist. Here we show that oral application of the compound
anle138b restores hippocampal synaptic and transcriptional
plasticity as well as spatial memory in a mouse model for Alzhei-
mer’s disease, when given orally before or after the onset of
pathology. At the mechanistic level, we provide evidence that
anle138b blocks the activity of conducting Ab pores without
changing the membrane embedded Ab-oligomer structure. In
conclusion, our data suggest that anle138b is a novel and promis-
ing compound to treat AD-related pathology that should be
investigated further.
Keywords Alzheimer’s disease; amyloid pathology; Ab channels; gene
expression; membrane pores
Subject Categories Chromatin, Epigenetics, Genomics & Functional Geno-
mics; Neuroscience; Pharmacology & Drug Discovery
DOI 10.15252/emmm.201707825 | Received 23 March 2017 | Revised 17
October 2017 | Accepted 20 October 2017
Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative
disorder causing a severe emotional and economic burden to our
societies. Due to increased life expectancies, the number of those
afflicted with AD is expected to double by 2025. Despite intensive
research, effective therapeutic approaches are still not available.
The pathogenesis of AD has been linked to protein aggregation,
namely the aggregation of amyloid-beta peptides (Ab) and tau
protein. The accumulation of pathogenic aggregates of Ab peptides
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in the brain appears to be a key event in the pathogenesis of AD
(Iversen et al, 1995; Tanzi, 2005; Jakob-Roetne & Jacobsen, 2009;
Goate & Hardy, 2012), and targeting amyloid pathology still repre-
sents a promising therapeutic strategy (Haass & Selkoe, 2007;
Sevigny et al, 2016). The precise molecular events that trigger
amyloid-induced decline of synaptic plasticity and neuronal cell
death are still not entirely resolved and are likely to be multifacto-
rial. One of the first explanations of neuronal dysfunction and toxic-
ity in AD is the channel hypothesis first proposed by Arispe and
coworkers (Arispe et al, 1993), which postulates that unregulated
Ab ion channels result in a loss of ionic homeostasis (primarily
through a gain of Ca2+) that eventually triggers neuronal dysfunc-
tion and cell death. In vivo evidence for this mechanism is, however,
still rare, and a compound that would block pores and be active in
mammalian animal models has not been reported yet. Thus, the
original request by Arispe and coworkers that a useful strategy for
drug discovery for treatment of AD should include screening
compounds for their ability to block or otherwise modify Ab chan-
nels is still left unsatisfied (Arispe et al, 1993).
In this work, we examine the efficacy of the diphenylpyrazole
(DPP) compound anle138b in an animal model of Ab deposition.
Oral application of anle138b ameliorates Ab-induced deficits in
synaptic plasticity and memory formation. Using in vivo and in vitro
approaches, we provide evidence that this effect is linked to the
capacity of anle138b to reduce the conductivity of Ab pores in lipid
bilayer membranes. Although other mechanisms likely contribute to
this effect, our data suggest the functional modulation of the
membrane bound Ab-oligomers as a mechanism for neuroprotection
and support the idea that anle138b should be taken into clinical
trials to treat aggregopathies, including AD.
Results
Synaptic plasticity and memory function in a mouse model
for deposition of amyloid b peptides after oral treatment
with anle138b
To initially test the potential of anle138b as therapeutic strategies to
treat amyloid aggregation in Alzheimer’s disease, we analyzed its
effect in a Drosophila model for amyloid-induced neurotoxicity. We
observed that treatment with anle138b improved survival times
when compared to a vehicle-treated group (Appendix Fig S1). On
the basis of these data, we decided to test the efficacy of anle138b in
a mouse model for amyloid deposition. We like to state that none of
the currently employed animal models for AD fully recapitulate the
phenotypes seen in AD patients, and thus, care has to be taken
when interpreting such data. In our study, we employed APPPS1D9
mice (Jankowsky et al, 2001), a well-established model for AD-
linked amyloid deposition. Since in the patients therapeutic inter-
vention is normally initiated only after the onset of amyloid plaque
formation, we decided to test anle138b in two experimental cohorts.
In the “pre-plaque group,” treatment was initiated before the onset
of pathology when mice were 2 months of age, while in the “post-
plaque group” treatment was initiated after the onset of amyloid
deposition and memory disturbances in 6-month-old mice (Fig EV1;
Jankowsky et al, 2004; Lalonde et al, 2005; Reiserer et al, 2007). In
both cohorts, anle138b was continuously provided via food pellets.
Thus, in the pre-plaque group, mice were subjected to anle138b or
placebo treatment from 2 months of age, and electrophysiological,
behavioral, and biochemical analyses were initiated at 6 months of
age. A group of wild-type mice (WT) treated with anle138b served
as an additional control. We first measured synaptic plasticity by
analyzing hippocampal long-term potentiation (LTP). While robust
hippocampal LTP at the Schaffer collateral synapse was observed in
WT control mice treated with anle138b (Fig 1A), LTP was signifi-
cantly impaired in APPPS1D9 mice that received placebo (Fig 1B).
Notably, this LTP deficit was completely rescued in APPPS1D9 mice
treated with anle138b (Fig 1C). These data suggest that oral applica-
tion of anle138b protects against Ab-induced impairment of
hippocampal synaptic plasticity. To test whether the effect of
anle138b on hippocampal plasticity also improved hippocampus-
dependent memory function, another group of anle138b and
placebo-treated mice were subjected to the Morris water maze test,
a well-established paradigm to assay spatial memory in rodents
(Morris, 1984). Anle138b-treated WT mice displayed robust spatial
learning as indicated by decreasing escape latency throughout the
8 days of training (Fig 1D). In contrast, APPPS1D9 mice treated
with placebo showed a significantly impaired escape latency
(Fig 1D). This deficit was partially rescued in APPPS1D9 mice that
received anle138b. Spatial reference memory was analyzed in a
probe test performed after 8 days of training. While WT mice
showed a significant preference for the target quadrant, no such
effect was observed in placebo-treated APPPS1D9 mice (Fig 1E),
confirming memory impairment in APPPS1D9 mice. In contrast,
anle138b-treated APPPS1D9 mice displayed a significant prefer-
ence for the target quadrant indicating restored spatial memory
(Fig 1E). Swim speed was similar amongst the groups (Fig 1F).
We also examined if anle138b would affect basal explorative
behavior (Fig 1G) or basal anxiety (Fig 1H). No difference was
found amongst the groups suggesting that oral administration
of anle138b can protect APPPS1D9 mice from deteriorating
hippocampal synaptic plasticity and hippocampus-dependent
memory consolidation.
Encouraged by these findings, we investigated whether anle138b
could also reinstate synaptic plasticity and memory function when
significant amyloid deposition had already occurred employing the
post-plaque group (Fig EV1). To this end, 6-month-old APPPS1D9
mice were treated with either anle138b or placebo for 4 months.
Wild-type mice treated with anle138b served as an additional
control group. Analysis was performed when mice were 10 months
of age. In a first cohort, we measured hippocampal LTP. WT mice
treated with anle138b showed robust LTP (Fig 2A), while LTP was
significantly impaired in placebo-treated APPPS1D9 mice (Fig 2B).
Notably, a complete restoration of hippocampal LTP was seen in
APPPS1D9 mice treated with anle138b (Fig 2C). In conclusion, simi-
lar to the pre-plaque group treatment with anle138b had a marked
ameliorating effect on LTP even after the onset of plaque deposition.
To analyze whether reinstatement of hippocampal plasticity
would also correlate with improved memory function, we subjected
mice to the Morris water maze test. WT mice treated with anle138b
rapidly learned the task as indicated by reduced escape latency
throughout the 8 days of training (Fig 2D). Placebo-treated 10-
month-old APPPS1D9 mice display impaired spatial learning as
indicated by the escape latency that did not significantly decrease
during the training (Fig 2D). When compared to the placebo group,
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Figure 1. Anle138b rescues hippocampal LTP deficits spatial memory in the pre-plaque group.
A In wild-type mice of the pre-plaque group (treated from 2 to 6 months of age with anle138b), robust LTP that lasts for at least 3 h is elicited upon a strong
tetanization (STET) (3 trains of 100 pulses at 100 Hz given 10 min apart, arrows) at the Schaffer collateral CA3-CA1 synapse (t-test, P = 0.00005; n = 16 comparing
before vs. after STET).
B LTP is not maintained in APPPS1D9 mice treated with placebo. Here, the potentiation declined to baseline after 3 h (t-test, P = 0.08; n = 20 comparing before vs.
after STET).
C APPPS1D9 treated with anle138b show a rescue of the LTP impairment (t-test, P = 0.0001; n = 23 comparing before vs. after STET).
D Escape latency in the Morris water maze test is impaired in placebo- but not in anle138b-treated APP mice (one-way ANOVA F = 16.01, **P = 0.0008; n = 15/group).
E Probe test performed 24 h after the last training session. The lower panel shows representative swimming path during the probe test. T = target quadrant compared
vs. other quadrants (t-test, ***P = 0.00002; n = 15/group).
F Average swim speed during water maze training (n = 15/group).
G Explorative behavior in the open field test. Upper panel: Representative motion tracks during the test session. Lower panels show the total distance travelled during
the 5-min test session (n = 15/group).
H Bar graph showing the time spent in the center vs. the corner of the open field (n = 15/group).
Data information: Error bars indicate SEM.
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APPPS1D9 mice treated with anle138b showed improved spatial
learning (Fig 2D). A probe test was performed after 8 days of train-
ing. WT mice treated with anle138b showed a significant preference
for the target quadrant indicative of intact spatial reference memory
(Fig 2E). Placebo-treated APPPS1D9 mice exhibited severely
impaired memory function (Fig 2E) and displayed no target prefer-
ence (Fig 2E). In APPPS1D9 mice treated with anle138b (Fig 2E),
target preference was improved significantly but did not reach WT
levels. Of note, swim speed was not different between the experi-
mental groups (Fig 2F). Explorative behavior (Fig 2G) and basal
anxiety (Fig 2H) were measured in the open field test. There was no
significant difference amongst groups. We also tested whether
anle138b treatment would affect memory function in wild-type mice
but did not observe any significant difference (Appendix Fig S2).
Thus, oral administration of anle138b partially restores hippocam-
pal plasticity and memory function in APPPS1D9 mice even at an
advanced stage of pathology.
Anle138b reinstate transcriptional homeostasis and ameliorates
amyloid pathology
Pathological alterations often lead to aberrant changes in transcrip-
tional plasticity indicating deregulated cellular homeostasis (Fischer,
2014a). In support of this, numerous studies demonstrated that AD
pathogenesis correlates with altered gene expression in various
brain regions (Fischer, 2014b; Benito et al, 2015; Matarin et al,
2015). Moreover, monitoring gene expression changes can inform
about the efficacy of therapeutic intervention (Benito et al, 2015). In
keeping with this idea, we performed RNA sequencing from
hippocampal tissue dissected from mice in the pre- and post-plaque
(Fig EV1) cohorts. Notably, there were no differences in hippocam-
pal gene expression when comparing WT placebo- vs. WT
anle138b-treated mice, suggesting that anle138b has no direct effect
on transcriptome plasticity. Thus, we first compared gene expres-
sion in placebo-treated WT and placebo-treated APPPS1DE9 mice of
the pre-plaque group. We identified 202 differentially expressed
genes of which 73 were up- and 129 were down-regulated (Fig 3A;
Dataset EV1). Pathway analysis shows that down-regulated genes
are linked to reduced energy metabolism, mitochondria function,
cytoskeleton integrity, and synaptic plasticity, while pathways
linked to cell growth were increased (Fig 3B). These data are in line
with previous reports of gene expression changes in AD (Benito
et al, 2015; Matarin et al, 2015) and were confirmed via qPCR
(Appendix Fig S3A).
Because anle138b restored LTP and spatial memory functions in
pre-plaque mice (see Fig 1), we hypothesized that the transcriptome
of APPPS1DE9 mice treated with anle138b may more closely resem-
ble that of wild-type mice. Indeed, a wild-type-like gene expression
profile is to a large extent reinstated in anle138b-treated APPPS1DE9
and only 27 genes were deregulated when comparing wild-type
mice treated with anle138b vs. APPPS1DE9 mice treated with
anle138b groups (Fig 3A). Thus, none of the pathways deregulated
in response to amyloid pathology (Fig 3B) remained significant after
anle138b treatment. Accordingly, no enrichment for any specific
pathway could be detected. The possibility remained that anle138b
treatment may simply reduce the expression levels of the APP and
PS1 transgenes specifically in APPPS1DE9. However, the RNA-seq
data showed that APP and PS1 are increased in placebo-treated
APPPS1DE9 mice when compared to placebo-treated wild-type mice
(see Dataset EV1). Similarly, APP and PS1 transgenes were elevated
in anle138b-treated APPPS1DE9 mice compared to anle138b-treated
wild-type mice (see Dataset EV1). These data were confirmed via
qPCR showing that the expression of APP and PS1 transgenes is
similar in placebo- and anle138b-treated APPPS1DE9 mice (Fig 3C);
the gene expression data are in line with the electrophysiological
and behavioral findings. It also shows that in the pre-plaque group,
anle138b treatment reinstates cellular homeostasis in the hippocam-
pus of APPPS1DE9 mice.
We next analyzed hippocampal gene expression in the post-
plaque group (Fig EV1). When comparing WT placebo and
APPPS1DE9 placebo mice, we found 130 differentially expressed
genes of which the majority (124) were up-regulated (Fig 3D), a
finding confirmed via qPCR (Appendix Fig S3A). The comparison of
anle138b-treated WT and anle138b-treated APPPS1DE9 mice revealed
220 differentially expressed genes, 207 up-regulated, and 13 down-
regulated (Fig 3D). Around half of these, 103 were also deregulated
in the comparison WT placebo vs. APPPS1DE9 placebo (Fig 3E), a
finding confirmed via qPCR (Appendix Fig S3B). Pathway analysis
revealed that gene expression changes almost exclusively represent
an induction of neuroinflammatory processes (Fig 3F) in response to
the APP and PS1 transgenes and this induction is not changed by
treatment with anle138b. These data suggest that anle138b treatment
does not have a major impact on inflammatory processes when given
at a stage of advanced amyloid pathology. Since anle138b treatment
nevertheless reinstated hippocampal synaptic plasticity and also
partially restored memory function, these findings indicate that the
therapeutic efficacy of anle138b is most likely not solely due to the
dampening of amyloid-induced inflammation.
A previous study reported that anle138b exhibits therapeutic
effect in TauP301S mice, a mouse model for Tau pathology
(Wagner et al, 2015). Taking into account that Tau and amyloid
pathology represent the two major causative factors for AD, we
wondered if anle138b would affect brain homeostasis as measured
by hippocampal gene expression also in TauP301S mice. To this
end, we obtained hippocampal brain tissue from the same experi-
ment using anle138b or vehicle-treated wild-type and TauP301S
mice as described by Wagner et al (2015). The experimental
design employed by Wagner et al is similar to our pre-plaque
group, since anle138b was feed to mice upon weaning. Similar to
our data, feeding anle138b to wild-type mice had a neglectable
effect on hippocampal gene expression when compared to vehicle
fed wild-type mice (Appendix Fig S4, Dataset EV1). The compar-
ison of vehicle-treated wild-type to vehicle-treated TauP301S mice
revealed 257 differentially expressed genes that mainly represent
increased pathways linked to neuroinflammation (Appendix Fig
S4). Of note, this gene expression signature was significantly
ameliorated in anle138b-treated TauP301S mice and only 16 genes
were differentially expressed when comparing vehicle- vs.
anle138b-treated TauP301S mice (Appendix Fig S4). These data
allow for a number of interesting conclusions. First, at the
hippocampal gene expression level, the overexpression of the
human Tau gene carrying the P301S mutation leads to inflamma-
tory response but in contrast to the data observed in APPPS1DE9
mice has very limited impact on the expression of genes linked to
synaptic plasticity and learning and memory. Second, treatment
with anle138b in TauP301S mice ameliorates the gene expression
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Figure 2. Anle138b rescues hippocampal LTP deficits and spatial memory in the post-plaque group.
A Wild-type mice of the post-plaque group (treated from 6 to 10 months of age) display robust LTP upon STET (arrows) that was maintained throughout the recording
session (t-test, P = 0.00006; n = 30 comparing before vs. after STET).
B Lasting LTP induced by STET was not observed in 10-month-old APPPS1D9 placebo-treated mice. The potentiation decayed to baseline after 3 h (t-test, P = 0.16;
n = 19 comparing before vs. after STET).
C Treatment with anle138b starting at 6 months of age rescues LTP deficit in 10-month-old APPPS1D9 mice (t-test, P = 0.0003; n = 20 comparing before vs. after
STET).
D Escape latency in the Morris water maze test is impaired in placebo-treated APP mice and partially restored to WT levels in anle138b-treated APP mice (one-way
ANOVA, F = 35.94, P = 0.00006; *P = 0.0309 for APP + anle138b vs. APP + placebo and P = 0.4 for APP + placebo vs. WT + anle138b; n = 7/group).
E Probe test performed 24 h after the last training session. The lower panel shows representative swimming path during the probe test. T = target quadrant compared
vs. other quadrants (t-test, **P = 0.0007, *P = 0.0031; n = 7/group).
F Average swim speed during water maze training (n = 7/group).
G Explorative behavior in the open field test. Upper panel: Representative motion tracks during the test session. Lower panels show the total distance travelled during
the 5-min test session (n = 7/group).
H Bar graph showing the time spent in the center vs. the corner of the open field (n = 7/group).
Data information: Error bars indicate SEM. In panels (A–C), triplets of arrows represent STET applied for inducing L-LTP. Insets in each graph represent typical fEPSP
traces recorded 15 min before (dotted line), 30 min after (broken line), and 3 h after (full line) STET.
ª 2017 The Authors EMBO Molecular Medicine
Ana Martinez Hernandez et al Ab-pore blocker anle138b rescues APPPS1D9 mice EMBO Molecular Medicine
5
Appendix
 
 129
A
D E F
B C
Figure 3. Hippocampal transcriptome analysis in anle138b-treated mice.
A Upper panel: Heat map showing differentially expressed genes in placebo-treated WT (n = 4), placebo-treated APPPS1DE9 mice (n = 4), and anle138b-treated
APPPS1DE9 mice (n = 4) of the pre-plaque group. Note that a WT-like gene expression profile is to a large extent reinstated in APPPS1DE9 mice upon treatment with
anle138b. Lower panel: Bar graph showing the number of up and down-regulated genes.
B Pathways down-regulated (blue) or up-regulated (red) in 6-month-old APPPS1DE9 mice when compared to age-matched WT controls (pre-plaque group; see Fig EV1).
C Expression of APP and PS1 genes in WT and APPPS1DE9 transgenic mice, placebo- or anle138b-treated in pre- and post-plaque groups. Note that anle138b treatment
does not affect the expression level of APP or PS1. Post hoc analysis revealed a significantly increased expression of APP and PS1 in transgenic mice when compared
to wild-type mice (*P < 0.05). Error bars indicate SEM.
D Upper panel: Heat map showing differentially expressed genes in placebo-treated WT (n = 4), placebo-treated APPPS1DE9 mice (n = 5), and anle138b-treated
APPPS1DE9 mice (n = 5) of the post-plaque group. Lower panel: Bar graph showing the number of up- and down-regulated genes.
E Venn diagram showing that 10-month-old mice treated with placebo or anle138b show very similar changes in hippocampal gene expression (post-plaque group; see
Fig EV1).
F Pathway analysis based on the 103 genes commonly increased in placebo- and anle138b-treated APPPS1DE9 mice at 10 months of age. Note that the pathways are
exclusively linked to neuroinflammation.
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changes, at least when treatment is initiated before the onset of
pathology, further confirming that treatment with anle138b helps
to reinstate hippocampal homeostasis.
Given that anle138b was shown to counter aggregation in models
for a-synuclein and prion toxicity (Wagner et al, 2013), it is likely
that at least part of the therapeutic effect observed in this study is
due to anle138b interfering with amyloid aggregation. To test this
hypothesis, we prepared brain slices for histochemical analysis. We
used thioflavin S, a common stain to quantify Ab plaques (Fig 4A).
We first assayed the amyloid plaques pathology in the hippocampus
and cortex in the pre-plaques group. Since no amyloid pathology
was detectable in WT mice, these mice served as negative control.
We observed a significant reduction in the number of plaques and
the total area covered by plaques in anle138b-treated mice (Fig 4A
and B). Similar results were obtained when we analyzed plaque
load in the post-plaques group (Fig 4B and C), although the pathol-
ogy was generally more severe in the post-plaque group. Thus, oral
administration of anle138b reduces amyloid pathology when given
before or after the onset of pathology.
Biophysical characterization of Ab in the presence of anle138b
To better understand the mechanisms that underlie the therapeutic
effect of anle138b, we analyzed its impact on Ab-induced pore
formation (Arispe et al, 1993). To this end, we employed black lipid
membranes (BLM) using a mixture of POPE and DOPS in a 1:1 ratio
or oxidized cholesterol/n-decane, an assay in which the current
passing through a membrane is a measure of membrane integrity
(Appendix Fig S5A). We first established that the conductance and
the morphology of POPE and DOPS lipids, as measured by atomic
force microscopy (AFM), lipid bilayers are not affected in the pres-
ence of anle138b or Ab peptides (Appendix Fig S6).
When we examined the effect of Ab1–42 in DOPS/POPE (1:1)
membranes, we observed a stepwise growth of bulk membrane
conductance. Such activity is indicative of the combined action of
many individual pores (Fig 5A). Pore “stacking” is likely the result
of prolonged open lifetimes and the formation and/or opening of
additional conducting pores. Anle138b-doped membranes demon-
strated fewer simultaneously active pores and significantly reduced
bulk conductance (Fig 5A and B, Appendix Fig S5) compared to
membranes lacking the anle138b compound (Fig 5A and B,
Appendix Fig S5). Our results indicate that treatment with anle138b
alters the pore dynamics, resulting in less stable and shorter lived
“open” pores. Decreased pore stability leads to a reduction in the
total number of simultaneously conducting pores and significantly
decreased conductance across the membrane. AFM data revealed
that anle138b treatment did not affect the surface structure of Ab1-42
pores (Fig EV2), suggesting that anle138b does not simply prevent
Ab1-42 from entering lipid bilayer membranes and forming pores.
Rather anle138b appears to render conducting Ab pores to non-
conducting ones—likely through structural change to the membrane
embedded region of Ab1–42—thereby providing one possible mecha-
nism by which anle138b ameliorates LTP and learning deficits in
APPPS1DE9 mice. Similar effects were observed when the conduc-
tance measurements were repeated in oxidized cholesterol
(Appendix Fig S5B).
To provide in vivo evidence for pore formation, we treated
primary hippocampal neurons with Ab1-40 monomers or oligomers
in the absence or presence of anle138b and assayed membrane
integrity. While the addition of Ab1-40 oligomers but not Ab1-40
monomers significantly damaged membrane integrity, this effect
was reversed by anle138b (Fig 5C). This restoration is not simply
due to an anle138b-mediated reduction in cell death, since the cell
viability of hippocampal neurons measured in the MTT assay was
identically affected by Ab1-40 monomer and oligomer treatment in
our experimental setting (Fig 5D). In this context, it is important
to state that different protocols for Ab treatment of neurons have
been used to study various effects of Ab on neuronal plasticity and
integrity. The concentration of Ab oligomers employed in our
study is within the range of these studies. Nevertheless, such data
always need to be interpreted with care since a cell culture system
cannot not fully recapitulate the situation observed in human
patients. Interestingly, anle138b treatment was also able to amelio-
rate the effect of toxic Ab species on membrane integrity if added
after neurons had been incubated with Ab oligomers and already
exhibited impaired viability, which is in line with our data show-
ing that anle138b completely ameliorated LTP and partially
restored memory defects in the post-plaque group (Appendix Fig
S7A and B). We also employed another experimental system to
test the effect of Ab1-42 oligomers and anle138b on biological
membranes. To this end, we employed the cytochrome release
assay (CRA) on isolated mitochondria that were exposed to either
a-synuclein, tau, or Ab1-42 oligomer in the presence or absence on
anle138b. Our data reveal a substantial damage to mitochondrial
membranes in all conditions that is attenuated by anle138b
(Appendix Fig S7C), suggesting that anle138b has general effect on
membrane integrity.
Discussion
In this work, we investigated the effect of anle138b in the estab-
lished APPPS1DE9 mouse model of AD. The APPPS1DE9 mouse
model is characterized by dysfunction of neurons and detected by
memory decline after 4 months and severe plaques formation after
6 months (Kummer et al, 2014). The most important findings of the
present study were that anle138b treatment completely restored
hippocampal LTP in the pre- and post-plaque groups of APPPS1DE9
mice. In line with this observation, spatial reference memory was
fully or partially restored in the pre- and post-plaque groups, respec-
tively. There have been numerous pre-clinical studies aiming to
restore synaptic plasticity and memory function in mouse models
for amyloid pathology. These range from therapeutic approaches
that aim to modulate causative factors including Ab-toxicity via anti-
body-based therapies (Selkoe & Hardy, 2016), small molecules that
modulated APP processing (Vassar et al, 2014), small molecules
that are thought to target toxic amyloid species directly (Doig &
Derreumaux, 2015) to symptomatic treatments not directly targeted
toward amyloids (Fischer, 2016). Anle138b belongs to the first cate-
gory. Its therapeutic effect resembles that of other small molecule
drugs. For example, epigallocatechin gallate (EGCG) was shown to
affect Ab toxicity by redirecting toxic Ab-structures into off-pathway
oligomers (Ehrnhoefer et al, 2008; Bieschke et al, 2010). This agent
was able to ameliorate spatial memory deficits in APP mice after the
onset of amyloid deposition (Liu et al, 2014). In this context, it is
interesting to note that when administered via dry food anle138b
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was previously found to be taken up to reach levels of 100 lM in
the brain (Wagner et al, 2015). Anle138b metabolites are very
hydrophilic, and they were detected in multiple organs but were
absent in brain (Wagner et al, 2013). This indicates that anle138b is
not metabolized in the brain. Anle138b was also found to be
non-toxic in mice up to a dose of 2 g/kg. Mice receiving similar
concentrations of anle138b as used in our study lived without any
detectable toxicity, even when the drug was given longer than a
year (Wagner et al, 2015). Also in our study, no negative or positive
effects of anle138b on WT mice were observed.
A
B
C
Figure 4. Amyloid plaque pathology is ameliorated by anle138b treatment in the pre-plaque (A) and post-plaque (B) groups.
A Reduced amyloid pathology as indicated by reduced number of plaques (left panel) and reduced area covered by plaques (right panel) in the pre-plaque group (t-test
***P = 0.00003; n = 5/group).
B Reduced amyloid pathology as indicated by reduced number of plaques (left panel) and reduced area covered by plaques in the post-plaque group (t-test
***P = 0.00007, **P = 0.005; n = 5/group).
C Representative images showing thioflavin S staining in the hippocampus and cortex of mice of the pre- and post-plaque groups. Scale bar = 200 lm.
Data information: Error bars indicate SEM.
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In addition to the restoration of hippocampal LTP and spatial
reference memory, we also observed restoration of physiological,
wild-type-like gene expression profile in the pre-plaque group, indi-
cating that hippocampal cells reinstate homeostasis. In APPPS1DE9
mice that received normal chow, genes linked to metabolic function
and neuronal plasticity were markedly down-regulated. Feeding with
anle138b-containing chow completely reversed this effect on gene
expression. Even in the placebo-treated pre-plaque group, we
observed little evidence for neuroinflammatory processes, which is
in contrast to the data from the post-plaque group. In fact, the gene
expression changes observed in the placebo-treated post-plaque
group were dominated by increased inflammation. These data
suggest that in APPPS1DE9 mice, the decline of synaptic plasticity
precedes inflammatory processes. Of note, anle138b treatment had
A
C D E
B
Figure 5. Anle138b ameliorates Ab1-40 and Ab1-42-induced membrane integrity.
A Ab1-42 induces pore-like step ionic current increases across lipid bilayer membranes and grows with inverted sign after voltage inversion to amplifier saturation
current. In the presence of anle138b, the current remains at low amplitude and does not increase beyond 30 pA.
B Expanded trace of anle138b-treated membrane presented in (A). Discreet conductance levels are highlighted suggesting multiple opening and closing events for three
individual pores.
C Hippocampal neurons (DIV 10) were treated with anle138b (1 lM) or vehicle before Ab1-40 oligomers or monomers were added (10 lM, n = 4/group). After 48 h,
membrane integrity was measured as fluorescence intensity using a CyQUANT assay (Thermo Fisher). In the vehicle group, membrane integrity was significantly
impaired when treated with Ab oligomers comparing with control neurons or Ab monomer-treated neurons, anle138b-treated neurons did not exhibit a difference
between addition of Ab monomers or Ab oligomers (t-test, **P = 0.007).
D Same experimental setting as in (C) but cell viability was measured using the MTT assay (t-test, *P = 0.002 vs. control). No difference in cell viability was observed for
Ab monomer or oligomer treatment in the absence or presence of anle138b.
E Schematic of potential mechanisms of activity inhibition for anle138b. In the absence of anle138b, Ab monomers and/or oligomers insert in the membrane and form
conducting pores. Treatment with anle138b renders these conductive channels inactive most probably due to reduced life time of the open state.
Data information: Error bars indicate SEM.
ª 2017 The Authors EMBO Molecular Medicine
Ana Martinez Hernandez et al Ab-pore blocker anle138b rescues APPPS1D9 mice EMBO Molecular Medicine
9
Appendix
 
 133
no effect on pathological gene expression pattern in the post-plaque
group, yet hippocampal LTP was completely restored and spatial
memory was partially restored. These data suggest that therapeutic
strategies that aim to reduce amyloid toxicity—at least in the
APPPS1DE9 model—may have little influence on neuroinflammation
when applied at an advanced stage of the disease. Nevertheless, a
significant therapeutic effect could be observed in the post-plaque
group. This might be explained by removal of toxic Ab species which
can lead to the restoration of synaptic function in neurons even in a
detrimental inflammatory environment. These data are highly inter-
esting, since one argument for the failure of clinical trials targeting
amyloid deposition or modulation of Ab cleavage is that such
treatments are ineffective when given at an advanced stage of
the diseases. Our data suggest, however, that anle138b targets Ab-
related pathological events that allow recovery of synaptic function
even if secondary pathological events such as inflammation
persist.
The finding that anle138b treatment ameliorates synaptic plastic-
ity and learning deficits in APPPS1DE9 is of utmost importance.
These data are in line with previous observations showing that the
same compounds have beneficial effects in animal models for
Creutzfeld-Jakob, Parkinson’s disease, and Tau pathology. Specifi-
cally, the latter finding is intriguing, since Tau and Ab pathology are
believed to be the main causative factors of AD pathogenesis. While
Wagner et al (2015) showed that anle138b in Tau P301S mice
rescues synaptic and neuronal loss, we could further substantiate
these data by showing that anle138b treatment also ameliorates
defects in hippocampal transcriptome plasticity in the same Tau
P301S mice. Taken together, these data suggest the revealing possi-
bility that anle138b is able to ameliorate Tau and Ab pathology.
Therefore, to the best of our knowledge, anle138b would be the first
small molecule that has a direct effect on the two major hallmarks
of AD.
These data are also important from a translational point of view.
Taking into account that the various animal models for AD only
recapitulate part of the pathogenesis observed in human patients, it
is intriguing that anle138b was able to rescue disease progression in
various different AD models and models for aggregopathies, raising
the hope that anle138b could also be effective in human patients.
The mechanism by which toxic Ab species induce synaptic
dysfunction and neurotoxicity is still unresolved. Proposed mecha-
nisms include NMDA receptor endocytosis (Shankar et al, 2007), a-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid surface recep-
tor modulation (Querfurth & LaFerla, 2010), and Ab pore formation
(Arispe et al, 1993). Moreover, the presence of amyloid plaques was
shown to change structural plasticity of neurons (Spires & Hyman,
2004). Nevertheless, amyloid plaques are unlikely the sole reason
for disturbed synaptic function and memory consolidation in AD
and it has even been suggested that they present a compensatory
mechanism of the brain in order to deal with toxic Ab species
(Selkoe & Hardy, 2016). This is further supported by our findings
that anle138b treatment in the post-plaque group was able to restore
hippocampal LTP and spatial reference memory, although the
plaque load was even higher when compared to placebo-treated
APPPS1DE9 mice of the pre-plaque group suggesting that the reduc-
tion in amyloid plaque load cannot be the main mechanisms by
which anle138b exerts its therapeutic action. The pore formation
hypothesis has long been proposed but tested experimentally to a
very limited degree, which is also due to the fact that an array of
various in vitro and in vivo methods needs to be combined to
address this issue. We focused on the question whether anle138b
modulates the pore forming activity of Ab because synaptic function
relies on the integrity of membranes and their ability to modulate
ion fluxes in a voltage-dependent way. This pore-based mechanism
has been envisaged to underlie impaired neuronal function and cell
death (Arispe et al, 1993). Modulation of pore formation was also
implicated in cell-based models for EGCG mode of action (Diaz
et al, 2009) and of its congeners MRS2481 and MRS2485 (Diaz et al,
2009). The observed stepwise growth of bulk membrane conduc-
tance in the presence of Ab (without anle138b) indicates that activ-
ity increases through the combined action of many individual pores.
Numerous molecular dynamics (MD) simulations (Jang et al,
2008; Arce et al, 2011; Gillman et al, 2014) and NMR spectroscopy-
based investigations (Sarkar et al, 2014) of Ab pores have pointed
to a b-barrel structure for the intramembrane region of the pore. It
was previously shown that Ab containing a point substituted proline
(F19P) showed pore structure by AFM but did not demonstrate ionic
conductance (Capone et al, 2012; Connelly et al, 2012b). The chem-
ical structure of proline introduces a “kink” in the peptide’s
secondary structure, which is known to disrupt b-sheet formation.
MD simulations of F19P barrel structure showed that b-sheet desta-
bilization led the highly charged N-terminal regions to bind at the
peptide mouth and collapsed the pore (Umehara et al, 2010;
Connelly et al, 2012a). Our data are consistent with such a model
and suggest that anle138b induces a conformational change within
Ab pores that greatly reduces or, in most pores eliminates, ionic
flux. Steric blockage by anle138b without a conformational change
of the pore is energetically unfavorable due to the hydrophobicity of
anle138b, as this scenario would require anle138b to be in contact
with water molecules inside the pore. The above-mentioned mecha-
nisms provide further insight into the method of action in prevent-
ing pore activity and reducing Alzheimer’s pathogenicity (Fig 5E).
It has to be mentioned, however, that all of the above-described
experiments are based on in vitro approaches using lipid bilayers. In
vivo evidence further supporting the notion that anle138b counter-
acts the detrimental effect of toxic Ab species on membrane integrity
stems from our finding that Ab1-40 administration to cultured
hippocampal neurons compromised membrane integrity, an effect
which was attenuated by anle138b. Our interpretation that conver-
sion of conducting to non-conduction Ab pores is one possible mode
of anle138b action. It may also explain that anle138b ameliorated all
tested disease phenotypes in the pre-plaque group, while in the
post-plaque group only LTP was completely restored. Hence, in the
post-plaque group, the presence of toxic Ab species may already
have induced secondary processes such as inflammation that persis-
tently affects memory function even if membrane integrity and LTP
are restored in neurons. Yet, we like to reiterate that while our data
point to the existence of Ab pores in vivo, a definite proof is still
missing. Further evidence in support of the Ab pores stems from a
study in which Ab oligomers induce single-channel calcium fluores-
cence transients in Xenopus oocytes (Demuro et al, 2011). Never-
theless, we cannot exclude that anle138b affects other cellular
processes than Ab-mediated conducting pores in membranes. Thus,
it is also possible for example that in vivo Ab sequesters membrane
lipids, thereby affecting membrane integrity, which is then
prevented by the action of anle138b.
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In conclusion, our data show that anle138b can reinstate
synaptic plasticity and memory function in a mouse model for
amyloid pathology via mechanisms that—at least in part—appear
to involve the blockage of Ab-induced pores in membranes. Care-
ful analysis of this activity indicates that the oligomers are still in
the membrane, but pores have a changed conductivity profile,
mainly staying open for shorter time and lacking the possibility of
building up large currents as seen when anle138b was absent.
Taking into account that anle138b was also shown to ameliorate
disease phenotypes in a mouse model for Tau pathology, thus
being to the best of our knowledge one of the first compounds
that seems to causatively interfere with both of the two major
hallmarks of AD, we suggest that anle138b to further be validated
in clinical trials for its potential to treat AD and perhaps other
aggregopathies.
Materials and Methods
Mouse experiments
The APP(Swe)/PS1ED9 (henceforth called: APPPS1DE9) mouse
model of AD was used for this study. The age of the animals is indi-
cated for each experiment. In brief, mice of the pre-plaque group
were analyzed at 6 months of age, while mice of the post-plaque
group were 10 months of age. Upon completion of treatment, these
and control mice underwent cognitive assessment by a behavior
battery of tests. Electrophysiology, RNA sequencing, and histochem-
ical analysis of plaque burden were also assessed. All mice were
male and were maintained on a C57BL/6 background. They were
kept in a 12-h dark/light cycle and housed in groups under constant
standard conditions of temperature and humidity. Mice had ad libi-
tum access to food and water. Animal care and handling were
carried out in compliance with the Declaration of Helsinki and
approved by local ethical committees.
Anle138b treatment
In order to investigate the prophylactic effect of anle138b, we
treated healthy, plaque-free, adult, APPPS1D9 mice with placebo-
or anle138b-containing dry food pellets for 4 months from 2 to
6 months of age (pre-plaque group; Fig EV1). Age- and sex-
matched wild-type littermates were also treated and served as
controls. Similarly, in order to investigate the therapeutic effect of
anle138b, we treated symptomatic APPPS1DE9 mice and treated
them for 4 months from 6 to 10 months of age (post-plaque group;
Fig EV1). Controls were age- and sex-matched wild-type litter-
mates treated with anle138b or placebo. Anle138b was adminis-
tered orally. Dry food pellets were prepared containing 2g
anle138b per kg food (SSNIFF). This amounted to an estimated
daily dose of 500 mg/kg (at an approx. 6-g daily food consumption
and a 25-g average body weight). Based on pharmacokinetic stud-
ies, 40–70 lM anle138b reached the brain during most of the wake
phase (Wagner et al, 2015). Placebo food was prepared from the
same batch but without anle138b (SSNIFF). Of note, our previous
PK studies in mice have shown that after a single bolus the half-
life of anle138b in the brain is approximately 4 h (Wagner et al,
2013).
Morris water maze (MWM)
Mice were single-caged and brought into the testing room at
least 1 week prior to the beginning of the experiment to allow
them to acclimate. In the MWM, mice were trained to find a
submerged 10 × 10 cm platform in a pool (1.10 m in diameter)
of milky water using spatial cues by the pool sides as orienta-
tion points. Mice were trained over 8 consecutive days with four
trials per day per mouse. Time and path to platform were
tracked and recorded (TSE systems). On day 9 (probe test), the
platform was removed and quadrant preference was recorded
(target quadrant being the one where the platform was previ-
ously located).
Open field
Mice were allowed to spend 5 min in an open arena (40 × 40 cm).
Path length while exploring and time in the center or corners were
quantified using the VideoMot2 System (TSE).
RNA sequencing
Library preparation and cluster generation for mRNA sequencing
were performed according to Illumina standard protocols (TruSeq,
Illumina). Libraries were quality-controlled and quantified using a
Nanodrop 2000 (Thermo Scientific), Agilent 2100 Bioanalyzer (Agi-
lent Technologies), and Qubit (Life Technologies). Data will be
made available upon publication via GEO (accession number
GSE104424). Base calling from raw images and file conversion to
fastq-files was achieved by Illumina pipeline scripts. Subsequent
steps included quality control (FastQC, https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/), mapping to reference genome
(mm10, STAR aligner v2.3.0 (Djebali et al, 2012) non-default
parameters), read counting on genes or exons (HTSeq, http://www-
huber.embl.de/users/anders/HTSeq, mode: intersection-non-
empty), and differential gene (DESeq2_1.4.5; Love et al, 2014)
usage biostatistical analysis. PCA and distance heat maps were
generated in R following instructions in the vignette for DESeq2.
Genes were considered differentially expressed with an adjusted
P-value lower than 0.05 (Benjamini-Hochberg). Gene set overlaps
were calculated using Venny (http://bioinfogp.cnb.csic.es/tools/ve
nny/). Pathway analysis was performed using Cytoscape (www.cy
toscape.com) and Cytoscape extension ClueGO.
Electrophysiology on hippocampal slices
Slice preparation
Acute hippocampal slices prepared from WT mice and APPPS1DE9
mice were used for electrophysiological recordings. All the proce-
dures were carried out in compliance to the guidelines from the
Animal Committee on Ethics in the Care and Use of Laboratory
Animals of TU-Braunschweig. Briefly, after anesthetization using
CO2, the mice were decapitated and the brains were quickly
removed and cooled in 2–4°C artificial cerebrospinal fluid (aCSF).
The hippocampi were dissected, and transverse hippocampal slices
(400 lm) were prepared by using a manual tissue chopper. Then,
slices were incubated for 3 h at 32°C in an interface chamber (Scien-
tific System Design), which was continuously perfused with
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oxygenated aCSF at a flow rate of 0.8 ml/min. The aCSF contained
the following (in mM): 124 NaCl, 4.9 KCl, 1.2 KH2PO4, 2.0 MgSO4,
2.0 CaCl2, 24.6 NaHCO3, 10 D-glucose, equilibrated with 95%
O2–5% CO2 (32 L/h).
Slice recordings
To evoke field EPSP (fEPSP) from Schaffer collateral/commissural-
CA1 synapses, one monopolar lacquer-coated, stainless-steel elec-
trode (5 MΩ; AM Systems) was positioned at the stratum radiatum
layer of the CA1 region. For recording fEPSP (measured as its initial
slope function), one electrode (5 MΩ; AM Systems) was placed in
the CA1 apical dendritic layer and signals were amplified by a dif-
ferential amplifier (Model 1700, AM Systems). The signals were
digitized using a CED 1401 analog-to-digital converter (Cambridge
Electronic Design). After the preincubation period, an input–output
curve (afferent stimulation vs. fEPSP slope) was generated. Test
stimulation intensity was adjusted to elicit fEPSP slope of ! 40% of
the maximal fEPSP response. Four 0.2-Hz biphasic constant current
pulses (0.1 ms/polarity) were used for baseline recording and test-
ing at each time point. Long-term potentiation (LTP) was elicited by
“strong” tetanus (STET) consisting of three stimulus trains of 100
pulses at 100 Hz delivered at 10-min intervals (300 pulses in total).
Data (fEPSP slope) were normalized to baseline and plotted as aver-
age " SEM. The average values of the slope function of the fEPSP
(millivolts per milliseconds) for each time point were analyzed
using paired t-test; P < 0.05 was considered as statistically
significant.
Thioflavin S staining
Thioflavin S staining was performed as previously described with
the some modifications (Guntern et al, 1992; Sun et al, 2002).
Briefly, mice were sacrificed and their brain quickly removed on ice.
Left hemispheres were embedded in OCT (Tissue TEK) and stored
at #80°C until ready to section. Sagittal, 25-lm-thick sections were
cut using a cryostat. And, five sets of five slides per brain containing
four sections/slide were made by taking every 5th section on the
same slide, so that each set consisted of 20 representative sections
throughout the brain. Sets to be used for thioflavin S staining were
then fixed with 4% PFA for 25 min at room temperature, washed
twice with 0.9% NaCl, and quickly rinsed with PBS. Staining was
performed using filtered 0.05% thioflavin S in 50% ethanol for
8 min in the dark and differentiated with two changes of 80%
ethanol for 10 s. This was followed by three washes with large
volumes of distilled water and an incubation step in high-concen-
trated phosphate buffer (411 mM NaCl, 8.1 mM KCl, 30 mM
Na2HPO4, 5.2 mM KH2PO4, pH 7.2) at 4°C for 30 min. Finally, slides
were briefly rinsed in PBST and covered with coverslips using
Vectashield Hard Set mounting media with DAPI (Vector). Slides
were allowed to set in the dark at 4°C and imaged immediately
thereafter. To control for background, unspecific staining, or tissue
auto-fluorescence, slides from age-matched wild-type brains were
used as negative controls. Images at 4× magnification of hippocam-
pus and cortex were captured using an Olympus IX70 fluorescence
microscope. Quantification of number of plaques, area covered by
the plaque, and average plaque size was performed using the parti-
cle analysis tool of the ImageJ software. Statistical analysis was
carried out using GraphPad Prism7.
Biophysical experiments on Ab1-42
Materials
Ab1–42 was purchased from Bachem and Anaspec (Fremont, CA).
The phospholipids 1.2-dioleoyl-sn-glycero-3-phosphoserine
(DOPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
(POPE) were purchased from Avanti Polar Lipids (Alabaster, AL).
All other chemicals were purchased from Sigma-Aldrich (St. Louis,
MO).
Peptide handling
For BLM experiments, Ab1–42 peptides were dissolved in Milli-Q
water to a concentration of 1 mg/ml prior to being aliquoted for
storage. These 50-ll aliquots were stored at #80°C for a maximum
of 60 days before use. Samples were thawed only once. For AFM
experiments, powder form of Ab1-42 (Bachem, Torrance, CA) was
first dissolved in 1% ammonium hydroxide until the peptides were
completely dissolved. They were subsequently sonicated for approx-
imately 2 min. Small volume of peptides were then aliquoted and
lyophilized using a lyophilizer (Labconco FreeZone 2.5 Plus, Kansas
City, KS). The aliquots were stored at #80°C until used. For every
experiment, aliquoted peptides were thawed and hydrated in
20 mM NaOH and HEPES buffer solutions at pH 7.4, sequentially.
The peptide concentration was measured using the 280 nm UV
absorbance (e = 1,490 M#1 cm#1).
Peptide aggregation
Synthetic Ab1-40 and Ab1-42 powders were dissolved in 20 mM
NaOH at 2 mg/ml concentration and incubated at 4°C for 1 h to
dissolve their pre-existing aggregates. The Ab stock solutions
were then brought to PBS, pH 7.4, at a final peptide concentra-
tion of 0.4 mg/ml, around 90 lM. After a short centrifugation
(16,000 g, 30 min), the supernatants were used either directly, as
the monomeric Ab, or following a 3-h incubation at 37°C (with-
out agitation), as the oligomeric-enriched Ab samples. The mono-
meric and oligomeric-enriched Ab samples were then added to
primary neuronal cultures for membrane integrity and viability
assays.
Electrical recording of planar lipid bilayer made of oxidized cholesterol/
n-decane
We prepared planar lipid bilayers using the Mu¨ller-Rudin technique
(Benz et al, 1978). The membranes were formed from a 1% (w/v)
solution of oxidized cholesterol in n-decane. Oxidized cholesterol
was prepared according to an established procedure (Benz et al,
1978). The lipid membranes were formed using a Teflon loop to
spread the lipid solution across a hole with a surface area of approx-
imately 0.3 mm2 in the wall dividing the two aqueous compart-
ments in a Teflon cell. After the membrane had turned black, the
Ab1–42 peptide-containing protein fractions were added to the aque-
ous phase on one or both sides of the membrane at final concentra-
tions 1 and 40 lM. For doping lipid bilayers with anle138b, the
compound was dissolved in chloroform. The chloroform of a sample
was then evaporated under vacuum. The lipid solution was added
to the dry anle138b in such an amount that a final concentration of
1 mM in the lipid solution was obtained. This lipid solution was
used for the normal protocol of bilayer formation as described
above.
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The current across the lipid bilayer membranes was measured
with a pair of Ag/AgCl electrodes with salt bridges switched in
series with a voltage source and a highly sensitive current amplifier
Keithley 427 (Keithley Instruments, INC. Cleveland, OH). The
output signal of the amplifier was recorded by a strip chart recorder
(Rikadenki Electronics GmbH, Freiburg, Germany). The temperature
was kept at 20°C throughout the experiment.
Planar lipid bilayer electrical recording using DOPS and POPE
We prepared planar lipid bilayers using the so-called painted
technique (Mueller et al, 1962). Anle138b was mixed with a 1:1
(w/w) solution of DOPS and POPE in chloroform at a concentra-
tion of 10 mM with respect to the volume of the lipids. A lipid
specific gravity of 0.8 was used for the calculation. This mixture
was subsequently dried in a Rotavapor R-210 (Buchi) and resus-
pended in decane at a total lipid concentration of 20 mg/ml.
Bilayers with embedded anle138b were formed from this solution.
Spontaneous membrane formation occurs following the addition
of lipid directly over a pore with a diameter of ~250 lm in a
Delrin septum (Warner Instruments, Delrin perfusion cup, volume
1 ml). In previous studies, this membrane composition was
shown to be stable for long recording times (~4 h; Capone et al,
2012). Control experiments establishing the stability of
membranes formed with the addition of anle138b were
performed. We used 150 mM KCl, 10 mM HEPES (pH 7.4), and
1 mM MgCl2 as the electrolyte.
We observed the following difficulty in the preparation of
anle138b loaded lipids. Anle138b was dissolved in decane along
with the lipids prior to membrane painting. Since anle138b is
soluble in both the decane and the lipids, the distribution of
compound in the lipid membrane that spontaneously forms upon
lipid deposition over the aperture can vary. Lipid monolayers bind
to either side of the partition and the bilayer membrane forms as the
monolayers fuse together at the center, excluding the decane solvent
to the perimeter. This solvent annulus acts as a bridge to the Delrin
partition and is essential for membrane stability (White, 1972). If a
significant proportion of the anle138b is mobile in the decane, the
compound could be partitioned to the solvent annulus rather than
incorporated into the membrane leading to BLM results that appear
similar to that seen with Ab1-42 in the absence of compound. This
can explain why anle138b modulated the activity of the pores in
only 50% of the cases.
Before performing electrical recordings, we verified that the
bilayer was stable for several minutes with low conductance
(<10 pS) across ! 100 mV applied voltage and that the system
capacitance was >110 pF. When both criteria were met, peptide was
added directly to the cis (hot wire) side and stirred for 5 min.
Peptide concentration in the bilayer chamber was approximately
10 lM. Bilayer stability was monitored by periodic capacitance
measurements throughout the course of the experiment.
All traces were recorded in voltage clamp mode using the 2 kHz
built-in filter cutoff of our BC-535 amplifier (Warner Instruments,
Hamden, CT). A sampling frequency of 15 kHz was used for all data
acquisition. We used a custom-made LabVIEW program to record
the current and Clampfit 10.2 (Molecular Devices, Sunnyvale, CA)
to analyze traces. We have filtered the recorded current versus time
traces with a digital Gaussian low-pass filter and a cutoff frequency
of 50 Hz for representation in figures.
Lipid bilayer preparation for AFM imaging
For liposome preparation, DOPS and POPE lipids were used in a 1:1
ratio (Avanti Polar Lipids, Alabaster, Al). Liposomes were prepared
by mixing 20 ll of each lipid (5 mg/ml) dissolved in chloroform,
and anle138b, also in chloroform, was added to a 1,000:1 lipid to
anle138b molar ratio. Then, liposomes were allowed to dry over-
night in vacuum. The dried lipid film (and anle138b) was hydrated
with peptide solution (1:60 peptide to lipid molar ratio) to facilitate
peptide incorporation in the lipid bilayer, resulting in proteolipo-
some formation. For controls, the dried lipid film (and anle138b)
was hydrated with 200 ll of HEPES buffer and vortexed occasion-
ally for an hour. The large multilamellar vesicles formed with this
procedure were sonicated for 5 min. Supported lipid bilayers were
formed by (proteo)liposome rupture and fusion on the mica
substrate (Lin et al, 2001; Quist et al, 2005; Liu et al, 2006;
Umehara et al, 2010; Connelly et al, 2012a,b). Lipid concentrations
of 0.1–1 mg/ml were deposited on freshly cleaved mica and incu-
bated for ~10 min on a hot plate above the lipid transition tempera-
ture to facilitate fusion of the ruptured proteoliposomes on the mica
surface. As a last step, samples were rinsed with buffer to remove
unruptured proteoliposomes still in solution.
AFM imaging on membranes
Topographic images were acquired using a Multimode AFM
equipped with a Nanoscope V controller (Bruker, Santa Barbara,
CA). Silicon nitride cantilevers with nominal spring constants of
0.08 N/m (OMCL-TR400, Olympus) were employed for imaging in
fluid using the tapping mode. Resonance frequencies of " 8 kHz
and drive amplitudes under 100 mV were used. All experiments
were performed at room temperature. Actual spring constants were
measured to be within 10% of its nominal value using thermal tune
before the experiments. To measure outer pore diameters, tip broad-
ening was taken into account by modeling the inserted oligomers as
a spherical cap protruding a height h above the surface of the lipid
bilayer in contact with a spherical tip of radius R (Lee et al, 2014).
Cell membrane integrity and viability
CyQUANT
Primary neuronal cultures were produced from E17.5 CD1 Swiss
embryos. On DIV, 10 cultures were treated conditioned medium
supplemented with anle138b to a final concentration of 1 lM in
0.05% DMSO (Roth, A994.2) or 0.05% DMSO as vehicle. After 24 h
Ab1-40 oligomers, monomers or buffer (n = 4 each) was applied at
10 lM and incubated for 48 h. CyQUANT! Direct Cell Proliferation
Assay (Thermo Fisher, C35011) was used according to manufac-
turer’s protocol to determine membrane integrity. After 30-min incu-
bation, fluorescence was measured with a Tecan infinite 200.
Statistical analysis was performed in GraphPad Prism.
MTT assay
Cell viability was measured using the MTT assay with the same
sample preparation as for the CyQUANT assay. Briefly, after anle138b
and Ab1-40 treatment, the cell culture medium was supplemented
with MTT to a final concentration of 0.5 mg/ml and incubated for
1 h at 37°C in a standard cell culture incubator. Subsequently,
medium was removed and metabolites suspended in 500 ll DMSO.
Absorption at 800 nm was measured using a Tecan infinite 200.
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Transgenic flies and survival assays
w[1118]; P{UAS-Arctic Ab 1-42 (Glu22Gly)}(arc2E) transgenic flies
were kindly provided by D. Crowther (Cambridge, UK; Crowther et al,
2005). The co-expression of Gal4 under a tissue specific promotor
leads to activation of an upstream activating sequence (UAS)
element that activates the transcription of Ab42 upon Gal4-UAS
binding (Brand & Perrimon, 1993). We controlled the temporal
expression of the Gal4-UAS system by a temperature-sensitive
Gal80ts under a ubiquitously expressing tubulin promoter (tub-
Gal80ts) (McGuire et al, 2003). Gal80ts represses the transcriptional
activity of Gal4 at the permissive temperature (18°C). Upon a shift
to the non-permissive temperature (30°C), Gal80ts becomes
dysfunctional and releases the Gal4-UAS system to allow transgene
expression. Neuron-specific and temperature-inducible expression
of Ab42 was achieved by crossing the w[1118]; Gal4-elav/CyO;
TM2/TM6 and w[1118]; Sp/CyO; tubGal80ts/TM2 lines obtained
from Bloomington (Bloomington Drosophila Stock Center (BDSC),
Indiana University, USA) to generate w[1118]; Gal4-elav/(CyO);
tubGal80ts/(TM6). The w[11118]; P{UAS-Arctic Ab 1-42 (Glu22Gly)}
line was crossed with w[1118]; Gal4-elav/(CyO);tubGal80 ts/(TM6).
w[1118]; Gal4-elav/UAS-arc2E;tubGal80/+ were used for subsequent
survival assays. As an overexpression control, we crossed w[1118];
Gal4-elav/(CyO);tubGal80/(TM6) with w[1118]; P{w[+mC]=UAS-
lacZ.NZ}20b (Bloomington Drosophila Stock Center (BDSC), Indi-
ana University, USA) to obtain w[1118]; Gal4-elav/+; tubGal80ts/
UAS-lacZ.
Survival assay
Male flies expressing Ab42 Glu22Gly arctic mutation and control
flies expressing lacZ were collected and maintained under a 12-h
light–dark cycle in 60% relative humidity and equal population
density per vial. Within 24 h after eclosion from the pupae, all flies
were transferred to the restrictive temperature. Compounds were
dissolved at 10 mM in DMSO and mixed with yeast. Fresh food was
added every 2nd–3rd day. As a control, Ab42 Glu22Gly transgenic
and lacZ control flies were treated with DMSO food without addition
of compounds. Surviving flies were counted every 2nd–3rd day. The
resulting Kaplan–Meier survival curves were calculated using SSPS
software. Differences between the genotypes were assessed by log-
rank test (SSPS software).
Statistical analysis
Unless specifically mentioned otherwise, data were analyzed by
unpaired Student’s t-test, two tailed t-test, Bonferroni test for multi-
ple comparisons, or one and two-way and ANOVA (analysis of vari-
ance) when appropriate. Errors are displayed as standard error of
mean (SEM). Unless otherwise stated, analysis was performed using
GraphPad Prism.
Data availability
RNA-sequencing datasets are available via GEO accession number:
GSE104424.
Expanded View for this article is available online.
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The paper explained
Problem
A hallmark of Alzheimer’s disease is the aggregation of Ab, yet the
mechanism of dysfunction of neurons and neuronal death is unclear
and disease-modifying therapeutic intervention is not yet possible.
Results
Using the APPPS1 overexpression model in mice, we show that the
diphenylpyrazole compound anle138b, an orally available small mole-
cule reaching 30 lM concentration in the brain when given orally,
ameliorated disease phenotypes such as hippocampal LTP, spatial
reference memory, and transcriptional homeostasis. Biophysical analy-
sis suggests that pore formation contributes to the dysfunctionaliza-
tion and death of neurons, while anle138b prevents pore formation
and thereby rescues these effects.
Impact
Our work provides evidence of the molecular mechanisms by which
Ab aggregation is contributing to Alzheimer’s disease, namely pore
formation in membranes by Ab oligomers whose conductivity is
reduced by more than a factor of 10 by anle138b treatment. The pore
conductivity reduction correlates with the full refunctionalization as
measured by LTP when anle138b is given before or after the onset of
amyloid deposition. Also memory function is improved. Our data
suggest that therapeutical effects can be expected to be achieved in
AD patients with anle138b.
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine Ab-pore blocker anle138b rescues APPPS1D9 mice Ana Martinez Hernandez et al
14
Appendix
 
 138
RNA-seq data. JW and MF treated Tau mice with anle138b and collected
tissue. MC, AC, and NV performed and interpreted the experiments on
cytochrome C release from mitochondria.
Conflict of interest
AG and CG are co-founders of MODAG. AL is partly employed by MODAG.
References
Arce FT, Jang H, Ramachandran S, Landon PB, Nussinov R, Lal R (2011)
Polymorphism of amyloid b peptide in different environments:
implications for membrane insertion and pore formation. Soft Matter 7:
5267 – 5273
Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein
forms calcium channels in bilayer membranes: blockade by tromethamine
and aluminum. Proc Natl Acad Sci USA 90: 567 – 571
Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, Jain G,
Capece V, Burkhardt S, Navarro-Sala M et al (2015) HDAC inhibitor-
dependent transcriptome and memory reinstatement in cognitive decline
models. J Clin Invest 17: 3572 – 3584
Benz R, Janko K, Boos W, Lauger P (1978) Formation of large, ion-permeable
membrane channels by matrix protein (Porin) of Escherichia-Coli. Biochem
Biophys Acta 511: 305 – 319
Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K,
Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-
beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107:
7710 – 7715
Brand AH, Perrimon N (1993) Targeted gene expression as a means of
altering cell fates and generating dominant phenotypes. Development 2:
401 – 415
Capone R, Jang H, Kotler SA, Kagan BL, Nussinov R, Lal R (2012) Probing
structural features of Alzheimer’s amyloid-beta pores in bilayers using
site-specific amino acid substitutions. Biochemistry 51: 776 – 785
Connelly L, Arce FT, Jang H, Capone R, Kotler SA, Ramachandran S, Kagan BL,
Nussinov R, Lal R (2012a) Atomic force microscopy and MD simulations
reveal pore-like structures of all-D-Enantiomer of Alzheimer’s b-amyloid
peptide: relevance to the ion channel mechanism of AD pathology. J Phys
Chem B 116: 1728 – 1735
Connelly L, Jang H, Arce FT, Ramachandran S, Kagan BL, Nussinov R, Lal R
(2012b) Effects of point substitutions on the structure of toxic Alzheimer’s
b-amyloid channels: atomic force microscopy and molecular dynamics
simulations. Biochemistry 51: 3031 – 3038
Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA (2005)
Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a
Drosophila model of Alzheimer’s disease. Neuroscience 132: 123 – 135
Demuro A, Smith M, Parker I (2011) Single-channel Ca(2+) imaging implicates
Ab1-42 amyloid pores in Alzheimer’s disease pathology. J Cell Biol 195:
515 – 524
Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB (2009) Small
molecule blockers of the Alzheimer A beta calcium channel potently
protect neurons from A beta cytotoxicity. Proc Natl Acad Sci USA 106:
3348 – 3353
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A,
Lagarde J, Lin WSF, Xue C et al (2012) Landscape of transcription in
human cells. Nature 489: 101 – 108
Doig AJ, Derreumaux P (2015) Inhibition of protein aggregation and amyloid
formation by small molecules. Curr Opin Struct Biol 30: 50 – 56
Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R,
Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic
polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol
15: 558 – 566
Fischer A (2014a) Epigenetic memory: the Lamarckian brain. EMBO J 33:
945 – 967
Fischer A (2014b) Targeting histone-modifications in Alzheimer’s disease.
What is the evidence that this is a promising therapeutic avenue?
Neuropsychopharmacology 80: 95 – 102
Fischer A (2016) Environmental enrichment as a method to improve cognitive
function. What can we learn from animal models? NeuroImage 1: 42 – 47
Gillman AL, Jang H, Lee J, Ramachandran S, Kagan BL, Nussinov R, Arce FT
(2014) Activity and architecture of pyroglutamate modified amyloid-b
(AbpE3-42) pores. J Phys Chem B 118: 7335 – 7344
Goate A, Hardy J (2012) Twenty years of Alzheimer’s disease-causing
mutations. J Neurochem 120: 3 – 8
Guntern R, Bouras C, Hof PR, Vallet PG (1992) An improved thioflavine-s
method for staining neurofibrillary tangles and senile plaques in
Alzheimers disease. Experientia 48: 8 – 10
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol
8: 112 – 116
Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (1995) The toxicity
in vitro of beta-amyloid protein. Biochem J 311: 1 – 16
Jakob-Roetne R, Jacobsen H (2009) Alzheimer’s disease: from pathology to
therapeutic approaches. Angew Chem Int Ed 48: 3030 – 3059
Jang H, Zheng J, Lal R, Nussinov R (2008) New structures help the
modeling of toxic amyloidb ion channels. Trends Biochem Sci 33:
91 – 100
Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR
(2001) Co-expression of multiple transgenes in mouse CNS: a comparison
of strategies. Biomol Eng 17: 157 – 165
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland
NG, Lee MK, Younkin LH, Wagner SL et al (2004) Mutant presenilins
specifically elevate the levels of the 42 residue beta-amyloid peptide
in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum
Mol Genet 13: 159 – 170
Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A,
Figura S, Stoll M, Schwartz S, Pape HC et al (2014) Ear2 deletion causes
early memory and learning deficits in APP/PS1 mice. J Neurosci 34:
8845 – 8854
Lalonde R, Kim HD, Maxwell JA, Fukuchi K (2005) Exploratory activity and
spatial learning in 12-month-old APP(695)SWE/co+PS1/Delta E9 mice with
amyloid plaques. Neurosci Lett 390: 87 – 92
Lee J, Gillman AL, Jang H, Ramachandran S, Kagan BL, Nussinov R, Arce FT
(2014) Role of the fast kinetics of pyroglutamate-modified amyloid-b
oligomers in membrane binding and membrane permeability. Biochemistry
53: 4704 – 4714
Lin HAI, Bhatia R, Lal R (2001) Amyloid b protein forms ion channels:
implications for Alzheimer’s disease pathophysiology. FASEB J 15:
2433 – 2444
Liu F, Arce FT, Ramachandran S, Lal R (2006) Nanomechanics of hemichannel
conformations – Connexin flexibility underlying channel opening and
closing. J Biol Chem 281: 23207 – 23217
Liu M, Chen F, Sha L, Wang S, Tao L, Yao L, He M, Yao Z, Liu H, Zhu Z et al
(2014) (-)-Epigallocatechin-3-gallate ameliorates learning and memory
deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1
transgenic mice. Mol Neurobiol 49: 1350 – 1363
ª 2017 The Authors EMBO Molecular Medicine
Ana Martinez Hernandez et al Ab-pore blocker anle138b rescues APPPS1D9 mice EMBO Molecular Medicine
15
Appendix
 
 139
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550
Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo
Solim MA, Moens TG, Paublete RM, Ali SS et al (2015) A genome-wide
gene-expression analysis and database in transgenic mice during
development of amyloid or tau pathology. Cell Rep 10: 633 – 644
McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL (2003) Spatiotemporal
rescue of memory dysfunction in Drosophila. Science 302: 1765 – 1768
Morris R (1984) Developments of a water-maze procedure for studying
spatial learning in the rat. J Neurosci Methods 11: 47 – 60
Mueller P, Rudin DO, Tien HT, Wescott WC (1962) Reconstitution of cell
membrane structure in vitro and its transformation into an excitable
system. Nature 194: 979 – 980
Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:
329 – 344
Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J,
Lal R (2005) Amyloid ion channels: a common structural link for protein-
misfolding disease. Proc Natl Acad Sci USA 102: 10427 – 10432
Reiserer RS, Harrison FE, Syverud DC, McDonald MP (2007) Impaired spatial
learning in the APP(Swe)+PSEN1 Delta E9 bigenic mouse model of
Alzheimer’s disease. Genes Brain Behav 6: 54 – 65
Sarkar B, Mithu VS, Chandra B, Mandal A, Chandrakesan M, Bhowmik D,
Madhu PK, Maiti S (2014) Significant structural differences between
transient amyloid-beta oligomers and less-toxic fibrils in regions known
to harbor familial Alzheimer’s mutations. Angew Chem Int Ed 53:
6888 – 6892
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Mol Med 8: 595 – 608
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R,
Salloway S, Chen T, Ling Y et al (2016) The antibody aducanumab reduces
Ab plaques in Alzheimer’s disease. Nature 537: 50 – 56
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL
(2007) Natural oligomers of the Alzheimer amyloid-beta protein induce
reversible synapse loss by modulating an NMDA-type glutamate receptor-
dependent signaling pathway. J Neurosci 27: 2866 – 2875
Spires TL, Hyman BT (2004) Neuronal structure is altered by amyloid plaques.
Rev Neurosci 15: 267 – 278
Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PW, Bauer C, Münzel
M, Wagner M, Müller M, Khan F et al (2013) Dynamic readers for 5-
(hydroxy)methylcytosine and its oxidized derivatives. Cell 152: 1146 – 1159
Sun A, Nguyen XV, Bing G (2002) Comparative analysis of an improved
thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for
neurofibrillary tangle demonstration on the same sections. J Histochem
Cytochem 50: 463 – 472
Tanzi RE (2005) The synaptic Abeta hypothesis of Alzheimer disease. Nat
Neurosci 8: 977 – 979
Umehara T, Nakamura Y, Jang MK, Nakano K, Tanaka A, Ozato K,
Padmanabhan B, Yokoyama S (2010) Structural basis for acetylated
histone H4 recognition by the human BRD2 bromodomain. J Biol Chem
285: 7610 – 7618
Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler
SF (2014) Function, therapeutic potential and cell biology of BACE
proteases: current status and future prospects. J Neurochem 130: 4 – 28
Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-
Montojo F, Bertsch U, Mitteregger-Kretzschmar G et al (2013) Anle138b: a
novel oligomer modulator for disease-modifying therapy of
neurodegenerative diseases such as prion and Parkinson’s disease. Acta
Neuropathol 125: 795 – 813
Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A,
Kleinknecht A, Göricke B, Weishaupt JH et al (2015) Reducing tau
aggregates with anle138b delays disease progression in a mouse model of
tauopathies. Acta Neuropathol 130: 619 – 631
White SH (1972) Analysis of the torus surrounding planar lipid bilayer
membranes. Biophys J 12: 432 – 445
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine Ab-pore blocker anle138b rescues APPPS1D9 mice Ana Martinez Hernandez et al
16
Appendix
Co-Author release forms 
For the publication entitled “The diphenylpyrazole compound anle138b blocks Ab channels and 
rescues disease phenotypes in a mouse model for amyloid pathology” .
  
 140
16/11/2017 
Hendrik Urbanke has my permission to include material, which was accepted for 
publication, of which I was a co-author, in his doctoral dissertation. 
• Ana Martinez Hernandez, Hendrik Urbanke, Alan L. Gillman, Joon Lee, Sergey 
Ryazanov, Hope Y. Agbemenyah, Eva Benito, Gaurav Jain, Lalit Kaurani, 
Gayane Grigorian, Andrei Leonov, Nasrollah Rezai-Ghaleh, Petra Wilken, 
Fernando Teran Arce, Markus Zweckstetter, Roland Benz, Armin Giese, Anja 
Schneider, Martin Korte*, Ratnesh Lal*, Christian Griesinger*, Gregor Eichele*, 
Andre Fischer* “The diphenylpyrazol compound anle138b blocks Aβ channels 
and rescues disease phenotypes in a mouse model for amyloid pathology” 
______________________ 
Alan L. Gillman 
16/11/2017 
Hendrik Urbanke has my permission to include material, which was accepted for 
publication, of which I was a co-author, in his doctoral dissertation. 
• Ana Martinez Hernandez, Hendrik Urbanke, Alan L. Gillman, Joon Lee, Sergey 
Ryazanov, Hope Y. Agbemenyah, Eva Benito, Gaurav Jain, Lalit Kaurani, 
Gayane Grigorian, Andrei Leonov, Nasrollah Rezai-Ghaleh, Petra Wilken, 
Fernando Teran Arce, Markus Zweckstetter, Roland Benz, Armin Giese, Anja 
Schneider, Martin Korte*, Ratnesh Lal*, Christian Griesinger*, Gregor Eichele*, 
Andre Fischer* “The diphenylpyrazol compound anle138b blocks Aβ channels 
and rescues disease phenotypes in a mouse model for amyloid pathology” 
______________________ 
Joon Lee 
 Bi
bl
iog
ra
ph
y
Bibliography
Bibliography 
(2014/15). "World Dementia Council, Annual Report."
Abramowicz, M. (2016). "Microcephaly risk with RUSC2." Dev Med Child Neurol 58(12): 
1211-1212.
Agbandje-McKenna, M. and J. Kleinschmidt (2011). AAV Capsid Structure and Cell Interactions. 
Adeno-Associated Virus: Methods and Protocols. R. O. Snyder and P. Moullier. 
Totowa, NJ, Humana Press: 47-92.
Agranoff, B. W. and P. D. Klinger (1964). "PUROMYCIN EFFECT ON MEMORY FIXATION IN 
THE GOLDFISH." Science 146(3646): 952-953.
Ahmed, T., A. Van der Jeugd, D. Blum, M. C. Galas, R. D'Hooge, L. Buee and D. Balschun 
(2014). "Cognition and hippocampal synaptic plasticity in mice with a homozygous 
tau deletion." Neurobiol Aging 35(11): 2474-2478.
Alarcon, J. M., G. Malleret, K. Touzani, S. Vronskaya, S. Ishii, E. R. Kandel and A. Barco (2004). 
"Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for 
the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration." Neuron 
42(6): 947-959.
Allis, C. D., T. Jenuwein and D. Reinberg (2007). "Epigenetics. Cold Spring Harbor Laboratory 
Press. 2007." Genetical Research 89(2): 124-125.
Alonso, A. C., T. Zaidi, I. Grundke-Iqbal and K. Iqbal (1994). "Role of abnormally phosphorylated 
tau in the breakdown of microtubules in Alzheimer disease." Proc Natl Acad Sci U 
S A 91(12): 5562-5566.
Alwadei, A. H., R. Benini, A. Mahmoud, A. Alasmari, E. J. Kamsteeg and M. Alfadhel (2016). 
"Loss-of-function mutation in RUSC2 causes intellectual disability and secondary 
microcephaly." Dev Med Child Neurol 58(12): 1317-1322.
Amenta, A. R., H. E. Creely, M. L. Mercado, H. Hagiwara, B. A. McKechnie, B. E. Lechner, S. G. 
Rossi, Q. Wang, R. T. Owens, E. Marrero, L. Mei, W. Hoch, M. F. Young, D. J. 
McQuillan, R. L. Rotundo and J. R. Fallon (2012). "Biglycan is an extracellular 
MuSK binding protein important for synapse stability." J Neurosci 32(7): 
2324-2334.
Anders, S., A. Reyes and W. Huber (2012). "Detecting differential usage of exons from RNA-seq 
data." Genome Res 22(10): 2008-2017.
Anders, S., A. Reyes and W. Huber (2012). "Detecting differential usage of exons from RNA-seq 
data." Genome Research 22(10): 2008-2017.
Arispe, N., E. Rojas and H. B. Pollard (1993). "Alzheimer disease amyloid beta protein forms 
calcium channels in bilayer membranes: blockade by tromethamine and 
aluminum." Proc Natl Acad Sci U S A 90(2): 567-571.
Arrigo, A. P., J. L. Darlix and P. F. Spahr (1983). "A cellular protein phosphorylated by the avian 
sarcoma virus transforming gene product is associated with ribonucleoprotein 
particles." Embo j 2(3): 309-315.
Attar, A., T. Liu, W. T. Chan, J. Hayes, M. Nejad, K. Lei and G. Bitan (2013). "A shortened 
Barnes maze protocol reveals memory deficits at 4-months of age in the triple-
transgenic mouse model of Alzheimer's disease." PLoS One 8(11): e80355.
 142
Bibliography
Aukrust, I., H. Hollas, E. Strand, L. Evensen, G. Trave, T. Flatmark and A. Vedeler (2007). "The 
mRNA-binding site of annexin A2 resides in helices C-D of its domain IV." J Mol 
Biol 368(5): 1367-1378.
Aukrust, I., L. A. Rosenberg, M. M. Ankerud, V. Bertelsen, H. Hollas, J. Saraste, A. K. Grindheim 
and A. Vedeler (2017). "Post-translational modifications of Annexin A2 are linked to 
its association with perinuclear nonpolysomal mRNP complexes." FEBS Open Bio 
7(2): 160-173.
Azevedo, F. A., L. R. Carvalho, L. T. Grinberg, J. M. Farfel, R. E. Ferretti, R. E. Leite, W. Jacob 
Filho, R. Lent and S. Herculano-Houzel (2009). "Equal numbers of neuronal and 
nonneuronal cells make the human brain an isometrically scaled-up primate brain." 
J Comp Neurol 513(5): 532-541.
Bach, D. R., A. Tzovara and J. Vunder (2017). "Blocking human fear memory with the matrix 
metalloproteinase inhibitor doxycycline." Mol Psychiatry.
Bacskai, B. J., B. Hochner, M. Mahaut-Smith, S. R. Adams, B. K. Kaang, E. R. Kandel and R. Y. 
Tsien (1993). "Spatially resolved dynamics of cAMP and protein kinase A subunits 
in Aplysia sensory neurons." Science 260(5105): 222-226.
Bailey, C. H., D. Bartsch and E. R. Kandel (1996). "Toward a molecular definition of long-term 
memory storage." Proc Natl Acad Sci U S A 93(24): 13445-13452.
Bailey, C. H. and E. R. Kandel (2008). "Synaptic remodeling, synaptic growth and the storage of 
long-term memory in Aplysia." Prog Brain Res 169: 179-198.
Bannister, A. J. and T. Kouzarides (2011). "Regulation of chromatin by histone modifications." 
Cell Res 21(3): 381-395.
Barco, A., J. M. Alarcon and E. R. Kandel (2002). "Expression of constitutively active CREB 
protein facilitates the late phase of long-term potentiation by enhancing synaptic 
capture." Cell 108(5): 689-703.
Barnes, C. A. (1979). "Memory deficits associated with senescence: a neurophysiological and 
behavioral study in the rat." J Comp Physiol Psychol 93(1): 74-104.
Barondes, S. H. and H. D. Cohen (1966). "Puromycin effect on successive phases of memory 
storage." Science 151(3710): 594-595.
Bartholomeeusen, K., Y. Xiang, K. Fujinaga and B. M. Peterlin (2012). "Bromodomain and extra-
terminal (BET) bromodomain inhibition activate transcription via transient release of 
positive transcription elongation factor b (P-TEFb) from 7SK small nuclear 
ribonucleoprotein." J Biol Chem 287(43): 36609-36616.
Bast, T., W. N. Zhang and J. Feldon (2001). "The ventral hippocampus and fear conditioning in 
rats. Different anterograde amnesias of fear after tetrodotoxin inactivation and 
infusion of the GABA(A) agonist muscimol." Exp Brain Res 139(1): 39-52.
Bender, A. R., M. Naveh-Benjamin and N. Raz (2010). "Associative Deficit in Recognition 
Memory in a Lifespan Sample of Healthy Adults." Psychology and aging 25(4): 
940-948.
Benito, E., B. Ramachandran, H. Schroeder, G. Schmidt, H. Urbanke, S. Burkhardt, V. Capece, 
C. Dean and A. Fischer (2017). "The BET/BRD inhibitor JQ1 improves brain 
plasticity in WT and APP mice." Translational Psychiatry 7(9): e1239.
Benito, E., H. Urbanke, B. Ramachandran, J. Barth, R. Halder, A. Awasthi, G. Jain, V. Capece, 
S. Burkhardt, M. Navarro-Sala, S. Nagarajan, A. L. Schutz, S. A. Johnsen, S. Bonn, 
R. Luhrmann, C. Dean and A. Fischer (2015). "HDAC inhibitor-dependent 
 143
Bibliography
transcriptome and memory reinstatement in cognitive decline models." J Clin Invest 
125(9): 3572-3584.
Bharadwaj, A., M. Bydoun, R. Holloway and D. Waisman (2013). "Annexin A2 heterotetramer: 
structure and function." Int J Mol Sci 14(3): 6259-6305.
Biernat, J., N. Gustke, G. Drewes, E. M. Mandelkow and E. Mandelkow (1993). 
"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: 
distinction between PHF-like immunoreactivity and microtubule binding." Neuron 
11.
Bindea, G., B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, W. H. Fridman, F. 
Pages, Z. Trajanoski and J. Galon (2009). "ClueGO: a Cytoscape plug-in to 
decipher functionally grouped gene ontology and pathway annotation networks." 
Bioinformatics 25(8): 1091-1093.
Blackwood, R. A. and J. D. Ernst (1990). "Characterization of Ca2(+)-dependent phospholipid 
binding, vesicle aggregation and membrane fusion by annexins." Biochem J 
266(1): 195-200.
Blalock, E. M., H. M. Buechel, J. Popovic, J. W. Geddes and P. W. Landfield (2011). "Microarray 
analyses of laser-captured hippocampus reveal distinct gray and white matter 
signatures associated with incipient Alzheimer's disease." J Chem Neuroanat 
42(2): 118-126.
Bliss, T. V. and G. L. Collingridge (1993). "A synaptic model of memory: long-term potentiation in 
the hippocampus." Nature 361(6407): 31-39.
Bliss, T. V. and T. Lomo (1973). "Long-lasting potentiation of synaptic transmission in the 
dentate area of the anaesthetized rabbit following stimulation of the perforant path." 
J Physiol 232(2): 331-356.
Bousiges, O., R. Neidl, M. Majchrzak, M. A. Muller, A. Barbelivien, A. Pereira de Vasconcelos, A. 
Schneider, J. P. Loeffler, J. C. Cassel and A. L. Boutillier (2013). "Detection of 
histone acetylation levels in the dorsal hippocampus reveals early tagging on 
specific residues of H2B and H4 histones in response to learning." PLoS One 8(3): 
e57816.
Bousiges, O., A. P. Vasconcelos, R. Neidl, B. Cosquer, K. Herbeaux, I. Panteleeva, J. P. 
Loeffler, J. C. Cassel and A. L. Boutillier (2010). "Spatial memory consolidation is 
associated with induction of several lysine-acetyltransferase (histone 
acetyltransferase) expression levels and H2B/H4 acetylation-dependent 
transcriptional events in the rat hippocampus." Neuropsychopharmacology 35(13): 
2521-2537.
Boyko, V., O. Mudrak, M. Svetlova, Y. Negishi, H. Ariga and N. Tomilin (1994). "A major cellular 
substrate for protein kinases, annexin II, is a DNA-binding protein." FEBS Lett 
345(2-3): 139-142.
Braak, H. and E. Braak (1991). "Neuropathological stageing of Alzheimer-related changes." Acta 
Neuropathol 82(4): 239-259.
Bramblett, G. T., M. Goedert, R. Jakes, S. E. Merrick, J. Q. Trojanowski and V. M. Lee (1993). 
"Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates 
development and contributes to reduced microtubule binding." Neuron 10(6): 
1089-1099.
Breen, K. C., M. Bruce and B. H. Anderton (1991). "Beta amyloid precursor protein mediates 
neuronal cell-cell and cell-surface adhesion." J Neurosci Res 28(1): 90-100.
 144
Bibliography
Bu, G. (2009). "Apolipoprotein E and its receptors in Alzheimer&#39;s disease: pathways, 
pathogenesis and therapy." Nature Reviews Neuroscience 10: 333.
Calderon-Garciduenas, L., W. Reed, R. R. Maronpot, C. Henriquez-Roldan, R. Delgado-
Chavez, A. Calderon-Garciduenas, I. Dragustinovis, M. Franco-Lira, M. Aragon-
Flores, A. C. Solt, M. Altenburg, R. Torres-Jardon and J. A. Swenberg (2004). 
"Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe 
air pollution." Toxicol Pathol 32(6): 650-658.
Canale, C., S. Seghezza, S. Vilasi, R. Carrotta, D. Bulone, A. Diaspro, P. L. San Biagio and S. 
Dante (2013). "Different effects of Alzheimer's peptide Abeta(1-40) oligomers and 
fibrils on supported lipid membranes." Biophys Chem 182: 23-29.
Capone, R., H. Jang, S. A. Kotler, B. L. Kagan, R. Nussinov and R. Lal (2012). "Probing 
structural features of Alzheimer's amyloid-beta pores in bilayers using site-specific 
amino acid substitutions." Biochemistry 51(3): 776-785.
Chang, C. H. and D. S. Luse (1997). "The H3/H4 tetramer blocks transcript elongation by RNA 
polymerase II in vitro." J Biol Chem 272(37): 23427-23434.
Chen, T. and M. Naveh-Benjamin (2012). "Assessing the associative deficit of older adults in 
long-term and short-term/working memory." Psychol Aging 27(3): 666-682.
Cheung, P., C. D. Allis and P. Sassone-Corsi (2000). "Signaling to chromatin through histone 
modifications." Cell 103(2): 263-271.
Chow, V. W., M. P. Mattson, P. C. Wong and M. Gleichmann (2010). "An Overview of APP 
Processing Enzymes and Products." Neuromolecular medicine 12(1): 1-12.
Clavaguera, F., T. Bolmont, R. A. Crowther, D. Abramowski, S. Frank, A. Probst, G. Fraser, A. K. 
Stalder, M. Beibel, M. Staufenbiel, M. Jucker, M. Goedert and M. Tolnay (2009). 
"Transmission and spreading of tauopathy in transgenic mouse brain." Nat Cell Biol 
11.
Connelly, L., H. Jang, F. T. Arce, R. Capone, S. A. Kotler, S. Ramachandran, B. L. Kagan, R. 
Nussinov and R. Lal (2012). "Atomic force microscopy and MD simulations reveal 
pore-like structures of all-D-enantiomer of Alzheimer's beta-amyloid peptide: 
relevance to the ion channel mechanism of AD pathology." J Phys Chem B 116(5): 
1728-1735.
Connelly, L., H. Jang, F. T. Arce, S. Ramachandran, B. L. Kagan, R. Nussinov and R. Lal (2012). 
"Effects of point substitutions on the structure of toxic Alzheimer's beta-amyloid 
channels: atomic force microscopy and molecular dynamics simulations." 
Biochemistry 51(14): 3031-3038.
Cook, C., Y. Carlomagno, T. F. Gendron, J. Dunmore, K. Scheffel, C. Stetler, M. Davis, D. 
Dickson, M. Jarpe, M. DeTure and L. Petrucelli (2014). "Acetylation of the KXGS 
motifs in tau is a critical determinant in modulation of tau aggregation and 
clearance." Hum Mol Genet 23(1): 104-116.
Cook, C., T. F. Gendron, K. Scheffel, Y. Carlomagno, J. Dunmore, M. DeTure and L. Petrucelli 
(2012). "Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau 
accumulation." Hum Mol Genet 21.
Cook, C., T. F. Gendron, K. Scheffel, Y. Carlomagno, J. Dunmore, M. DeTure and L. Petrucelli 
(2012). "Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau 
accumulation." Hum Mol Genet 21(13): 2936-2945.
 145
Bibliography
Cook, C., J. N. Stankowski, Y. Carlomagno, C. Stetler and L. Petrucelli (2014). "Acetylation: a 
new key to unlock tau’s role in neurodegeneration." Alzheimer's Research & 
Therapy 6(3): 29.
Coon, K. D., A. J. Myers, D. W. Craig, J. A. Webster, J. V. Pearson, D. H. Lince, V. L. Zismann, 
T. G. Beach, D. Leung, L. Bryden, R. F. Halperin, L. Marlowe, M. Kaleem, D. G. 
Walker, R. Ravid, C. B. Heward, J. Rogers, A. Papassotiropoulos, E. M. Reiman, J. 
Hardy and D. A. Stephan (2007). "A high-density whole-genome association study 
reveals that APOE is the major susceptibility gene for sporadic late-onset 
Alzheimer's disease." J Clin Psychiatry 68(4): 613-618.
Copenhaver, P. F. and J. M. Ramaker (2016). "Neuronal migration during development and the 
amyloid precursor protein." Curr Opin Insect Sci 18: 1-10.
Cosgrove, M. S., J. D. Boeke and C. Wolberger (2004). "Regulated nucleosome mobility and 
the histone code." Nat Struct Mol Biol 11(11): 1037-1043.
Cowan, N. (2008). Chapter 20 What are the differences between long-term, short-term, and 
working memory? Essence of Memory: 323-338.
Cripps, D., S. N. Thomas, Y. Jeng, F. Yang, P. Davies and A. J. Yang (2006). "Alzheimer 
disease-specific conformation of hyperphosphorylated paired helical filament-Tau is 
polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation." J Biol 
Chem 281.
Cui, Z., C. R. Gerfen and W. S. Young, 3rd (2013). "Hypothalamic and other connections with 
dorsal CA2 area of the mouse hippocampus." J Comp Neurol 521(8): 1844-1866.
da Motta, L. L., I. Ledaki, K. Purshouse, S. Haider, M. A. De Bastiani, D. Baban, M. Morotti, G. 
Steers, S. Wigfield, E. Bridges, J. L. Li, S. Knapp, D. Ebner, F. Klamt, A. L. Harris 
and A. McIntyre (2017). "The BET inhibitor JQ1 selectively impairs tumour 
response to hypoxia and downregulates CA9 and angiogenesis in triple negative 
breast cancer." Oncogene 36(1): 122-132.
Dale, N. and E. R. Kandel (1993). "L-glutamate may be the fast excitatory transmitter of Aplysia 
sensory neurons." Proc Natl Acad Sci U S A 90(15): 7163-7167.
Das, C. and J. K. Tyler (2013). "Histone exchange and histone modifications during transcription 
and aging()." Biochimica et biophysica acta 1819(0): 332-342.
Das, S., P. Shetty, M. Valapala, S. Dasgupta, Z. Gryczynski and J. K. Vishwanatha (2010). 
"Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of 
annexin A2 in prostate cancer cells." Biochemistry 49(10): 2216-2226.
Dash, P. K., B. Hochner and E. R. Kandel (1990). "Injection of the cAMP-responsive element 
into the nucleus of Aplysia sensory neurons blocks long-term facilitation." Nature 
345(6277): 718-721.
Dauth, S., R. F. Sirbulescu, S. Jordans, M. Rehders, L. Avena, J. Oswald, A. Lerchl, P. Saftig 
and K. Brix (2011). "Cathepsin K deficiency in mice induces structural and 
metabolic changes in the central nervous system that are associated with learning 
and memory deficits." BMC Neurosci 12: 74.
Davie, J. R. and L. C. Murphy (1990). "Level of ubiquitinated histone H2B in chromatin is 
coupled to ongoing transcription." Biochemistry 29(20): 4752-4757.
de Calignon, A., M. Polydoro, M. Suarez-Calvet, C. William, D. H. Adamowicz, K. J. Kopeikina, 
R. Pitstick, N. Sahara, K. H. Ashe, G. A. Carlson, T. L. Spires-Jones and B. T. 
 146
Bibliography
Hyman (2012). "Propagation of tau pathology in a model of early Alzheimer's 
disease." Neuron 73(4): 685-697.
de Ruijter, A. J., A. H. van Gennip, H. N. Caron, S. Kemp and A. B. van Kuilenburg (2003). 
"Histone deacetylases (HDACs): characterization of the classical HDAC family." 
Biochem J 370(Pt 3): 737-749.
Deeg, A. A., A. M. Reiner, F. Schmidt, F. Schueder, S. Ryazanov, V. C. Ruf, K. Giller, S. Becker, 
A. Leonov, C. Griesinger, A. Giese and W. Zinth (2015). "Anle138b and related 
compounds are aggregation specific fluorescence markers and reveal high affinity 
binding to alpha-synuclein aggregates." Biochim Biophys Acta 1850(9): 1884-1890.
Deora, A. B., G. Kreitzer, A. T. Jacovina and K. A. Hajjar (2004). "An annexin 2 phosphorylation 
switch mediates p11-dependent translocation of annexin 2 to the cell surface." J 
Biol Chem 279(42): 43411-43418.
Derbyshire, Z. E., U. M. Halfter, R. L. Heimark, T. H. Sy and R. R. Vaillancourt (2005). 
"Angiotensin II stimulated transcription of cyclooxygenase II is regulated by a novel 
kinase cascade involving Pyk2, MEKK4 and annexin II." Mol Cell Biochem 
271(1-2): 77-90.
Dey, A., F. Chitsaz, A. Abbasi, T. Misteli and K. Ozato (2003). "The double bromodomain protein 
Brd4 binds to acetylated chromatin during interphase and mitosis." Proc Natl Acad 
Sci U S A 100(15): 8758-8763.
Dhalluin, C., J. E. Carlson, L. Zeng, C. He, A. K. Aggarwal and M. M. Zhou (1999). "Structure 
and ligand of a histone acetyltransferase bromodomain." Nature 399(6735): 
491-496.
Dickson, D. W. (1997). "Neuropathological diagnosis of Alzheimer's disease: a perspective from 
longitudinal clinicopathological studies." Neurobiol Aging 18(4 Suppl): S21-26.
Dickson, D. W., N. Kouri, M. E. Murray and K. A. Josephs (2011). "Neuropathology of 
frontotemporal lobar degeneration-tau (FTLD-tau)." J Mol Neurosci 45(3): 384-389.
Ding, H., P. J. Dolan and G. V. Johnson (2008). "Histone deacetylase 6 interacts with the 
microtubule-associated protein tau." J Neurochem 106(5): 2119-2130.
Ding, H., P. J. Dolan and G. V. W. Johnson (2008). "Histone deacetylase 6 interacts with the 
microtubule-associated protein tau." Journal of neurochemistry 106(5): 2119-2130.
Dityatev, A. and M. Schachner (2003). "Extracellular matrix molecules and synaptic plasticity." 
Nature Reviews Neuroscience 4: 456.
Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson and 
T. R. Gingeras (2013). "STAR: ultrafast universal RNA-seq aligner." Bioinformatics 
29(1): 15-21.
Doig, A. J. and P. Derreumaux (2015). "Inhibition of protein aggregation and amyloid formation 
by small molecules." Curr Opin Struct Biol 30: 50-56.
Dompierre, J. P., J. D. Godin, B. C. Charrin, F. P. Cordelieres, S. J. King, S. Humbert and F. 
Saudou (2007). "Histone deacetylase 6 inhibition compensates for the transport 
deficit in Huntington's disease by increasing tubulin acetylation." J Neurosci 27(13): 
3571-3583.
Dorval, V. and P. E. Fraser (2006). "Small ubiquitin-like modifier (SUMO) modification of natively 
unfolded proteins tau and alpha-synuclein." J Biol Chem 281(15): 9919-9924.
 147
Bibliography
Drechsel, D. N., A. A. Hyman, M. H. Cobb and M. W. Kirschner (1992). "Modulation of the 
dynamic instability of tubulin assembly by the microtubule-associated protein tau." 
Mol Biol Cell 3(10): 1141-1154.
Drubin, D. G. and M. W. Kirschner (1986). "Tau protein function in living cells." J Cell Biol 103(6 
Pt 2): 2739-2746.
Drucker, P., M. Pejic, H. J. Galla and V. Gerke (2013). "Lipid segregation and membrane 
budding induced by the peripheral membrane binding protein annexin A2." J Biol 
Chem 288(34): 24764-24776.
Dudai, Y. (1996). "Consolidation: fragility on the road to the engram." Neuron 17(3): 367-370.
Dudai, Y. (2002). "Memory from A to Z keywords, concepts, and beyon."
Eberhard, D. A., L. R. Karns, S. R. VandenBerg and C. E. Creutz (2001). "Control of the 
nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 
binding." J Cell Sci 114(Pt 17): 3155-3166.
Ennaceur, A. and J. Delacour (1988). "A new one-trial test for neurobiological studies of memory 
in rats. 1: Behavioral data." Behavioural Brain Research 31(1): 47-59.
Ezkurdia, I., D. Juan, J. M. Rodriguez, A. Frankish, M. Diekhans, J. Harrow, J. Vazquez, A. 
Valencia and M. L. Tress (2014). "Multiple evidence strands suggest that there may 
be as few as 19 000 human protein-coding genes." Human Molecular Genetics 
23(22): 5866-5878.
Farr, S. A., K. Uezu, J. F. Flood and J. E. Morley (1999). "Septo-hippocampal drug interactions 
in post-trial memory processing." Brain Res 847(2): 221-230.
Fellner, L., D. Kuzdas-Wood, J. Levin, S. Ryazanov, A. Leonov, C. Griesinger, A. Giese, G. K. 
Wenning and N. Stefanova (2016). "Anle138b Partly Ameliorates Motor Deficits 
Despite Failure of Neuroprotection in a Model of Advanced Multiple System 
Atrophy." Front Neurosci 10: 99.
Filbin, M. E. and J. S. Kieft (2009). "Toward a structural understanding of IRES RNA function." 
Curr Opin Struct Biol 19(3): 267-276.
Filipenko, N. R., T. J. MacLeod, C. S. Yoon and D. M. Waisman (2004). "Annexin A2 is a novel 
RNA-binding protein." J Biol Chem 279(10): 8723-8731.
Filippakopoulos, P. and S. Knapp (2012). "The bromodomain interaction module." FEBS Lett 
586(17): 2692-2704.
Fischer, A. (2014). "Epigenetic memory: the Lamarckian brain." EMBO J 33(9): 945-967.
Fischer, A. (2014). "Targeting histone-modifications in Alzheimer's disease. What is the evidence 
that this is a promising therapeutic avenue?" Neuropharmacology 80: 95-102.
Fischer, A., F. Sananbenesi, A. Mungenast and L. H. Tsai (2010). "Targeting the correct 
HDAC(s) to treat cognitive disorders." Trends Pharmacol Sci 31(12): 605-617.
Fischer, A., F. Sananbenesi, X. Wang, M. Dobbin and L. H. Tsai (2007). "Recovery of learning 
and memory is associated with chromatin remodelling." Nature 447(7141): 
178-182.
Flexner, J. B., L. B. Flexner, E. Stellar, G. De La Haba and R. B. Roberts (1962). "Inhibition of 
protein synthesis in brain and learning and memory following puromycin." J 
Neurochem 9: 595-605.
 148
Bibliography
Flood, J. F., M. R. Rosenzweig, E. L. Bennett and A. E. Orme (1973). "The influence of duration 
of protein synthesis inhibition on memory." Physiol Behav 10(3): 555-562.
Fontan-Lozano, A., R. Romero-Granados, J. Troncoso, A. Munera, J. M. Delgado-Garcia and A. 
M. Carrion (2008). "Histone deacetylase inhibitors improve learning consolidation 
in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice." Mol 
Cell Neurosci 39(2): 193-201.
Forstl, H. and A. Kurz (1999). "Clinical features of Alzheimer's disease." Eur Arch Psychiatry 
Clin Neurosci 249(6): 288-290.
Frey, U. and R. G. Morris (1998). "Synaptic tagging: implications for late maintenance of 
hippocampal long-term potentiation." Trends Neurosci 21(5): 181-188.
Friedhoff, P., M. von Bergen, E. M. Mandelkow, P. Davies and E. Mandelkow (1998). "A 
nucleated assembly mechanism of Alzheimer paired helical filaments." 
Proceedings of the National Academy of Sciences of the United States of America 
95(26): 15712-15717.
Gabel, M., F. Delavoie, V. Demais, C. Royer, Y. Bailly, N. Vitale, M. F. Bader and S. Chasserot-
Golaz (2015). "Annexin A2-dependent actin bundling promotes secretory granule 
docking to the plasma membrane and exocytosis." J Cell Biol 210(5): 785-800.
Gauthier-Kemper, A., C. Weissmann, N. Golovyashkina, Z. Sebo-Lemke, G. Drewes, V. Gerke, 
J. J. Heinisch and R. Brandt (2011). "The frontotemporal dementia mutation 
R406W blocks tau's interaction with the membrane in an annexin A2-dependent 
manner." J Cell Biol 192(4): 647-661.
Gerhardt, K. P., E. J. Olson, S. M. Castillo-Hair, L. A. Hartsough, B. P. Landry, F. Ekness, R. 
Yokoo, E. J. Gomez, P. Ramakrishnan, J. Suh, D. F. Savage and J. J. Tabor (2016). 
"An open-hardware platform for optogenetics and photobiology." Sci Rep 6: 35363.
Gerke, V., C. E. Creutz and S. E. Moss (2005). "Annexins: linking Ca2+ signalling to membrane 
dynamics." Nat Rev Mol Cell Biol 6(6): 449-461.
Gerke, V. and S. E. Moss (2002). "Annexins: from structure to function." Physiol Rev 82(2): 
331-371.
Gibbs, M. E. and K. T. Ng (1977). "Counteractive effects of norepinephrine and amphetamine on 
quabain-induced amnesia." Pharmacol Biochem Behav 6(5): 533-537.
Goate, A. and J. Hardy (2012). "Twenty years of Alzheimer's disease-causing mutations." J 
Neurochem 120 Suppl 1: 3-8.
Goedert, M. and R. Jakes (1990). "Expression of separate isoforms of human tau protein: 
correlation with the tau pattern in brain and effects on tubulin polymerization." 
EMBO J 9(13): 4225-4230.
Goedert, M., M. Masuda-Suzukake and B. Falcon (2017). "Like prions: the propagation of 
aggregated tau and alpha-synuclein in neurodegeneration." Brain 140(2): 266-278.
Goedert, M., M. G. Spillantini, M. C. Potier, J. Ulrich and R. A. Crowther (1989). "Cloning and 
sequencing of the cDNA encoding an isoform of microtubule-associated protein tau 
containing four tandem repeats: differential expression of tau protein mRNAs in 
human brain." EMBO J 8(2): 393-399.
Goelet, P., V. F. Castellucci, S. Schacher and E. R. Kandel (1986). "The long and the short of 
long-term memory--a molecular framework." Nature 322(6078): 419-422.
 149
Bibliography
Gold, M. (2017). "Phase II clinical trials of anti-amyloid beta antibodies: When is enough, 
enough?" Alzheimers Dement (N Y) 3(3): 402-409.
Gold, P. E. (2008). "Protein synthesis and memory." Neurobiology of learning and memory 
89(3): 199-200.
Goldgaber, D., M. I. Lerman, O. W. McBride, U. Saffiotti and D. C. Gajdusek (1987). 
"Characterization and chromosomal localization of a cDNA encoding brain amyloid 
of Alzheimer's disease." Science 235(4791): 877-880.
Gomez-Ramos, P. and M. Asuncion Moran (2007). "Ultrastructural localization of intraneuronal 
Abeta-peptide in Alzheimer disease brains." J Alzheimers Dis 11(1): 53-59.
Gong, C. X., I. Grundke-Iqbal and K. Iqbal (1994). "Dephosphorylation of Alzheimer's disease 
abnormally phosphorylated tau by protein phosphatase-2A." Neuroscience 61(4): 
765-772.
Govindarajan, N., P. Rao, S. Burkhardt, F. Sananbenesi, O. M. Schluter, F. Bradke, J. Lu and A. 
Fischer (2013). "Reducing HDAC6 ameliorates cognitive deficits in a mouse model 
for Alzheimer's disease." EMBO Mol Med 5(1): 52-63.
Grindheim, A. K., H. Hollas, A. M. Raddum, J. Saraste and A. Vedeler (2016). "Reactive oxygen 
species exert opposite effects on Tyr23 phosphorylation of the nuclear and cortical 
pools of annexin A2." J Cell Sci 129(2): 314-328.
Grindheim, A. K., H. Hollas, J. Ramirez, J. Saraste, G. Trave and A. Vedeler (2014). "Effect of 
serine phosphorylation and Ser25 phospho-mimicking mutations on nuclear 
localisation and ligand interactions of annexin A2." J Mol Biol 426(13): 2486-2499.
Grindheim, A. K., J. Saraste and A. Vedeler (2017). "Protein phosphorylation and its role in the 
regulation of Annexin A2 function." Biochim Biophys Acta 1861(11 Pt A): 
2515-2529.
Grossman, N., V. Poher, M. S. Grubb, G. T. Kennedy, K. Nikolic, B. McGovern, R. Berlinguer 
Palmini, Z. Gong, E. M. Drakakis, M. A. Neil, M. D. Dawson, J. Burrone and P. 
Degenaar (2010). "Multi-site optical excitation using ChR2 and micro-LED array." J 
Neural Eng 7(1): 16004.
Grundke-Iqbal, I., K. Iqbal, Y. C. Tung, M. Quinlan, H. M. Wisniewski and L. I. Binder (1986). 
"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in 
Alzheimer cytoskeletal pathology." Proc Natl Acad Sci USA 83.
Guan, J. S., S. J. Haggarty, E. Giacometti, J. H. Dannenberg, N. Joseph, J. Gao, T. J. Nieland, 
Y. Zhou, X. Wang, R. Mazitschek, J. E. Bradner, R. A. DePinho, R. Jaenisch and L. 
H. Tsai (2009). "HDAC2 negatively regulates memory formation and synaptic 
plasticity." Nature 459(7243): 55-60.
Guan, Z., M. Giustetto, S. Lomvardas, J. H. Kim, M. C. Miniaci, J. H. Schwartz, D. Thanos and 
E. R. Kandel (2002). "Integration of long-term-memory-related synaptic plasticity 
involves bidirectional regulation of gene expression and chromatin structure." Cell 
111(4): 483-493.
Guo, Z., L. A. Cupples, A. Kurz, S. H. Auerbach, L. Volicer, H. Chui, R. C. Green, A. D. 
Sadovnick, R. Duara, C. DeCarli, K. Johnson, R. C. Go, J. H. Growdon, J. L. 
Haines, W. A. Kukull and L. A. Farrer (2000). "Head injury and the risk of AD in the 
MIRAGE study." Neurology 54(6): 1316-1323.
Gustafson, D., E. Rothenberg, K. Blennow, B. Steen and I. Skoog (2003). "An 18-year follow-up 
of overweight and risk of Alzheimer disease." Arch Intern Med 163(13): 1524-1528.
 150
Bibliography
Haass, C. and D. J. Selkoe (2007). "Soluble protein oligomers in neurodegeneration: lessons 
from the Alzheimer's amyloid beta-peptide." Nat Rev Mol Cell Biol 8(2): 101-112.
Hall, C. S. (1934). "Emotional behavior in the rat. I. Defecation and urination as measures of 
individual differences in emotionality." Journal of Comparative Psychology 18(3): 
385-403.
Hallmann, A. L., M. J. Arauzo-Bravo, L. Mavrommatis, M. Ehrlich, A. Ropke, J. Brockhaus, M. 
Missler, J. Sterneckert, H. R. Scholer, T. Kuhlmann, H. Zaehres and G. Hargus 
(2017). "Astrocyte pathology in a human neural stem cell model of frontotemporal 
dementia caused by mutant TAU protein." Sci Rep 7: 42991.
Handa, A., S.-i. Muramatsu, J. Qiu, H. Mizukami and K. E. Brown (2000). "Adeno-associated 
virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to 
transduction with AAV-2-based vectors." Journal of General Virology 81(8): 
2077-2084.
Harada, A., K. Oguchi, S. Okabe, J. Kuno, S. Terada, T. Ohshima, R. Sato-Yoshitake, Y. Takei, 
T. Noda and N. Hirokawa (1994). "Altered microtubule organization in small-calibre 
axons of mice lacking tau protein." Nature 369(6480): 488-491.
Hardy, J. and D. J. Selkoe (2002). "The amyloid hypothesis of Alzheimer's disease: progress 
and problems on the road to therapeutics." Science 297(5580): 353-356.
Harrison, F. E., A. H. Hosseini and M. P. McDonald (2009). "Endogenous anxiety and stress 
responses in water maze and Barnes maze spatial memory tasks." Behav Brain 
Res 198(1): 247-251.
Hasegawa, M., M. Morishima-Kawashima, K. Takio, M. Suzuki, K. Titani and Y. Ihara (1992). 
"Protein sequence and mass spectrometric analyses of tau in the Alzheimer's 
disease brain." J Biol Chem 267.
Hebbes, T. R., A. L. Clayton, A. W. Thorne and C. Crane-Robinson (1994). "Core histone 
hyperacetylation co-maps with generalized DNase I sensitivity in the chicken beta-
globin chromosomal domain." EMBO J 13(8): 1823-1830.
Hebert, L. E., J. Weuve, P. A. Scherr and D. A. Evans (2013). "Alzheimer disease in the United 
States (2010–2050) estimated using the 2010 census." Neurology 80(19): 
1778-1783.
Hempen, B. and J. P. Brion (1996). "Reduction of acetylated alpha-tubulin immunoreactivity in 
neurofibrillary tangle-bearing neurons in Alzheimer's disease." J Neuropathol Exp 
Neurol 55(9): 964-972.
Hendrickx, A., N. Pierrot, B. Tasiaux, O. Schakman, P. Kienlen-Campard, C. De Smet and J. N. 
Octave (2014). "Epigenetic regulations of immediate early genes expression 
involved in memory formation by the amyloid precursor protein of Alzheimer 
disease." PLoS One 9(6): e99467.
Hitchcock, J. K., A. A. Katz and G. Schafer (2014). "Dynamic reciprocity: the role of annexin A2 
in tissue integrity." J Cell Commun Signal 8(2): 125-133.
Hnilicova, J., S. Hozeifi, E. Duskova, J. Icha, T. Tomankova and D. Stanek (2011). "Histone 
deacetylase activity modulates alternative splicing." PLoS One 6(2): e16727.
Hollas, H., I. Aukrust, S. Grimmer, E. Strand, T. Flatmark and A. Vedeler (2006). "Annexin A2 
recognises a specific region in the 3'-UTR of its cognate messenger RNA." Biochim 
Biophys Acta 1763(11): 1325-1334.
 151
Bibliography
Hou, Y., L. Yang, M. Mou, Y. Hou, A. Zhang, N. Pan, R. Qiang, L. Wei and N. Zhang (2008). 
"Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells." 
Cancer Invest 26(8): 809-815.
Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang and 
T. P. Yao (2002). "HDAC6 is a microtubule-associated deacetylase." Nature 
417(6887): 455-458.
Hussong, M., C. Kaehler, M. Kerick, C. Grimm, A. Franz, B. Timmermann, F. Welzel, J. Isensee, 
T. Hucho, S. Krobitsch and M. R. Schweiger (2017). "The bromodomain protein 
BRD4 regulates splicing during heat shock." Nucleic Acids Res 45(1): 382-394.
Im, H. I. and P. J. Kenny (2012). "MicroRNAs in neuronal function and dysfunction." Trends 
Neurosci 35(5): 325-334.
international, A. s. D. (2016). "World Alzheimer Report 2016." World Alzheimer Report.
International Human Genome Sequencing, C. (2004). "Finishing the euchromatic sequence of 
the human genome." Nature 431: 931.
Iqbal, K., H. M. Wiśniewski, M. L. Shelanski, S. Brostoff, B. H. Liwnicz and R. D. Terry (1974). 
"Protein changes in senile dementia." Brain Research 77(2): 337-343.
Iwatsubo, T., A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina and Y. Ihara (1994). "Visualization of 
Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence 
that an initially deposited species is Aβ 42(43)." Neuron 13(1): 45-53.
Izquierdo, J. M. (2008). "Hu antigen R (HuR) functions as an alternative pre-mRNA splicing 
regulator of Fas apoptosis-promoting receptor on exon definition." J Biol Chem 
283(27): 19077-19084.
Jaitin, D. A., E. Kenigsberg, H. Keren-Shaul, N. Elefant, F. Paul, I. Zaretsky, A. Mildner, N. 
Cohen, S. Jung, A. Tanay and I. Amit (2014). "Massively parallel single-cell RNA-
seq for marker-free decomposition of tissues into cell types." Science 343(6172): 
776-779.
Jenuwein, T. and C. D. Allis (2001). "Translating the histone code." Science 293(5532): 
1074-1080.
Jeon, B. N., W. I. Choi, M. Y. Yu, A. R. Yoon, M. H. Kim, C. O. Yun and M. W. Hur (2009). 
"ZBTB2, a novel master regulator of the p53 pathway." J Biol Chem 284(27): 
17935-17946.
Jindal, H. K., W. G. Chaney, C. W. Anderson, R. G. Davis and J. K. Vishwanatha (1991). "The 
protein-tyrosine kinase substrate, calpactin I heavy chain (p36), is part of the 
primer recognition protein complex that interacts with DNA polymerase alpha." J 
Biol Chem 266(8): 5169-5176.
Johnson, C. A. and B. M. Turner (1999). "Histone deacetylases: complex transducers of nuclear 
signals." Semin Cell Dev Biol 10(2): 179-188.
Jonsson, T., J. K. Atwal, S. Steinberg, J. Snaedal, P. V. Jonsson, S. Bjornsson, H. Stefansson, 
P. Sulem, D. Gudbjartsson, J. Maloney, K. Hoyte, A. Gustafson, Y. Liu, Y. Lu, T. 
Bhangale, R. R. Graham, J. Huttenlocher, G. Bjornsdottir, O. A. Andreassen, E. G. 
Jonsson, A. Palotie, T. W. Behrens, O. T. Magnusson, A. Kong, U. Thorsteinsdottir, 
R. J. Watts and K. Stefansson (2012). "A mutation in APP protects against 
Alzheimer's disease and age-related cognitive decline." Nature 488(7409): 96-99.
Jung, M., M. Philpott, S. Müller, J. Schulze, V. Badock, U. Eberspächer, D. Moosmayer, B. 
Bader, N. Schmees, A. Fernández-Montalván and B. Haendler (2014). "Affinity 
 152
Bibliography
Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and 
the Small Molecule Inhibitor JQ1." The Journal of Biological Chemistry 289(13): 
9304-9319.
Kadavath, H., R. V. Hofele, J. Biernat, S. Kumar, K. Tepper, H. Urlaub, E. Mandelkow and M. 
Zweckstetter (2015). "Tau stabilizes microtubules by binding at the interface 
between tubulin heterodimers." Proc Natl Acad Sci U S A 112(24): 7501-7506.
Kahn, I. and D. Shohamy (2013). "Intrinsic connectivity between the hippocampus, nucleus 
accumbens, and ventral tegmental area in humans." Hippocampus 23(3): 187-192.
Kaludov, N., K. E. Brown, R. W. Walters, J. Zabner and J. A. Chiorini (2001). "Adeno-associated 
virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for 
hemagglutination and efficient transduction but differ in sialic acid linkage 
specificity." J Virol 75(15): 6884-6893.
Kamakaka, R. T. and S. Biggins (2005). "Histone variants: deviants?" Genes Dev 19(3): 
295-310.
Kandel, E. R. (2001). "The molecular biology of memory storage: a dialogue between genes 
and synapses." Science 294(5544): 1030-1038.
Kandel, E. R., Y. Dudai and M. R. Mayford (2014). "The molecular and systems biology of 
memory." Cell 157(1): 163-186.
Kang, J., H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzeschik, G. 
Multhaup, K. Beyreuther and B. Muller-Hill (1987). "The precursor of Alzheimer's 
disease amyloid A4 protein resembles a cell-surface receptor." Nature 325(6106): 
733-736.
Kanno, T., Y. Kanno, R. M. Siegel, M. K. Jang, M. J. Lenardo and K. Ozato (2004). "Selective 
recognition of acetylated histones by bromodomain proteins visualized in living 
cells." Mol Cell 13(1): 33-43.
Kern, A., K. Schmidt, C. Leder, O. J. Müller, C. E. Wobus, K. Bettinger, C. W. Von der Lieth, J. A. 
King and J. A. Kleinschmidt (2003). "Identification of a Heparin-Binding Motif on 
Adeno-Associated Virus Type 2 Capsids." Journal of Virology 77(20): 11072-11081.
Khatoon, S., I. Grundke-Iqbal and K. Iqbal (1992). "Brain levels of microtubule-associated 
protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for 
nanograms of the protein." J Neurochem 59(2): 750-753.
Kim, C., H. Choi, E. S. Jung, W. Lee, S. Oh, N. L. Jeon and I. Mook-Jung (2012). "HDAC6 
inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in 
hippocampal neurons." PLoS One 7(8): e42983.
Kim, K. H., M. Moon, S. B. Yu, I. Mook-Jung and J. I. Kim (2012). "RNA-Seq analysis of frontal 
cortex and cerebellum from 5XFAD mice at early stage of disease pathology." J 
Alzheimers Dis 29(4): 793-808.
Kim, M. Y., D. I. Koh, W. I. Choi, B. N. Jeon, D. Y. Jeong, K. S. Kim, K. Kim, S. H. Kim and M. W. 
Hur (2015). "ZBTB2 increases PDK4 expression by transcriptional repression of 
RelA/p65." Nucleic Acids Res 43(3): 1609-1625.
Kitamura, T., S. K. Ogawa, D. S. Roy, T. Okuyama, M. D. Morrissey, L. M. Smith, R. L. Redondo 
and S. Tonegawa (2017). "Engrams and Circuits Crucial for Systems Consolidation 
of a Memory." Science (New York, N.Y.) 356(6333): 73-78.
Klevanski, M., U. Herrmann, S. W. Weyer, R. Fol, N. Cartier, D. P. Wolfer, J. H. Caldwell, M. 
Korte and U. C. Muller (2015). "The APP Intracellular Domain Is Required for 
 153
Bibliography
Normal Synaptic Morphology, Synaptic Plasticity, and Hippocampus-Dependent 
Behavior." J Neurosci 35(49): 16018-16033.
Kokawa, A., S. Ishihara, H. Fujiwara, M. Nobuhara, M. Iwata, Y. Ihara and S. Funamoto (2015). 
"The A673T mutation in the amyloid precursor protein reduces the production of 
beta-amyloid protein from its beta-carboxyl terminal fragment in cells." Acta 
Neuropathol Commun 3: 66.
Kopke, E., Y. C. Tung, S. Shaikh, A. C. Alonso, K. Iqbal and I. Grundke-Iqbal (1993). 
"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired 
helical filament pool in Alzheimer disease." J Biol Chem 268(32): 24374-24384.
Korb, E., M. Herre, I. Zucker-Scharff, R. B. Darnell and C. D. Allis (2015). "BET protein Brd4 
activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice." 
Nat Neurosci 18(10): 1464-1473.
Kornberg, R. D. and Y. Lorch (1999). "Twenty-five years of the nucleosome, fundamental 
particle of the eukaryote chromosome." Cell 98(3): 285-294.
Korzus, E., M. G. Rosenfeld and M. Mayford (2004). "CBP histone acetyltransferase activity is a 
critical component of memory consolidation." Neuron 42(6): 961-972.
Kosarussavadi, S., Z. T. Pennington, J. Covell, A. P. Blaisdell and B. A. Schlinger (2017). 
"Across sex and age: Learning and memory and patterns of avian hippocampal 
gene expression." Behav Neurosci 131(6): 483-491.
Koshibu, K., J. Graff, M. Beullens, F. D. Heitz, D. Berchtold, H. Russig, M. Farinelli, M. Bollen 
and I. M. Mansuy (2009). "Protein phosphatase 1 regulates the histone code for 
long-term memory." J Neurosci 29(41): 13079-13089.
Krajewski, W. A. and P. B. Becker (1998). "Reconstitution of hyperacetylated, DNase I-sensitive 
chromatin characterized by high conformational flexibility of nucleosomal DNA." 
Proc Natl Acad Sci U S A 95(4): 1540-1545.
Kumble, K. D., P. L. Iversen and J. K. Vishwanatha (1992). "The role of primer recognition 
proteins in DNA replication: inhibition of cellular proliferation by antisense 
oligodeoxyribonucleotides." J Cell Sci 101 ( Pt 1): 35-41.
Kummer, M. P., T. Hammerschmidt, A. Martinez, D. Terwel, G. Eichele, A. Witten, S. Figura, M. 
Stoll, S. Schwartz, H. C. Pape, J. L. Schultze, D. Weinshenker, M. T. Heneka and I. 
Urban (2014). "Ear2 deletion causes early memory and learning deficits in APP/
PS1 mice." J Neurosci 34(26): 8845-8854.
Kwak, H., N. J. Fuda, L. J. Core and J. T. Lis (2013). "Precise Maps of RNA Polymerase Reveal 
How Promoters Direct Initiation and Pausing." Science (New York, N.Y.) 339(6122): 
950-953.
Kwak, H., M. W. Park and S. Jeong (2011). "Annexin A2 binds RNA and reduces the 
frameshifting efficiency of infectious bronchitis virus." PLoS One 6(8): e24067.
Lacor, P. N., M. C. Buniel, P. W. Furlow, A. S. Clemente, P. T. Velasco, M. Wood, K. L. Viola and 
W. L. Klein (2007). "Abeta oligomer-induced aberrations in synapse composition, 
shape, and density provide a molecular basis for loss of connectivity in Alzheimer's 
disease." J Neurosci 27(4): 796-807.
Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, 
M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. Howland, L. 
Kann, J. Lehoczky, R. LeVine, P. McEwan, K. McKernan, J. Meldrim, J. P. Mesirov, 
C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos, A. Sheridan, 
 154
Bibliography
C. Sougnez, Y. Stange-Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. 
Rogers, J. Sulston, R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. 
Carter, A. Coulson, R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, 
L. French, D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, 
C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne, J. C. Mullikin, A. Mungall, 
R. Plumb, M. Ross, R. Shownkeen, S. Sims, R. H. Waterston, R. K. Wilson, L. W. 
Hillier, J. D. McPherson, M. A. Marra, E. R. Mardis, L. A. Fulton, A. T. Chinwalla, K. 
H. Pepin, W. R. Gish, S. L. Chissoe, M. C. Wendl, K. D. Delehaunty, T. L. Miner, A. 
Delehaunty, J. B. Kramer, L. L. Cook, R. S. Fulton, D. L. Johnson, P. J. Minx, S. W. 
Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T. Slezak, 
N. Doggett, J. F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, R. 
A. Gibbs, D. M. Muzny, S. E. Scherer, J. B. Bouck, E. J. Sodergren, K. C. Worley, 
C. M. Rives, J. H. Gorrell, M. L. Metzker, S. L. Naylor, R. S. Kucherlapati, D. L. 
Nelson, G. M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A. Toyoda, T. 
Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J. Weissenbach, R. Heilig, W. 
Saurin, F. Artiguenave, P. Brottier, T. Bruls, E. Pelletier, C. Robert, P. Wincker, D. R. 
Smith, L. Doucette-Stamm, M. Rubenfield, K. Weinstock, H. M. Lee, J. Dubois, A. 
Rosenthal, M. Platzer, G. Nyakatura, S. Taudien, A. Rump, H. Yang, J. Yu, J. 
Wang, G. Huang, J. Gu, L. Hood, L. Rowen, A. Madan, S. Qin, R. W. Davis, N. A. 
Federspiel, A. P. Abola, M. J. Proctor, R. M. Myers, J. Schmutz, M. Dickson, J. 
Grimwood, D. R. Cox, M. V. Olson, R. Kaul, C. Raymond, N. Shimizu, K. Kawasaki, 
S. Minoshima, G. A. Evans, M. Athanasiou, R. Schultz, B. A. Roe, F. Chen, H. Pan, 
J. Ramser, H. Lehrach, R. Reinhardt, W. R. McCombie, M. de la Bastide, N. 
Dedhia, H. Blocker, K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J. A. 
Bailey, A. Bateman, S. Batzoglou, E. Birney, P. Bork, D. G. Brown, C. B. Burge, L. 
Cerutti, H. C. Chen, D. Church, M. Clamp, R. R. Copley, T. Doerks, S. R. Eddy, E. 
E. Eichler, T. S. Furey, J. Galagan, J. G. Gilbert, C. Harmon, Y. Hayashizaki, D. 
Haussler, H. Hermjakob, K. Hokamp, W. Jang, L. S. Johnson, T. A. Jones, S. Kasif, 
A. Kaspryzk, S. Kennedy, W. J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. Kulp, D. 
Lancet, T. M. Lowe, A. McLysaght, T. Mikkelsen, J. V. Moran, N. Mulder, V. J. 
Pollara, C. P. Ponting, G. Schuler, J. Schultz, G. Slater, A. F. Smit, E. Stupka, J. 
Szustakowki, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. 
Williams, Y. I. Wolf, K. H. Wolfe, S. P. Yang, R. F. Yeh, F. Collins, M. S. Guyer, J. 
Peterson, A. Felsenfeld, K. A. Wetterstrand, A. Patrinos, M. J. Morgan, P. de Jong, 
J. J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, Y. J. Chen and J. Szustakowki 
(2001). "Initial sequencing and analysis of the human genome." Nature 409(6822): 
860-921.
Landgraf, S., J. Steingen, Y. Eppert, U. Niedermeyer, E. van der Meer and F. Krueger (2011). 
"Temporal information processing in short- and long-term memory of patients with 
schizophrenia." PLoS One 6(10): e26140.
Landré, L., C. Destrieux, F. Andersson, L. Barantin, Y. Quidé, G. Tapia, N. Jaafari, D. Clarys, P. 
Gaillard, M. Isingrini and W. El-Hage (2012). "Working memory processing of 
traumatic material in women with posttraumatic stress disorder." Journal of 
Psychiatry & Neuroscience : JPN 37(2): 87-94.
Lasagna-Reeves, C. A., D. L. Castillo-Carranza, U. Sengupta, A. L. Clos, G. R. Jackson and R. 
Kayed (2011). "Tau oligomers impair memory and induce synaptic and 
mitochondrial dysfunction in wild-type mice." Mol Neurodegener 6: 39.
Lauritzen, S. P., T. L. Boye and J. Nylandsted (2015). "Annexins are instrumental for efficient 
plasma membrane repair in cancer cells." Semin Cell Dev Biol 45: 32-38.
 155
Bibliography
Lee, I. and R. P. Kesner (2003). "Time-dependent relationship between the dorsal hippocampus 
and the prefrontal cortex in spatial memory." J Neurosci 23(4): 1517-1523.
Lee, T. I. and R. A. Young (2000). "Transcription of eukaryotic protein-coding genes." Annu Rev 
Genet 34: 77-137.
Levenson, J. M., K. J. O'Riordan, K. D. Brown, M. A. Trinh, D. L. Molfese and J. D. Sweatt 
(2004). "Regulation of histone acetylation during memory formation in the 
hippocampus." J Biol Chem 279(39): 40545-40559.
Levin, J., F. Schmidt, C. Boehm, C. Prix, K. Botzel, S. Ryazanov, A. Leonov, C. Griesinger and 
A. Giese (2014). "The oligomer modulator anle138b inhibits disease progression in 
a Parkinson mouse model even with treatment started after disease onset." Acta 
Neuropathol 127(5): 779-780.
Lewandowsky, S., M. Duncan and G. D. Brown (2004). "Time does not cause forgetting in short-
term serial recall." Psychon Bull Rev 11(5): 771-790.
Li, J., J. Ma, G. Meng, H. Lin, S. Wu, J. Wang, J. Luo, X. Xu, D. Tough, M. Lindon, I. Rioja, J. 
Zhao, H. Mei, R. Prinjha and Z. Zhong (2016). "BET bromodomain inhibition 
promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells." 
Stem Cell Res 17(2): 212-221.
Lin, M. T. and M. F. Beal (2006). "Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases." Nature 443: 787.
Ling, Q., A. T. Jacovina, A. Deora, M. Febbraio, R. Simantov, R. L. Silverstein, B. Hempstead, 
W. H. Mark and K. A. Hajjar (2004). "Annexin II regulates fibrin homeostasis and 
neoangiogenesis in vivo." J Clin Invest 113(1): 38-48.
Ling, Q., A. T. Jacovina, A. Deora, M. Febbraio, R. Simantov, R. L. Silverstein, B. Hempstead, 
W. H. Mark and K. A. Hajjar (2004). "Annexin II regulates fibrin homeostasis and 
neoangiogenesis in vivo." Journal of Clinical Investigation 113(1): 38-48.
Liu, J., C. A. Rothermund, J. Ayala-Sanmartin and J. K. Vishwanatha (2003). "Nuclear annexin II 
negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu 
prevents nucleo-cytoplasmic shuttling of annexin II." BMC Biochem 4: 10.
Liu, J. and J. K. Vishwanatha (2007). "Regulation of nucleo-cytoplasmic shuttling of human 
annexin A2: a proposed mechanism." Mol Cell Biochem 303(1-2): 211-220.
Liu, L., V. Drouet, J. W. Wu, M. P. Witter, S. A. Small, C. Clelland and K. Duff (2012). "Trans-
synaptic spread of tau pathology in vivo." PLoS One 7.
Liu, L., A. B. Fisher and U. J. Zimmerman (1995). "Lung annexin II promotes fusion of isolated 
lamellar bodies with liposomes." Biochim Biophys Acta 1259(2): 166-172.
Liu, Y., H. K. Myrvang and L. V. Dekker (2015). "Annexin A2 complexes with S100 proteins: 
structure, function and pharmacological manipulation." Br J Pharmacol 172(7): 
1664-1676.
Lonze, B. E. and D. D. Ginty (2002). "Function and regulation of CREB family transcription 
factors in the nervous system." Neuron 35(4): 605-623.
Lopez Sanchez, M. I. G., H. S. Waugh, A. Tsatsanis, B. X. Wong, J. G. Crowston, J. A. Duce 
and I. A. Trounce (2017). "Amyloid precursor protein drives down-regulation of 
mitochondrial oxidative phosphorylation independent of amyloid beta." Sci Rep 
7(1): 9835.
 156
Bibliography
Lott, I. T. and E. Head (2005). "Alzheimer disease and Down syndrome: factors in 
pathogenesis." Neurobiol Aging 26(3): 383-389.
Lubin, F. D., S. Gupta, R. R. Parrish, N. M. Grissom and R. L. Davis (2011). "Epigenetic 
mechanisms: critical contributors to long-term memory formation." Neuroscientist 
17(6): 616-632.
Luchsinger, J. A., M. X. Tang, S. Shea and R. Mayeux (2002). "Caloric intake and the risk of 
Alzheimer disease." Arch Neurol 59(8): 1258-1263.
Lum, J. A. G., G. Conti-Ramsden, D. Page and M. T. Ullman (2012). "Working, declarative and 
procedural memory in specific language impairment." Cortex; a Journal Devoted to 
the Study of the Nervous System and Behavior 48(9): 1138-1154.
Luo, W., G. Yan, L. Li, Z. Wang, H. Liu, S. Zhou, S. Liu, M. Tang, W. Yi, Z. Dong and Y. Cao 
(2008). "Epstein-Barr virus latent membrane protein 1 mediates serine 25 
phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/PKCbeta 
pathway." Mol Carcinog 47(12): 934-946.
Luo, X. and W. L. Kraus (2012). "On PAR with PARP: cellular stress signaling through 
poly(ADP-ribose) and PARP-1." Genes Dev 26(5): 417-432.
MacDuffie, K. E., A. S. Atkins, K. E. Flegal, C. M. Clark and P. A. Reuter-Lorenz (2012). 
"Memory Distortion in Alzheimer’s Disease: Deficient Monitoring of Short and Long-
term Memory." Neuropsychology 26(4): 509-516.
Madabhushi, R., F. Gao, A. R. Pfenning, L. Pan, S. Yamakawa, J. Seo, R. Rueda, T. X. Phan, H. 
Yamakawa, P. C. Pao, R. T. Stott, E. Gjoneska, A. Nott, S. Cho, M. Kellis and L. H. 
Tsai (2015). "Activity-Induced DNA Breaks Govern the Expression of Neuronal 
Early-Response Genes." Cell 161(7): 1592-1605.
Madureira, P. A., R. Hill, P. W. Lee and D. M. Waisman (2012). "Genotoxic agents promote the 
nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage." 
PLoS One 7(11): e50591.
Magistri, M., D. Velmeshev, M. Makhmutova, P. Patel, G. C. Sartor, C.-H. Volmar, C. Wahlestedt 
and M. A. Faghihi (2016). "The BET-Bromodomain Inhibitor JQ1 Reduces 
Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of 
Alzheimer’s Disease." Current Alzheimer Research 13(9): 985-995.
Mahut, H., S. Zola-Morgan and M. Moss (1982). "Hippocampal resections impair associative 
learning and recognition memory in the monkey." J Neurosci 2(9): 1214-1220.
Maji, S., P. Chaudhary, I. Akopova, P. M. Nguyen, R. J. Hare, I. Gryczynski and J. K. 
Vishwanatha (2017). "Exosomal Annexin II Promotes Angiogenesis and Breast 
Cancer Metastasis." Mol Cancer Res 15(1): 93-105.
Martin, K. C., A. Casadio, H. Zhu, E. Yaping, J. C. Rose, M. Chen, C. H. Bailey and E. R. 
Kandel (1997). "Synapse-specific, long-term facilitation of aplysia sensory to motor 
synapses: a function for local protein synthesis in memory storage." Cell 91(7): 
927-938.
Masters, C. L., G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther 
(1985). "Amyloid plaque core protein in Alzheimer disease and Down syndrome." 
Proc Natl Acad Sci U S A 82(12): 4245-4249.
Mattson, M. P. (2004). "Pathways towards and away from Alzheimer's disease." Nature 
430(7000): 631-639.
 157
Bibliography
Mawuenyega, K. G., T. Kasten, W. Sigurdson and R. J. Bateman (2013). "Amyloid-beta Isoform 
Metabolism Quantitation by Stable Isotope Labeled Kinetics." Analytical 
biochemistry 440(1): 56-62.
McClure, C., K. L. Cole, P. Wulff, M. Klugmann and A. J. Murray (2011). "Production and titering 
of recombinant adeno-associated viral vectors." J Vis Exp(57): e3348.
McIlwain, K. L., M. Y. Merriweather, L. A. Yuva-Paylor and R. Paylor (2001). "The use of 
behavioral test batteries: effects of training history." Physiol Behav 73(5): 705-717.
Mickleburgh, I., B. Burtle, H. Hollas, G. Campbell, Z. Chrzanowska-Lightowlers, A. Vedeler and 
J. Hesketh (2005). "Annexin A2 binds to the localization signal in the 3' 
untranslated region of c-myc mRNA." Febs j 272(2): 413-421.
Mietzsch, M., F. Broecker, A. Reinhardt, P. H. Seeberger and R. Heilbronn (2014). "Differential 
adeno-associated virus serotype-specific interaction patterns with synthetic 
heparins and other glycans." J Virol 88(5): 2991-3003.
Miller, C. A., S. L. Campbell and J. D. Sweatt (2008). "DNA methylation and histone acetylation 
work in concert to regulate memory formation and synaptic plasticity." Neurobiol 
Learn Mem 89(4): 599-603.
Miller, G. A. (1956). "The magical number seven plus or minus two: some limits on our capacity 
for processing information." Psychol Rev 63(2): 81-97.
Mills, J. D., T. Nalpathamkalam, H. I. Jacobs, C. Janitz, D. Merico, P. Hu and M. Janitz (2013). 
"RNA-Seq analysis of the parietal cortex in Alzheimer's disease reveals 
alternatively spliced isoforms related to lipid metabolism." Neurosci Lett 536: 90-95.
Milward, E. A., R. Papadopoulos, S. J. Fuller, R. D. Moir, D. Small, K. Beyreuther and C. L. 
Masters (1992). "The amyloid protein precursor of Alzheimer's disease is a 
mediator of the effects of nerve growth factor on neurite outgrowth." Neuron 9(1): 
129-137.
Min, S. W., X. Chen, T. E. Tracy, Y. Li, Y. Zhou, C. Wang, K. Shirakawa, S. S. Minami, E. 
Defensor, S. A. Mok, P. D. Sohn, B. Schilling, X. Cong, L. Ellerby, B. W. Gibson, J. 
Johnson, N. Krogan, M. Shamloo, J. Gestwicki, E. Masliah, E. Verdin and L. Gan 
(2015). "Critical role of acetylation in tau-mediated neurodegeneration and 
cognitive deficits." Nat Med 21(10): 1154-1162.
Min, S. W., S. H. Cho, Y. Zhou, S. Schroeder, V. Haroutunian, W. W. Seeley, E. J. Huang, Y. 
Shen, E. Masliah, C. Mukherjee, D. Meyers, P. A. Cole, M. Ott and L. Gan (2010). 
"Acetylation of tau inhibits its degradation and contributes to tauopathy." Neuron 
67.
Ming, G. L. and H. Song (2005). "Adult neurogenesis in the mammalian central nervous 
system." Annu Rev Neurosci 28: 223-250.
Molfese, D. L. (2011). "Advancing neuroscience through epigenetics: molecular mechanisms of 
learning and memory." Dev Neuropsychol 36(7): 810-827.
Mongillo, G., O. Barak and M. Tsodyks (2008). "Synaptic theory of working memory." Science 
319(5869): 1543-1546.
Montminy, M. R. and L. M. Bilezikjian (1987). "Binding of a nuclear protein to the cyclic-AMP 
response element of the somatostatin gene." Nature 328(6126): 175-178.
Montminy, M. R., M. J. Low, L. Tapia-Arancibia, S. Reichlin, G. Mandel and R. H. Goodman 
(1986). "Cyclic AMP regulates somatostatin mRNA accumulation in primary 
 158
Bibliography
diencephalic cultures and in transfected fibroblast cells." J Neurosci 6(4): 
1171-1176.
Mootha, V. K., C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. 
Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, N. Houstis, M. J. Daly, N. 
Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. 
Hirschhorn, D. Altshuler and L. C. Groop (2003). "PGC-1alpha-responsive genes 
involved in oxidative phosphorylation are coordinately downregulated in human 
diabetes." Nat Genet 34(3): 267-273.
Morales, V. and H. Richard-Foy (2000). "Role of Histone N-Terminal Tails and Their Acetylation 
in Nucleosome Dynamics." Molecular and Cellular Biology 20(19): 7230-7237.
Moriniere, J., S. Rousseaux, U. Steuerwald, M. Soler-Lopez, S. Curtet, A. L. Vitte, J. Govin, J. 
Gaucher, K. Sadoul, D. J. Hart, J. Krijgsveld, S. Khochbin, C. W. Muller and C. 
Petosa (2009). "Cooperative binding of two acetylation marks on a histone tail by a 
single bromodomain." Nature 461(7264): 664-668.
Morris, M., G. M. Knudsen, S. Maeda, J. C. Trinidad, A. Ioanoviciu, A. L. Burlingame and L. 
Mucke (2015). "Tau post-translational modifications in wild-type and human 
amyloid precursor protein transgenic mice." Nat Neurosci 18(8): 1183-1189.
Morris, R. G. M. (1981). "Spatial localization does not require the presence of local cues." 
Learning and Motivation 12(2): 239-260.
Moser, E., M. B. Moser and P. Andersen (1993). "Spatial learning impairment parallels the 
magnitude of dorsal hippocampal lesions, but is hardly present following ventral 
lesions." J Neurosci 13(9): 3916-3925.
Mosmann, T. (1983). "Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays." J Immunol Methods 65(1-2): 55-63.
Moss, S. E. and R. O. Morgan (2004). "The annexins." Genome Biol 5(4): 219.
Mussunoor, S. and G. I. Murray (2008). "The role of annexins in tumour development and 
progression." J Pathol 216(2): 131-140.
Nazmi, A. R., G. Ozorowski, M. Pejic, J. P. Whitelegge, V. Gerke and H. Luecke (2012). "N-
terminal acetylation of annexin A2 is required for S100A10 binding." Biol Chem 
393(10): 1141-1150.
Noack, M., J. Leyk and C. Richter-Landsberg (2014). "HDAC6 inhibition results in tau 
acetylation and modulates tau phosphorylation and degradation in 
oligodendrocytes." Glia 62(4): 535-547.
Oh, Y. S., P. Gao, K. W. Lee, I. Ceglia, J. S. Seo, X. Zhang, J. H. Ahn, B. T. Chait, D. J. Patel, Y. 
Kim and P. Greengard (2013). "SMARCA3, a chromatin-remodeling factor, is 
required for p11-dependent antidepressant action." Cell 152(4): 831-843.
Panza, F., V. Frisardi, V. Solfrizzi, B. P. Imbimbo, G. Logroscino, A. Santamato, A. Greco, D. 
Seripa and A. Pilotto (2012). "Immunotherapy for Alzheimer's disease: from anti-
beta-amyloid to tau-based immunization strategies." Immunotherapy 4(2): 213-238.
Parker, E. S., L. Cahill and J. L. McGaugh (2006). "A case of unusual autobiographical 
remembering." Neurocase 12(1): 35-49.
Pavlov, P. I. (2010). "Conditioned reflexes: An investigation of the physiological activity of the 
cerebral cortex." Annals of Neurosciences 17(3): 136-141.
 159
Bibliography
Peleg, S., F. Sananbenesi, A. Zovoilis, S. Burkhardt, S. Bahari-Javan, R. C. Agis-Balboa, P. 
Cota, J. L. Wittnam, A. Gogol-Doering, L. Opitz, G. Salinas-Riester, M. Dettenhofer, 
H. Kang, L. Farinelli, W. Chen and A. Fischer (2010). "Altered histone acetylation is 
associated with age-dependent memory impairment in mice." Science 328(5979): 
753-756.
Pellow, S., P. Chopin, S. E. File and M. Briley (1985). "Validation of open : closed arm entries in 
an elevated plus-maze as a measure of anxiety in the rat." Journal of Neuroscience 
Methods 14(3): 149-167.
Peterson, L. R. and M. J. Peterson (1959). "Short-term retention of individual verbal items." J 
Exp Psychol 58: 193-198.
Pittenger, C., Y. Y. Huang, R. F. Paletzki, R. Bourtchouladze, H. Scanlin, S. Vronskaya and E. R. 
Kandel (2002). "Reversible inhibition of CREB/ATF transcription factors in region 
CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory." 
Neuron 34(3): 447-462.
Plagg, B., D. Ehrlich, K. M. Kniewallner, J. Marksteiner and C. Humpel (2015). "Increased 
Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic 
Alzheimer’s Mice and in Human Patients." Current Alzheimer research 12(8): 
752-760.
Polster, M. R., L. Nadel and D. L. Schacter (1991). "Cognitive neuroscience analyses of 
memory: a historical perspective." J Cogn Neurosci 3(2): 95-116.
Porsolt, R. D., M. Le Pichon and M. Jalfre (1977). "Depression: a new animal model sensitive to 
antidepressant treatments." Nature 266(5604): 730-732.
Portelius, E., G. Brinkmalm, A. J. Tran, H. Zetterberg, A. Westman-Brinkmalm and K. Blennow 
(2009). "Identification of novel APP/Abeta isoforms in human cerebrospinal fluid." 
Neurodegener Dis 6(3): 87-94.
Price, J. L. and J. C. Morris (1999). "Tangles and plaques in nondemented aging and 
"preclinical" Alzheimer's disease." Ann Neurol 45(3): 358-368.
Priller, C., T. Bauer, G. Mitteregger, B. Krebs, H. A. Kretzschmar and J. Herms (2006). "Synapse 
formation and function is modulated by the amyloid precursor protein." J Neurosci 
26(27): 7212-7221.
Qiu, H., A. L. Jackson, J. E. Kilgore, Y. Zhong, L. L. Chan, P. A. Gehrig, C. Zhou and V. L. Bae-
Jump (2015). "JQ1 suppresses tumor growth through downregulating LDHA in 
ovarian cancer." Oncotarget 6(9): 6915-6930.
Qiu, W. Q., A. Ferreira, C. Miller, E. H. Koo and D. J. Selkoe (1995). "Cell-surface beta-amyloid 
precursor protein stimulates neurite outgrowth of hippocampal neurons in an 
isoform-dependent manner." J Neurosci 15(3 Pt 2): 2157-2167.
Rapti, K., V. Louis-Jeune, E. Kohlbrenner, K. Ishikawa, D. Ladage, S. Zolotukhin, R. J. Hajjar 
and T. Weber (2012). "Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 
in sera of commonly used animal models." Mol Ther 20(1): 73-83.
Raynal, P. and H. B. Pollard (1994). "Annexins: the problem of assessing the biological role for 
a gene family of multifunctional calcium- and phospholipid-binding proteins." 
Biochim Biophys Acta 1197(1): 63-93.
Reeves, E. K., H. Gordish-Dressman, E. P. Hoffman and Y. Hathout (2009). "Proteomic profiling 
of glucocorticoid-exposed myogenic cells: Time series assessment of protein 
translocation and transcription of inactive mRNAs." Proteome Sci 7: 26.
 160
Bibliography
Rintala-Dempsey, A. C., A. Rezvanpour and G. S. Shaw (2008). "S100-annexin complexes--
structural insights." Febs j 275(20): 4956-4966.
Risso, D., J. Ngai, T. P. Speed and S. Dudoit (2014). "Normalization of RNA-seq data using 
factor analysis of control genes or samples." Nat Biotech 32(9): 896-902.
Roberson, E. D., B. Halabisky, J. W. Yoo, J. Yao, J. Chin, F. Yan, T. Wu, P. Hamto, N. Devidze, 
G. Q. Yu, J. J. Palop, J. L. Noebels and L. Mucke (2011). "Amyloid-beta/Fyn-
induced synaptic, network, and cognitive impairments depend on tau levels in 
multiple mouse models of Alzheimer's disease." J Neurosci 31(2): 700-711.
Rodriguez, F., J. C. Lopez, J. P. Vargas, C. Broglio, Y. Gomez and C. Salas (2002). "Spatial 
memory and hippocampal pallium through vertebrate evolution: insights from 
reptiles and teleost fish." Brain Res Bull 57(3-4): 499-503.
Rojas-Duran, M. F. and W. V. Gilbert (2012). "Alternative transcription start site selection leads 
to large differences in translation activity in yeast." RNA 18(12): 2299-2305.
Rousseaux, S. and S. Khochbin (2015). "Histone Acylation beyond Acetylation: Terra Incognita 
in Chromatin Biology." Cell J 17(1): 1-6.
Rudy, J. W., N. C. Huff and P. Matus-Amat (2004). "Understanding contextual fear conditioning: 
insights from a two-process model." Neurosci Biobehav Rev 28(7): 675-685.
Sakabe, K., Z. Wang and G. W. Hart (2010). "Beta-N-acetylglucosamine (O-GlcNAc) is part of 
the histone code." Proc Natl Acad Sci U S A 107(46): 19915-19920.
Sarkar, S., R. Swiercz, C. Kantara, K. A. Hajjar and P. Singh (2011). "Annexin A2 mediates up-
regulation of NF-kappaB, beta-catenin, and stem cell in response to progastrin in 
mice and HEK-293 cells." Gastroenterology 140(2): 583-595.e584.
Sartor, G. C., S. K. Powell, S. P. Brothers and C. Wahlestedt (2015). "Epigenetic Readers of 
Lysine Acetylation Regulate Cocaine-Induced Plasticity." J Neurosci 35(45): 
15062-15072.
Saunders, R. C. and D. L. Rosene (1988). "A comparison of the efferents of the amygdala and 
the hippocampal formation in the rhesus monkey: I. Convergence in the entorhinal, 
prorhinal, and perirhinal cortices." J Comp Neurol 271(2): 153-184.
Schafe, G. E., K. Nader, H. T. Blair and J. E. LeDoux (2001). "Memory consolidation of 
Pavlovian fear conditioning: a cellular and molecular perspective." Trends Neurosci 
24(9): 540-546.
Schafer, G., J. K. Hitchcock, T. M. Shaw, A. A. Katz and M. I. Parker (2015). "A novel role of 
annexin A2 in human type I collagen gene expression." J Cell Biochem 116(3): 
408-417.
Scharfman, H. E. (2007). "The CA3 “Backprojection” to the Dentate Gyrus." Progress in brain 
research 163: 627-637.
Schindowski, K., A. Bretteville, K. Leroy, S. Begard, J. P. Brion, M. Hamdane and L. Buee 
(2006). "Alzheimer's disease-like tau neuropathology leads to memory deficits and 
loss of functional synapses in a novel mutated tau transgenic mouse without any 
motor deficits." Am J Pathol 169(2): 599-616.
Schmidt, M., A. Voutetakis, S. Afione, C. Zheng, D. Mandikian and J. A. Chiorini (2008). "Adeno-
associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and 
heparan sulfate proteoglycan-independent transduction activity." J Virol 82(3): 
1399-1406.
 161
Bibliography
Schoenenberger, P., D. Gerosa and T. G. Oertner (2009). "Temporal Control of Immediate Early 
Gene Induction by Light." PLoS One 4(12).
Schor, I. E. and A. R. Kornblihtt (2009). "Playing inside the genes: Intragenic histone acetylation 
after membrane depolarization of neural cells opens a path for alternative splicing 
regulation." Communicative & Integrative Biology 2(4): 341-343.
Scoville, W. B. and B. Milner (1957). "Loss of recent memory after bilateral hippocampal 
lesions." J Neurol Neurosurg Psychiatry 20(1): 11-21.
Selenica, M. L., L. Benner, S. B. Housley, B. Manchec, D. C. Lee, K. R. Nash, J. Kalin, J. A. 
Bergman, A. Kozikowski, M. N. Gordon and D. Morgan (2014). "Histone 
deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse 
model of tau deposition." Alzheimers Res Ther 6(1): 12.
Selkoe, D. J. and J. Hardy (2016). "The amyloid hypothesis of Alzheimer's disease at 25 years." 
EMBO Mol Med 8(6): 595-608.
Senechal, Y., P. H. Kelly and K. K. Dev (2008). "Amyloid precursor protein knockout mice show 
age-dependent deficits in passive avoidance learning." Behav Brain Res 186(1): 
126-132.
Senkov, O., P. Andjus, L. Radenovic, E. Soriano and A. Dityatev (2014). "Neural ECM molecules 
in synaptic plasticity, learning, and memory." Prog Brain Res 214: 53-80.
Serrano-Pozo, A., M. P. Frosch, E. Masliah and B. T. Hyman (2011). "Neuropathological 
Alterations in Alzheimer Disease." Cold Spring Harbor Perspectives in Medicine: 
1(1): a006189.
Seto, E. and M. Yoshida (2014). "Erasers of Histone Acetylation: The Histone Deacetylase 
Enzymes." Cold Spring Harbor Perspectives in Biology 6(4): a018713.
Sewal, A. S., H. Patzke, E. J. Perez, P. Park, E. Lehrmann, Y. Zhang, K. G. Becker, B. R. 
Fletcher, J. M. Long and P. R. Rapp (2015). "Experience Modulates the Effects of 
Histone Deacetylase Inhibitors on Gene and Protein Expression in the 
Hippocampus: Impaired Plasticity in Aging." J Neurosci 35(33): 11729-11742.
Shadmehr, R. and T. Brashers-Krug (1997). "Functional Stages in the Formation of Human 
Long-Term Motor Memory." The Journal of Neuroscience 17(1): 409.
Sharma, M. C. and M. Sharma (2007). "The role of annexin II in angiogenesis and tumor 
progression: a potential therapeutic target." Curr Pharm Des 13(35): 3568-3575.
Shiio, Y. and R. N. Eisenman (2003). "Histone sumoylation is associated with transcriptional 
repression." Proc Natl Acad Sci U S A 100(23): 13225-13230.
Shin, R.-W., K. Ogino, A. Kondo, T. C. Saido, J. Q. Trojanowski, T. Kitamoto and J. Tateishi 
(1997). "Amyloid β-Protein (Aβ) 1–40 But Not Aβ1–42 Contributes to the 
Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain." The 
Journal of Neuroscience 17(21): 8187-8193.
Spellman, D. S., K. Deinhardt, C. C. Darie, M. V. Chao and T. A. Neubert (2008). "Stable 
isotopic labeling by amino acids in cultured primary neurons: application to brain-
derived neurotrophic factor-dependent phosphotyrosine-associated signaling." Mol 
Cell Proteomics 7(6): 1067-1076.
Spires-Jones, T. L., K. J. Kopeikina, R. M. Koffie, A. de Calignon and B. T. Hyman (2011). "Are 
tangles as toxic as they look?" J Mol Neurosci 45(3): 438-444.
 162
Bibliography
Star, E. N., D. J. Kwiatkowski and V. N. Murthy (2002). "Rapid turnover of actin in dendritic 
spines and its regulation by activity." Nat Neurosci 5(3): 239-246.
Stefanko, D. P., R. M. Barrett, A. R. Ly, G. K. Reolon and M. A. Wood (2009). "Modulation of 
long-term memory for object recognition via HDAC inhibition." Proc Natl Acad Sci U 
S A 106(23): 9447-9452.
Strahl, B. D. and C. D. Allis (2000). "The language of covalent histone modifications." Nature 
403(6765): 41-45.
Strosznajder, R. P., H. Jesko and A. Adamczyk (2005). "Effect of aging and oxidative/genotoxic 
stress on poly(ADP-ribose) polymerase-1 activity in rat brain." Acta Biochim Pol 
52(4): 909-914.
Stucki, M., J. A. Clapperton, D. Mohammad, M. B. Yaffe, S. J. Smerdon and S. P. Jackson 
(2005). "MDC1 directly binds phosphorylated histone H2AX to regulate cellular 
responses to DNA double-strand breaks." Cell 123(7): 1213-1226.
Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. 
Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander and J. P. Mesirov (2005). 
"Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles." Proc Natl Acad Sci U S A 102(43): 
15545-15550.
Suh, Y. H., A. Terashima, R. S. Petralia, R. J. Wenthold, J. T. R. Isaac, K. W. Roche and P. A. 
Roche (2010). "A neuronal role for SNAP-23 in postsynaptic glutamate receptor 
trafficking." Nature neuroscience 13(3): 338-343.
Summerford, C. and R. J. Samulski (1998). "Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions." J Virol 72(2): 
1438-1445.
Sutherland, R. J., J. O'Brien and H. Lehmann (2008). "Absence of systems consolidation of fear 
memories after dorsal, ventral, or complete hippocampal damage." Hippocampus 
18(7): 710-718.
Sutherland, R. J. and J. W. Rudy (1988). "Place learning in the Morris place navigation task is 
impaired by damage to the hippocampal formation even if the temporal demands 
are reduced." Psychobiology 16(2): 157-163.
Tan, M., H. Luo, S. Lee, F. Jin, J. S. Yang, E. Montellier, T. Buchou, Z. Cheng, S. Rousseaux, N. 
Rajagopal, Z. Lu, Z. Ye, Q. Zhu, J. Wysocka, Y. Ye, S. Khochbin, B. Ren and Y. 
Zhao (2011). "Identification of 67 histone marks and histone lysine crotonylation as 
a new type of histone modification." Cell 146(6): 1016-1028.
Taverna, S. D., H. Li, A. J. Ruthenburg, C. D. Allis and D. J. Patel (2007). "How chromatin-
binding modules interpret histone modifications: lessons from professional pocket 
pickers." Nat Struct Mol Biol 14(11): 1025-1040.
Terni, B. and I. Ferrer (2015). "Abnormal Expression and Distribution of MMP2 at Initial Stages 
of Alzheimer's Disease-Related Pathology." J Alzheimers Dis 46(2): 461-469.
Thierry, A. M., Y. Gioanni, E. Degenetais and J. Glowinski (2000). "Hippocampo-prefrontal 
cortex pathway: anatomical and electrophysiological characteristics." Hippocampus 
10(4): 411-419.
Thornton, A. E. and N. Raz (1997). "Memory impairment in multiple sclerosis: a quantitative 
review." Neuropsychology 11(3): 357-366.
 163
Bibliography
Tomas, A. and S. E. Moss (2003). "Calcium- and cell cycle-dependent association of annexin 11 
with the nuclear envelope." J Biol Chem 278(22): 20210-20216.
Tomlinson, B. E., G. Blessed and M. Roth (1970). "Observations on the brains of demented old 
people." Journal of the Neurological Sciences 11(3): 205-242.
Trudeau, L. E. and V. F. Castellucci (1993). "Excitatory amino acid neurotransmission at 
sensory-motor and interneuronal synapses of Aplysia californica." J Neurophysiol 
70(3): 1221-1230.
Tseng, J.-H., L. Xie, S. Song, Y. Xie, L. Allen, D. Ajit, J.-S. Hong, X. Chen, R. B. Meeker and T. 
J. Cohen (2017). "The Deacetylase HDAC6 Mediates Endogenous Neuritic Tau 
Pathology." Cell reports 20(9): 2169-2183.
Tsilibary, E., A. Tzinia, L. Radenovic, V. Stamenkovic, T. Lebitko, M. Mucha, R. Pawlak, R. 
Frischknecht and L. Kaczmarek (2014). Chapter 6 - Neural ECM proteases in 
learning and synaptic plasticity. Progress in Brain Research. A. Dityatev, B. Wehrle-
Haller and A. Pitkänen, Elsevier. 214: 135-157.
Tyan, S. H., A. Y. Shih, J. J. Walsh, H. Maruyama, F. Sarsoza, L. Ku, S. Eggert, P. R. Hof, E. H. 
Koo and D. L. Dickstein (2012). "Amyloid precursor protein (APP) regulates 
synaptic structure and function." Mol Cell Neurosci 51(1-2): 43-52.
Umehara, T., Y. Nakamura, M. K. Jang, K. Nakano, A. Tanaka, K. Ozato, B. Padmanabhan and 
S. Yokoyama (2010). "Structural basis for acetylated histone H4 recognition by the 
human BRD2 bromodomain." J Biol Chem 285(10): 7610-7618.
Valapala, M., S. Maji, J. Borejdo and J. K. Vishwanatha (2014). "Cell Surface Translocation of 
Annexin A2 Facilitates Glutamate-induced Extracellular Proteolysis." The Journal of 
Biological Chemistry 289(23): 15915-15926.
Van der Jeugd, A., D. Blum, S. Raison, S. Eddarkaoui, L. Buee and R. D'Hooge (2013). 
"Observations in THY-Tau22 mice that resemble behavioral and psychological 
signs and symptoms of dementia." Behav Brain Res 242: 34-39.
Vassar, R., P. H. Kuhn, C. Haass, M. E. Kennedy, L. Rajendran, P. C. Wong and S. F. 
Lichtenthaler (2014). "Function, therapeutic potential and cell biology of BACE 
proteases: current status and future prospects." J Neurochem 130(1): 4-28.
Vasudevan, A., M. S. Ho, M. Weiergraber, R. Nischt, T. Schneider, A. Lie, N. Smyth and R. 
Kohling (2010). "Basement membrane protein nidogen-1 shapes hippocampal 
synaptic plasticity and excitability." Hippocampus 20(5): 608-620.
Vedeler, A. and H. Hollas (2000). "Annexin II is associated with mRNAs which may constitute a 
distinct subpopulation." Biochem J 348 Pt 3: 565-572.
Vedeler, A., H. Hollas, A. K. Grindheim and A. M. Raddum (2012). "Multiple roles of annexin A2 
in post-transcriptional regulation of gene expression." Curr Protein Pept Sci 13(4): 
401-412.
Venter, J. C., M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural, G. G. Sutton, H. O. Smith, M. 
Yandell, C. A. Evans, R. A. Holt, J. D. Gocayne, P. Amanatides, R. M. Ballew, D. H. 
Huson, J. R. Wortman, Q. Zhang, C. D. Kodira, X. H. Zheng, L. Chen, M. Skupski, 
G. Subramanian, P. D. Thomas, J. Zhang, G. L. Gabor Miklos, C. Nelson, S. 
Broder, A. G. Clark, J. Nadeau, V. A. McKusick, N. Zinder, A. J. Levine, R. J. 
Roberts, M. Simon, C. Slayman, M. Hunkapiller, R. Bolanos, A. Delcher, I. Dew, D. 
Fasulo, M. Flanigan, L. Florea, A. Halpern, S. Hannenhalli, S. Kravitz, S. Levy, C. 
Mobarry, K. Reinert, K. Remington, J. Abu-Threideh, E. Beasley, K. Biddick, V. 
Bonazzi, R. Brandon, M. Cargill, I. Chandramouliswaran, R. Charlab, K. 
 164
Bibliography
Chaturvedi, Z. Deng, V. Di Francesco, P. Dunn, K. Eilbeck, C. Evangelista, A. E. 
Gabrielian, W. Gan, W. Ge, F. Gong, Z. Gu, P. Guan, T. J. Heiman, M. E. Higgins, 
R. R. Ji, Z. Ke, K. A. Ketchum, Z. Lai, Y. Lei, Z. Li, J. Li, Y. Liang, X. Lin, F. Lu, G. V. 
Merkulov, N. Milshina, H. M. Moore, A. K. Naik, V. A. Narayan, B. Neelam, D. 
Nusskern, D. B. Rusch, S. Salzberg, W. Shao, B. Shue, J. Sun, Z. Wang, A. Wang, 
X. Wang, J. Wang, M. Wei, R. Wides, C. Xiao, C. Yan, A. Yao, J. Ye, M. Zhan, W. 
Zhang, H. Zhang, Q. Zhao, L. Zheng, F. Zhong, W. Zhong, S. Zhu, S. Zhao, D. 
Gilbert, S. Baumhueter, G. Spier, C. Carter, A. Cravchik, T. Woodage, F. Ali, H. An, 
A. Awe, D. Baldwin, H. Baden, M. Barnstead, I. Barrow, K. Beeson, D. Busam, A. 
Carver, A. Center, M. L. Cheng, L. Curry, S. Danaher, L. Davenport, R. Desilets, S. 
Dietz, K. Dodson, L. Doup, S. Ferriera, N. Garg, A. Gluecksmann, B. Hart, J. 
Haynes, C. Haynes, C. Heiner, S. Hladun, D. Hostin, J. Houck, T. Howland, C. 
Ibegwam, J. Johnson, F. Kalush, L. Kline, S. Koduru, A. Love, F. Mann, D. May, S. 
McCawley, T. McIntosh, I. McMullen, M. Moy, L. Moy, B. Murphy, K. Nelson, C. 
Pfannkoch, E. Pratts, V. Puri, H. Qureshi, M. Reardon, R. Rodriguez, Y. H. Rogers, 
D. Romblad, B. Ruhfel, R. Scott, C. Sitter, M. Smallwood, E. Stewart, R. Strong, E. 
Suh, R. Thomas, N. N. Tint, S. Tse, C. Vech, G. Wang, J. Wetter, S. Williams, M. 
Williams, S. Windsor, E. Winn-Deen, K. Wolfe, J. Zaveri, K. Zaveri, J. F. Abril, R. 
Guigo, M. J. Campbell, K. V. Sjolander, B. Karlak, A. Kejariwal, H. Mi, B. Lazareva, 
T. Hatton, A. Narechania, K. Diemer, A. Muruganujan, N. Guo, S. Sato, V. Bafna, S. 
Istrail, R. Lippert, R. Schwartz, B. Walenz, S. Yooseph, D. Allen, A. Basu, J. 
Baxendale, L. Blick, M. Caminha, J. Carnes-Stine, P. Caulk, Y. H. Chiang, M. 
Coyne, C. Dahlke, A. Mays, M. Dombroski, M. Donnelly, D. Ely, S. Esparham, C. 
Fosler, H. Gire, S. Glanowski, K. Glasser, A. Glodek, M. Gorokhov, K. Graham, B. 
Gropman, M. Harris, J. Heil, S. Henderson, J. Hoover, D. Jennings, C. Jordan, J. 
Jordan, J. Kasha, L. Kagan, C. Kraft, A. Levitsky, M. Lewis, X. Liu, J. Lopez, D. Ma, 
W. Majoros, J. McDaniel, S. Murphy, M. Newman, T. Nguyen, N. Nguyen, M. 
Nodell, S. Pan, J. Peck, M. Peterson, W. Rowe, R. Sanders, J. Scott, M. Simpson, 
T. Smith, A. Sprague, T. Stockwell, R. Turner, E. Venter, M. Wang, M. Wen, D. Wu, 
M. Wu, A. Xia, A. Zandieh and X. Zhu (2001). "The sequence of the human 
genome." Science 291(5507): 1304-1351.
Violet, M., L. Delattre, M. Tardivel, A. Sultan, A. Chauderlier, R. Caillierez, S. Talahari, F. 
Nesslany, B. Lefebvre, E. Bonnefoy, L. Buee and M. C. Galas (2014). "A major role 
for Tau in neuronal DNA and RNA protection in vivo under physiological and 
hyperthermic conditions." Front Cell Neurosci 8: 84.
Vishwanatha, J. K., H. K. Jindal and R. G. Davis (1992). "The role of primer recognition proteins 
in DNA replication: association with nuclear matrix in HeLa cells." J Cell Sci 101 
( Pt 1): 25-34.
Vogel, F. (1964). "A PRELIMINARY ESTIMATE OF THE NUMBER OF HUMAN GENES." 
Nature 201: 847.
Vogelauer, M., J. Wu, N. Suka and M. Grunstein (2000). "Global histone acetylation and 
deacetylation in yeast." Nature 408(6811): 495-498.
Voronkov, M., S. P. Braithwaite and J. B. Stock (2011). "Phosphoprotein phosphatase 2A: a 
novel druggable target for Alzheimer’s disease." Future Medicinal Chemistry 3(7): 
821-833.
Wagner, J., S. Krauss, S. Shi, S. Ryazanov, J. Steffen, C. Miklitz, A. Leonov, A. Kleinknecht, B. 
Goricke, J. H. Weishaupt, D. Weckbecker, A. M. Reiner, W. Zinth, J. Levin, D. 
Ehninger, S. Remy, H. A. Kretzschmar, C. Griesinger, A. Giese and M. Fuhrmann 
 165
Bibliography
(2015). "Reducing tau aggregates with anle138b delays disease progression in a 
mouse model of tauopathies." Acta Neuropathol 130(5): 619-631.
Wagner, J., S. Ryazanov, A. Leonov, J. Levin, S. Shi, F. Schmidt, C. Prix, F. Pan-Montojo, U. 
Bertsch, G. Mitteregger-Kretzschmar, M. Geissen, M. Eiden, F. Leidel, T. 
Hirschberger, A. A. Deeg, J. J. Krauth, W. Zinth, P. Tavan, J. Pilger, M. 
Zweckstetter, T. Frank, M. Bahr, J. H. Weishaupt, M. Uhr, H. Urlaub, U. Teichmann, 
M. Samwer, K. Botzel, M. Groschup, H. Kretzschmar, C. Griesinger and A. Giese 
(2013). "Anle138b: a novel oligomer modulator for disease-modifying therapy of 
neurodegenerative diseases such as prion and Parkinson's disease." Acta 
Neuropathol 125(6): 795-813.
Waisman, D. M. (1995). "Annexin II tetramer: structure and function." Mol Cell Biochem 
149-150: 301-322.
Wang, C. Y. and C. F. Lin (2014). "Annexin A2: its molecular regulation and cellular expression 
in cancer development." Dis Markers 2014: 308976.
Wang, P., N. R. Chintagari, D. Gou, L. Su and L. Liu (2007). "Physical and functional 
interactions of SNAP-23 with annexin A2." Am J Respir Cell Mol Biol 37(4): 
467-476.
Watson, J. D. (2014). Molecular biology of the gene.
Wei, Y. H. and H. C. Lee (2002). "Oxidative stress, mitochondrial DNA mutation, and impairment 
of antioxidant enzymes in aging." Exp Biol Med (Maywood) 227(9): 671-682.
Weingarten, M. D., A. H. Lockwood, S. Y. Hwo and M. W. Kirschner (1975). "A protein factor 
essential for microtubule assembly." Proceedings of the National Academy of 
Sciences 72(5): 1858-1862.
Whishaw, I. Q. and J. Tomie (1996). "Of mice and mazes: similarities between mice and rats on 
dry land but not water mazes." Physiol Behav 60(5): 1191-1197.
White, R. J. and S. P. Jackson (1992). "The TATA-binding protein: a central role in transcription 
by RNA polymerases I, II and III." Trends Genet 8(8): 284-288.
Wiera, G., D. Nowak, I. van Hove, P. Dziegiel, L. Moons and J. W. Mozrzymas (2017). 
"Mechanisms of NMDA Receptor- and Voltage-Gated L-Type Calcium Channel-
Dependent Hippocampal LTP Critically Rely on Proteolysis That Is Mediated by 
Distinct Metalloproteinases." J Neurosci 37(5): 1240-1256.
Winocur, G., J. M. Wojtowicz, M. Sekeres, J. S. Snyder and S. Wang (2006). "Inhibition of 
neurogenesis interferes with hippocampus-dependent memory function." 
Hippocampus 16(3): 296-304.
Wirths, O., G. Multhaup, C. Czech, V. Blanchard, S. Moussaoui, G. Tremp, L. Pradier, K. 
Beyreuther and T. A. Bayer (2001). "Intraneuronal Abeta accumulation precedes 
plaque formation in beta-amyloid precursor protein and presenilin-1 double-
transgenic mice." Neurosci Lett 306(1-2): 116-120.
Wolfe, M. S. (2008). "Inhibition and modulation of gamma-secretase for Alzheimer's disease." 
Neurotherapeutics 5(3): 391-398.
Woodcock, C. L. and S. Dimitrov (2001). "Higher-order structure of chromatin and 
chromosomes." Curr Opin Genet Dev 11(2): 130-135.
Xiong, Y., K. Zhao, J. Wu, Z. Xu, S. Jin and Y. Q. Zhang (2013). "HDAC6 mutations rescue 
human tau-induced microtubule defects in Drosophila." Proc Natl Acad Sci USA 
110.
 166
Bibliography
Xiu, D., L. Liu, F. Qiao, H. Yang, L. Cui and G. Liu (2016). "Annexin A2 Coordinates STAT3 to 
Regulate the Invasion and Migration of Colorectal Cancer Cells In Vitro." 
Gastroenterol Res Pract 2016: 3521453.
Yan, G., W. Luo, Z. Lu, X. Luo, L. Li, S. Liu, Y. Liu, M. Tang, Z. Dong and Y. Cao (2007). 
"Epstein-Barr virus latent membrane protein 1 mediates phosphorylation and 
nuclear translocation of annexin A2 by activating PKC pathway." Cell Signal 19(2): 
341-348.
Yao, Z. G., L. Zhang, L. Huang, H. Zhu, Y. Liu, C. M. Ma, S. L. Sheng and C. Qin (2013). 
"Regional and cell-type specific distribution of HDAC2 in the adult mouse brain." 
Brain Struct Funct 218(2): 563-573.
Yu, W. and E. Krook-Magnuson (2015). "Cognitive Collaborations: Bidirectional Functional 
Connectivity Between the Cerebellum and the Hippocampus." Frontiers in Systems 
Neuroscience 9: 177.
Yun, M., J. Wu, J. L. Workman and B. Li (2011). "Readers of histone modifications." Cell Res 
21(4): 564-578.
Zeng, L. and M. M. Zhou (2002). "Bromodomain: an acetyl-lysine binding domain." FEBS Lett 
513(1): 124-128.
Zhang, B., S. Kirov and J. Snoddy (2005). "WebGestalt: an integrated system for exploring gene 
sets in various biological contexts." Nucleic Acids Res 33(Web Server issue): 
W741-748.
Zhang, Y., N. Li, C. Caron, G. Matthias, D. Hess, S. Khochbin and P. Matthias (2003). "HDAC-6 
interacts with and deacetylates tubulin and microtubules in vivo." The EMBO 
Journal 22(5): 1168-1179.
Zhang, Z., M. Song, X. Liu, S. S. Kang, I. S. Kwon, D. M. Duong, N. T. Seyfried, W. T. Hu, Z. Liu, 
J. Z. Wang, L. Cheng, Y. E. Sun, S. P. Yu, A. I. Levey and K. Ye (2014). "Cleavage 
of tau by asparagine endopeptidase mediates the neurofibrillary pathology in 
Alzheimer's disease." Nat Med 20(11): 1254-1262.
Zhao, W. Q., D. M. Waisman and M. Grimaldi (2004). "Specific localization of the annexin II 
heterotetramer in brain lipid raft fractions and its changes in spatial learning." J 
Neurochem 90(3): 609-620.
Zheng, L., K. Foley, L. Huang, A. Leubner, G. Mo, K. Olino, B. H. Edil, M. Mizuma, R. Sharma, 
D. T. Le, R. A. Anders, P. B. Illei, J. E. Van Eyk, A. Maitra, D. Laheru and E. M. 
Jaffee (2011). "Tyrosine 23 phosphorylation-dependent cell-surface localization of 
annexin A2 is required for invasion and metastases of pancreatic cancer." PLoS 
One 6(4): e19390.
Zhou, H. L., M. N. Hinman, V. A. Barron, C. Geng, G. Zhou, G. Luo, R. E. Siegel and H. Lou 
(2011). "Hu proteins regulate alternative splicing by inducing localized histone 
hyperacetylation in an RNA-dependent manner." Proc Natl Acad Sci U S A 108(36): 
E627-635.
Zhou, H. L., G. Luo, J. A. Wise and H. Lou (2014). "Regulation of alternative splicing by local 
histone modifications: potential roles for RNA-guided mechanisms." Nucleic Acids 
Res 42(2): 701-713.
 167
 Ac
kn
ow
led
ge
m
en
ts
Acknowledgements 
First and foremost I want to sincerely thank Andre for giving me the opportunity to do my PhD in 
his lab. I also want to thank him for the incredible freedom and support he gave me, for being 
open to ideas that do not necessarily fall into the scope of his research and for creating a 
friendly environment in which it was a pleasure to carry out my work for this thesis. 
Also I want to thank Prof. Dr. Tiago Outeiro for reviewing this thesis and being a critical but 
always positive member of my thesis committee. Further, I want to thank Prof. Dr. Siegrid Löwel 
for exciting discussions and honest feedback during my thesis committee meetings. Additionally 
I want to express my gratitude in advance to all members of my extended examination board 
Prof. Dr. Ralf Heinrich, Prof. Dr. André Fiala, and Prof. Dr. Martin Göpfert. All of which impacted 
my studies here in Göttingen starting from the bachelors and continuing through the master 
programme. I appreciate the gesture of them being present for my defense.
At this point I also want to express my sincere gratitude to the Hans and Ilse Breuer Foundation 
for their generous support of work.
I want to express my gratitude to Alan Gillman, and Joon Lee for the collaboration on anle138b 
and for agreeing to incorporate their data into this thesis. Also I want to thank Nadin 
Zimmermann for the collaboration on the H4K12ac pulldown. 
Now to the Fischerlab old and new, it would not have been the same without them and I want to 
thank everyone making this such a memorable experience. 
Particularly I want to express my greatest gratitude and appreciation to Eva. I believe words 
don’t suffice for all she has done as colleague and friend. Some specific things however: I want 
to thank her for her comments on this thesis, for being Evapedia, for never being (too) annoyed, 
for keeping the spirits up and for all the crazy time we spent together. Without her I do not 
believe I would’ve started this adventure and yes I’m still glad I did! Further, I want to thank Ana 
She has been a delight as a bench buddy and I am grateful for giving me the opportunity to 
contribute to her project and of course for her suggestions on this thesis. Also I want to express 
my thankfulness to Tea for her input on this thesis and for simply making the lab a better place. 
Speaking of which, I am very grateful to Susi for her amazing work. Somehow it seems like her 
day simply has more hours than most. Also I want to thank Rashi for her help with the FACS. 
Aiiiiiii! Magda! I am very grateful for having this mentally person to share my entire time as a 
PhD and I want to thank her for keeping my spirits up. Mucho! Then I am very thankful to 
Henning for helping with my experiments during a time of sickness and caring for my mental 
health and throwing sweets at me when needed. Also I want to thank Christian for his input on 
the methods and simply being the relaxed person he is. Vincezo! I thank him for the great job 
he’s doing and his patience with certain projects… one day we’ll drink pools of champagne and 
laugh about it. I want to thank Gaurav for his ambitions in analysis just anything. Further, I want 
to thank Ulrike and Daniel for their amazing job they are doing and helping wherever they can.
To my friends here in Göttingen. This has been a ride! We spent now almost 10 years together 
starting from our very first day as bachelor students. You are - without a doubt - the best bunch 
of crazy people in the world. Thank you for being there and making this the best time. 
Franzi, I am so very grateful for having you in my life. Thank you for caring for me and all of your 
patience and acceptance during the past months and of course your untiring accuracy and input 
on this thesis. 
Last but not least I want to thank my family. Claus, vielen Dank für deine Ratschläge zu dieser 
Arbeit. Lisa ich bin so unendlich froh dass du seit meinem aller ersten Tag da bist. Danke für 
deine Unterstützung, dein Verständnis wenn es mal wieder drunter und drüber ging. Das 
wichtigste zu guter Letzt. Ich möchte meiner Mutter danken. Danke für all deine Güte, deine 
Gedult mit mir und dein Verständnis für die gesammte Zeit. Vielen Dank für unseren 
philosophischen Austausch und einfach dafür, dass es dich gibt. Mit Sicherheit wäre ich ohne 
deine Unterstützung niemals so weit gekommen. Danke. 
 169
Curriculum Vitae 
PERSONAL
Name:       Hendrik Urbanke 
Date of birth:       09/06/1987
Place of birth:       Nürnberg, Germany
EDUCATION
Since 01/2014 German Center for Neurodegenerative Diseases 
 (DZNE), Göttingen
• Ph.D. student, work group ‘Epigenetics of Neurodegenerative Diseases’, 
Prof. Dr. Andre Fischer
06/2012 - 11/2012 University Göttingen
• Research assistant, work group ‘Behavioural Molecular Neurobiology’, 
Prof. Dr. André Fiala, Schwann-Schleiden-Forschungszentrum, 
establishing the basis to investigate laterality in D. melanogaster
10/2011 - 10/2013 Georg- August- University Göttingen
• Master of Science in developmental-, neural- and behavioural biology, 
with distinction, focus on molecular neuroscience
10/2008 - 09/2011 Georg- August- University Göttingen
• Bachelor of Science, biology, focus on neuroscience and morphology
09/1998 - 06/2007 Scheffel- Gymnasium Bad Säckingen
• Abitur
HONORARY OFFICE
09/2014 - 11/2016 PhD Student Representative DZNE - Göttingen
AWARDS & FELLOWSHIPS
2016 “Innovation to Application Award” for inventing and engineering of a method 
and interface. The complementary developed assay allows precise temporal 
stimulation using optogenetics and sequencing of single cells depending on 
their function in a heterogenous cellular network.
Since 01/2015 PhD fellowship of the Hans und Ilse Breuer Alzheimer foundation for 
outstanding young scientists.
PUBLICATIONS
2017 “The diphenylpyrazole compound anle138b blocks Aβ channels and rescues 
disease phenotypes in a mouse model for amyloid pathology” 
Martinez Hernandez A*, Urbanke H*, Gillman AL*, Lee J*, Ryazanov S, 
Agbemenyah HY, Benito E, Jain G, Kaurani L, Grigorian G, Leonov A, 
Rezaei-Ghaleh N, Wilken P, Arce FT, Wagner J, Fuhrman M, Caruana M, 
Camilleri A, Vassallo N, Zweckstetter M, Benz R, Giese A, Schneider A, 
Korte M, Lal R, Griesinger C, Eichele G, Fischer A. EMBO Mol Med. 
December 2017; *equal author contribution
“The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice”
Benito E, Ramachandran B, Schroeder H, Schmidt G, Urbanke H, Burkhardt 
S, Capece V, Dean C, Fischer A. Transl Psychiatry. September 2017
“KMT2A and KMT2B Mediate Memory Function by Affecting Distinct 
Genomic Regions” Kerimoglu C, Sakib MS, Jain G, Benito E, Burkhardt S, 
Capece V, Kaurani L, Halder R, Agís-Balboa RC, Stilling R, Urbanke H, 
Kranz A, Stewart AF, Fischer A. Cell Rep. July 2017
2015 “HDAC inhibitor-dependent transcriptome and memory reinstatement in 
cognitive decline models” 
Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, Jain 
G, Capece V, Burkhardt S, Navarro-Sala M, Nagarajan S, Schütz AL, 
Johnsen SA, Bonn S, Lührmann R, Dean C, Fischer A. J Clin Invest. 
September 2015
2014 “K-Lysine acetyltransferase 2a regulates a hippocampal gene expression 
network linked to memory formation” 
Stilling RM, Rönicke R, Benito E, Urbanke H, Capece V, Burkhardt S, 
Bahari-Javan S, Barth J, Sananbenesi F, Schütz AL, Dyczkowski J, 
Martinez-Hernandez A, Kerimoglu C, Dent SY, Bonn S, Reymann KG, 
Fischer A. The EMBO Journal July 2014 
 171
